|
Guerbet SA is a healthcare company that develops and commercializes contrast agents, injection systems, medical devices, and digital solutions for diagnostic imaging and interventional radiology. The company operates in three main business segments: Diagnostic Imaging, Interventional Radiology, and Digital & AI. Its product portfolio includes iodinated and gadolinium-based contrast agents for X-ray and MRI, as well as injectors and embolization devices. Key brands include Lipiodol, Dotarem, Xenetix, and Elucirem. Guerbet also offers AI-based diagnostic support tools through its subsidiary Intrasense, including DUOnco Pancreas and Liflow. The company serves healthcare professionals globally. Guerbet was founded in 1926 and acquired Mallinckrodt's contrast and injection systems business in 2015 to expand its international footprint. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Medical Devices | Homepage guerbet.com |
| Sector Healthcare | IR page guerbet.com/investors | |
|
Tags
contrast agents, diagnostic imaging, interventional radiology, medical devices, artificial intelligence, oncology, radiology, injection systems, embolization, healthcare, Lipiodol, Dotarem, Xenetix, Elucirem, Intrasense, DUOnco Pancreas, Liflow, OptiStar Elite, OptiVantage, Angiomat Illumena, Lipiojoint
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | € 97.86M |
| Market cap (USD) | $ 108.889M |
| P/E | -0.70 |
| PEG | — |
| P/BV | 0.42 |
| P/S | 0.11 |
| P/OCF | 1.36 |
| P/FCF | 1.91 |
| Dividend yield | 10.6% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -33.2% |
| ROI | -41.7% |
| ROIC | -25.4% |
| Profit margin | -13.8% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | Yes |
| Diluting (TTM) | — |
| Debt/Equity | 208.2% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 36 |
| Quality score | -29.4% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||
| Cash and deposits (EUR) | 96.7M | 116M | 41.7M | 51.3M | 50.2M | 116M |
| Intangible assets (EUR) | 188M | 189M | — | — | — | — |
| Cash flow detail | ||||||
| Operating cash flow (EUR) | 120M | 116M | 30.4M | 27.4M | 81.2M | 81.1M |
| Purchases of property, plant and equipment (EUR) | -39.8M | -37.5M | -43.8M | -41.6M | -32M | -29.9M |
| Purchases of intangible assets (EUR) | -19.9M | -11.4M | -6.69M | -12.5M | -24.9M | -6.75M |
| Change in receivables (cash effect) (EUR) | 14M | -6.64M | -1.56M | -29M | -27.3M | 27.3M |
| Change in inventories (cash effect) (EUR) | 17.4M | 4.58M | -68.2M | -36.3M | -6.57M | -18.6M |
| Change in payables (cash effect) (EUR) | 4.61M | 16M | 22.1M | -10.3M | 1.89M | -7.04M |
| Dividends paid (cash effect) (EUR) | -8.83M | -8.81M | -10.7M | -6.31M | -6.31M | 0.00 |
| Interest paid (cash effect) (EUR) | -4.89M | -5.25M | -4.55M | -10.6M | -20.5M | -19.8M |
| Share-based compensation (EUR) | -1.31M | 610,000 | -399,000 | 205,000 | 717,000 | -680,000 |
| Operating cash flow before change in receivables (EUR) | 106M | 123M | 32M | 56.4M | 109M | 53.8M |
| Free cash flow (OCF - PPE - intangibles) (EUR) | 60.8M | 67M | -20.1M | -26.6M | 24.2M | 44.5M |
| Income detail | ||||||
| Total comprehensive income (EUR) | -17M | 44.6M | -12.4M | 492,000 | 19.6M | -128M |
| Comprehensive income to owners (EUR) | — | — | — | 2.19M | 22.2M | -124M |
| Reported | Apr 5, 2022 | Apr 5, 2022 | Mar 31, 2023 | Apr 3, 2025 | Apr 3, 2025 | Mar 20, 2026 |
Podcast Mentions
Regulated information filed with the AMF (info-financiere.gouv.fr), newest first, titles as filed. Voting-rights totals, own-share transactions, threshold crossings and availability notices are left out. The link opens the filed document. Press releases from the company's own website, newest first.
Back Close
Guerbet Worldwide
English
- English
- French
-
-
Home of MRI Innovations
-
Injectors, Accessories & Consumables
-
Service & Support

UNIK: Diagnostic Imaging Interconnected Solutions
-
Contrast Agents
-
Injectors, Accessories & Consumables
-
Service & Support

UNIK: Diagnostic Imaging Interconnected Solutions
-
Contrast Agents
-
Injectors, Accessories & Consumables
-
Service & Support

UNIK: Diagnostic Imaging Interconnected Solutions
-
Pharmaceutical Drugs
-
Medical Devices

Interventional Imaging Solutions
-
Pharmaceutical Drugs

Women’s Health
-
Revenue at 30 September 2026
10/22/2026 - Revenue at 30 September 2026
,
Business in line with Group expectations
-
Revenue at 30 September 2026 of €573.8m, down 1.3% at CER and like-for-like; excluding China, business grew by 1%, with a positive contribution from the three regions (EMEA, Americas and Asia)
-
In the third quarter, revenue fell by 3.6% at CER and like-for-like, and was stable excluding China
All financial targets confirmed for 2026
Villepinte, 22 October 2026, 5.45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is publishing its revenue for the first nine months of 2026.
At 30 September 2026, Group revenue totalled €573.8 million, down 2.2% on a reported basis compared with the first nine months of 2025. At constant exchange rates (CER)1, the decline was 1.3% over the period, with the negative exchange rate effect of €4.8 million confined to the first six months of the year and largely linked to the depreciation of the Japanese yen. As there was a very small scope effect, the change at CER and like-for-like² was also -1.3%. Excluding China, where the healthcare product market is undergoing a major restructuring, Guerbet's revenue would have grown over the period (+1%). In the third quarter alone, revenue at CER and like-for-like was down 3.6%, but was stable excluding China.
Geographical breakdown of consolidated revenue (IFRS)
| In € millions | Q3 | 9 months | |||||||
| 2025 | 2026 | % change | % chg. at CER | 2025 | 2026 | % change | % chg. at CER | ||
| Sales in EMEA | 86.2 | 86.0 | -0.2% | -0.4% | 255.8 | 259.0 | +1.3% | +1.0% | |
| Sales in the Americas | 58.8 | 61.6 | +4.9% | +0.2% | 176.5 | 178.5 | +1.1% | +0.9% | |
| Sales in Asia | 53.7 | 46.9 | -12.7% | -13.0% | 152.4 | 134.7 | -11.6% | -7.9% | |
| Total like-for-like | 198.7 | 194.6 | -2.1% | -3.6% | 584.7 | 572.2 | -2.1% | -1.3% | |
| Out-of-scope activities* | 0.0 | 0.0 | - | - | 1.8 | 1.6 | - | - | |
| Total | 198.7 | 194.6 | -2.1% | -3.7% | 586.5 | 573.8 | -2.2% | -1.3% |
*sales of components and finished products related to the urology business (sold in July 2024)
In EMEA, revenue came to €259.0 million at 30 September 2026, up 1.0% at CER and like-for-like, impacted by a continuous recovery in activity in France and a decrease in indirect sales (distributors). Revenue in the third quarter was virtually stable (-0.4%) despite a difficult comparison base (+10.2% in the third quarter of 2025).
In the Americas, sales reached €178.5 million at end-September, up 0.9% at CER and like-for-like. After a sharp recovery in the second quarter (+4.8%), the third quarter was stable (+0.2%) amid a continued normalisation at the Raleigh industrial site, where a return to normative batch release levels is still expected at the end of the financial year.
In Asia, revenue amounted to €134.7 million for the first nine months, down 7.9% at CER and like-for-like, of which -13.0% in the third quarter alone. This decline is attributable to the ongoing contraction in sales in China, where the policy to sharply reduce healthcare spending is leading to a profound recomposition of the market, linked to a gradual elimination of intermediaries (CSO business model) and a more widespread use of volume-based tenders (VBP business model).
Breakdown of consolidated revenue by activity (IFRS)
| In € millions | Q3 | 9 months | |||||||
| 2025 | 2026 | % change | % chg. at CER | 2025 | 2026 | % change | % chg. at CER | ||
| Diagnostic Imaging | 174.0 | 166.9 | -4.0% | -5.7% | 508.0 | 492.1 | -3.1% | -2.5% | |
| MRI | 65.0 | 62.0 | -4.7% | -5.8% | 192.5 | 185.8 | -3.5% | -2.7% | |
| X-ray | 108.9 | 105.0 | -3.6% | -5.6% | 315.4 | 306.3 | -2.9% | -2.4% | |
| Interventional Radiology | 24.8 | 27.7 | +11.7% | +10.7% | 76.7 | 80.0 | +4.4% | +6.6% | |
| Total like-for-like | 198.7 | 194.6 | -2.1% | -3.6% | 584.7 | 572.2 | -2.1% | -1.3% | |
| Out-of-scope activities* | 0.0 | 0.0 | - | - | 1.8 | 1.6 | - | - | |
| Total | 198.7 | 194.6 | -2.1% | -3.7% | 586.5 | 573.8 | -2.2% | -1.3% |
*sales of components and finished products related to the urology business (sold in July 2024)
By business, revenue in Diagnostic Imaging came to €492.1 million in the first nine months, down 2.5% at CER and like-for-like, including a 5.7% decline in the third quarter alone.
-
Sales of the IRM division amounted to €185.8 million, down 2.7% at CER and like-for-like. The decline in the third quarter (-5.8%) was due entirely to the contraction in sales to third parties, linked to the planned slowdown in subcontracting activities at Gadopiclenol, which will take place, as expected, in two stages: end-2026 for Fill & Finish and end-2028 at the earliest for the production of active pharmaceutical ingredients (API). Meanwhile, sales of Elucirem™ remained very dynamic over the period.
-
Revenue in the X-ray division came to €306.3 million, down 2.4% at CER and like-for-like (-5.6% in the third quarter). The favourable price effect over the period was not enough to offset the fall in volumes of Optiray® and Xenetix®, largely due to the contraction of sales in China.
Revenue in Interventional Radiology came to €80.0 million in the first nine months, up 6.6% at CER and on a like-for-like basis. Growth accelerated in the third quarter (+10.7%), still driven by momentum in sales of Lipiodol® in the vascular embolization market.
2026: full-year financial targets confirmed
At the end of the third quarter, in line with the Group’s expectations, Guerbet reiterated all of its financial targets. For 2026, the Group’s targets are:
-
Revenue stable or showing a slight decrease at CER and on a like-for-like basis.
-
Restated EBITDA margin rate of around 8%, including around €35 million related to the costs of the remediation plan at the Raleigh site.
-
Strongly negative free cash flow of between -€50 million and -€70 million, due to the expected decrease in restated EBITDA, the increase in the CAPEX plan and non-recurring restructuring costs linked to the Group’s transformation plan, including in particular the redundancy plan in France.
Continuation of discussions with financial partners
Guerbet is continuing its discussions with its financial partners on its refinancing, as mentioned in its recent communications.
As a reminder, the Group has secured waivers from its financial partners relating to the leverage ratio tested at 30 June 2026, 31 December 2026 and 30 June 2027.
Next event:
2026 annual sales
February 4, 2027 after market close
About Guerbet
At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. As pioneers in contrast products for 100 years, with 2,746 employees worldwide, we continuously innovate and devote 10% of our revenue to Research and Development in four centers in France and the United States. Guerbet (GBT) is listed in Compartment B of Euronext Paris and generated revenue of €786 million in 2025. For more information, please visit www.guerbet.com.
Forward-looking statements
Certain information contained in this press release is not historical data but constitutes forward-looking statements. These forward-looking statements are based on estimates, forecasts and assumptions including, without limitation, assumptions regarding the Group’s current and future strategy and the economic environment in which the Group
operates. They involve known and unknown risks, uncertainties and other factors, which may result in a significant difference between the Group’s actual performance and results and those presented explicitly or implicitly in these forward-looking statements.
These forward-looking statements are only valid as of the date of this press release and the Group expressly disclaims any obligation or commitment to issue an update or revision of the forward-looking statements contained in this press release to reflect changes in the assumptions, events, conditions or circumstances on which such forward-looking statements are based. Forward-looking statements contained in this press release are for illustrative purposes only. Forward-looking statements and information are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and generally beyond the control of the Group.
These risks and uncertainties include, but are not limited to, uncertainties inherent in research and development, future clinical data and analyses, including post-marketing analyses, decisions by regulatory authorities, such as the Food and Drug Administration or the European Medicines Agency, whether or not to approve, and when, the application for a drug, process or biological product for one of these candidate products, as well as their labeling decisions and other factors that may affect the availability or commercial potential of these candidate products. A detailed description of the risks and uncertainties related to the Group’s activities can be found in chapter 4.8 “Risk factors” of the Group’s Universal Registration Document registered by the AMF under number D.25-0220 on April 3, 2025, available on the Group’s website (www.guerbet.com ).
Glossary
EBITDA: EBITDA is defined as operating income plus net depreciation, amortization, impairment and provisions for risks.
Free cash flow (FCF): Free cash flow is defined as the change in net debt from one year to the next.
Net financial debt: Net financial debt is defined as the sum of current and non-current borrowings less cash and cash equivalents and marketable securities.
Like-for-like basis: Like-for-like basis refers to the scope excluding the urology and Accurate businesses, sold in July 2024 and January 2025 respectively.
At constant exchange rates: At constant exchange rates means the impact of exchange rates is eliminated by recalculating sales for the period based on the exchange rates used for the previous year.
1 Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year.
2 Excluding sales in 2026 of components and finished products related to the urology business (sold in July 2024) and sales in 2025 of microcatheters.
3 Restated EBITDA excludes non-recurring expenses related to restructuring
2026 Half year results
September 29, 2026
WELCOME
KARIM BOUSSEBAA Chief Executive Officer
JÉRÔME ESTAMPES Chief Financial Officer
1
A stronger executive committee to accelerate the transformation plan 3 Regional Directors and a Chief Transformation Officer reinforcing the executive committee
KARIM BOUSSEBAA
CHRISTINE ALLARD
CHARLOTTE BAMIÈRE
PHILIPPE BOURRINET
VALÉRIE BRISSART
ADRIANO CALDAS
FRANÇOIS CONVENANT
Chief Executive Officer
EVP Communications, Public Affairs & CSR
Chief Legal and Compliance Officer
EVP Development, Medical & Regulatory Affairs
EVP Marketing Diagnostic Imaging
EVP Commercial EMEA
EVP Interventional Radiology
HENNING MUELLER
MARIE-FLORE NABOR
FRANÇOIS NICOLAS
EVA OHLSSON
EVP Commercial APAC
EVP Commercial Americas
Chief Strategy Officer & EVP Innovation
Chief People Officer
JÉRÔME ESTAMPES
ERIC KUMMER
Chief Financial Officer
EVP Operations
OCÉANE MIGNOT Chief Transformation Officer
Commercial development of the 3 geographic regions and transformation at the heart of Guerbet's governance 2
01
H1 Activity & highlights
01 Activity & highlights | 02 Financial results | 03 Financial outlook | 3
H1 2026: a financial performance impacted by the Raleigh situation SALES ▪ H1 revenue of €379.2 million, nearly stable (-0.1%) at like-for-like and CER Vs. H1 2025 ▪ A resilient performance despite headwinds at the Raleigh site and weakness in China PROFITABILITY
▪ Restated EBITDA margin* at 9.1% of sales, Vs. 12.9% a year ago ▪ This includes €14.3m related to the costs of the remediation plan at the Raleigh site, partly offset by tight control of operating expenses (decrease in staff costs) FINANCIAL STRUCTURE ▪ FCF came in at -€30.2m (Vs. -€8.4m in H1 2025) ▪ Net debt at €355.9m (equivalent to 1.5x shareholder equity)
*Restated EBITDA excludes non-recurring charges related to restructuring 4
Resilient activity despite a challenging backdrop Sales on a like-for-like basis in millions of euros and variation in % -0.1% At current FX
-2.2%
At CER
H1 2026 sales evolution
-2.5% +2.6%
386.0
-2.9%
377.6 385.4
▪
€385.4m in half-year sales at constant exchange rates (CER) and on a like-for-like (LFL) basis (-0.1%)
▪
Q1 growth of 2.6%, followed by a Q2 decline of -2.5%
-1.3% 207.8 178.2
Q1 2025
175.8
201.7
202.6
182.8
Q1 2026
Q2 2025
Q2 2026
H1 2025
H1 2026
5
Stable DI business, continued growth in IR DIAGNOSTIC IMAGING (DI) (revenues in m€ at CER and on a LFL basis, variation in %)
INTERVENTIONAL RADIOLOGY (IR) (revenues in m€ at CER and on a LFL basis, variation in %)
-0.7%
-1.2%
X RAY
206.5
205.0
MRI
+4.7%
14%
33%
127.5
126.0
H1 2025
H1 2026
INTERVENTIONAL
51.9
54.4
H1 2025
H1 2026
53% H1 2025
H1 2026
▪ DI business at -0.9% in H1 2026 at CER and on a LFL basis ▪ X-Ray sales nearly stable (-0.7%) in a context of broadly positive price trends
▪ Continued positive momentum for IR business (+4.7% in H1)
▪ MRI evolution (-1.2%) impacted by sales to third parties; strong momentum in EluciremTM sales
▪ A performance driven by the success of Lipiodol® in vascular embolization
6
Core markets, France and the United States, back on a growth path Split of sales & evolution by zone (in m€ at CER and on a LFL basis, variation in %)
EMEA: return to strong growth in France ▪ Good volumes in the region driven by steady demand
H1 2026
▪ Reform effects now absorbed, France resumes strong growth (+9.3% in H1)
APAC -5.0%
Americas: recovery driven by normalization in Raleigh
93.7
172.6
EMEA +1.8%
▪ Growth in H1 (+1.2%) thanks to a recovery in Q2 (+4.8%) driven by North America ▪ Ongoing normalization in Raleigh with significant improvement in the batch release rate
Americas +1.2%
119.2
APAC: weak performance due to reforms in China ▪ H1 decrease (-5.0%) concentrated in the second quarter alone (-14.0%)
EMEA
Americas
APAC
▪ Contraction in China due to reduced healthcare spending and market reshaping
7
China - A deep reshaping of the market underway THE CONTEXT
Authorities implementing sharp cuts in healthcare spending, driven by: ▪ Simplification of the sales models: termination of the Contract Sales Organizations (CSO) ▪ Generalization of volume-based procurement (VBP)
CHINA ACTIONS
▪ Decision taken in August 2026 to end CSO partnerships ▪ Transition to a direct sales model in China
Short term: market share loss and price pressure Longer term: improved control over execution
8
USA – Solid fundamentals restored, ready for growth RALEIGH: normalization on track
Strong fundamentals in place
Q4 2025 Launch of the remediation plan
New management and renewed team
Consultants hired to address FDA observations
Q2 2026
Plant upgraded with new processes and equipment
Normalization on track Significant improvement in the batch release rate
Strong loyalty of Guerbet's customer base
End of 2026 Product release back to normal
Successful refocusing on client acquisition
9
02
Financial results
01 Activity & highlights | 02 Financial results | 03 Financial outlook |
10
An unfavorable FX impact largely due to the yen and dollar
Half year sales (in €m)
FX impact on H1 2026 sales (in €m)
Reported basis -0.1%
H1 2026 evolution
-2.2% 387.8
379.2
387.2
Americas -2 €m
APAC -6 €m
H1 2025 At current FX
▪
A total negative foreign exchange effect of €-8.0m in H1 2026
▪
A movement mainly due to the depreciation of the Japanese yen and the US dollar
H1 2026 At CER
11
EBITDA IFRS €m Net sales
H1 2025
% revenue
H1 2026
% revenue
Variation
387.8
100.0%
379.2
100.0%
-2.2%
7.0
1.8%
7.5
2.0%
+7.8%
Supplies used in operations
(80.5)
(20.8%)
(88.1)
(23.2%)
+9.4%
Staff costs
(142.0)
(36.6%)
(132.1)
(34.8%)
-6.9%
External expenses
(116.7)
(30.1%)
(123.1)
(32.5%)
+5.5%
Taxes other than on income
(9.5)
(2.5%)
(7.4)
(2.0%)
-22.1%
Other operating income and expenses
0.1
0.02%
(5.3)
(1.4%)
EBITDA published
46.1
11.9%
30.6
8.1%
-33.5%
EBITDA restated*
50.0
12.9%
34.3
9.1%
-31.4%
Other revenues
*Restated EBITDA excludes non-recurring charges related to restructuring
External expenses include €14.3 million in exceptional costs related to the remediation plan at the Raleigh site (consulting fees) 12
EBITDA Evolution 55 12.9%
50 11.9%
-3.1
+3.9
45
40
-14.3
35
9.1%
50.0 46.1
-3.7
30 -8.4
+10.0 34.3 30.6
25
20
8.1%
EBITDA HY Restructuring 2025 published charges
EBITDA HY 2025 restated
FX Impact
Raleigh Remediation
Inventory Dest.
Costs
EBITDA HY 2026 restated
Restructuring EBITDA HY charges 2026 published
13
Operating & Net Income H1 2025 As published
% revenue
H1 2026 As published
% revenue
Variation
EBITDA
46.1
11.9%
30.6
8.1%
-33.5%
Allowances for depreciation
(29.4)
(7.6%)
(31.1)
(8.2%)
+5.8%
Provisions
(1.7)
(0.4%)
(17.9)
(4.7%)
+956.0%
Operating Income
15.0
3.9%
(18.4)
(4.8%)
Net interest expense
(9.9)
(2.6%)
(13.3)
(3.5%)
+34.5%
Net currency gains/losses & Other Financial income/loss
(2.4)
(0.6%)
3.4
0.9%
Income tax
(1.3)
(0.3%)
(4.3)
(1.1%)
+223.1%
Net Income
1.3
0.3%
(32.7)
(8.6%)
IFRS €m
The €17.9m of provisions recognized in H1 2026 cover restructuring costs related to the transformation plan, including the French PSE 14
Balance sheet ASSETS
December 31, 2025 As published
June 30, 2026 As published
Non-current assets
329
333
of which fixed assets
276
274
EQUITY & LIABILITIES
December 31, 2025 As published
June 30, 2026 As published
Shareholders’ equity Non controlling interests
267 -7
245 -10
429 392
71 34
Inventories
294
311
Non-current liabilities* of which financial debt
Trade receivables
145
156
Trade payables
85
88
Other current assets of which CCE
161 115
175
132
Other current liabilities* of which financial debt
156 49
581 354
Total Balance sheet
930
975
Total Balance sheet
930
975
*The waivers obtained on 1 July result in the reclassification of the debt from non-current to current liabilities. This does not mean, however, that the debt has become due for repayment in the short term. 15
Free cash-flow
IFRS in €m
H1 2025
H1 2026
Cash-flow from operations
46.6
31.5
Change in WCR
(18.6)
(11.8)
Net capital expenditure
(17.2)
(30.2)
Interest paid
(10.1)
(14.4)
Income tax paid
(4.8)
(4.9)
Exchange
(4.3)
(0.5)
Free cash-flow
(8.4)
(30.2)
16
Net debt evolution Net debt
364.9
Net debt / EBITDA
353.3
Net debt / Shareholder Equity
355.9
5.3
3.2
H1 2024
H1 2025
H1 2026
H1 2024
1.46
0.94
0.94
H1 2024
H1 2025
3.4
H1 2025
H1 2026
H1 2026
17
03
2026 financial outlook
01 Activity & highlights | 02 Financial results | 03 Financial outlook |
18
2026: Resilient activity, profitability hit by remediation and restructuring
ACTIVITY
▪
Expected growth in H2 in all regions excluding China
▪
Continued good momentum for Lipiodol® and Elucirem
PROFITABILITY
▪
▪
€35m of exceptional expenses over the year related to the remediation plan at Raleigh, including stock destruction Benefits of the transformation plan will materialize in 2027
CASH GENERATION
FCF impacted by: ▪
Increase in CAPEX
▪
Non-recurring costs linked to Raleigh remediation and transformation plan (incl. the redundancy plan in France)
19
Financial outlook for 2026 ACTIVITY
Revenue at constant exchange rates and on a like-for-like basis
PROFITABILITY
Restated EBITDA margin rate*
CASH GENERATION
Free cash flow (FCF)
Stable or slightly down
Around 8%
Between -€50m and -€70m
*Restated EBITDA excludes non-recurring charges related to restructuring 20
04
Our strategic priorities
01 Activity & highlights | 02 Financial results | 03 Financial outlook | 21
Our mid-term strategic priorities
Restore sustained growth
Improve margin and streamline the organization
Capture high growth in Interventional Radiology
22
Restore sustained growth, improve margin and streamline the organization Activity
Profitability
Empower the regions to better address their market needs
Strengthen supply reliability and reduce cost of non-quality
Strengthen commercial excellence, with a sharper focus on segmentation and customer acquisition
Improve COGS competitiveness
Focus resources on our top priority markets
Simplify the organization to improve agility and efficiency
23
Capture high growth in Interventional Radiology Beyond HCC*, new growth drivers for Lipiodol®
Solid double-digit growth over a decade Interventional Radiology revenue (Reported sales in €m)
Maintaining our position in HCC treatment ▪ Lipiodol® as gold standard ▪ Leveraging emerging new therapeutic strategies against HCC
100
Accelerating in Vascular Embolization
80
▪ VE indication expansion in Europe to be leveraged in other countries ▪ Deployment through partnerships
60
CAGR +16.1%
40 Capturing Musculoskeletal potential ▪ R&D investments in new applications ▪ Lipiojoint clinical study preparation to claim benefits in osteoarthritis
20 0
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
*Hepatocellular carcinoma (Liver cancer) 24
What’s next?
25
Financial communication calendar Financial communication calendar
2026 3rd quarter sales
Half-year Sales 2023 2026 annual sales
2023 Half-year results 2026 annual results
April 20, 2023 October 22, 2026 after trading after market close
July 20, 2023 February 4, 2027 after trading after market close
March 10, 2027 after market close
26
Content
Activity report
3
2026 HALF-YEAR RESULTS
3
PRINCIPAL RISKS AND UNCERTAINTIES FOR THE REMAINING SIX MONTHS OF THE FINANCIAL YEAR
6
MAIN RELATED THIRD-PARTY TRANSACTIONS
6
Key figures
7
Guerbet stock
7
Condensed consolidated half-year financial statements at June 30, 2026
8
SUMMARY STATEMENTS
9
ACCOUNTING POLICIES
13
HIGHLIGHTS OF THE FIRST HALF OF 2026
14
SEASONAL ASPECT
15
DIVIDEND PAYMENT
15
FINANCIAL RISK MANAGEMENT
16
ADDITIONAL INFORMATION
19
DESCRIPTIVE NOTES (IN € THOUSANDS)
20
Report by the Statutory Auditors on the half-year financial information
24
Conclusion on the financial statements
24
Specific verification
24
Statement of the person responsible for the half-year financial report
Half-year financial report 2026| Guerbet | 2
25
Activity report 2026 HALF-YEAR RESULTS Revenue presentation and analysis (in millions of € – IFRS standards)
Revenue Divested businesses (urology and Accurate) (2)
H1 2026
H1 2025
379.2
387.8
1.6
1.8
As of June 30, 2026, Group revenue stood at €379.2 million, down 2.2 %. Excluding the currency effect (-€8.0 million), mainly attributable to the depreciation of the yen and the dollar, revenue at CER1 was down by a slight 0.2 %. It was nearly stable (-0.1 %) at CER and on a like-for-like basis2, in line with the Group's forecast for the full year. This reflects the resilience of the business despite the situation at the Raleigh site (North Carolina) and the disruptions on the Chinese market. H1 2026
H1 2025
EMEA
172.9
169.6
Americas
116.9
117.8
Asia
87.7
98.6
Total like-for-like
377.6
386.0
1.6
1.8
379.2
387.8
Breakdown of revenue by geographic region
Divested businesses (urology and Accurate) (2) Total
In EMEA, H1 revenue came to €172.9 million, up 1.8 % at CER and like-for-like. It was marked by the return to strong growth in France (+9 % over the period), where the effects of the reform of contrast agent supply methods have now been fully absorbed. In the Americas, sales in the first half of 2026 amounted to €116.9 million, up 1.2 % at CER and like-for-like, incorporating a sharp increase in the second quarter (+4.8 %) thanks to a significant improvement in the batch release rate at the Raleigh site. In Asia, H1 revenue came to €87.7 million, down 5 % at CER and like-for-like. The decline was concentrated in the second quarter (-14 %) and was linked to the profound restructuring underway on the Chinese market associated with the authorities’ policy of reducing healthcare spending. H1 2026
Breakdown of revenue by product range
Diagnostic Imaging
H1 2025
325.2
334.0
MRI
123.9
127.5
X-ray
201.3
206.5
Interventional Imaging
52.4
51.9
Total like-for-like
377.6
386.0
Divested businesses (urology and Accurate) (2) Total
1.6
1.8
379.2
387.8
By business, H1 revenue in Diagnostic Imaging came to €325.2 million, down by a slight 0.9 % at CER and like-for-like, as a result of: • Within the MRI division (-1.2 %), a performance affected by Dotarem® sales in export market, while momentum remained strong on sales of EluciremTM. • In X-ray sales, a slight decline in volumes and an overall positive trend in prices. In Interventional Imaging H1 revenue reached €52.4 million, up 4.7 % at CER and like-for-like, driven by the success of Lipiodol® in the field of vascular embolization.
1
2
At constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous fiscal year. Excluding sales in H1 2026 of components and finished products related to the urology business (sold in July 2024) and sales in H1 2025 of microcatheters.
Half-year financial report 2026| Guerbet | 3
Results presentation and analysis H1 2026
H1 2025
Revenue
379.2
387.8
Costs of the compliance plan
14.3
—
EBITDA (1)
30.6
46.1
% of revenue
8.1 %
11.9 %
Restated EBITDA (2)
34.3
50.0
% of revenue
9.1 %
12.9 %
Operating income (expense)
(18.4)
15.0
(in millions of € – IFRS standards)
Net income (loss)
(32.7)
1.3
Net financial debt
355.9
353.3
(1) EBITDA refers to the operating income plus net amortization, depreciation and provisions. (2) Restated EBITDA excludes non-recurring expenses related to restructuring.
Profitability affected by exceptional costs related to the Raleigh site and restructuring At June 30, 2026, the Group posted EBITDA of €30.6 million, a decrease of €15.5 million. As announced, the good control of current operating expenses - particularly personnel expenses (-6.9 %) - was offset by the remediation plan at the Raleigh industrial site. This plan generated €14.3 million in exceptional costs over the period. It gave rise to an increase in external expenses (+5.5 % in the first half of 2026) related to the technical experts mobilized to implement the plan. EBITDA margin came to 8.1 % of revenue over the period. The restated margin rate, calculated excluding non-recurring expenses related to restructuring, was 9.1 % (versus 12.9 % a year earlier). The Group booked €31.1 million in depreciation and amortization charges in H1 (versus €29.4 million in the first half of 2025) and €17.9 million in provisions (versus €1.7 million), covering restructuring costs linked to the transformation plan, including the redundancy plan in France. As a result, it made an operating loss of €18.4 million at June 30 (versus operating income of €15 million a year earlier). After taking into account financial expenses of €13.3 million, a foreign exchange gain of €3.4 million and a tax expense of €4.3 million, the Group posted a net loss of €32.7 million, compared with net income of €1.3 million in H1 2025. Negative free cash flow and a rise in net debt Free cash flow (FCF) was negative at -€30.2 million (compared with -€8.4 million a year earlier), mainly due to the fall in EBITDA and the increase in CAPEX. The latter amounted to €30.2 million in H1, compared with €17.2 million in H1 2025 when investment was at a low level. On the balance sheet, shareholders’ equity stood at €245 million at June 30, 2026, compared with €267 million at the end of 2025. Net financial debt amounted to €355.9 million, compared with €325.7 million six months earlier. Financial leverage (net financial debt/EBITDA) was 5.3x. Update on financing and discussions with financial partners As indicated in the H1 revenue release (press release of July 23, 2026), the Group has secured waivers from its financial partners relating to the leverage ratio tested at June 30, 2026, December 31, 2026 and June 30, 2027. Discussions are ongoing between Guerbet and its financial partners with a view to finalizing by October 31, 2026 the terms and conditions of a refinancing arrangement that will enable the Company to settle on an appropriate financial structure and finance its activity as part of the normalization of activity at the Raleigh site. In this regard, Guerbet draws attention to the risk factors relating to the refinancing of its debt, as presented in note 6.3 "Liquidity risk" of this document. Update on financing needs At June 30, 2026, the Group’s total gross financial debt was €488.1 million3, with cash and cash equivalents of €132 million. As the waivers were obtained after June 30, 2026, debt was reclassified as current debt at June 30, 2026 in the amount of €438.6 million. Taking into account the waivers obtained in July, the maturities of this debt are €53.6 million in the second half of 2026, €10 million in 2027, €275 million in 2028 and €100 million beyond 2028. With respect to the financing of current operations, the Company expects its 12-month liquidity requirements will be covered by cash.
3
It being specified that no collateral is provided for this debt.
Half-year financial report 2026| Guerbet | 4
Raleigh site: confirmation of timeline for the normalization of activity At the Raleigh site, the remediation plan initiated in the fourth quarter of 2025 is progressing in line with the Group's expectations. Guerbet confirms the timetable communicated during the publication of its 2025 annual results: return to a normative batch release rate expected at the end of the 2026 fiscal year, with the site also preparing for a new FDA inspection from that date onward. The Group will be able to operate under normal conditions throughout the 2027 fiscal year. Accelerated execution of the transformation plan In autumn 2025, the Group launched a transformation plan to strengthen sales momentum and improve profitability over the long term, with the first significant effects expected in 2027. Over the coming months, the implementation of this plan will be accelerated, drawing on the strategic priorities defined: • In Diagnostic Imaging, restore sustained growth, improve margins and streamline the organization. Commercial revitalization has already begun, notably through greater autonomy granted to each of the three regions and a particular focus on Guerbet's key markets; at the same time, operational efficiency measures are being deployed, which involves securing the production chain, improving the cost of sales (COGS), and simplifying the organization. • In Interventional Radiology, capitalize on the strong growth in business. A standard treatment for HCC (liver cancer), Lipiodol® is expected to see an increase in use in vascular embolization, with growth drivers ensured through new indications, such as musculoskeletal disorders. To support the accelerated execution of the transformation plan, Océane Mignot was appointed Chief Transformation Officer and given a seat on the Executive Committee. 2026: confirmation of financial targets for the full year Guerbet reiterates all of the full-year financial targets communicated on July 23. For 2026, the Group is therefore targeting: • Revenue either stable or down slightly at CER and on a like-for-like basis; • A restated EBITDA margin4 of around 8 %, including around €35 million related to the costs of the remediation plan at the Raleigh site; • Materially negative free cash flow at between -€50 million and -€70 million due to the expected decrease in restated EBITDA, the increase in the CAPEX plan and non-recurring restructuring costs linked to the Group's transformation plan, including in particular the redundancy plan in France. These forecasts take into account the following business outlook for the different regions for the second half of 2026: • On the one hand, continued positive trends are expected in both EMEA and the Americas; this should be supported by confirmation of both the return to growth in France and the recovery in the United States. • On the other hand, a positive performance in APAC excluding China. In China, the policy to sharply reduce healthcare spending is leading to a profound recomposition of the market with a gradual decrease in the intermediary-based (CSO) business model and a more widespread increase in volume-based procurement (VBP). As a result of this, in August 2026 Guerbet began to switch to a direct sales model in China.
4
Restated EBITDA excludes non-recurring expenses related to restructuring.
Half-year financial report 2026| Guerbet | 5
PRINCIPAL RISKS AND UNCERTAINTIES FOR THE REMAINING SIX MONTHS OF THE FINANCIAL YEAR Readers can refer to the 2025 Universal Registration Document filed with the French Financial Markets Authority (AMF) on March 20, 2026 under number D.26-0121. It can be viewed directly on the websites of the AMF and Guerbet (https://www.guerbet.com). As of June 30, 2026, the Group did not identify any new risks and uncertainties compared to December 31, 2025. The risk disclosed in the 2025 Universal Registration Document relating to the consequences of a high level of debt associated with an event impacting business continuity, is being closely monitored by Guerbet and has not worsened since December 31, 2025. Recent developments are described in section 6.3 “Liquidity Risk” of this interim financial report.
MAIN RELATED THIRD-PARTY TRANSACTIONS Readers can refer to note 24 to the consolidated financial statements and note 30 (describing the list of the parent company's holdings) of the 2025 Universal Registration Document filed with the French Financial Markets Authority (AMF) on March 20, 2026 under number D.26-0121, which can be viewed directly on the websites of the AMF and Guerbet (https://www.guerbet.com).
Half-year financial report 2026| Guerbet | 6
Key figures 30/06/2026
30/06/2025
31/12/2025
Revenue
379,192
387,756
786,443
EBITDA (1)
30,635
46,093
82,261
Operating result (EBIT)
(18,390)
14,962
(88,164)
Net income
(32,714)
1,295
(112,654)
(in thousands of € – IFRS standards)
Earnings per share
€(2.59)
€0.10
€(8.91)
Shareholders' equity, Group share
244,511
376,114
266,994
Net financial debt (2)
355,851
353,275
325,697
Net financial debt/EBITDA (3)
5.33
3.38
3.96
Net financial debt/Shareholders' equity, Group share
1.46
0.94
1.22
(1) EBITDA refers to the operating result plus net amortization, depreciation and provisions. (2) Net financial debt is calculated by adding up current and non-current financial debts and subtracting cash and cash equivalents. (3) Ratio calculated with rolling EBITDA based on the last 12 months and net financial debt.
Guerbet stock Data on share price and transactions
2025
2026
Month
Highest price in a Lowest price in a trading session trading session (in Number of shares Capital traded (in (in €) €) traded millions of €)
January
28.7
26.1
290,840
7.96
February
27.8
24.7
283,225
7.39
March
28.2
18.3
499,200
11.58
April
20.8
17.4
435,482
8.35
May
21.6
19.3
222,545
4.54
June
22.6
19.9
450,664
9.69
July
23.7
21.0
273,846
6.13
August
23.1
20.0
242,278
5.17
September
20.6
12.7
1,109,046
15.78
October
16.3
13.1
353,551
5.13
November
18.3
14.6
220,571
3.62
December
18.2
11.2
435,855
6.05
January
15,1
13.6
191,352
2.73
February
14.2
13.2
176,538
2.42
March
13.2
8.0
531,256
5.24
April
12.7
8.6
359,682
3.63
May
11.6
9.4
284,442
2.88
June
10.8
8.7
327,968
3.13
Half-year financial report 2026| Guerbet | 7
Condensed consolidated half-year financial statements at June 30, 2026 In thousands of euros (€) On September 28, 2026, the Board of Directors approved the publication of Guerbet's condensed consolidated half-year financial statements for the period from January 1 to June 30, 2026. The condensed consolidated half-year financial statements at June 30, 2026 are to be read in conjunction with the consolidated financial statements for the financial year ended December 31, 2025, as indicated in the Universal Registration Document filed with the French Financial Markets Authority (AMF) on March 20, 2026, under number D.26-0121.
Half-year financial report 2026| Guerbet | 8
SUMMARY STATEMENTS
1.1
Consolidated balance sheet
Assets (net values) 30/06/2026
31/12/2025
(in thousands of €)
Note
Intangible assets
8.1
52,800
61,531
Tangible assets
8.1
220,915
214,682
30,453
25,983
Other non-current financial assets Deferred taxes – Assets
28,818
27,150
Total non-current assets
332,986
329,347
310,883
294,454
155,609
145,328
Inventories
8.2
Trade receivables Other current financial assets
43,126
45,365
Cash and cash equivalents
132,204
115,524
Total current assets
641,822
600,669
TOTAL ASSETS
974,808
930,016
30/06/2026
31/12/2025
Liabilities (net values) Notes
(in thousands of €)
Capital
12,641
12,641
Other reserves
8.3
317,997
424,662
Net income
(29,591)
(108,331)
Translation adjustment
(56,537)
(61,977)
Shareholders' equity, Group share
244,511
266,994
Net income and reserves, non-controlling interests
(10,040)
(6,917)
Total shareholders' equity
234,471
260,077
33,775
392,121
981
1,910
Non-current financial debt
8.5
Other non-current financial liabilities Deferred taxes – Liabilities
8,440
5,697
27,552
29,010
Total non-current liabilities
70,748
428,739
Trade and other payables
88,498
85,284
Non-current provisions
8.4
Current financial debt
454,280
49,100
Other current liabilities
8.5
74,857
71,217
Current tax liabilities
18,479
20,851
Other short-term liabilities
33,475
14,747
Total current liabilities
8.4
669,589
241,200
TOTAL LIABILITIES
974,808
930,016
Half-year financial report 2026| Guerbet | 9
1.2
Consolidated income statement
(in thousands of €)
Revenue
30/06/2026
30/06/2025
Notes
(6 months)
(6 months)
7
379,192
387,756
4,873
3,604
Usage fees Other operating income Purchases consumed and change in inventories Staff costs
8.6
External charges Taxes Amortization, depreciation, and impairment
2,638
3,363
(88,118)
(80,530)
(132,130)
(141,981)
(123,117)
(116,695)
(7,412)
(9,521)
(31,138)
(29,437)
Net provisions
8.4
(17,888)
(1,694)
Other operating income and expenses
8.7
(5,292) (18,390)
96 14,962
Current operating income Income from cash and cash equivalents
1,017
150
Net borrowing costs
(14,366) (13,349)
(10,073) (9,923)
Currency gains/losses
3,442
(169)
(70)
(2,231)
CONSOLIDATED NET INCOME
(4,346) (32,714)
(1,345) 1,295
Net income, Group share
(29,591)
2,634
Net income from non-controlling interests Net earnings per share, Group share with €1 nominal value (in euros)
(3,123) (2.34)
(1,340) 0.21
Diluted net earnings per share, Group share with €1 nominal value (in euros)
(2.34)
0.21
Gross borrowing costs
Other financial income and expenses Income tax
1.3
8.8
Statement of net income and gains and losses recognized directly in shareholders' equity 30/06/2026
30/06/2025
(in thousands of €)
(6 months)
(6 months)
Consolidated net income for the period
(32,714)
1,295
283
852
—
—
478
469
—
—
912
(105)
4,540 (26,501)
(21,973) (19,462)
Income and expenses recognized directly in equity Non-reclassifiable: Actuarial gains and losses for IAS 19 obligations Deferred tax on actuarial gains and losses on IAS 19 obligations Actuarial gains and losses for IFRS 2 obligations Deferred tax on actuarial gains and losses on IFRS 2 obligations Reclassifiable: Hedging instruments Change in translation adjustments NET INCOME AND GAINS AND LOSSES RECOGNIZED DIRECTLY IN EQUITY
Half-year financial report 2026| Guerbet | 10
1.4
Consolidated cash flow statement 30/06/2026
30/06/2025
(in thousands of €)
(6 months)
(6 months)
Net income
(32,714)
1,295
Change in amortization, depreciation, and provisions on fixed assets and other current assets Net provisions for risks
30,071
33,409
17,417
(2,125)
Change in fair value of assets held for sale
—
—
Change in fair value of hedging instruments
1,879
(4,666)
Costs of stock options and free shares
478
469
Cash flow from net borrowing costs and taxes
380 17,510
(153) 28,228
Net borrowing costs
14,373
10,080
Taxes (including deferred taxes) Cash flow before net borrowing costs and taxes
4,346 36,230
1,345 39,652
Taxes paid
(4,893)
(1,195)
(Increase) / Decrease in inventories
(12,731)
(39,849)
(Increase) / Decrease in trade receivables
(6,122)
15,128
Income from disposal of fixed assets and other adjustments
Increase / (Decrease) in trade payables
2,329
4,897
(Increase) / Decrease in other assets
(2,459)
(3,944)
Increase / (Decrease) in other liabilities
1,009
7,858
NET CASH FLOW FROM OPERATING ACTIVITIES (A)
(17,974) 13,363
(15,910) 22,547
Investments
(16,775)
(14,960)
Intangible assets
(1,818)
(4,259)
Tangible assets
(13,907)
(9,709)
Financial assets
(1,050)
(992)
Asset disposals
658
10,126
Intangible assets
—
9,494
Tangible assets
658
631
Financial assets
—
—
Acquisition of Intrasense net of cash acquired
—
—
(2,792) (18,909)
(10,653) (15,488)
Change in operating WCR
Increase / (Decrease) in amounts payable on fixed assets NET CASH FLOW FROM INVESTMENT ACTIVITIES (B) Dividends paid
—
—
Loan issues
110,545
21,958
Loan repayments
(75,304)
(16,773)
Net financial interest paid (including finance lease agreements)
(14,362) 20,879
(10,070) (4,884)
NET CHANGE IN CASH (A) + (B) + (C) + (D)
1,292 16,626
(2,422) (248)
STARTING CASH
115,375
50,116
ENDING CASH
132,001
49,868
NET CASH FLOW FROM FINANCING ACTIVITIES (C) Effect of exchange rate changes (D)
Half-year financial report 2026| Guerbet | 11
1.5
Statement of changes in shareholders' equity
(in thousands of €)
Capital
Consolidated reserves
Position at 31/12/2024
Change in translation Result adjustments
Shareholders' equity, Group share
Noncontrolling interests
Shareholders' equity
12,641
408,848
16,084
(43,336)
394,237
(2,665)
391,572
Allocation of 2024 income
—
16,084
(16,084)
—
—
—
—
Dividend payments
—
—
—
—
—
—
—
H1 2025 consolidated income
—
—
2,634
—
2,634
(1,340)
1,295
Actuarial gains and losses
—
1,321
—
—
1,321
18
1,339
Change in fair value of hedging instruments Translation adjustments
—
(105)
—
—
(105)
—
(105)
—
—
—
(21,973)
(21,973)
—
(21,973)
Capital increase
—
—
—
—
—
—
—
Other transactions
— 12,641
— 426,148
— 2,634
— (65,309)
— 376,115
— (3,987)
— 372,128
POSITION AT 30/06/2025
(in thousands of €)
Capital
Consolidated reserves
Position at 31/12/2024
Result
Change in Shareholders' translation equity, Group adjustments share
12,641
408,848
16,084
(43,336)
Allocation of 2024 income
–
16,084
(16,084)
–
Dividend payments
–
–
–
–
–
–
–
2025 consolidated income
–
– (108,331)
–
(108,331)
(4,323)
(112,654)
3,091
29
3,120
Actuarial gains and losses
3,091
394,237
Noncontrolling Shareholders' interests equity
(2,665)
391,572 –
Translation adjustments
–
–
–
(18,641)
(18,641)
–
(18,641)
Capital increase
–
–
–
–
–
–
–
Other transactions
– 12,641
(3,361) – 424,662 (108,332)
– (61,977)
(3,361) 266,994
42 (6,917)
(3,319) 260,077
Position at 31/12/2025 Allocation of 2025 income
(108,331)
Dividend payments Actuarial gains and losses
(29,591)
(29,591)
(3,123)
(32,714)
761 912
—
761 912
(6)
5,441
—
—
12,641
— 317,998
— 244,511
(29,591)
(56,536)
Half-year financial report 2026| Guerbet | 12
—
5,435
—
Other transactions
—
—
761 912
Change in fair value of hedging instruments Translation adjustments
POSITION AT 30/06/2026
—
—
H1 2026 consolidated income
Capital increase
108,331
5,435 —
—
(10,040)
— 234,471
ACCOUNTING POLICIES
The accounting principles applied in preparing the condensed consolidated financial statements at June 30, 2026, are identical to those used in the consolidated financial statements at December 31, 2025 (which can be viewed on the Group's website: www.guerbet.com) with the exception of the principle adopted for recognizing the income tax expense (recognized based on an estimate of the Group’s expected effective tax rate for the full financial year) and the application of new standards and interpretations effective for financial years beginning on or after January 1, 2026 (described in note 2.1 below). The condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements for the 2025 financial year, with the exception of standards, amendments, and interpretations applicable for the first time beginning January 1, 2026. The condensed consolidated half-year financial statements at June 30, 2026, were prepared in accordance with IAS 34 "Interim Financial Reporting," which allows a selection of explanatory notes to be presented.
2.1
Main mandatory standards, amendments, and interpretations applicable beginning January 1, 2026
The standards and amendments listed below, effective from January 1, 2026, do not have a significant impact on the Guerbet Group: • amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments; • amendments to IFRS 9 and IFRS 7 regarding Renewable Electricity Contracts; • annual Improvements to IFRS Accounting Standards – Volume 11.
2.2
Main standards, amendments, and interpretations published by the IASB not yet mandatory on January 1, 2026, within the European Union
The Group has not opted for the early adoption of any standards, amendments, or interpretations that were not mandatory on January 1, 2026. Regarding IFRS 18 "Presentation and Disclosure in Financial Statements", which becomes effective on January 1, 2027, the Group's assessment of the impact of adopting this new standard and its implementation throughout the Group remains ongoing.
Half-year financial report 2026| Guerbet | 13
HIGHLIGHTS OF THE FIRST HALF OF 2026
3.1
Status of the Raleigh site remediation plan
As a reminder, following an inspection conducted by the U.S. Food and Drug Administration (FDA) during the first half of 2025 and the warning letter received in October 2025, Liebel-Flarsheim Co. LLC, the U.S. subsidiary of the Guerbet Group, defined and implemented a remediation plan to restore compliance at its Raleigh manufacturing site. The key corrective actions launched at the end of 2025 have continued throughout 2026. While the site's manufacturing operations have not been significantly affected, the Quality certification (or release) of batches has not yet returned to its normal level. This situation has had a significant impact on the Group as a whole, given that the Raleigh site accounts for approximately 40 % of the Group's production and is the Group's sole manufacturing facility for prefilled syringes. The Company remains confident in its ability to complete the implementation of the remediation plan, including all site compliance activities, by the end of the year.
3.2
Breach of covenant
Given the current level of activity and profitability which have been adversely impacted by the Raleigh situation, the Group anticipated that it would not meet the net financial debt to EBITDA ratio of 3.5x tested at June 30, 2026 under the terms of the €350 million syndicated loan agreement and the €50 million EuroPP and €50 million “Relance” bond issue contracts. On July 22, 2026, the Group secured waivers from its financial partners relating to the financial debt ratio tested at June 30, 2026, December 31, 2026 and June 30, 2027. As these waivers were obtained after June 30, 2026, they do not allow the related borrowings to be maintained in accordance with their original contractual maturity schedule (see note 8.5 for further information).
3.3
Debt refinancing
Guerbet has continued discussions with its financial partners with a view to finalizing, before October 31, 2026, the terms and conditions of a refinancing arrangement that will enable the Company to settle on an appropriate financial structure and finance its activity as part of the normalization of activity at the Raleigh site. In this regard, Guerbet draws attention to the risk factors relating to the refinancing of its debt. Further information is provided in section 6.3 "Liquidity Risk".
3.4
Employment Protection Plan
As part of the continued implementation of its transformation plan launched in 2025 to strengthen commercial momentum and sustainably restore the Group's profitability, Guerbet announced in March 2026 a redundancy plan in France. The proposed plan was approved by the French authorities at the end of June 2026. Accordingly, the impacts of the plan have been reflected in the Group’s financial statements as of June 30, 2026 (see note 8.4 "Provisions").
3.5
Governance
On January 28, 2026, the Board of Directors appointed Mr. Karim Boussebaa as Chief Executive Officer, effective February 2, 2026. Following his appointment as a director by the Annual General Meeting on May 22, 2026, Mr. Antoine Fady was appointed Chairman of the Board of Directors. The Annual General Meeting also appointed three new directors representing the majority shareholder: • Ms. Emmanuelle Louvet, replacing Mr. Nicolas Louvet, whose term of office expired; • Mr. Vincent Dagommer, replacing Mr. Marc Massiot, who resigned from his position; • Mr. Olivier Guerbet, replacing Ms. Carine Dagommer, whose term of office expired.
3.6
Macroeconomic context
The international environment during the first half of 2026 continued to be affected by the conflicts in Ukraine and the Middle East, as well as by ongoing uncertainty regarding the future evolution of US custom duties. Russian-Ukrainian conflict Through its investment in Intrasense, Guerbet has exposure to territories affected by the conflict in Ukraine, particularly Russia and Belarus. As a result of this investment, the Group's exposure to the region has increased; however, the impact on its operations and financial performance remains limited at the consolidated level. Half-year financial report 2026| Guerbet | 14
Middle East Conflict Guerbet continues to closely monitor developments in the Middle East in view of potential indirect consequences on the economic environment in which it operates, including increases in raw material, procurement and transportation costs. The Company has no direct interests in the conflict areas, and the impact of the situation on its operations and financial performance has remained limited. With respect to oil price increases, the Group's exposure remains limited. Freight costs amounted to €6.8 million for the six months ended June 30, 2026, compared with €6.7 million for the six months ended June 30, 2025. On a full-year basis, freight costs represent approximately €15 million compared with approximately €380 million of operating expenses, accounting for around 4 % of the Group's total cost base. U.S. Customs duties As of June 30, 2026, Guerbet had not experienced any material impact from U.S. customs tariff measures. The Group believes it is well positioned to mitigate the effects of potential increases in tariffs through the use of its manufacturing facilities located in the United States.
SEASONAL ASPECT
There is no significant seasonal aspect to the activity.
DIVIDEND PAYMENT
No dividends were paid during the period.
Half-year financial report 2026| Guerbet | 15
FINANCIAL RISK MANAGEMENT
6.1
Currency risk
6.1.1
Currency risk exposure and hedging at June 30, 2026
Given its international footprint, the Group is exposed to currency risk in several currencies, as described below: USD
BRL
JPY
HKD
KRW
CNY
CLP
COP
Accounting risk before hedging (1)
91.10
37.40
22.90
(24.50)
10.00
11.50
11.20
7.20
Positions before hedging
91.10
37.40
22.90
(24.50)
10.00
11.50
11.20
7.20
Currency risk hedging
(72.90)
—
(16.00)
—
—
—
—
—
Net currency position
18.10
37.40
6.80
(24.50)
10.00
11.50
11.20
7.20
(in € millions)
(1) Accounting risk includes the non-functional currency positions of the Guerbet Group's entities.
The exposure in USD mainly results from the net borrowing balance of Guerbet's current accounts with its various entities through the cash-pooling mechanism. The exposure in BRL mainly stems from the Group's industrial entities, which invoice Brazilian entities in local currency in accordance with Group policy. The JPY foreign exchange position is due to Guerbet's financing of its Japanese subsidiary. Guerbet Asia Pacific (Hong Kong)'s invoicing in foreign currencies to third-party customers and its sales to its Chinese subsidiary in CNY are the source of the Group's exposure to HKD purchases. The exposure in KRW stems from trade receivables due from Korean subsidiaries to Guerbet S.A. and the Group's U.S. industrial subsidiary. Finally, the exposure in CLP and COP also results from commercial transactions between the Group's U.S. industrial subsidiary and the commercial entities Guerbet Chile and Guerbet Colombia. The Group uses swaps and foreign exchange forward contracts to hedge part of its currency risk exposure. Although these instruments provide an economic hedge, they are not designated as hedging instruments for accounting purposes. Changes in the fair value of these derivatives are therefore recognized in financial income and expense. As of June 30, 2026, the mark-to-market value of foreign exchange derivative instruments amounted to €(1.5) million.
6.1.2
Analysis of sensitivity of the financial result to accounting currency risk at June 30, 2026
Sensitivity is calculated on the accounting balance before hedging for the main currencies. The table below shows the impact on the financial result of a 10 % change in these currencies against the euro on the accounting foreign exchange position at June 30, 2026: 30/06/2026
30/06/2025
USD
1.81
0.43
BRL
3.74
3.15
HKD
(2.45)
(2.57)
JPY
0.69
0.59
KRW
1.00
1.58
CNY
1.15
1.84
CLP
1.12
0.75
COP
0.72
0.39
(in € millions)
Half-year financial report 2026| Guerbet | 16
6.2
Interest rate risk
6.2.1
Interest rate risk and hedging at June 30, 2026
In July 2023, Guerbet finalized the refinancing of its debt by setting up a syndicated floating-rate credit line to replace the credit facility maturing in March 2024. This €350 million line was drawn down in two tranches of €250 million over five years. This was supplemented by the issue of €50 million in fixed-rate EuroPP bonds over six and a half years and €50 million in fixed-rate recovery bonds over eight years. In 2026, as a precautionary measure, the Group decided to draw the remaining available amount under Tranche C of its committed credit facility, representing an additional €33 million, and to renew the drawdowns made in 2025. Debt under Tranche C (€100 million) bears interest at a floating rate. In addition, in November 2023, Guerbet hedged tranche B (€150 million) of the new syndicated loan through various instruments: half in the form of interest-rate swaps and half in the form of tunnels (purchase of caps and sale of floors) maturing on June 30, 2028. The mark-to-market value of derivative instruments traded and backed by the new debt was -€0.6 million at June 30, 2026. These hedging instruments qualify for cash flow hedge accounting and have a 100 % effectiveness test at the end of the reporting period. The mark-to-market valuation of these instruments had a negligible impact on the Group’s net financial income, amounting to €30 thousand. The portion of the Group's financial debt at floating rates before hedging is 70 %. Below is a breakdown of debt due within one year and in more than one year. Less than 1 year
More than 1 year
Total
Fixed-rate financial liabilities
(113,777)
(33,721)
(147,498)
Floating-rate financial liabilities
(337,511)
—
(337,511)
(in € thousands)
Fixed-rate financial assets
—
—
—
132,204
—
132,204
• fixed rate
(113,777)
(33,721)
(147,498)
• floating rate
(205,307)
—
(205,307)
—
(75,000)
(75,000)
• fixed rate
(113,777)
(108,721)
(222,498)
• floating rate
(205,307)
75,000
(130,307)
Floating-rate financial assets Net management position (1)
Off-balance sheet (2) Net position after management
(1) Sum of differences (assets – liabilities) at fixed rates and (assets – liabilities) at floating rates. (2) Interest rate swaps (receive floating rates and pay fixed rates).
6.2.2
Analysis of sensitivity of the financial results to interest rate risk at June 30, 2026
More than 96 % of the Group’s debt is in euros. The sensitivity calculated in this note therefore relates only to debt in euros. An increase of 100 basis points in the 3-month Euribor would result in an increase in the cost of debt of €2.5 million over one year, while a decrease of 100 basis points in the same index would result in a reduction in the cost of debt of €2.1 million year on year.
6.3
Liquidity risk
In July 2023, Guerbet finalized the refinancing of its debt by setting up a €350 million syndicated credit line, including a €100 million confirmed credit line with a five-year term and two successive one-year extension options (subject to the banks’ agreement). At June 30, 2026, this confirmed line was available in full. This was supplemented by the issue of €50 million in fixed-rate EuroPP bonds over six and a half years and €50 million in recovery bonds over eight years, allowing Guerbet to diversify its sources of financing, stagger its debt maturities, and increase their average maturity. As of June 30, 2026, the Group's total gross financial debt amounted to €488.1 million, it being specified that no collateral is provided for this debt. Cash and cash equivalents amounted to €132 million as of the same date. Given the current level of activity and profitability, which have been adversely impacted by the situation at the Raleigh site, the Group anticipated that it would not comply with the net financial debt to EBITDA ratio of 3.5x tested as of June 30, 2026 under the terms of the €350 million syndicated loan agreement and the €50 million EuroPP and €50 million "Relance" bonds issue contracts. On July 22, 2026, the Group obtained waivers from its financial partners relating to the financial debt ratio tested at June 30, 2026, December 31, 2026 and June 30, 2027. As these waivers were obtained after June 30, 2026, they do not allow the
Half-year financial report 2026| Guerbet | 17
related borrowings to be maintained in accordance with their original contractual maturity schedule for accounting purposes and therefore require classification as current liabilities. Consequently, as of June 30, 2026, gross financial debt classified as current liabilities amounted to €438.6 million. Although the waivers were obtained in July 2026, the contractual maturities of this debt are €53.6 million in the second half of 2026, €10 million in 2027, €275 million in 2028 and €100 million beyond 2028. In this context, the Company entered into discussions with its financial partners with a view to finalizing the terms and conditions of a refinancing arrangement before October 31, 2026. In this regard, the family shareholders, through their representatives, have expressed their support for this process and confirmed their commitment to assist the Company in this context. New financial covenants apply during the interim period: • monthly liquidity ratios, which were met in July and August 2026. The Company considers that this covenant will also be met in September 2026; and • a consolidated EBITDA covenant tested as of June 30, 2026, which was met. The Company considers that this covenant will also be met as of September 30, 2026. As of the date of this report, discussions between Guerbet and its financial partners remain ongoing in order to agree the terms of the refinancing that would enable the Company to establish an appropriate capital structure and finance its operations as activity at the Raleigh site progressively normalizes. With respect to the financing of current operations, the Company expects its 12-month liquidity requirements will be covered by cash. Should the Company and its financial partners fail to execute financing documentation formalizing an agreement by October 31, 2026, this would, in accordance with the terms of the waivers, constitute an event of default under the existing financing documentation. This would entitle the relevant creditors, acting in accordance with the required majority provisions, to accelerate the repayment of the debt owed to them. Furthermore, if such an event of default were still continuing on November 17, 2026, the lenders under the revolving credit facility would no longer be required to roll over their participation in the outstanding €100 million RCF drawings maturing on November 20, 2026, thereby making the relevant drawings immediately payable. The Company remains confident regarding the successful outcome of the negotiations and does not anticipate a significant risk that an agreement will not be reached. On this basis, the Board of Directors approved the financial statements on a going concern basis, having considered the information available to it regarding the future and, in particular, the cash forecasts for the next twelve months.
Half-year financial report 2026| Guerbet | 18
ADDITIONAL INFORMATION
The Group operates in a single business segment, namely the research, development, manufacture and sale of contrast media for medical imaging. Consequently, the Group does not present segment information as defined by IFRS 8 Operating Segments. However, in order to provide a more meaningful analysis of its business performance, the Group presents revenue information by geographic area. This information is consistent with the internal reporting reviewed by management for the purpose of monitoring and managing the Group's operations. Additional information on revenue by product range is also provided. 30/06/2026 (in € millions)
REVENUE
EMA
Americas
Asia
Total
172.9
116.9
87.7
377.6
Amortization, depreciation, and impairments
—
—
—
-31.1
Net movements in provisions
—
—
—
-17.9
CURRENT OPERATING RESULT
—
—
—
-18.4
NET INCOME
—
—
—
(32.7)
30/06/2025 (in € millions)
EMEA
Americas
Asia
Total
REVENUE(a)
169.6
117.8
98.6
386.0
Amortization, depreciation, and impairments
—
—
—
(29.4)
Net movements in provisions
—
—
—
(1.7)
CURRENT OPERATING RESULT
—
—
—
15.0
NET INCOME
—
—
—
1.3
30/06/2026
30/06/2025
(a)
(a) Excluding divested activities (urology) for €1.6 million.
(a) Excluding divested activities (Accurate and urology) for €1.8 million.
The breakdown of revenue by product range is as follows:
Diagnostic Imaging
85.8 %
86.1 %
X-ray
53.1 %
53.3 %
MRI
32.7 %
32.9 %
Interventional Imaging
14.2 %
13.9 %
100,0 %
100.0 %
TOTAL
Half-year financial report 2026| Guerbet | 19
DESCRIPTIVE NOTES (IN € THOUSANDS)
8.1
Tangible and intangible assets 30/06/2026
31/12/2025
Variation
Tangible assets (gross)
905,510
878,437
27,072
Amortization
(620,485)
(600,221)
(20,264)
Impairment
(64,110)
(63,534)
(576)
TANGIBLE ASSETS (NET)
220,915
214,682
6,233
Intangible assets (gross)
275,601
273,354
2,247
Amortization
(186,786)
(166,745)
(20,041)
Impairment
(36,015)
(45,078)
9,063
52,800
61,531
(8,732)
INTANGIBLE ASSETS (NET)
Additional information on the main intangible assets The review of impairment indicators required under IAS 36, based on the external and internal information available as of June 30, 2026, did not identify any indication that would suggest the need for further impairment of the Group's cash-generating units (CGUs), with the exception of the assets relating to the Myrian® solutions, for which an impairment loss of €3.4 million was recognized. Despite an uncertain economic environment and the residual effects of certain events that impacted the previous financial year, notably the remediation activities undertaken at the Raleigh site, operating performance during the first half of 2026 remained broadly in line with the assumptions reflected in the Group's updated forecasts.
8.2
Inventory 31/12/2025
30/06/2026
Provisions
Carrying amount
Gross carrying amount
Provisions
Carrying amount
75,426
(4,196)
71,229
74,107
(5,894)
68,212
284,567
(44,913)
239,654
266,988
(40,747)
226,241
359,992
(49,109)
310,883
341,095
(46,641)
294,454
Gross carrying amount
Raw materials and spare parts Finished, intermediate, and in-progress and goods NET VALUES
The change in inventories of +€16.4 million in net value compared with December 31, 2025, was mainly due to the industrial scope.This is due to the anticipated summer technical shutdown and lower-than-expected performance at our Fill & Finish sites, which led to a temporary increase in inventory levels. The increase in inventory provisions of €2.5 million was mainly driven by the revaluation of existing inventories following the update of standard costs and by the recognition of additional reserves related to quality issues identified at the Fill & Finish sites.
8.3
Capital
At December 31, 2025, the parent company’s capital consisted of 12,641,115 shares with a par value of €1. Guerbet shares were unchanged in the first half of 2026. The Group held 95,377 treasury shares at June 30, 2026.
Half-year financial report 2026| Guerbet | 20
8.4
Provisions Translation adjustment Changes in Reversals Reversals s and Change in scope of (provisions (provisions reclassifica actuarial used) not used) tions assumptions 30/06/2026 31/12/2025 consolidation Allowances
Non-current
29,010
–
1,144
(2,102)
(210)
(7)
(283)
27,552
Of which deferred staff benefits
26,669
–
1,124
(2,102)
(210)
(7)
(283)
25,191
Tax disputes
1,757
–
146
(536)
(2)
111
–
1,476
Commercial disputes
16
–
(10)
–
–
2,730
Current 2,724
–
Provisions for staff disputes
903
–
760
–
(393)
–
–
1,270
Miscellaneous obligations (1) Total current provisions
9,364 14,747
– –
22,744 23,666
(3,652) (4,188)
(489) (894)
32 143
– –
27,999 33,475
TOTAL PROVISIONS
43,757
–
24,811
(6,290)
(1,104)
136
(283)
61,027
(1) Mainly includes restructuring provisions of €22.7 million, comprising €20.7 million recognized by Guerbet SA and €1.5 million by Guerbet France, partly offset by reversals of restructuring provisions of €2.5 million at Medex and €1 million at Intrasense.
8.5
Borrowings
Non-current debt, of which: Special investment reserve (frozen current accounts) IFRS 16 lease liabilities Loans from credit institutions
30/06/2026
31/12/2025
33,775
392,121
1
1
13,744
8,208
552
267,168
Other borrowings (1)
17,240
114,469
Current debts, of which:
454,280
49,100
IFRS 16 lease liabilities
8,093
6,745
Loans from credit institutions
338,720
37,783
Other borrowings (2)
101,743
1,038
5,521
3,385
Accrued interest Current profit-sharing reserve Bank financing TOTAL FINANCIAL DEBT
—
—
203
149
488,055
441,221
(1) In December 2008, the request for aid for the Franco-German research project "Iseult" filed with OSEO was approved by the European Commission. The aid agreement provides for funding of half of the expenditures incurred, including 39 % in the form of repayable advances and 61 % in the form of grants. An amendment to the agreement was signed in June 2020 to review the conditions for achieving the latest milestones and the payment of the associated aid, but also to change the terms of financial returns in the event that a product resulting from the project is placed on the market. In view of the progress of the project and the negotiation with the BPI of the repayment clauses, the Group, in accordance with IFRS 9, updated the fair value measurement of the financial liability. This led to the recognition of approximately €1.7 million in additional repayable advances for discounting purposes, with an offsetting entry posted to financial expenses. At June 30, 2025, the financial liability totaled €17.3 million. The valuation of this liability includes a potential additional financial return of up to €10.2 million expected after 2030, estimated at each reporting date, taking into account the growth in sales of Gadopiclenol in particular. (2) Includes €50 million in private placements (EuroPP) and €50 million in recovery bonds.
Borrowings include a clause providing for a maximum value of the “Net debt/adjusted EBITDA"(1) ratio, the threshold of which varies
H1 2026 Results • Revenue of €379.2m, nearly stable (-0.1%) at CER1 and like-for-like2, in line with the Group’s forecast for the full year • EBITDA of €30.6m, in line with the Group’s forecast for the full year • Restated EBITDA margin3 of 9.1%, versus 12.9% a year earlier, including €14.3m in exceptional costs related to the remediation plan at the Raleigh site • Financial leverage of 5.3x; ongoing discussions with financial partners to agree a refinancing arrangement by October 31, 2026 • Raleigh industrial site: confirmation of timeline for the normalization of activity • Accelerated execution of the transformation plan to strengthen sales momentum and sustainably improve profitability • Executive Committee changes • Confirmation of all financial targets for 2026
Villepinte, September 28, 2026, 5:45 pm: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is publishing its consolidated financial statements for the first half of 2026. As of June 30, 2026, Group revenue stood at €379.2 million, down 2.2%. Excluding the currency effect (-€8.0 million), mainly attributable to the depreciation of the yen and the dollar, revenue at CER1 was down by a slight 0.2%. It was nearly stable (-0.1%) at CER and on a like-for-like basis2, 1 At constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the
exchange rates used for the previous fiscal year. 2 Excluding sales in H1 2026 of components and finished products related to the urology business (sold in July 2024) and sales in H1 2025 of microcatheters. 3 Restated EBITDA excludes non-recurring expenses related to restructuring.
H1 2026 revenue H1 activity • Revenue of €379.2m at 30 June 2026, nearly stable at CER1 and on a like-for-like basis2 (-0.1%) • A 2.5% decline in Q2 at CER and on a like-for-like basis, marked by a solid recovery in the Americas (+4.8%), almost stable revenue in EMEA (-0.7%) and a contraction in Asia (-14.0%)
Financial targets for 2026 • Revenue stable or slightly down at CER and on a like-for-like basis • Restated EBITDA margin rate3 of around 8%, including around €35m related to the costs of the remediation plan at the Raleigh site • Free cash flow between -€50m and -€70m, as a result of the expected decrease in restated EBITDA, the increase in the CAPEX plan and non-recurring restructuring costs related to the Group’s transformation plan
Update on the Group’s financing Executive Committee strengthened to accelerate the transformation plan
1 Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the
exchange rates used for the previous fiscal year. 2 Excluding sales in H1 2026 on inventories of components and finished products of the urology business (sold in July 2024) and sales in H1 2025 on microcatheters. 3 Restated EBITDA excludes non-recurring costs related to restructuring, the optimisation of the operating plan and changes in the sales model.
Changes to the Composition of Guerbet’s Board of Directors
•
Appointment of Mr. Antoine Fady as an independent director and Chairman of the Board of Directors
•
Appointment of three new directors representing the majority shareholder: Vincent Dagommer, Olivier Guerbet, and Emmanuelle Louvet
Villepinte, May 22, 2026
Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the following, after its Annual General Meeting held on May 22, 2026:
•
The appointment of Mr. Antoine Fady as Chairman of the Board of Directors, in accordance with the previously announced timetable (press release dated March 11, 2026);
•
The appointment of three directors representing the majority shareholder: Ms. Emmanuelle Louvet and Messrs. Vincent Dagommer and Olivier Guerbet.
Appointment of Mr. Antoine Fady as an Independent Director and Chairman of the Board of Directors Following his approval as a director by the General Meeting held today at the Group’s headquarters[1], Guerbet’s Board of Directors, upon the recommendation of the Nominating and Compensation Committee, unanimously decided to appoint Mr. Antoine Fady as Chairman of the Board of Directors. This appointment terminates, with immediate effect, the role of censor that he had held since March 11, 2026.
Q1 2026 revenue Quarterly activity • Revenue: €177.4m, up 2.6% at CER1 and on a like-for-like basis2 • Increase driven by EMEA (+4.5%), with an improvement in the situation in France, and by Asia (+6.0%); a decline in the Americas, impacted as anticipated by the situation at the Raleigh site
Operational deployment • Continued implementation of the remediation plan at the Raleigh site, in accordance with the action plan • Rollout of the Group’s transformation plan in line with schedule, and the start of a procedure for informing and consulting the Economic and Social Committee a procedure for informing and consulting the Economic and Social Committee on a redundancy plan in France • 2026 financial targets to be communicated by 23 July at the latest Villepinte, 23 April 2026, 5.45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is publishing its revenue for the first quarter of the year. For the quarter ended 31 March 2026, the Group’s sales increased by 2.6% at constant exchange rates (CER)1 and on a like-for-like basis2, and by 2.5% at CER. On a reported basis, first-quarter revenue amounted to €177.4 million, representing a slight decrease of 1.5% compared with the same period in 2025, including a negative foreign exchange impact of €7.2 million, mainly due to the depreciation of the US dollar and certain Asian currencies, particularly the Japanese yen and the Korean won. As announced, this development incorporates the negative impact of the situation at the Raleigh industrial site in North Carolina. It benefited from a favourable comparison base, as the first quarter of 2025 was marked by a contraction in activity in France following the reform of supply methods for contrast agents. The second
1
At constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year. 2 Excluding sales on inventories of components and finished products of the urology business (sold in July 2024). 3 Excluding non-recurring costs related to the optimisation of the operating plan and changes in the sales model.
2025 UNIVERSAL REGISTRATION DOCUMENT INCLUDING THE ANNUAL FINANCIAL REPORT
CONTENT
1 2
Interview with Jérôme Estampes
2
Guerbet in brief
4
Strategy
8
Significant events
10
Save the date
12
91
4.1
Analysis of the Group’s activity and results
92
4.2
Major events since the start of the 2026 fiscal year
96
4.3
Consolidated companies
96
4.4
Results of subsidiaries held by Guerbet S.A.
96
4.5
Companies directly or indirectly controlled by Guerbet S.A.
96
4.6
Transactions in treasury shares of Guerbet S.A.
97
4.7
Risk management, internal control, and internal audit
97
THE GUERBET GROUP
13
1.1
A model for sustainable value creation
14
1.2
History of the Company
16
1.3
Overview of activities
18
1.4
Industrial and logistics activity
26
1.5
Innovation, research, and development
27
4.8
Risk factors
102
1.6
Group governance structure at December 31, 2025
34
4.9
Other legal information
109
SUSTAINABILITY STATEMENT
113
5.1
General information
114
5.2
Planet (environmental data)
129
5
CORPORATE GOVERNANCE
37
2.1
Report of the Board of Directors on corporate governance
38
2.2
Board of Directors
38
5.3
People (social data)
149
59
5.4
Business conduct information – ESRS G1
172
Environmental taxonomy
178
2.3
General management
2.4
Compensation of corporate officers
61
5.5
2.5
Exceptions to the Afep-Medef Code
77
5.6
Methodologies and special circumstances
184
Agreements referred to in article L. 225-37-4-2° of the French Commercial Code
78
5.7
CSRD annex
195
5.8
203
2.7
Delegations of authority regarding capital increases
78
Report on the certification of sustainability information and verification of the disclosure requirements under Article 8 of Regulation (EU) 2020/852
2.8
Provisions in the articles of association relating to General Meetings
78
2.9
Factors that could have an impact in the event of a takeover or exchange offer referred to in article L. 225-37-5 of the French Commercial Code
80
2.6
3
4
MANAGEMENT REPORT
CAPITAL AND SHAREHOLDING STRUCTURE
81
3.1
Stock market data
82
3.2
Relations with the financial community
83
3.3
Distributed dividends
83
3.4
Shareholding structure
84
3.5
Share buyback program
85
3.6
Additional information about the capital
85
6
7
FINANCIAL STATEMENTS AND RELATED NOTES
207
6.1
Consolidated financial statements and notes
208
6.2
Statutory auditors’ report on the consolidated financial statements
247
6.3
Individual financial statements and notes
251
6.4
Statutory auditors’ report on the annual financial statements
279
6.5
Statutory auditors’ special report on regulated agreements
284
ADDITIONAL INFORMATION
287
7.1
Person responsible for the Universal Registration Document
288
7.2
Statement by the person responsible for the Universal Registration Document
288
7.3
Persons responsible for auditing the financial statements
288
7.4
Share capital
289
7.5
Public access to this document
289
7.6
General information about the Company
290
7.7
Articles of association (excerpts)
291
7.8
Concordance tables
293
Limited company with a Board of Directors (Société Anonyme à Conseil d’administration) with a capital of 12,641,115 HEAD OFFICE 15, rue des Vanesses 93420 Villepinte – France 308 491 521 – R.C.S. Bobigny
This Universal Registration Document was filed on March 20, 2026, with the AMF in its capacity as the competent authority under Regulation (EU) 2017/1129, without prior approval in accordance with article 9 of that regulation. The Universal Registration Document may be used for the purpose of a public offering of financial securities or the admission of financial securities for trading on a regulated market if it is supplemented by a securities note and, if applicable, a summary and any amendments made to the Universal Registration Document. The resulting set of documents is approved by the AMF in accordance with Regulation (EU) 2017/1129. Pursuant to article 19 of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017, the following documents are included by reference in this Universal Registration Document: • the consolidated financial statements for the fiscal year ended December 31, 2024, as well as the related report of the Statutory Auditors, contained in sections 6.1 and 6.2 of the Registration Document filed with the AMF on April 3, 2025, under number D.25-0220 (https://www.guerbet.com/sites/default/files/2025-07/guerbet_deuuk_2024-28-04-2025.pdf); • the consolidated financial statements for the fiscal year ended December 31, 2023, as well as the related report of the Statutory Auditors, contained in sections 6.1 and 6.2 of the Registration Document filed with the AMF on April 3, 2024, under number D.24-0224 (https://www.guerbet.com/sites/default/files/2025-07/guerbet_urd-uk_2023-1.pdf). This Universal Registration Document, including the Annual Financial Report, is a reproduction of the official version prepared in ESEF format and available at https://www.guerbet.com.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
1
INTERVIEW WITH JÉRÔME ESTAMPES
A TRANSFORMATION GUIDED BY OUR HERITAGE AND VISION Jérôme Estampes CFO and Interim CEO – Guerbet
2
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
Interview with Jérôme Estampes
— — —
1|
|
2|
|
In a context of significant regulatory changes and economic challenges, Guerbet reaffirms its determination to remain a key player in medical imaging. Driven by solid governance and a long-term strategic vision, our Group draws on innovation, operational performance, and social responsibility to build sustainable growth. A buoyant but changing market The global medical imaging market remains dynamic, supported by innovation and growing demand in emerging economies. Guerbet maintains its position as a leader and continues to invest to meet the needs of healthcare professionals and patients, despite major challenges such as the supply reform in France, pressures from US tariffs, and currency volatility. Innovation and differentiation: Our strategic levers
Focus on sustainable performance Our priorities are clear:
3|
|
• to stabilize activity in areas affected by regulatory changes; • to improve operational efficiency and increase value generation; • to prepare for long-term growth, supported by a strong product portfolio and an ambitious CSR strategy.
4|
|
On the eve of our 100th anniversary, Guerbet is moving forward with clarity and determination. A new CEO, Karim Boussebaa, joined Guerbet in February: he has the commitment of the teams and Shareholders behind him to roll out this strategy by 2033.
5|
|
The Guerbet Group remains a key player in medical imaging, resolutely forward-looking.
Our ambition remains unchanged: to innovate to transform medical imaging. Ramping up solutions that allow us to stand out and accelerating Interventional Radiology projects points to our ability to create value in high-growth segments. We are also strengthening our environmental commitment to decarbonize our operations.
6|
|
7|
|
1926
9.6%
à Date that Guerbet was founded
à of revenue dedicated to Research & Development
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
3
GUERBET IN BRIEF
OUR INTERNATIONAL FOOTPRINT Guerbet offers a complete range of contrast media, medical devices, and digital and AI solutions for Diagnostic Imaging and Interventional Radiology. This is in keeping with its purpose, as the Group has been a pioneer in the field of contrast media for almost a century. In a world that is changing at an accelerating pace – an aging population, rising healthcare costs, and growth in the MRI and X-ray markets – Guerbet’s solutions are designed to help prescribers, radiologists, and patients face the new challenges of medical imaging.
Present in
114 COUNTRIES
2,746 EMPLOYEES
4
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
Guerbet in brief Our international footprint
— — —
1|
|
2|
|
3|
|
4|
|
5|
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
5
Guerbet in brief Our international footprint
à REVENUE EMEA
€343.7M 43.8% AMERICAS
ASIA
€233M
€207.9M
29.7%
26.5%
à BREAKDOWN OF REVENUE BY PRODUCT RANGE
86.5% Diagnostic Imaging comprising
WORLD
13.5% Interventional Radiology
€786.4M
n X-ray 54.4% n MRI 32.1%
à EBITDA
10.5% 2025 2024
6
GUERBET
à OPERATING INCOME
EBITDA margin rate
2025
€82.3M €119.4M
2025 UNIVERSAL REGISTRATION DOCUMENT
2024
(€88.1M) €49.6M
Guerbet in brief Our international footprint
à NET INCOME
— — —
à NET EARNINGS PER SHARE
(€112.7M)
2025 2024
€13.5M
2025
(€8.91)
2024
€1.07
1|
|
à FREE CASH FLOW
2|
à GROSS INVESTMENTS RESTATED
|
FOR DEBTS ON FIXED ASSETS
2025 2024
€19.2M
2025
€44.9M
(€9.1M)
3|
|
2024
€58.2M
4|
|
à SHAREHOLDERS’ EQUITY
à NET FINANCIAL DEBT
2025
€325.7M
2025
2024
€344.9M
2024
€267M
5|
|
€394.2M
6|
|
7|
|
à NET FINANCIAL DEBT/EBITDA
à NET FINANCIAL DEBT/ SHAREHOLDERS’ EQUITY
2025 2024
3.96
2025
1.22
2.89 2024
0.87
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
7
STRATEGY
OUR FOUR STRATEGIC PRIORITIES Aligned with its corporate purpose and values, Guerbet has structured its strategy around two key priorities: development and transformation. It has one strong ambition: to strengthen its position as a global leader in medical imaging.
01
Strengthen our leadership in MRI à Consolidate our positions with Elucirem™ (gadopiclenol) and Dotarem® (gadoteric acid)
à Continue growth in our X-ray contrast media and injection solutions
02
Develop Interventional Radiology by capitalizing on the potential of Lipiodol® à Strengthen the resources allocated to Interventional Radiology to conquer new markets
à Explore new therapeutic applications
03
Enhance our Operational excellence à Optimize our processes à Improve our on-time and in-full delivery rate with a target of over 95% of our orders
04
Explore new growth drivers à Strengthen our footprint in our key countries à Enter new markets à Expand our activities beyond diagnostic imaging à Develop our AI solutions for oncology
8
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
Strategy Our CSR roadmap: People & Planet
OUR CSR ROADMAP: PEOPLE & PLANET
— — —
In harmony with the Group’s corporate purpose, Guerbet’s CSR commitment is structured around two pillars. An approach that combines a commitment to preserving life, a pursuit of sustainability, and a pioneering spirit.
PLANET
1|
|
PEOPLE
Preserving our planet KEY AREAS
2|
|
Protecting people KEY AREAS
à Sustainable partnerships: strengthening engagement with stakeholders
à Prevention: applying Operational Excellence to protect
3|
|
the health and safety of all those involved in our operations
à Circular economy: improving the environmental performance of our products
à Decarbonization: achieving our decarbonization targets à Preservation of resources: implementing the three Rs: Reduce, Reuse, Recycle
à Control of discharges: applying Operational Excellence
à Quality: applying Operational Excellence to support patients by ensuring the availability of safe, effective, and high quality products
4|
à Engagement: fostering engagement and motivation
|
à Development: fostering employee development to ensure sustainable performance
à Inclusion: encouraging diversity and aiming for gender
5|
equality
|
6|
|
7|
Achieving silver medal status
|
Guerbet was awarded EcoVadis Silver Medal status, a distinction that places us in the top 15% of companies. This recognition highlights the commitment and the maturity of our sustainability approach and the effective integration of environmental, social, and ethical issues into our practices, throughout our value chain.(1)
(1) https://recognition.ecovadis.com/Rn7tVSVyMU6rugwmVZwWMw.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
9
SIGNIFICANT EVENTS
KEY HIGHLIGHTS OF 2025 GOVERNANCE
Fresh faces on the Board of Directors To support its growth ambitions, Guerbet strengthened its Board of Directors by welcoming two Independent Directors: Michèle Lesieur and Éric Drapé. FOCUSES OF OUR WORK
Spotlight on France at the RSNA (Radiological Society of North America) 2025 meeting At its stand, Guerbet hosted the France pavilion for French Healthcare members, with a view to fostering discussions and cooperation around innovative “Made in France” healthcare solutions. The aim of this national initiative is to unite French companies, institutions, and stakeholders in the healthcare sector in order to promote medical and technological excellence internationally.
ELUCIREM™ – continuing global expansion Following authorizations in the US, the EU, Switzerland, and the UK, Elucirem™ (gadopiclenol) now has approval in four additional countries: Chile, Mexico, Taiwan, and Australia. This novel high-relaxivity macrocyclic contrast agent is indicated for MRI in adults and children from 2 years of age. Its innovative formulation reduces the amount of gadolinium administered, helping to improve patient safety and limit the environmental impact. This advance is evidence of Guerbet’s commitment to providing state-of-theart solutions on all continents.
10
GUERBET
• Michèle Lesieur brings renowned expertise in medical imaging, having led international business at Philips and chaired Philips France. • Éric Drapé has extensive experience in the pharmaceutical industry, having held global responsibilities in operations and quality at Teva, Ipsen, and Novo Nordisk. This development demonstrates the Group’s desire for complementary skills to draw on to support its development and increase its agility.
Three new Directors to support Guerbet’s industrial ambition In fall 2025, Guerbet strengthened the management of its industrial sites with the arrival of Frédéric Jouillerot in Marans, Vincent Testaud in Lanester, and Shane Conway in Dublin. With extensive experience in the chemical and pharmaceutical industry, they will manage key sites for the production of Elucirem™, Dotarem®, Xenetix®, Lipiodol®, and the supply of Ioversol® and Optiray®. These appointments attest to Guerbet’s ambition to accelerate its industrial momentum, strengthen its Operational Excellence and support the international growth of the Group.
2025 UNIVERSAL REGISTRATION DOCUMENT
RESEARCH & DEVELOPMENT
US Food and Drug Administration (FDA) grants Breakthrough Device status to Guerbet Lipiojoint & DUOnco™ Pancreas In 2025, Guerbet reached a major strategic milestone, obtaining US Food and Drug Administration (FDA) Breakthrough Device designation for two innovative solutions addressing unmet medical needs. This status is given to medical devices that offer a more effective treatment or diagnosis for serious or debilitating diseases. It means that their development and evaluation can be accelerated through priority support from the FDA. • Lipiojoint, a transient liquid embolic agent, aims to relieve pain and improve mobility in patients with knee osteoarthritis through a minimally invasive approach. • DUOnco™ Pancreas, AI-assisted analysis software, boosts the opportunistic detection of pancreatic lesions on scans performed for other indications to improve the early diagnosis of pancreatic cancer. These awards bear witness to Guerbet’s commitment to developing standout technologies to improve patient care and support healthcare professionals.
Significant events Key highlights of 2025
— — — ENVIRONMENT
ANNIVERSARY
Faster green transition with Lanester’s evapo-concentrator
30 years of Xenetix®: a landmark anniversary in Lanester
On December 9, 2025, Guerbet celebrated the launch of its evapoconcentrator project at the Lanester site, in the presence of Michaël Gally and Florence Bessy from the local Prefecture, President of the Lorient business cluster, Fabrice Loher, and Mayor of Lanester, Gilles Carréric.
In Lanester, Guerbet celebrated 30 years of Xenetix®, an essential iodinated contrast agent for CT scans, which has been helping to improve diagnostic accuracy and quality of care for three decades. This anniversary day was marked by former employees meeting with their counterparts of today for an enjoyable gathering retracing the highlights of this success story. Everyone who has contributed to making Xenetix® a world leader in medical imaging was acknowledged through speeches, testimonials, and discussions, on a day that also strengthened the link between generations and the spirit of innovation that drives the Group.
This project, supported by a grant of €2.32 milion from the ADEME under the France 2030 DECARB IND program, represents a total investment of €7.2 million. It will make it possible to recover a portion of solvent effluents and to significantly reduce the environmental impact of the site, while optimizing energy consumption through the recovery of waste heat. The expected benefits are major: 3,700 tonnes of CO2 avoided per year, 15% reduction in waste, 25% of the Group target for direct emissions (scopes 1 & 2), and estimated savings and revenues of more than €3.3 million per year. This is a concrete step forward for decarbonization and the circular economy.
3,700 tonnes of CO2 avoided per year
1|
|
2|
|
RSE
Guerbet on the podium of the Green Index! Guerbet was ranked 2nd in the CAHPP CSR Green Index in the Medicines category, with the maximum score of A++ (84/100 for medicines, 88/100 for medical devices). This performance, which exceeds that of our main competitors, rewards the collective commitment of the teams and the implementation of concrete actions: responsible purchasing, water and energy performance, optimizing packaging, and eco-design. A great incentive to continue to improve our CSR practices.
3|
|
4|
|
5|
|
6|
|
7|
|
2nd place in the CAHPP Green Index CSR ranking
à in the Medicines category
Å
Ceremony to mark the launch of the evapo-concentrator project
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
11
SAVE THE DATE
OUR MAJOR EVENTS IN 2026 A look at the key events that Guerbet will be taking part in throughout 2026.
Europe ECR
MARCH 4–8, 2026 Vienna, Austria JFR
OCTOBER 1–4, 2026 Paris, France CIRSE
SEPTEMBER 5–9, 2026 Copenhagen, Denmark ECIO
APRIL 26–30, 2026 Basel, Switzerland
ET
JUNE 17–20, 2026 Valencia, Spain
Americas SIR
APRIL 11–15, 2026 Toronto, Canada
RSNA
NOVEMBER 29–DECEMBER 3, 2026 Chicago, United States
SIO
FEBRUARY 4–8, 2026 Savannah, United States
SOBRICE
OCTOBER 15–17, 2026 JPR
APRIL 30–MAY 3, 2026 São Paulo, Brazil
Asia KCR
SEPTEMBER 20–23, 2026 Seoul, South Korea APSCVIR
JUNE 11–14, 2026 Suzhou – China
12
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
— — —
1|
|
2|
|
THE
3|
|
GUERBET GROUP
4|
|
1.1
A MODEL FOR SUSTAINABLE VALUE CREATION
14
1.5
INNOVATION, RESEARCH, AND DEVELOPMENT
27
1.5.1 Organization
27
1.5.2 Therapeutic areas
28
1.2
HISTORY OF THE COMPANY
16
1.5.3 Diagnostic Imaging
29
1.3
OVERVIEW OF ACTIVITIES
18
1.5.4 Interventional Radiology
30
1.3.1 Medical imaging techniques
18
1.5.5 Public-private partnerships
31
1.3.2 Markets
24
1.5.6 Research and Development costs
31
1.3.3 Main competitors
25
1.5.7 Research and Development portfolio
32
1.5.8 Intellectual property
33
1.5.9 Clinical data protection
33
1.6
34
1.4
INDUSTRIAL AND LOGISTICS ACTIVITY
26
1.4.1 An integrated network of plants
26
1.4.2 A regionalized logistics platform
26
1.4.3 Development based on investment and continuous improvement
26
5|
|
6|
|
7|
|
GROUP GOVERNANCE STRUCTURE AT DECEMBER 31, 2025
1.6.1 An international presence
34
1.6.2 Property owned
36
1.6.3 Distribution
36
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
13
THE GUERBET GROUP A model for sustainable value creation
1.1
A MODEL FOR SUSTAINABLE VALUE CREATION
A MODEL FOR SUSTAINABLE VALUE CREATION OUR STRATEGIC ROADMAP
STRENGTHEN OUR LEADERSHIP IN MRI
ACCELERATE THE DEVELOPMENT OF LIPIODOL®
OUR RESOURCES à 2,746 employees worldwide
OUR CORPORATE PURPOSE
à 8 production plants across Europe, North America, and Latin America
At Guerbet, we build lasting connections to improve lives by:
à 4 R&D centers across Europe and North America
à Caring for others
à A culture of excellence and innovation: 9.6% of revenue dedicated to R&D
à Prioritizing patient benefits à Continuously delivering innovative solutions à Making bold choices à Progressing through knowledgesharing This is our corporate purpose.
14
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
ENHANCE OUR OPERATIONAL EXCELLENCE
à 429 patents à Teams driven by a deep sense of commitment
CONQUER NEW MARKETS
OUR BUSINESS LINES à
Diagnostic Imaging Contrast media and solutions
à
Interventional Radiology Contrast Media and Medical Devices
à
Digital & AI
— — —
Digital & AI solutions
1|
|
O
A UR
DDE
AL DV
UE
… AND FOR OUR OTHER STAKEHOLDERS
2|
|
Supporting employee growth and development à Policy focused on skills development, internal mobility, and talent management
FOR PATIENTS AND THE MEDICAL PROFESSION
à Adoption of a global ethics charter for all employees, also applicable to stakeholders and healthcare professionals à Commitment to responsible procurement
à Providing early and precise diagnoses for more personalized treatments
Accelerating our commitment to the environment and decarbonization
à Leveraging 99 years of expertise to deliver reliable and innovative solutions for patient health
à CSR commitment: People & Planet
à Bringing the latest innovations to patients and using advanced technologies to meet the most demanding medical needs
à EcoVadis Silver Medal (1)
5|
|
à Circular economy à Decarbonization: “Well-below 2 °C” trajectory 2032 à Preservation of natural resources
à Emphasizing the safety of individuals and the quality of our products and services by applying the strictest standards to our activities
Optimizing our economic and social impact locally
à Marketing our products in more than 114 countries, as close to patients as possible
4|
|
à Engagement and sustainable partnerships
à Offering the least invasive procedures possible to reduce risks and improve patient safety and comfort
à Training healthcare professionals in the optimal use of our products and solutions
3|
|
à Control of discharges
6|
|
à Optimizing our economic and social impact locally à Generating economic benefits and creating jobs in the regions where we operate
7|
|
à Contributing to local economies through tax policies and short supply chains à Supporting young people in accessing long-term employment à Engaging our employees in solidarity initiatives through our program à Implementing an anti-corruption program
Ensuring robust corporate governance à The Guerbet family holds 54.32% of the capital, while current employees, former employees, and mutual funds hold 3.89%
(1) https://recognition.ecovadis.com/Rn7tVSVyMU6rugwmVZwWMw.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
15
THE GUERBET GROUP History of the Company
1.2
HISTORY OF THE COMPANY
HISTORY OF THE COMPANY Guerbet is a French healthcare company that has been supporting healthcare professionals specialized in Diagnostic Medical Imaging and Interventional Radiology since 1926. Guerbet develops and markets contrast media, delivery systems, medical devices, and related solutions adapted to their needs. Today, the Guerbet Group sells a comprehensive range of products suitable for X-ray and magnetic resonance imaging (MRI). Thanks to the products provided by the Group, images are used to guide radiologists when administering treatments,
1901
1980
Lipiodol®, the first iodinated contrast medium, discovered by Marcel Guerbet (1861-1938)
Lipiodol® in Interventional Radiology
The international scientific community contributes to the success of Lipiodol®: it is used as a therapeutic product (in the form of sugar-coated pills, capsules, slabs of chocolate, etc.) and as a contrast medium for diagnostic purposes to make cavities like the lungs opaque.
give insight into the functioning of organs, speed up diagnoses, assess the severity of an illness and enable early validation of the efficacy of treatments. The Guerbet Group has developed a new area of activity based on digital technologies and artificial intelligence with two objectives: first, to improve the productivity of radiologists, e.g. with diagnostic assistance tools, and second, to obtain tumor tissue characterization through imaging to better guide treatments or even eventually replace biopsies.
The first chemoembolizations are performed in Japan with Lipiodol® to treat hepatocellular carcinoma patients.
1986 Guerbet is listed on the Paris Stock Exchange
1989
2015
Dotarem® is launched in France
Acquisition of Mallinckrodt’s “contrast media and delivery systems” business
Dotarem® is the only macrocyclic and ionic contrast medium.
1995 Xenetix®, a new product for X-rays
1926 Laboratoire André Guerbet founded At the age of 25, André Guerbet, son of Marcel Guerbet, becomes its general manager. He opens a chemical and pharmaceutical manufacturing plant in Saint-Ouen.
16
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
2002 and 2005 OptiStar® Elite, OptiVantage®, and Angiomat Illumena These three injectors by Mallinckrodt are marketed by Guerbet in France, Belgium and Switzerland.
Guerbet takes on a new international dimension and expands its product portfolio. The workforce increases from 1,500 to more than 2,500 employees.
2018 New area of activity: Artificial Intelligence
The Group begins working on Artificial Intelligence in order to develop AI-based diagnostic support solutions designed to improve the accuracy and efficiency of medical imaging professionals.
THE GUERBET GROUP History of the Company
2025 Lipiojoint Lipiojoint is granted Breakthrough Device status by the FDA for its indication in the treatment of osteoarthritis of the knee. This distinction, reserved for breakthrough technologies that meet major unmet medical needs, means that the FDA can provide stronger support and accelerate the regulatory pathway, thus bringing patients closer to an innovative therapeutic solution more quickly.
— — —
1|
Elucirem™ – Global expansion Following authorizations in the US, Europe and the UK, Elucirem™ (gadopiclenol) is approved in four additional countries: Chile, Mexico, Taiwan and Australia (TGA).
|
2|
|
3|
|
2020
2024
Gadopiclenol
Guerbet recognised at the JFR
End of phase III clinical trial.
Guerbet receives the Innovation Award in the Jury’s Favorite category for Elucirem™ (gadopiclenol).
4|
|
5|
|
®
Liflow
2021 Gadopiclenol Guerbet continues the development of gadopiclenol with the announcement of positive results from two phase III studies, examining the diagnostic efficacy and safety of this product. Guerbet and Bracco Imaging announce a global strategic collaboration agreement on manufacturing and for research and development of future indications.
2022
2023
Elucirem™
Elucirem™
Guerbet announces FDA approval for the contrast medium Elucirem™ (gadopiclenol).
First sales of Elucirem™ in the United States. EU Marketing Authorization for Elucirem™ received in December 2023 by the European Medicines Agency.
Artificial Intelligence Guerbet obtains funding of €1 million from the Banque Publique d’Investissement (BPI project France 2030) for its project on Artificial Intelligence in the early detection of pancreatic cancer.
Guerbet, Intrasense, Gustave-Roussy and Angers University Hospital obtain €5.9 million in funding from Bpifrance for Liflow®, an innovative oncology imaging solution.
6|
|
7|
|
Intrasense Guerbet acquires a majority stake in Intrasense to become a major player in Artificial Intelligence for medical imaging.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
17
THE GUERBET GROUP Overview of activities
1.3
OVERVIEW OF ACTIVITIES
1.3.1
Medical imaging techniques
Medical imaging is a medical specialty that aims to inform or confirm a diagnosis and/or guide a therapeutic intervention. It explores the inside of the human body mainly through four techniques: • X-ray; • magnetic resonance imaging (MRI); • ultrasound; • nuclear medicine. Discovered in 1885, X-ray radiography is the oldest form of medical imaging. Its development was revolutionized by the invention of CT (computerized tomography) scanners.
18
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
These methods and potentially associated products play a role at various stages of patient diagnosis and treatment: • diagnostic support; • assessing the severity/seriousness of an illness; • intervention support; • treatment and therapeutic monitoring support; • advancement of knowledge of research teams. In Interventional Radiology, image capture guides a medical or surgical procedure.
THE GUERBET GROUP Overview of activities
By encompassing all of the techniques used in medicine for the diagnosis and treatment of a large number of illnesses, medical imaging has revolutionized medicine and provided immediate and reliable access to information essential to clinical diagnostics, revealing new anatomical characteristics in terms of both the metabolism and the actual functioning of organs. Medical imaging techniques no longer just provide a “snapshot” of the tissue or organ being examined. They give a visual representation based on specific physical or chemical characteristics. These examinations have been made possible by contrast media adapted to imaging techniques and equipment that are pushing back the boundaries of knowledge concerning the human body. Technological and IT developments in the 21st century have ushered in a new era for medical imaging. Rapid scanning, high-definition images and the advent of big data are factors that are further improving early diagnosis and therapeutic monitoring. We are currently witnessing a revolution in radiologists’ practice thanks to the introduction of Artificial Intelligence solutions. This revolution has been made possible by, among other things, advances in the field of deeplearning. These solutions should help radiologists by improving their productivity and the quality of diagnoses. Examples of potential applications include automatic segmentation or reset, patient prioritization based on algorithm-assessed severity, preliminary reading with identification and segmentation of lesions of interest, second reading for screening purposes, decision support to guide treatment, and tumor tissue characterization to avoid biopsies. This revolution will not occur overnight and will probably take a few years, but the significant level of current investments and communications about new solutions at radiology conferences indicate that it is underway.
The products and solutions developed and marketed by Guerbet are part of a complex approach with many challenges. • Regulatory issues: • Contrast media are drugs, and delivery solutions/systems and Artificial-Intelligence tools are medical devices. Guerbet products are therefore regulated by two of the most stringent regulatory systems in the world. This explains the development time (several years) for new products or improvements to existing products, as their quality, efficacy, and safety need to be proven. These regulations are constantly evolving, and the products marketed by Guerbet must adapt and comply with these regulatory changes on an ongoing basis. • The diagnostic examinations to be performed for different types of pathologies and their methods of implementation (including the use of contrast media) are governed by recommendations issued by international scientific societies or by commissions/committees of experts at the national level. These recommendations change frequently with improvements in imaging and they influence how and how much patients or hospitals/radiology centers are reimbursed for examinations and products.
— — —
1|
|
2|
|
• Technological issues: • Unlike “conventional” drugs, contrast media are never used alone but always in conjunction with an imaging technique, which is itself constantly evolving and improving. As such, acquisition sequences for CT and MRI scans have undergone considerable changes since their creation, allowing for images and diagnostic information of ever-higher quality. The products and solutions offered by Guerbet must support and adapt continuously to these changes in associated imaging techniques.
3|
|
4|
|
• Societal issues: • Guerbet has an obligation to offer products and solutions in line with societal expectations and challenges such as the protection of the environment and biodiversity. These actions can cover various complementary approaches such as manufacturing processes and the use of more environmentally friendly materials or compounds, a responsible purchasing policy, and packaging that limits the amount of unused product leftovers, thus avoiding the risk of uncontrolled discharges into the environment.
5|
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
19
THE GUERBET GROUP Overview of activities
1.3.1.1
Diagnostic Imaging
A) Contrast media Contrast media are drugs that are suited to the imaging techniques used because of their nature and method of action: • the medium of choice for X-ray Imaging is iodine or barium due to their ability to absorb this radiation; • in magnetic resonance imaging (MRI), gadolinium in the form of complexes is the raw material most commonly used, being chosen for its paramagnetic properties. The injection of a gadolinium complex in response to a radiofrequency wave in a magnetic field speeds up the paramagnetic relaxation of the protons in water molecules, enhancing the contrast of the signal observed through MRI in the organs where the product is present; • the contrast media used for ultrasound scans consist of microbubbles of gas that interact with the ultrasound waves and boost the ultrasound signal; • in nuclear medicine, the radioactive agent or tracer is the source of the radiation that is then detected. These products are used to reveal the invisible. They are useful for medical purposes, as they increase the contrast so that an anatomical structure can be viewed separately from the surrounding tissues. These agents play a crucial role, for example, in assessing the functioning of an organ such as the kidney or a tissue such as the heart when measuring the myocardial perfusion of the heart. The diagnostic efficacy sought by radiologists and clinicians is therefore very closely linked to the suitability of the information received as a result of the contrast medium’s enhancing properties and its development over time after injection. This translates into high-quality static or dynamic images that provide data about the anatomy and functioning of organs, the structure of arterial and venous blood vessels, and perfusion parameters. Diagnostic quality is a key factor in clinicians’ decisions regarding treatment and surgery.
20
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
These rapid advances also have a direct impact on patients’ quality of life. Because they result in earlier diagnoses and improved selection of treatment options suited to each patient’s profile, these drugs play a decisive role in the development of personalized medicine while meeting the economic imperative of reducing healthcare costs to the community.
B) Our range of contrast media X-ray Guerbet’s range of X-ray contrast media consists mainly of two non-ionic iodinated low-osmolar contrast media (LOCM): • Optiray®, available in four concentrations: 240, 300, 320 and 350 mg iodine/ml. It comes in vials and pre-filled syringes, a form of packaging that is especially appropriate for single-patient injections. The product is used in CT examinations, and its physicochemical profile is especially suited to arterial investigations (Cath Lab); • Xenetix®, available in three concentrations: 250, 300 and 350 mg iodine/ml. It comes in vials and polypropylene bags (ScanBag® by Xenetix®). The 350 mg/ml concentration should preferably be used for cardiovascular disorders, and the 300 mg/ml concentration for the investigation of parenchymal conditions (e.g. diseases of the liver or kidneys). In 2021, Xenetix® was granted a new indication in certain countries for use in spectral mammography with contrast enhancement to identify known or suspected breast lesions. This technique is being developed in many countries as part of breast cancer screening campaigns.
THE GUERBET GROUP Overview of activities
In the X-ray contrast media range, Guerbet also sells three highosmolality iodinated media and a range of barium media:
• Artirem®, an MRI medium specifically used for bone and joint examinations, available in certain countries in Europe.
• Telebrix® Gastro and MD Gastroview®, iodinated media oral solutions that are particularly useful in the examination of digestive pathologies, especially in colorectal cancer screening with virtual colonoscopy.
It was the first ready-to-use medium indicated for such conditions able to be injected directly into the joints. It expands Guerbet’s MRI range and sets it apart from the competition.
MD Gastroview® is available for sale only in the United States and Central America; • Conray and Cysto-Conray , iodinated media used for various vascular or intravesical radiological examinations. ®
®
They are available for sale only in North and Central America; • Micropaque®, Micropaque® Scanner, and Microtrast are barium sulfate-based media used for the investigation of digestive pathologies. These media are available for sale in certain European countries.
MRI Guerbet’s MRI range includes: • Dotarem®, a non-specific gadolinium-based macrocyclic contrast medium, which is a leader in many markets worldwide. Thanks to its physicochemical properties and its safety profile, it is the benchmark MRI agent. Dotarem® is used for the MRI examination of many diseases, in particular conditions affecting the central nervous system as well as abdominal, bone and joint, and vascular disorders; • Elucirem™, a new gadolinium-based macrocyclic contrast medium. Its high relaxivity (a parameter governing contrast power) allows it to be administered at half the gadolinium dose of conventional products, reducing patient gadolinium exposure and the environmental footprint. Elucirem™ was approved in the United States by the Food and Drug Administration in 2022, after an expedited review process for imaging the central nervous system and various other anatomical regions (head and neck, thorax, abdomen, pelvis, and musculoskeletal system). Elucirem™ was launched in the United States in 2023. After its approval by the European Commission in late 2023, and by the United Kingdom, Switzerland, Norway, and Finland, Elucirem™ was launched in Europe in 2024. New authorizations were obtained in 2025 in Asia-Pacific and Central and Latin America;
C) Injectors and contrast media delivery systems Injection devices are divided into two main categories: injectors, which are permanent devices connected to a power source that enable the completely safe programming, management, and monitoring of contrast media injections, and the associated consumables. These consumables are single- or multiple-use sterile medical devices that deliver the contrast medium to the patient from receptacles in the form of vials, prefilled syringes, or pouches. Iodinated contrast media injectors are now essential devices. Scanners have such high computing power that they can produce images of the whole body in just a few seconds. These rapid scanning sequences therefore require a highly accurate injection rate that can only be provided by electromechanical devices to synchronize signal acquisition with the arrival of the contrast medium. The use of injectors also protects radiology technicians from the ionizing radiation emitted during examinations using X-ray imaging (because the injector can be controlled remotely). Lastly, high injection flow rates are sensitive to the viscosity of injected solutions, which results in high injection pressures and therefore mechanical power that only a machine can provide. In MRI, the use of injectors is also growing significantly. In fact, in the same way as for scanning using X-rays, technological development is leading to faster image acquisition and requires more complex and precise injection protocols that only an injector can perform. Both injectors and the associated consumables are vital to the daily work of radiology technicians and must be easy, intuitive, quick, and safe to use. There are also considerable economic challenges for imaging plates, and Guerbet is responding to them by offering competitive solutions.
— — —
1|
|
2|
|
3|
|
4|
|
5|
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
21
THE GUERBET GROUP Overview of activities
D) Our range of delivery systems Guerbet has a portfolio of syringe and softbag injectors. Delivery Systems and Services are a major growth driver. Trademarks
Injectors
OptiVantage®/OptiVantage® Multi-use Dual-head CT scan injector
ü
Illumena® Néo Cath Lab injector (new Néo version)
ü
OptiOne® Single-head CT scan injector
ü
Consumables for all types of injectors
OptiStar® Elite MRI injector
ü
Complete range of extension lines
ü
ü
Secufill Patient-side connector with secure double-check valve
ü
ü
Manyfill® Filling system for syringe injectors (use on multiple patients)
ü
ü
®
OptiVantage® is a syringe injector for CT imaging studies, available in a multi-use version. OptiStar® is a dedicated syringe injector for MRI.
E) Digital and Artificial Intelligence solutions I) Artificial Intelligence Artificial Intelligence refers to diagnostic support solutions or, more generally, medical decision support solutions, which can be provided by software using Artificial Intelligence technologies. This is an area where strong growth is expected in radiology for several reasons: firstly, the need is enormous given the lack of radiologists worldwide to cope with population aging and the development of chronic diseases; secondly, machine learning technologies, in particular those using deep learning networks, have made spectacular progress in recent years and allow high-performance tools to be developed relatively quickly. Lastly, there is a strong promise of improved health thanks to these solutions, which should reduce variability in image interpretation, increase radiologist productivity, and ultimately identify new predictive biomarkers of disease progression (cancers and neurodegenerative diseases in particular) and thus reduce the number of biopsies required thanks to characterization of lesions by imaging.
22
GUERBET
MRI
X-ray Scanner
Medical devices
2025 UNIVERSAL REGISTRATION DOCUMENT
Interventional Radiology
ü
ü
An initiative to explore new opportunities related to Artificial Intelligence was implemented at Guerbet with the recruitment of a Chief Digital Officer in September 2017. In June 2018, a significant first milestone was achieved with the signing of a strategic partnership with IBM Watson Health, which became Merative in July 2022. In November 2022, Guerbet signed an agreement with Merative to terminate their collaboration. This partnership aimed to design, develop, and market software solutions to assist in the diagnosis and monitoring of liver and prostate cancers. Initially motivated by a change in Merative’s strategy for Artificial Intelligence in its imaging portfolio, this agreement provides Guerbet with the strategic latitude now required to continue the work in progress and plan the marketing of solutions. In particular, it allows Guerbet to recover all assets developed by the partnership, such as source codes and algorithms, and the relevant intellectual property. In January 2023, Guerbet announced an investment in Intrasense, a Montpellier-based SME that develops and markets advanced visualization software for radiology. Following a takeover bid launched in the second quarter, Guerbet holds a majority stake of approximately 56%. Alongside this, the two companies signed a licensing agreement in June 2023 to allow AI algorithms developed by Guerbet to be integrated into Intrasense products. The aim is to improve the time-to-market for AI products, with the launch of the first products in Europe planned for 2024.
THE GUERBET GROUP Overview of activities
1.3.1.2
Interventional Radiology
— — —
1|
|
2|
|
Interventional Radiology covers any minimally invasive medical procedure whose purpose is to diagnose and/or treat a disease. The process is guided and controlled by an imaging method (X-ray, ultrasound, or MRI), where the contrast medium is used to guide the hand of the interventional radiologist and trace the drugs used during the procedure as close as possible to the lesion to be treated. It is used in innovative ways for many indications.
treatment of hepatocellular carcinoma (HCC), where Lipiodol® is used as a visualizer (contrast medium), an antineoplastic drug carrier, and an embolic agent. cTACE is recommended by many scientific societies for the treatment of patients with intermediate- and early-stage HCC in Europe, Japan, China, and the United States. The main indications for Lipiodol® worldwide are chemoembolization of hepatocellular carcinoma, lymphography, vascular embolization with surgical glue, and hysterosalpingography. Approved indications and their wordings may vary from country to country;
Interventional Radiology therefore allows diagnosis and treatment to be combined in a single procedure thanks to radiological techniques. These minimally invasive procedures, often considered an alternative to surgery, shorten hospitalization times and considerably limit post-procedure complications. The best known of these therapies are vascular angioplasty, embolization, and percutaneous (radiofrequency, cryotherapy, electroporation) or chemical (in situ chemoembolization or radioembolization) tumor ablations.
• Qitexio® is a range of medical devices resistant to Lipiodol® including syringes and a stopcock. Qitexio® is used in all procedures using Lipiodol®;
• Lipiodol® Ultra Fluid (ethyl esters of iodinated fatty acids of poppy seed oil) was initially developed for Diagnostic Imaging, lymphography, and hysterosalpingography.
This indication makes it possible to decide whether to perform aggressive surgery concerning the extent of lymph node dissection.
3|
|
4|
|
5|
|
• Patent Blue V is a sterile injectable dye. It is used for imaging of the lymphatic system, mainly for intraoperative sentinel lymph nodes mapping in breast cancer surgery.
6|
|
It is now often used in Interventional Radiology for conventional transarterial chemoembolization (cTACE) in the
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
23
THE GUERBET GROUP Overview of activities
1.3.2
Markets
1.3.2.1
Diagnostic Imaging market
For Guerbet, the Diagnostic Imaging market is divided between contrast media for X-ray imaging, MRI, and injection solutions:
X-ray imaging contrast media Guerbet is number 4 worldwide in X-ray imaging contrast media, a market with an estimated value of €3.7 billion in 2025(1). This estimation of the market is based on sustained volume growth compared with 2024, combined with price increases due to iodine price inflation (1).
MRI contrast media Guerbet is number 2 worldwide in MRI contrast media, a market with an estimated value of more than €1.4 billion in 2025 (1). This estimation of the market is based on sustained volume growth compared with 2024 (1).
Injectors and medical injection devices Guerbet is number 3 worldwide in the market for injectors and medical injection devices for Diagnostic Imaging, which has an estimated value of €2 billion in 2025 (1). This market is supported by the increased number of examinations involving injections and installations of CT and MRI equipment.
Trends in these markets The following factors influence these markets:
- growing number of CT/MRI scanners;
- The increased number of procedures, and therefore examinations involving injections, also due to improved examination productivity;
- The spread of Artificial Intelligence tools in imaging, responding to the need for efficiency and opening up new medical possibilities (early detection, diagnostic precision, etc.);
- The strengthening and geographic expansion of the range of generic contrast media offered. Overall, these markets have grown since 2025. In addition, the services market is burgeoning due to the development of digital technologies.
(1)
24
Source: financial reports and specific market studies.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
1.3.2.2
Interventional Radiology market
The transarterial embolization market was valued at €3.5 billion in 2025, of which neurovascular applications accounted for €1.6 billion and peripheral applications (rest of the body including interventional oncology and excluding interventional cardiology) €1.9 billion. Today, Guerbet’s development is mainly in peripheral applications due to the strong position of Lipiodol® in liver cancer treatment. Lipiodol® is also used in neurovascular medicine, in particular for glue embolization of arteriovenous malformations and peripherally on various interventions. The market for peripheral transarterial embolization can be analyzed as follows:
- Oncology (mainly in liver cancer treatment), with a market estimated at €920 million in 2025. Today, cTACE accounts for three out of four of these procedures worldwide (dominant in Asia), the main alternatives being DEBTACE and radioembolization, which are growing in popularity in Europe and the United States. Changing practices in the treatment of liver cancer and the advent of immunotherapies has confirmed a renewed interest in cTACE.
- Embolization (excluding oncology), with a market estimated at €1.1 billion in 2025. This market includes procedures such as the treatment of benign tumors (uterine fibroids, prostate hyperplasia), varicoceles and pelvic varicose veins, hemorrhages, vascular malformations, and aneurysms using a portfolio of products including coils, plugs, particles, and embolic fluids. Guerbet is present in this market today through the use of Lipiodol® in glue embolization, and in certain European countries this application could outstrip its use in oncology in terms of volume. The expected growth of these markets depends on the indications and respective development of practices within the countries. The peripheral transarterial embolization market is seeing robust growth of 3% to 9%, supported by the demonstrated benefits of minimally invasive treatments (efficacy, patient quality of life, and cost). The development of new practices for conditions such as osteoarthritis, still in clinical studies, could accelerate the use of Interventional Radiology in the coming years.
THE GUERBET GROUP Overview of activities
1.3.3
Main competitors
Guerbet’s portfolio consists of: • MRI and X-ray contrast media for Diagnostic Imaging; • delivery Systems and Services; • products for Interventional Radiology. Its main competitors differ according to the activities – Diagnostic or Interventional Imaging – some of which are not present in these two markets. Diagnostic Imaging Company
MRI
X-ray
Injection Systems and Services
Interventional Radiology
Guerbet
ü
ü
ü
ü
Bayer Healthcare
ü
ü
ü
ü
GE Healthcare
ü
ü
Bracco
ü
ü
— — —
1|
|
ü ü
Nemoto
ü
Medtron
ü
Ulrich Medical
ü
ü
2|
|
Merit Medical
ü
Sirtex Medical
ü
Terumo
ü
Boston Scientific/BTG
ü
Medtronic
ü
Siemens Healthineers/Varian
ü
3|
|
4|
|
The leading companies selling X-ray and MRI contrast media worldwide are Guerbet, Bayer Healthcare, General Electric Healthcare, and Bracco, which offer the following main products: Company
Nationality
MRI
X-ray
Guerbet
France
• Dotarem® (Magnescope® in Japan)
• Optiray®/Optiject®
Germany
• Elucirem™ • Gadovist® (Gadavist® in the US)
• Xenetix® • Ultravist®
• Primovist®
• Radioselectan®
Bayer Healthcare
• GE Healthcare
United States
Generic of Dotarem®
Italy
• • Multihance®
• Omnipaque® • Iomeron®
• Prohance®
• Iopamiron®
•
6|
|
• Visipaque®
• Omniscan™ Generic of Dotarem®
Bracco
5|
|
7|
|
Vueway®
Note that generics of Dotarem® are available for sale in many countries, including the United States, European countries, South Korea, China, and India, by companies such as GE Healthcare, Sanochemia, Bayer Healthcare and its subsidiaries, T2Pharma, b.e. imaging, Dongkook Pharmaceutical, Jiangsu Hengrui Medicine, and Fresenius Kabi.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
25
THE GUERBET GROUP Industrial and logistics activity
1.4
INDUSTRIAL AND LOGISTICS ACTIVITY
This activity is under the responsibility of the Technical Operations Division, which manages the entire supply chain, from raw materials to delivery to end customers, so as to optimize turnaround times and costs while guaranteeing the quality required from one end of the chain to the other. In all its decisions, Guerbet pays particular attention to fulfilling its CSR commitments. They are set out in chapter 5.
1.4.1
An integrated network of plants
Guerbet develops, industrializes, and manufactures most of its products in its integrated network of specialized plants. The goal is to adapt volumes and capacities to market demand and reduce manufacturing costs through a policy of continuous improvement of industrial performance and synthesis processes.
• the Raleigh plant in North Carolina (USA) is a filling plant for X-ray (Optiray® and Conray®) and MRI (Dotarem® and Elucirem™) products. These products are packaged in syringes for all world markets and in vials for the North and South American markets;
The active ingredients used as raw materials in contrast media are mainly produced in Europe (France and Ireland) at the Group’s three specialized chemical plants:
• the Rio de Janeiro plant (Brazil), specialized in packaging Xray (Optiray® and Xenetix®) and MRI (Dotarem®) products in vials, serves the Latin American markets.
• the Lanester (France) plant, a factory specialized in the production of the active ingredients iobitridol (Xenetix®) for use in X-ray and gadopiclenol (Elucirem™) for MRI;
The active ingredient (gadopiclenol) of Elucirem™ is produced at the Marans and Lanester sites, while Raleigh and Aulnaysous-Bois manufacture the finished product.
• the Dublin (Ireland) plant, dedicated to producing the active ingredient ioversol (Optiray®) for the X-ray activity;
To prepare for the launch of the new MRI product Elucirem™ in new countries and to reduce production costs, additional investments were made in 2025 at Marans and Lanester, supplementing the investments made at the Lanester, Marans, Aulnay-sous-Bois, and Raleigh plants since 2019.
• the Marans (France) plant, which manufactures the active ingredients of Dotarem® and Lipiodol® as well as the intermediate product used as a precursor for gadopiclenol production. Active ingredient formulation, solution preparation, and filling activities take place at the Group’s three pharmaceutical plants located on three continents:
The support of external partners, specialized in Europe but also in Asia, is required for certain targeted productions, such as the filling of Lipiodol® for all the markets served and for a limited number of X-ray media, for specific markets.
• the Aulnay-sous-Bois plant (France), Guerbet’s long-standing site where X-ray (Optiray® and Xenetix®) and MRI (Dotarem® and Elucirem™) product filling takes place, mainly serves the European, Middle Eastern, African, and Asian markets;
Injectors and medical devices are designed and assembled mainly at Guerbet’s Cincinnati plant (USA) and its Lyon plant (Medex). The manufacture of consumables associated with injectors is completely outsourced to specialized partners.
1.4.2
A regionalized logistics platform
Guerbet delivers its products to all markets in line with optimal delivery time and quality standards through a network of distribution centers located very close to its customers. Regional distribution platforms in Europe, Asia, North America, and South America contribute to this supply chain.
1.4.3
Development based on investment and continuous improvement
Guerbet is continuing with its program of industrial investments and expansion of its network in order to ensure: • the safety and regulatory compliance of operations by harmonizing the production and quality management systems; • a high-quality service and reliable supplies by increasing capacity and by improving plant reliability and supply chain planning;
26
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
• the competitiveness of our industrial platform, and especially its environmental performance, by modernizing plants and improving production processes. This investment program was reinforced by a global Operational Excellence program aimed at rolling out best practices from the Group or external benchmarks in all the plants and strengthening the Group’s continuous improvement culture.
THE GUERBET GROUP Innovation, research, and development
1.5
INNOVATION, RESEARCH, AND DEVELOPMENT
Guerbet’s research ambition is to offer radiology professionals and patients safe and innovative solutions consisting of drugs and medical devices (including “software” solutions) that meet their needs. Guerbet’s work is focused on two medical imaging segments: Diagnostic Imaging and Interventional Radiology.
1.5.1
Organization
The Research team, which is involved in the Diagnostic Imaging and Interventional Radiology activities, has scientific and technical expertise organized across four departments to investigate and validate areas of research: • Research & Innovation (R&I): research and innovation team for pharmaceuticals and medical devices (chemistry, physicochemistry, formulation, mass spectrometry – bioanalysis, exploratory and regulatory preclinical studies, and public and/or private partnerships) and the Patents Department (patent portfolio management, patent filing, industrial property studies, etc.); • Development & Engineering (D&E): engineering team specialized in the development of medical devices (injectors, consumables, and digital technology (software, IT, and health)); • Artificial Intelligence (AI): research and development team for Artificial Intelligence solutions. The Development and Medical & Regulatory Affairs team is organized into four main sections: • Clinical development: all the activities involved in conducting clinical studies for drugs and medical devices, from phase I to phase IV, from designing the protocol to writing the final research report, including publication of the results by scientific journals; • Regulatory affairs: all the activities involved in managing the portfolio of registrations of all products, drugs, and medical devices for every country; • Drug and medical device safety monitoring: all the activities involved in collecting side effect information and/or postmarketing data and writing periodic summary risk/benefit analysis reports to be submitted to the regulatory authorities and/or the notified bodies; • Medical affairs: all activities aimed at developing scientific partnerships to optimize patient care through the organization of symposiums, expert committees, and scientific exchanges with health professionals. This head office organization is backed up by Quality Assurance and Medical Writing/Scientific Documentation departments and regional structures in Europe, North America, Latin America, and the Asia-Pacific region for faster response times to meet the local demands of patients, radiologists, or the authorities.
— — — The discovery of a new product, whether in Diagnostic Imaging or Interventional Radiology, follows a precise procedure: • identifying and analyzing the medical need; • defining the product(s) meeting the need;
1|
|
• developing and validating a prototype (formulation and characterization); • developing and validating the product’s manufacturing processes; • validating the concept in preclinical experimentation;
2|
|
• validating the technical solution with the end user; • developing the product in preclinical and clinical experimentation in accordance with regulatory requirements. As with therapeutic drugs, the clinical development of new contrast media is carried out in several successive phases over a period of 10 to 15 years: • phase I to study the clinical and biological tolerance in healthy volunteers and the pharmacokinetics (how the product is distributed, metabolized, and eliminated within the organism) of increasing doses of the product and thereby determine the maximum tolerated dose;
3|
|
4|
|
• phase II to study, in patients, the diagnostic efficacy of different doses of the product, usually compared with a baseline product already approved or a baseline technique; • phase III to confirm, for a large cohort of patients, the diagnostic effectiveness and tolerance profile of the product compared with a baseline product or technique. Some medical devices may also require clinical investigations to validate their development:
5|
|
6|
|
• clinical feasibility investigation: the results are used to refine design inputs; • pivotal study: confirms safety and performance. An authorization for clinical investigation is given by the issuing authority (for example, the Agence nationale de sécurité des médicaments et des produits de santé – ANSM in France) on the basis of existing preclinical and clinical data. All the results of the clinical studies are then summarized in the clinical evaluation report, including the data from the literature.
7|
|
The main objective of Life Cycle Management (LCM) activities is to manage the life cycle of products that are already for sale. Typical LCM activities include obtaining approval for new indications, developing new formulations or presentations, securing registrations in new geographic regions, and the clinical studies that take place in the marketing phase (phase IV).
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
27
THE GUERBET GROUP Innovation, research, and development
1.5.2
Therapeutic areas
The two types of radiology, Diagnostic Imaging and Interventional Radiology, are studied in terms of their application in three main therapeutic areas of oncology, cardiology, and neurology. In oncology, the incidence of the most common forms of cancer (lung, breast, prostate, colorectal, pancreatic, and liver) is constantly growing. For example, around 34 million examinations use contrast media injections each year in the five largest European countries. This increase is due to a combination of longer life expectancy and known risk factors, such as smoking, unhealthy eating, stress, and environmental risks. This is resulting in a greater number of diagnostic examinations at increasingly early stages aimed at improving patient care and quality of life and the monitoring of patient treatment. The trend in the treatment of breast cancer is a perfect example of the role played by the various types of medical imaging, as MRI plays a vital role in screening for and/or monitoring the disease. European data indicate that more than 40 million women over the age of 50 should be routinely screened by imaging. This procedure makes earlier diagnosis easier, radically changing the treatment strategy and allowing disease-free remission from the condition. Furthermore, in the case of surgery, sentinel lymph node mapping can be used in this same disease to limit surgical intervention to what is strictly necessary. Similarly, the Group is committed to developing technologies for earlier diagnosis of certain cancers, including pancreatic cancers, to enable treatment at a very early stage. These technologies include the use of an algorithm designed to analyze a large amount of data and detect a cancer that would be difficult to see in a traditional clinical detection device. For some types of cancer, such as hepatocellular carcinoma (HCC), Interventional Radiology is of great benefit, as it enables the precise imaging and mapping of hepatic lesions and even the administering of anti-cancer drugs within these tumor lesions through transarterial chemoembolization, usually as an outpatient procedure. In cardiology, the assessment of cardiovascular diseases through imaging by injecting contrast media is vital for investigating the consequences of serious diseases for patients who are symptomatic and/or present associated risk factors (such as obesity, diabetes, high cholesterol, stress, high blood pressure, and smoking).
28
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
More than 8 million examinations are carried out worldwide each year to analyze the condition of blood vessels (detecting significant narrowing of vessels due to arterial plaque) and the impact on the blood flow rate needed to adequately supply essential tissues such as the heart (risk of a heart attack) or the brain (risk of stroke). Appropriate diagnosis allows patients to be categorized according to their risk profile and the presence or absence of clinical signs to determine the most appropriate treatment options: preventive monitoring, choice of one drug alone or several drugs in combination, or a strategy of major or interventional surgery. In this specialty, for example, the injection of contrast media in Interventional Radiology provides a view of the narrowed part of blood vessels needing medical attention, guides endovascular procedures, and provides an immediate check on the effectiveness of the resulting dilation. This type of treatment, which is less invasive for the patient and less costly for the community in terms of hospitalization time and patient monitoring, has replaced surgery in many cases. In neurology, MRI has proven its worth through central nervous system (CNS) imaging, by making it possible, for the first time, to diagnose lesions that cannot be seen using an X-Ray scanner. Injections of contrast media during CNS imaging allow the investigation of tumor diseases (primary brain tumors or brain metastases linked to a primary cancer), inflammatory diseases (such as multiple sclerosis), degenerative conditions (such as Alzheimer’s disease), vascular disorders (such as strokes), and infectious diseases (such as brain abscesses). Most of these pathologies are chronic, and the drugs available to stop their progression are still insufficient. It is a major public health issue due to population aging, longer life expectancy, and the high cost of caring for these dependent patients. Interventional Radiology can also be used to successfully treat a large number of cerebral arteriovenous malformations without surgery.
THE GUERBET GROUP Innovation, research, and development
1.5.3
Diagnostic Imaging
For MRI, Guerbet recently released to its first few markets a highly innovative contrast medium: gadopiclenol (Elucirem™). This contrast agent is distinguished by its high relaxivity and high stability, resulting in images of equivalent quality to the macrocyclic gadolinium contrast agents currently available on the market, while using half the dose of gadolinium. In fact, a dose of 0.05 mmol/kg is sufficient, compared with 0.1 mmol/ kg for other macrocyclic gadolinium contrast media. In addition, the gadolinium dose reduced by half optimizes the use of natural resources by reducing the quantity of this resource needed to produce a unit dose and reduces the quantity of gadolinium released into the environment by the patient. Indicated in the European Union for adults and children of 2 years of age and older, Elucirem™ improves the detection and visualization of conditions associated with the disruption of the blood-brain barrier(1) and/or abnormal vascularization in: • the brain, spine, and other associated tissues of the central nervous system (CNS); • the liver, kidney, pancreas, breast, lung, prostate and musculoskeletal system (FN1). in the US, the application received an expedited review, and the FDA granted marketing authorization on September 21, 2022. In Europe, the European Commission approved Elucirem™ on December 11, 2023, followed immediately by approvals in Switzerland and the UK, paving the way for its launch in Europe in 2024. In 2025, new MAs (Marketing Authorizations) were obtained in Asia and Central and Latin America, and new applications were submitted in these same regions. As provided for in the Pediatric Investigation Plan agreed upon with the European and US authorities, a clinical study in children from 0 to 2 years of age started in 2022 and was completed in 2024. The MA application for this indication in
children aged 0 to 2 years was submitted in Europe and the USA in 2025, in accordance with our commitments to the authorities in these countries. In December 2025, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on this dossier, which is now awaiting final approval by the European Commission. On December 14, 2021, Guerbet and Bracco Imaging announced the signing of a partnership agreement for R&D activities on gadopiclenol. Guerbet and Bracco both market gadopiclenol independently, under two different brand names. New clinical studies of gadopiclenol are underway or planned, in collaboration with Bracco, to gain new indications and carry out post-marketing studies required by certain health authorities. In 2024, Guerbet received the JFR (Journées Francophones de Radiologie) 2024 Innovation Prize in the Jury’s Favorite category for this product, which represents a major advance in the field of magnetic resonance imaging (MRI). This prestigious recognition for the Group encourages it to pursue innovation in the field of medical imaging, for the benefit of patients and healthcare professionals.
— — —
1|
|
2|
|
3|
|
With regard to Delivery Systems and Services, the Innovation, Research, and Development engineers are currently focusing on the following strategic areas: • connecting injectors to imaging equipment; • ensuring the safety of medical procedures through innovative injection devices, whether single-use or designed for safer multi-use practices. The Group is also exploring the development of new generations of products, thus initiating patent research on new molecules.
4|
|
5|
|
6|
|
7|
|
(1)
The main function of the blood-brain barrier is to protect the brain from foreign substances/pathogens circulating in the blood.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
29
THE GUERBET GROUP Innovation, research, and development
1.5.4
Interventional Radiology
Commercial growth and expansion of Lipiodol® applications Established 40 years ago as a standard in the treatment of liver cancer, Lipiodol® also has a strong foothold in other fields – including vascular embolization, lymphography, and hysterosalpingography (HSG) – which now account for a significant proportion of sales volumes and future growth. The development potential for new innovative indications appears significant, especially in the treatment of musculoskeletal disorders, venous diseases, and post-surgery disorders and cancers. Research and development efforts will be stepped up to explore new applications for Lipiodol®.
Innovations in digital health In radiology, the Group develops its own solutions based on Artificial Intelligence, integrated into innovative software. These solutions aim in particular to speed up the analysis and interpretation of images but also to improve their quality thanks to machine learning. The aim is to provide diagnostic and medical decision-making support solutions. This type of innovation promises to improve health, not only by increasing the productivity of radiologists and their working conditions, but also by providing strong societal value. Indeed, given the aging of populations and the rise in chronic diseases and in a global context of scarcity of radiologists, the hope is that this type of innovation may guarantee optimal patient monitoring. Furthermore, these solutions are expected to reduce variability in image interpretation and, over time, help identify new predictive biomarkers of disease progression (cancers and neurodegenerative diseases in particular) and thus reduce the number of biopsies required thanks to characterization of lesions by imaging. Artificial Intelligence can also be used to improve the detection of certain cancers. In this context, Guerbet developed DUOnco™ Liver with Intrasense, a company specializing in medical imaging software solutions. This algorithm, designed for the detection of focal liver lesions, aims to make diagnoses more accurate, faster and more accessible, thus improving patient management.
(1)
30
GLOBOCAN 2020 study.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
In addition, Guerbet’s prostate AI has been integrated into Intrasense solutions. This AI, when integrated into tools dedicated to clinical routine, facilitates diagnosis and therapeutic decision-making. This solution automatically analyses CT scans and alerts radiologists at the first signs of suspected cancer. This innovation could thus increase the number of patients eligible for curative treatments, thereby significantly improving survival rates. For this project, Guerbet received €1 million in financial support from BPI under the France 2030 program, following the Group’s participation in a call for projects concerning the digital health acceleration strategy. In 2024, Intrasense and Guerbet obtained CE certification for the Myrian® 2.12 platform, which integrates prostate AI, enabling it to be marketed in Europe. With this platform, radiologists are able to more easily interpret medical imaging examinations, thus facilitating the diagnosis of this very common cancer (1.4 million new cases each year worldwide(1)). Once again this year, Guerbet, Intrasense, Gustave-Roussy and Angers University Hospital obtained €5.9 million in funding from Bpifrance for Liflow®, an innovative solution dedicated to oncology imaging incorporating multi-organ AI developed by Guerbet. As part of Bpifrance’s call for projects pertaining to “Innovation in medical imaging”, Liflow® was recognized for its innovative nature in digital healthcare. One of the strengths of the project lies in the integration of several AI algorithms dedicated to several organs, providing benchmark oncology monitoring indicators that are unprecedented in the clinical setting, such as the calculation and automated measurement of tumor burden. This indicator will be of great help to medical teams in optimizing treatments. Bpifrance’s support will thus make it possible to conduct several clinical studies aimed at demonstrating the impact and performance of new technologies on the daily practice of clinicians. The main objective is to provide healthcare professionals with tools to enable faster evaluation of patients’ response (or non-response) to treatments, leading to therapeutic optimization and improved care. The first year of the project will be devoted to the development of the Liflow® platform and all its innovative functionalities: automation of the analysis of oncology examinations by anatomical region, easy access to the results of multi-organ AI tools, automated calculation of tumor progression.
THE GUERBET GROUP Innovation, research, and development
1.5.5
Public-private partnerships
To meet its Innovation, Research, and Development objectives, Guerbet is building a strategy of partnership, collaboration, and open-innovation agreements. Thanks to this outwardlooking approach, it is able to benefit from international scientific expertise. Medical imaging is a multidisciplinary field requiring expertise in chemistry, physics, computing, image processing, electronics, biology, and medicine. Several collaborative research programs are being conducted. One of the most important projects, Iseult, financed by Bpifrance (Banque publique d’investissement), was completed in 2020. The expected benefit of these new technologies is improved sensitivity in the detection of small brain lesions that cannot be detected using standard techniques. Gadopiclenol (Elucirem™) was developed as part of this program. Some collaborative research partnerships involve two types of financial clauses: • repayment of advances if product sales are successful;
Investments continue to be made in the BioMedTech FPCI fund, initiated in 2017. This fund is managed by Truffle Capital, a specialist investor in start-ups developing breakthrough technologies and products in the life sciences sector. This investment is part of the Group’s innovation strategy and also illustrates its diversification strategy to seek growth beyond contrast media by linking up with high-potential French MedTech or BioTech start-ups in the field of interventional medicine. Finally, in 2024, Guerbet entered into a strategic partnership with Nuclidium, a company specializing in advanced copperbased radiopharmaceuticals. This partnership combines Guerbet’s expertise in medical imaging research, production and commercialization with Nuclidium’s know-how in copper radioisotope production and theranostic development. Among the benefits of these copper-based products is a more accurate detection of the extent of a tumor’s aggressiveness thus making it possible to determine the most appropriate treatment for the patient.
— — —
1|
|
2|
|
• payment of a share of the profits based on the revenue and/or operating profit generated by the products resulting from these projects.
3|
|
1.5.6
Research and Development costs
The table below presents the Research and Development costs incurred by Guerbet Group over the last two years.
4|
|
2025*
2024*
Research and Development costs (in € thousands)
75,545
76,180
Research and Development costs (as % of revenue)
9.6%
9.1%
- Including the research tax credit (CIR).
Guerbet is continuing its investments: • in Diagnostic Imaging with the development of new indications for gadopiclenol (Elucirem™) in MRI; • in the digital sector by developing imaging solutions coupled with Artificial Intelligence.
5|
|
In 2025, regulatory approvals were obtained in Europe (CE marking) for AI-based products designed to assist in the detection of bone lesions (DUOnco™ Bone) and pancreatic lesions (DUOnco™ Pancreas). Through its subsidiary Intrasense, Guerbet wishes to accelerate the marketing of these solutions in 2025, while continuing to expand its product range with the development planned for 2026 of a multi-organ AI tool to facilitate oncology monitoring by CT scans.
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
31
THE GUERBET GROUP Innovation, research, and development
1.5.7
32
GUERBET
Research and Development portfolio
2025 UNIVERSAL REGISTRATION DOCUMENT
THE GUERBET GROUP Innovation, research, and development
1.5.8
Intellectual property
Intellectual property is vital, as it compensates for part of the time and cost involved in innovation, while allowing companies to reap the benefits of researchers’ work. A patent has a term of 20 years from the date on which the application is filed. In practice, product development times, especially for drugs, are such that the exclusivity period is often considerably reduced. The expiration of a patent may lead to the emergence of very strong competition due to the arrival of generic products. In some cases, and where the patent relates to the active ingredient of a drug, it may be extended for up to five more years through a protection extension known as a Supplementary Protection Certificate in Europe or a Patent Term Extension in the United States and other countries. Products may also be protected by other patents during the development and/or marketing phase. Guerbet has a portfolio of patents covering active ingredients (e.g. contrast and
1.5.9
radiotherapy media), new pharmaceutical formulations, emulsions, formulation and manufacturing processes, delivery systems, medical devices (syringes, tubing, microcatheters, etc.), and methods based on Artificial Intelligence. The Guerbet Group and its subsidiaries have 429 patents and patent registration applications pending (mainly in the names of Guerbet, Liebel-Flarsheim Company LLC, IBM-Merative, and Medex), 1,774 trademarks registered or pending registration, and 22 industrial models. The portfolio of patents, trademarks, and industrial models contributes to the Group’s valuation and strengthens its position in the growing market for contrast media combined with medical devices. In 2025, the Guerbet Group and its subsidiaries were granted nine patents worldwide. Patents have been granted for Elucirem™ and its active ingredient. This product will thus be protected until 2040.
— — —
1|
|
2|
|
Clinical data protection
Clinical data protection is a complement to protection by patent. This is a period of exclusivity during which a regulatory administrative authority will refuse:
• or the granting of a Marketing Authorization for a generic based on the clinical data covered by this protection relating to an originator drug.
3|
|
• a Marketing Authorization application for a competing product;
4|
|
5|
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
33
THE GUERBET GROUP Group governance structure at December 31, 2025
34
1.6
GROUP GOVERNANCE STRUCTURE AT DECEMBER 31, 2025
1.6.1
An international presence
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
THE GUERBET GROUP Group governance structure at December 31, 2025
— — —
1|
|
2|
|
3|
|
4|
|
5|
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
35
THE GUERBET GROUP Group governance structure at December 31, 2025
1.6.2
Property owned
Country
Town/City
Address
Brazil
Rio de Janeiro
Rua André Rocha, 3000, Jacarepaguá, CEP 22710, 568 – Rio de Janeiro
Cincinnati
2111 E Galbraith Road, Cincinnati – Ohio 45237
Raleigh
8800 Durant Road, Raleigh – North Carolina 27616
Aulnay-sous-Bois
16/24, rue Jean-Chaptal and 1, rue Nicéphore-Niépce – 93600 Aulnay-sous-Bois
Marans
16, rue des Fours-à-Chaux – 17320 Marans
Lanester
ZI de Kerpont, 705, rue Denis-Papin – 56600 Lanester
Villepinte
15, rue des Vanesses – 93420 Villepinte
Dublin
Damastown Mulhuddart – Dublin 15
United States
France
Ireland
1.6.3
Distribution
Guerbet markets its products in more than 114 countries across five continents in several ways: • directly through its subsidiaries and branches; • through distributors; • through license holders.
Direct operations The Group has direct operations in more than 20 countries in Europe, Asia, Oceania, North America, and Latin America.
Distribution agreements For markets in which Guerbet does not have direct operations or a licensing agreement, it has agreements with distributors. The main agreements cover Scandinavia, Eastern Europe, Greece, Africa and the Middle East, Canada, and some countries in South America, Asia, and Oceania. These distributors are now joined by a network of companies dedicated to providing after-sales services for injectors.
36
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
Customer types Guerbet’s local customer structure in each of its national markets, excluding distributors and licensees, differs from one country to the next. Nevertheless, there are two factors common to most countries: • a very significant share of sales is made to hospitals and clinics, which account for 60% of sales, and radiology centers, which account for 40% of sales. Purchasing groups generally fall into one of these two categories. In the vast majority of cases, such sales are based on negotiated contracts or calls for tenders; • a second major category of customers consists of wholesale distributors, which in turn supply pharmacies. Since the recent reform of contrast agents, this segment is significantly smaller than the one described above. This is because the contrast agents available in pharmacies come in containers of less than 50 ml, which account for a tiny fraction of the market.
— — —
1|
|
2|
|
CORPORATE
3|
|
GOVERNANCE 2.1
2.2
REPORT OF THE BOARD OF DIRECTORS ON CORPORATE GOVERNANCE
38
BOARD OF DIRECTORS
38
2.2.1 Composition of the Board of Directors
38
2.2.2 Operation and powers of the Board of Directors
54
2.2.3 Organization of the work of the Board of Directors and the Committees
55
2.2.4 Assessment of the Board of Directors and its Committees
58
2.3
59
GENERAL MANAGEMENT
4|
|
2.4.7 Equity ratios
73
2.4.8 Annual changes in compensation and company performance
75
2.4.9 Commitments made to corporate officers when taking up, changing, or terminating their duties
76
2.4.10 Plans for the allocation of purchase options to corporate officers
76
6|
|
2.5
EXCEPTIONS TO THE AFEP-MEDEF CODE
77
2.6
AGREEMENTS REFERRED TO IN ARTICLE L. 225-37-4-2° OF THE FRENCH COMMERCIAL CODE
78
7|
|
2.3.1 Chief Executive Officer
59
2.3.2 Deputy CEO – Chief Pharmacist
59
2.3.3 Executive Committee
60
2.7
DELEGATIONS OF AUTHORITY REGARDING CAPITAL INCREASES
78
2.4
61
2.8
PROVISIONS IN THE ARTICLES OF ASSOCIATION RELATING TO GENERAL MEETINGS
78
2.9
FACTORS THAT COULD HAVE AN IMPACT IN THE EVENT OF A TAKEOVER OR EXCHANGE OFFER REFERRED TO IN ARTICLE L. 225-37-5 OF THE FRENCH COMMERCIAL CODE
80
COMPENSATION OF CORPORATE OFFICERS
2.4.1 Compensation policy for corporate officers
61
2.4.2 Compensation of the Chairperson of the Board of Directors, Hugues Lecat
66
2.4.3 Compensation of the Chief Executive Officer, David Hale, from January 1 to September 22, 2025
68
2.4.4 Compensation of the Acting Chief Executive Officer, Jérôme Estampes, from September 22 to December 31, 2025
70
2.4.5 Compensation of the Deputy Chief Executive Officer, Philippe Bourrinet
71
2.4.6 Directors’ compensation
73
5|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
37
CORPORATE GOVERNANCE Report of the Board of Directors on corporate governance
2.1
REPORT OF THE BOARD OF DIRECTORS ON CORPORATE GOVERNANCE
In accordance with article L. 225-37-6 of the French Commercial Code, we are pleased to present you with the Board’s report on Guerbet’s corporate governance. In particular, this report gives an account of the composition, conditions for preparation and organization of the Board’s work, the organization of the General Management, as well as the principles and rules for determining the compensation and benefits of any kind granted to the executive officers. This report was approved by the Board of Directors on March 11, 2026. Guerbet has adopted the Corporate Governance Code published by Afep-Medef (French Association of Private-Sector Companies/French Business Confederation) in force (December 2022). Any deviations from this Code are indicated in the summary table at the end of this report. The Afep-Medef Code,
Guerbet is a French public limited company (société anonyme) with a Board of Directors and the functions of the Chairperson of the Board and CEO are separated. The separation of the functions of Chairperson of the Board of Directors and Chief Executive Officer has been in place at Guerbet since the form of the Company was changed to an S.A. with a Board of Directors (it was previously in the form of an S.A. with an Executive Board and a Supervisory Board) by its Board of Directors on May 21, 2010.
2.2
BOARD OF DIRECTORS
2.2.1
Composition of the Board of Directors
2.2.1.1
General principles governing the composition of the Board of Directors
The operation of the Board of Directors is governed by the Company’s articles of association and the law. It also has Internal Regulations that specify and supplement the procedures governing its operation and the operation of its Committees. The articles of association and the Internal Regulations are available on the Guerbet Group website (under “Investors” – “Corporate governance” section). The main principles governing the composition of the Board of Directors are as follows: • the Board of Directors is composed of: (i) three (3) to eighteen (18) non-executive directors appointed by the Ordinary General Meeting and (ii) one (1) to two (2) Directors representing the employees, elected from and by the staff of the Company and that of its direct or indirect subsidiaries whose head office is located on French territory
(1)
38
which the Company has adopted, and the guide to its application published by the Haut Comité de Gouvernement d’Entreprise [High Committee for Corporate Governance] for interpretation purposes, are available on the AFEP and MEDEF websites.
depending on whether the Board of Directors is composed of fewer than eight (8) Directors or more than eight (8) Directors; • directors, whether they are natural persons or legal entities, are appointed for a term of one (1) to four (4) year(s) by the General Meeting on the recommendation of the Board of Directors after consulting the Appointments and Compensation Committee(1). Each Board member, with the exception of the Directors representing the employees, must own at least 200 Company shares (as provided for in article 9.b of the articles of association). If, on the day of his or her appointment, a Board member does not hold the requisite number of shares, or if, during his or her term of office, a Board member ceases to own them, the Board member is automatically deemed to have resigned if the situation is not rectified within six (6) months; • the reappointment, resignation, co-optation if a vacancy arises, and dismissal of Board members are carried out under the conditions provided for by law.
This term may exceptionally be between one and three years in order to stagger the term of office of Directors.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
CORPORATE GOVERNANCE Board of Directors
2.2.1.2
Current composition of the Board of Directors
As of December 31, 2025, the Board of Directors had nine members, including one Director representing the employees:
Position
Independence
Audit Committee
Appointments and Compensation Committee
Ethics, Governance, and CSR Committee
Hugues Lecat
Chairperson and Director
Yes
Member
Member
Carine Dagommer
Director
No
Member
Chairperson
Éric Drapé
Director
Yes
Member
Member
Marie de la Simone
Employee Director
No
Member
Member
Éric Guerbet
Director
No
Céline Lamort
Director
No
Michèle Lesieur Director
Yes
Chairperson
Nicolas Louvet
Director
No
Member
Marc Massiot
Director
No
Member
• 44% women on the Board and balanced representation of women and men on each Committee;
End of term
Member
May 24, 2024
2028 GM
May 20, 2022
GM 2026
May 23, 2025
GM 2029
November 22, 2023
November 22, 2027
Member
May 19, 2017
GM 2027
Member
May 29, 2015
2027 GM
Member
May 23, 2025
GM 2028
May 27, 2016
GM 2026
May 28, 2021
GM 2029
Member
Member
In view of its reference shareholding structure, the Board of Directors has a majority proportion of Directors representing the Shareholder Agreement. In general, the Board of Directors and the Appointments and Compensation Committee seek to balance the composition of the bodies in the selection of Directors and to pursue a strong diversity policy. This is reflected in the following factors monitored annually by the Board:
Strategy and Innovation Date of first Committee appointment
Chairperson Chairperson
• the average age of the Directors is 57 years, and the distribution of Directors is as follows: Directors over 60 years of age (44%), those between 50 and 59 years of age (22%), and those under 50 years of age (33%);
— — —
1|
|
2|
|
3|
|
• 38% are Independent Directors; • a diversity of skills and professional experience to best meet its needs and carry out its work. Specific training may also be organized to strengthen the skills of Directors and thus guide them in certain decision-making. For example, CSR training was offered in January 2025.
4|
|
5|
|
AUTHORITY OF THE BOARD OF DIRECTORS
6|
|
7|
|
In accordance with the law and the articles of association, the Directors have been appointed for a four-year term. This period may exceptionally be between one and three years to allow reappointments to be staggered, in accordance with the recommendations of the Afep-Medef Code and market practices.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
39
CORPORATE GOVERNANCE Board of Directors
2.2.1.3
Director declarations
No convictions for fraud, involvement in bankruptcy, or incrimination and/or official public sanctions To Guerbet’s knowledge, as of the date of preparation of this document, none of the Directors has been convicted of fraud, been the subject of government proceedings, or involved in bankruptcy, receivership, or liquidation proceedings.
Conflicts of interest In 2025, the Board of Directors was not informed of any potential conflicts of interest likely to prevent a Director from performing their duties throughout the year. General declarations of non-conflict of interest are drawn up in writing each year and signed by each Director, in accordance with the internal procedure validated by the Board of Directors.
Service contracts It should be noted that during the 2025 fiscal year, the Company entered into a service agreement with a company owned by a Director (see section 2.6 on regulated agreements and the related Statutory Auditors’ report). No other member of the Board of Directors or the General Management is bound by a service contract with Guerbet S.A. or any of its subsidiaries that would provide for the granting of benefits under such a contract.
40
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
Internal procedure for related-party agreements and “ordinary” agreements The procedure was established in accordance with:
- the regulation applicable to ordinary and related-party agreements and commitments, as in force following the promulgation of French law No. 2019-486 of May 22, 2019, known as the PACTE law;
- the recommendations of the Autorité des financiers. The purpose of the procedure is to:
marchés
a. recap the regulatory framework applicable to relatedparty agreements and commitments and clarify the methodology applied internally to describe the various agreements entered into; and b. implement, in accordance with the provisions of article L. 22-10-12 of the French Commercial Code, a procedure for regularly assessing ordinary agreements. The procedure was approved by Guerbet’s Board of Directors on March 11, 2026, and is available on Guerbet’s website.
CORPORATE GOVERNANCE Board of Directors
2.2.1.4
Independent Directors
Each year, after consulting the Appointments and Compensation Committee, the Board of Directors reviews the individual situation of each Director in view of all the independence requirements of the Afep-Medef Code (article 10). According to the Code, a Director is independent “when he or she has no relationship of any kind whatsoever with the corporation, its group, or its management that may interfere with his or her freedom of judgment. Accordingly, an Independent Director is understood to be any non-executive director of the corporation or the group who has no particular bonds of interest (significant Shareholder, employee, etc.) with them.” In view of these criteria, at its meeting on December 18, 2025, and on recommendation of the Ethics, Governance, and CSR Committee, the Board of Directors deemed that three Directors are eligible for Independent Director status: Hugues Lecat, Éric Drapé and Michèle Lesieur. The criteria used to assess the independence of the Directors are as follows: • criterion 1: not to be and not to have been within the previous five years: • an employee or executive officer of the Corporation, • an employee, executive officer, or Director of a company consolidated within the Corporation, • an employee, executive officer, or Director of the Corporation’s parent company or a company consolidated within this parent company;
Directors
Criterion 1
Criterion 2
• criterion 2: not to be an executive officer of a company in which the Corporation holds a directorship, directly or indirectly, or in which an employee appointed as such or an executive officer of the Corporation (currently in office or having held such office within the last five years) holds a directorship; • criterion 3: not to be a customer, supplier, commercial banker, investment banker, or consultant that is significant to the Corporation or its group or for which the Corporation or its group represents a significant portion of its activity. The evaluation of the significance or otherwise of the relationship with the Corporation or its group must be debated by the Board, and the quantitative and qualitative criteria that led to this evaluation (continuity, economic dependence, exclusivity, etc.) must be explicitly stated in the report on corporate governance;
1|
|
• criterion 4: not to be related by close family ties to a company office; • criterion 5: not to have been an auditor of the Corporation within the previous five years;
2|
|
• criterion 6: not to have been a Director of the Corporation for more than 12 years; • criterion 7: Directors representing major Shareholders of the Corporation or its parent company may be considered independent, provided these Shareholders do not take part in the control of the Corporation. Nevertheless, beyond a 10% threshold in capital or voting rights, the Board, upon a report from the Appointments Committee, should systematically review the qualification as independent in the light of the composition of the Corporation’s capital and the existence of a potential conflict of interest.
Criterion 3
Criterion 4
Criterion 5
Criterion 6
3|
|
4|
|
Criterion 7
INDEPENDENT DIRECTORS
5|
|
Hugues Lecat
Compliant
Compliant
Compliant
Compliant
Compliant
Compliant
Compliant
Éric Drapé
Compliant
Compliant
Compliant
Compliant
Compliant
Compliant
Compliant
Michèle Lesieur* Compliant NON-INDEPENDENT DIRECTORS
Compliant* Compliant
Compliant
Compliant
Compliant
Compliant
Carine Dagommer
Compliant
Compliant
Compliant
Compliant
Compliant
Compliant
Not Compliant
Éric Guerbet
Compliant
Compliant
Compliant
Compliant
Compliant
Compliant
Not Compliant
Céline Lamort
Compliant
Compliant
Compliant
Compliant
Compliant
Compliant
Not Compliant
Nicolas Louvet
Compliant
Compliant
Compliant
Compliant
Compliant
Compliant
Not Compliant
Compliant
Compliant
Compliant
Compliant
Compliant
Not Compliant
Compliant
Compliant
Compliant
Compliant
Compliant
Compliant
Marc Massiot Compliant Marie de la Simone (Director representing the employees) Not Compliant *
— — —
6|
|
7|
|
Michèle Lesieur’s status as Independent Director was specifically examined by the Board of Directors and its Ethics, Governance, and CSR Committee. Michèle Lesieur served as an independent director at Intrasense (a company 55.50% owned by Guerbet and within its consolidation scope) until May 2025, with her term ending prior to her appointment to the Guerbet Board of Directors. The Board of Directors and its Ethics, Governance, and CSR Committee concluded that these circumstances did not prevent Michèle Lesieur from serving her directorship completely independently with regard to the criteria of the Afep-Medef Code. The rationale behind this was: (i) in addition to her professional experience in the field of radiology, the previous mandate would provide the Company’s Board of Directors with useful insight into Intrasense’s strategy and activity, (ii) any potential conflict of interest would be resolved by the Director abstaining from any decision and/or vote concerning Intrasense, (iii) in view of the overall activity of the Guerbet Group (Intrasense accounted for 0.26% of the Group’s sales in 2024) and the small number of decisions directly concerning Intrasense submitted for the approval of Guerbet’s Board of Directors, any abstentions would be unlikely to call into question Michèle Lesieur’s effectiveness as an Independent Director. Furthermore, Michèle Lesieur’s term of office in the consolidated company was strictly non-executive, and only an executive term of office in a consolidated company is likely to impact whether a director can be considered independent. Michèle Lesieur’s previous circumstances do not therefore call into question her status as an Independent Director.
As of December 31, 2025, 38% of the Board members were independent (employee-elected Directors are not included in this calculation in accordance with the Afep-Medef Code).
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
41
CORPORATE GOVERNANCE Board of Directors
2.2.1.5
Changes in the composition of the Board of Directors during the 2025 fiscal year
Following a proposal by the Board of Directors and in accordance with the recommendations of the Afep-Medef Code, the 2025 General Meeting approved a reduction in the Directors’ term of office from six to four years. The General Meeting also: • accepted the resignation of one Director and the nonrenewal of three Directors’ terms of office due to end; • approved the reappointment of Directors Céline Lamort and Marc Massiot; and • approved the appointment of two new Directors deemed to be independent, Éric Drapé and Michèle Lesieur. As a result of these changes, the Board of Directors is now composed of nine members, three of whom are independent, and one Director representing the employees.
2.2.1.6
Training and orientation of Directors
New Directors undergo a dedicated orientation process. Information sessions prior to the first Board meeting are held with the Chairperson of the Board of Directors and the Secretary of the Board and of the Committees. This program enables new Directors to quickly understand Guerbet Group and its challenges. It includes a review of the Group’s strategy, current projects, the Company’s internal organization and the challenges facing the main departments, the competitive environment, the medium-term and long-term outlook, and corporate governance. Whenever possible, this orientation process includes visits to the industrial plants. In addition, any Director can receive ad hoc training on topics of interest to the Company or to expand certain knowledge.
42
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
The Group organized a one-day CSR training course for members of the Board of Directors in early 2025. The aim is to make CSR a real lever for value creation, growth, and strategic differentiation. This training, aimed at strengthening key skills, was organized in two stages: • e-learning, to acquire a solid general culture around sustainable development and CSR: CSR issues, climate and biodiversity focus, sectoral impacts and engagement, and CSRD focus; • a face-to-face session to assess the maturity of the organizations, identify the levers for creating the Company’s shared value, and take CSR into account to adopt a forward-looking vision linked to changes in business models.
2.2.1.7
Ending terms of office
The terms of office of Carine Dagommer and Nicolas Louvet will expire at the General Meeting of May 22, 2026. The terms of office of the other Directors will end at the following General Meetings: GM 2027
Marie de la Simone Éric Guerbet Céline Lamort
GM 2028
Hugues Lecat Michèle Lesieur
GM 2029
Éric Drapé Marc Massiot
The reappointment date of Marie de la Simone, Director representing the employees, is November 22, 2027.
CORPORATE GOVERNANCE Board of Directors
2.2.1.8
Mandates and functions exercised by the members of the Board of Directors
As of December 31, 2025, the Board of Directors consisted of the following members:
Hugues LECAT — — —
CHAIRPERSON OF THE BOARD OF DIRECTORS Independent CAREER HISTORY
• CEO of the Ethypharm group (2010–2019)
1|
|
• CEO Cooper Consumer Health (2008–2009) Date of birth: March 17, 1956 Business address: Guerbet 15, rue des Vanesses 93420 Villepinte – France First appointment to the Board: May 24, 2024 Date of most recent reappointment: Not applicable End of term: 2028 General Meeting
• Head of Base Business Division, Sanofi France (2006–2008) • CEO Sanofi-Aventis OTC (2003–2006) • Finance and Business Development Departments at Aventis and Medtronic (1995–2003)
2|
|
EDUCATION
• MBA – INSEAD Business School (1985) • NEOMA Business School (1979) CURRENT OFFICES HELD
3|
|
At Guerbet • Independent Director • Member of the Strategy and Innovation Committee • Member of the Appointments and Compensation Committee
4|
|
• Audit Committee member 2025 meeting attendance rate
• Board of Directors: 100% • Strategy and Innovation Committee: 100% • Appointments and Compensation Committee: 100%
5|
|
• Audit Committee: 100% CURRENT OFFICES HELD IN FRENCH COMPANIES
• Chairperson of the Supervisory Board of the Ethypharm group (since 2019)
6|
|
OTHER ROLES PERFORMED IN FRENCH COMPANIES
• Chairperson of the Ethypharm Group Audit Committee CURRENT OFFICES HELD IN FOREIGN COMPANIES
• None
7|
|
OFFICES HELD OVER THE LAST FIVE YEARS
French companies • Chairperson of the Arkopharma Strategic Committee (2020) Foreign companies • None
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
43
CORPORATE GOVERNANCE Board of Directors
Carine DAGOMMER DIRECTOR Non-independent: member of the Guerbet family CAREER HISTORY
• Marketing management positions in the Biocodex, Uriage, Puressentiel, and Nuxe laboratories, Paris (since 2018) • Head of Sales and Marketing – Valeur Absolue Parfums, Geneva (2014–2015) Date of birth: July 10, 1970 Business address: Guerbet 15, rue des Vanesses 93420 Villepinte – France Board co-optation date: September 22, 2021 First appointment to the Board: May 20, 2022 End of term: 2026 General Meeting
• International Marketing Manager for makeup and fragrance – Elizabeth Arden International, Geneva (2001–2011) • Export Manager for the Latin America & Caribbean region, then Key Accounts Manager for France & Belgium – Escada Beauté Group, Paris (1998–2001) • Department store manager – Parfums Grès, Paris (1996–1998) EDUCATION
• Master 2 (DESS) International Business (Université R. Schuman, Strasbourg) • ESSEC Global BBA CURRENT OFFICES HELD
At Guerbet • Director • Audit Committee member • Chairperson of the Appointments and Compensation Committee 2025 meeting attendance rate
• Board of Directors: 100% • Audit Committee: 100% • Appointments and Compensation Committee: 100% CURRENT OFFICES HELD IN FRENCH COMPANIES
None CURRENT OFFICES HELD IN FOREIGN COMPANIES
None OFFICES HELD OVER THE LAST FIVE YEARS
French companies None Foreign companies None
44
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
CORPORATE GOVERNANCE Board of Directors
Éric DRAPÉ DIRECTOR Independent CAREER HISTORY
• Teva Pharma: Executive Vice-President, Head of Global Operations at Teva, and member of the Executive Committee, Tel Aviv, Israel (2020–2024)
— — —
• Teva Pharma: Executive Vice-President and Head of Quality, USA (2015–2020) Date of birth: May 30, 1961
• Teva Pharma: Head of Biological Operations, USA (2014–2017)
Business address: Guerbet 15, rue des Vanesses 93420 Villepinte – France
• Ipsen Pharma: Executive Vice-President, Technical Operations (2007–2014)
First appointment to the Board: May 23, 2025 End of term: 2029 General Meeting
• Teva Pharma: Senior Vice-President, Technical Operations for Sterile, Respiratory, and Biological Products, France (2014–2015)
1|
|
• Novo Nordisk: Senior Vice-President, Finished Products for Diabetes (2004–2007) • Novo Nordisk: Vice-President and Site General Manager, France (1999–2004) • Novo Nordisk: Vice-President, International Quality Assurance and Support, Denmark (1996–1999)
2|
|
• Novo Nordisk: Head of Quality Control, then Director of Quality Assurance, Chartres site, France (1990–1996) • Technologie Servier: Analytical Development Chemist (1988–1990) • Air Force R&D: Analytical Development (1987–1988)
3|
|
EDUCATION
• Doctor of Pharmacy: University of Paris XI (1986) • DESS (postgraduate diploma) in Analytical Chemistry: University of Paris XI (1987) • Executive MBA: SIMI/Copenhagen Business School (1999)
4|
|
CURRENT OFFICES HELD
At Guerbet • Director • Member of the Strategy and Innovation Committee
5|
|
• Member of the Appointments and Compensation Committee • Member of the Ethics, Governance, and CSR Committee 2025 meeting attendance rate
6|
|
• Board of Directors: 93% • Strategy and Innovation Committee: 100% • Appointments and Compensation Committee: 100% • Ethics, Governance, and CSR Committee: 100%
7|
CURRENT OFFICES HELD IN FRENCH COMPANIES
|
• Member of the Board of Directors – Eukarÿs (2025) • Independent Director – LFB (2018) OTHER ROLES PERFORMED IN FRENCH COMPANIES
• Member of the Strategic, Audit and Compensation Committees – LFB (since 2018) CURRENT OFFICES HELD IN FOREIGN COMPANIES
• Director of Lonza (Switzerland) since May 14, 2025 • External Senior Advisor – Cabinet McKinsey OFFICES HELD OVER THE LAST FIVE YEARS
French companies None Foreign companies • Director of Teva-Takeda Business Venture, Japan (2017–2022)
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
45
CORPORATE GOVERNANCE Board of Directors
Marie de la SIMONE DIRECTOR REPRESENTING THE EMPLOYEES Non-independent: Guerbet employee CAREER HISTORY
• Head of Marketing Operations and Strategy – Guerbet France (since June 2024) • Global Marketing Director – Artificial Intelligence, Guerbet S.A. (2021–June 2024) • Marketing Director France, Microport CRM (2018–2021) Date of birth: September 28, 1974
• Key Account Manager, Siemens Healthineers (2017–2018)
Business address: Guerbet 15, rue des Vanesses 93420 Villepinte – France
• Global Marketing Director, EOS Imaging (2006–2013)
First appointment to the Board: November 22, 2023
• Biomedical Engineer, UTC (Université de Technologie de Compiègne)
Date of most recent reappointment: Not applicable End of term: November 22, 2027
• Business Unit Manager, Advance Therapy Division, Siemens Healthineers (2013–2017) • Marketing Manager, Praxim Medivision (2001–2006) EDUCATION
• Master of Business Administration (IAE Aix-en-Provence)
CURRENT OFFICES HELD
At Guerbet • Director • Member of the Ethics, Governance, and CSR Committee • Member of the Appointments and Compensation Committee 2025 meeting attendance rate
• Board of Directors: 100% • Ethics, Governance, and CSR Committee: 100% • Appointments and Compensation Committee: 100% CURRENT OFFICES HELD IN FRENCH COMPANIES
None CURRENT OFFICES HELD IN FOREIGN COMPANIES
None OFFICES HELD OVER THE LAST FIVE YEARS
French companies None Foreign companies None
46
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
CORPORATE GOVERNANCE Board of Directors
Éric GUERBET DIRECTOR Non-independent: member of the Guerbet family Secretary of the Shareholders’ Agreement CAREER HISTORY
Date of birth: August 4, 1976
• Head of the IT Global Regulatory & Transaction Reporting program at BNP Paribas – Corporate & Institutional Banking – Global Markets, Paris (since June 2021)
— — —
• Head of the IT Global P&L (Profit & Loss) program at BNP Paribas – Corporate & Institutional Banking – Global Markets, Paris (2016–2021)
Business address: Guerbet 15, rue des Vanesses 93420 Villepinte – France
• Head of the IT Murex BO Settlement/Interest Rate & Credit Derivatives program at BNP Paribas – Corporate & Institutional Banking – Global Markets, Paris (2010–2015)
First appointment to the Board: May 19, 2017
EDUCATION
Date of most recent reappointment: 2023 General Meeting
CURRENT OFFICES HELD
End of term: 2027 General Meeting
• Member of the Strategy and Innovation Committee
1|
|
• IT Project Manager at BNP Paribas, London (2003–2009) • IT Project Manager at BNP Paribas, Singapore (2000–2003)
2|
|
• Information Systems Engineer (ESME engineering school)
At Guerbet • Director
3|
|
• Member of the Ethics, Governance, and CSR Committee 2025 meeting attendance rate
4|
|
• Board of Directors: 100% • Strategy and Innovation Committee: 100% • Ethics, Governance, and CSR Committee: 100% CURRENT OFFICES HELD IN FRENCH COMPANIES
5|
|
• Director of holding company Hakea SAS CURRENT OFFICES HELD IN FOREIGN COMPANIES
None OFFICES HELD OVER THE LAST FIVE YEARS
6|
|
French companies None Foreign companies None
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
47
CORPORATE GOVERNANCE Board of Directors
Céline LAMORT DIRECTOR Non-independent: member of the Guerbet family CAREER HISTORY
• Industrial strategy and project management consulting (since 2021) • Director of Operations at Cartamundi (2021–2022) • Head of Strategic Projects at Barry Callebaut (2016–2021) Date of birth: March 30, 1982
• Head of Operations and other operational responsibilities (Production, Maintenance, Supply Chain, and Continuous Improvement) at Royal DSM N.V. (2006–2016)
Business address: Guerbet 15, rue des Vanesses 93420 Villepinte – France
EDUCATION
First appointment to the Board: May 29, 2015 Date of most recent reappointment: May 23, 2025 End of term: 2027 General Meeting
• IFA/Sciences Po Paris – Company Director Certificate • Unitech International Program • École Nationale Supérieure de Chimie de Paris (ENSCP) CURRENT OFFICES HELD
At Guerbet • Director • Member of the Strategy and Innovation Committee • Member of the Appointments and Compensation Committee 2025 meeting attendance rate
• Board of Directors: 100% • Strategy and Innovation Committee: 100% • Appointments and Compensation Committee: 100% CURRENT OFFICES HELD IN FRENCH COMPANIES
• Director of holding company Hakea SAS CURRENT OFFICES HELD IN FOREIGN COMPANIES
• Director of C.C.G.M Projects BV • Director of Covalence BV (a Belgian company) OFFICES HELD OVER THE LAST FIVE YEARS
French companies None Foreign companies None
48
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
CORPORATE GOVERNANCE Board of Directors
Michèle LESIEUR DIRECTOR Independent CAREER HISTORY
• CEO and Board Member of Supersonic Imagine, Public Company, Medical Imaging (2016–2020)
— — —
• CEO of Philips France and Managing Director of Philips Healthcare France (2011–2016) Date of birth: March 21, 1959 Business address: Guerbet 15, rue des Vanesses 93420 Villepinte – France First appointment to the Board: May 23, 2025 End of term: 2028 General Meeting
• Senior Vice President, Global Sales & Service International – Imaging Systems, Philips Healthcare (2006–2011) • CEO of the Sales and Services Division of Philips Medical Systems in France (2000–2006)
1|
|
• General Manager, Philips Business Electronics & Consumer Electronics (1997–2000) • Key Accounts Manager (Philips) (1989–1991) • Developer, then Product Manager at Portenseigne (Philips) (1983–1989) EDUCATION
2|
|
• DEA (master of advanced studies) in “Optical Transmission, Signal Processing,” Higher Institute of Optics & Paris XI, Orsay (1983) • Master’s in Physics, Paris-XI, Orsay (1982) • High Potential and Leadership Programs – Philips (1989–2007)
3|
|
CURRENT OFFICES HELD
At Guerbet • Director • Chairperson of the Audit Committee • Member of the Strategy and Innovation Committee
4|
|
2025 meeting attendance rate
• Board of Directors: 100% • Audit Committee: 100% • Strategy and Innovation Committee: 100%
5|
|
CURRENT OFFICES HELD IN FRENCH COMPANIES
• Chairperson of the Board of Directors – Prodways Group OTHER ROLES PERFORMED IN FRENCH COMPANIES
• Independent member of the Strategic Committee — MAG4Health
6|
|
CURRENT OFFICES HELD IN FOREIGN COMPANIES
None OFFICES HELD OVER THE LAST FIVE YEARS
French companies • Independent Director on the Board of Directors of Intrasense (2020-2025) • Independent Director on the Board of Directors of Provepharm and Member of the Audit Committee (2022–2023)
7|
|
• Independent Director on the Board of Directors of EOS imaging (2020-2021) Foreign companies • Independent Director and Chairperson of the Compensation Committee of Intelligent Ultrasound (UK-listed company) (2021-2025)
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
49
CORPORATE GOVERNANCE Board of Directors
Nicolas LOUVET DIRECTOR Non-independent: member of the Guerbet family CAREER HISTORY
• Sales & Marketing Director West and South EMEA region, Electronic Systems and Components, Yazaki Corporation (since 2025) Date of birth: June 27, 1976 Business address: Guerbet 15, rue des Vanesses 93420 Villepinte – France First appointment to the Board: May 27, 2016
• Sales & Marketing Director, Electronic Systems (2024) and Components, Stellantis/ Iveco/Ferrari (2022–2024) • Director of Global Value Improvement, Stellantis BU, Yazaki Corporation (2021–2024) • Head of the BU Improvement Plan at Yazaki Europe Limited (2013–2020) • Head of component key accounts at Yazaki Europe Limited (2012–2015) • Head of Strategic Projects at Yazaki Europe Limited (2007–2012) • R&D Engineer, then Project Manager at Valeo Éclairage et Signalisation (2001–2007) EDUCATION
• Engineer, graduate of UTC (Université de Technologie de Compiègne) CURRENT OFFICES HELD
Date of most recent reappointment: May 20, 2022
At Guerbet • Director
End of term: 2026 General Meeting
• Audit Committee member
• Chairperson of the Ethics, Governance, and CSR Committee
2025 meeting attendance rate
• Board of Directors: 100% • Ethics, Governance, and CSR Committee: 100% • Audit Committee: 100% CURRENT OFFICES HELD IN FRENCH COMPANIES
• Director of holding company Hakea SAS CURRENT OFFICES HELD IN FOREIGN COMPANIES
None OFFICES HELD OVER THE LAST FIVE YEARS
French companies None Foreign companies None
50
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
CORPORATE GOVERNANCE Board of Directors
Marc MASSIOT DIRECTOR Non-independent: member of the Guerbet family Treasurer of the Shareholder Agreement
— — —
CAREER HISTORY
• Chairperson of HAKEA SAS, holding • Founding Director, Enaxante, Business consulting in the healthcare sector (since 2007) Date of birth: June 16, 1960 Business address: Guerbet 15, rue des Vanesses 93420 Villepinte – France
• Director, Espace Santé Saint-Bernard – Physiotherapy, Osteopathy, Sports Health (since 2017) • Chief Executive Officer, Indiba France, medical device manufacturing (2013–2016)
1|
|
• Director or Training and Evaluation, Executive Committee member, LPG System, medical device manufacturer (2000–2007) • Member of the high council of paramedical professions (MK Commission) with the French ministry of health (1996–2000)
First appointment to the Board: May 28, 2021
• Instructor, Institut de Formation des Cadres de Santé at CRF and in the Paris and Rouen IFMK
Date of most recent reappointment: May 23, 2025
• Publications of books, articles, and communications in health and human sciences
End of term: 2029 General Meeting
• Research master’s degree in Education Sciences, Université de Provence, Aix-Marseille 1 (2006)
2|
|
EDUCATION
• EM Lyon Business School – LLL: Management & Budget general program (2007)
3|
|
• Health executive diploma (1993), osteopathy diploma (1992), State diploma in physiotherapy (1984)
4|
|
CURRENT OFFICES HELD
At Guerbet • Director • Chairperson of the Strategy and Innovation Committee
5|
|
2025 meeting attendance rate
• Board of Directors: 93% • Strategy and Innovation Committee: 100%
6|
CURRENT OFFICES HELD IN FRENCH COMPANIES
|
• Chairperson of holding company Hakea SAS • Manager of Société Enaxante SARL CURRENT OFFICES HELD IN FOREIGN COMPANIES
None
7|
|
OFFICES HELD OVER THE LAST FIVE YEARS
French companies None Foreign companies None
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
51
CORPORATE GOVERNANCE Board of Directors
2.2.1.9
Offices and positions held by executive directors: CEO and Deputy CEO
Jérôme ESTAMPES Acting CHIEF EXECUTIVE OFFICER – Guerbet CAREER HISTORY
• Acting CEO of Guerbet (September 22, 2025, to February 2, 2026) • Chief Financial Officer for Information Technology, Business Development and Licensing, Guerbet (since 2019) • Head of Integration and Transformation, Coty (2017–2019) Date of birth: May 22, 1968 Business address: Guerbet 15, rue des Vanesses 93420 Villepinte – France Appointed Chief Executive Officer of Guerbet: September 22, 2025, to February 2, 2026 (acting)
• Head of Finance and Operations, Pat McGrath Cosmetics (2015) • Financial Controller, then Group Director of Management Control and Strategic Plan, Coty, France and USA (2002–2015) • Chief Financial Officer, France, Health and Beauty, Crown Holdings (1997) • Management Controller, Alphacan, France (1995) • Financial Controller, Technip, Brazil (1993) EDUCATION
• Master’s, Audencia Business School CURRENT OFFICES HELD
At Guerbet • Interim CEO (September 22, 2025, to February 2, 2026) • Chief Financial Officer for Information Technology, Business Development and Licensing, Guerbet (since 2019) CURRENT OFFICES HELD IN FRENCH COMPANIES
• Director of Intrasense (term of office ended on November 14, 2025) CURRENT OFFICES HELD IN FOREIGN COMPANIES
None OFFICES HELD OVER THE LAST FIVE YEARS
French companies None Foreign companies None The Chief Executive Officer is not a member of the Board of Directors.
52
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
CORPORATE GOVERNANCE Board of Directors
Philippe BOURRINET DEPUTY CHIEF EXECUTIVE OFFICER Chief Pharmacist Senior Vice President of Development, Medical & Regulatory Affairs CAREER HISTORY
Guerbet: • Senior VP of Development, Medical & Regulatory Affairs (since January 2020) Date of birth: October 29, 1968 Business address: Guerbet 15, rue des Vanesses 93420 Villepinte – France
— — —
• Chief Pharmacist – Deputy Chief Executive Officer (since March 2021) • Head of Group Regulatory Affairs (2006–2019)
1|
• Head of Preclinical Development (1998–2019)
|
• Development Project Manager (1997–2005) UPSA: • Head of Pharmacokinetics, then Biological Screening (1994–1997) • Study Director in Pharmacokinetics (1993–1994)
Appointed Deputy CEO and Chief Pharmacist: March 24, 2021
Other: • Honorary Chair of the French Society of Toxicology
2|
|
• Member of the National Academy of Pharmacy (France) EDUCATION
• Doctorate in Pharmacy – Université Paris-V (1992)
3|
|
• DSP Biodynamics and Biopharmacy – University of Paris-V (1993) • Postgraduate diploma in Pharmacokinetics and Metabolism of Medicines – Université Paris-XI (1993)
4|
CURRENT OFFICES HELD
|
At Guerbet • Deputy Chief Executive Officer • Chief Pharmacist
5|
CURRENT OFFICES HELD IN FRENCH COMPANIES
|
None CURRENT OFFICES HELD IN FOREIGN COMPANIES
None
6|
OFFICES HELD OVER THE LAST FIVE YEARS
|
French companies None Foreign companies None
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
53
CORPORATE GOVERNANCE Board of Directors
2.2.2
Operation and powers of the Board of Directors
In accordance with article L. 225-35 of the French Commercial Code, the Board of Directors sets the guidelines for the Company’s activity and oversees its implementation in keeping with its corporate interest, taking into consideration the social, environmental, cultural, and sporting implications of its activity. Within the powers expressly granted by law to General Meetings of Shareholders and within the limits of the Company’s purpose, it deals with all issues affecting the Company’s operations and regulates the Company’s affairs. It performs the controls and verifications it deems appropriate. The agenda of Board meetings is drawn up by the Board Secretary after discussion with the Chairperson, taking into account the agendas of the meetings of the specialized Committees and the proposals of the Directors.
54
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
All Directors each receive all the information necessary to carry out their duties and can obtain the documents that they deem useful for this purpose. The Board of Directors grants the authorizations provided for by law (particularly those under the provisions of article L. 225-38 of the French Commercial Code). The Board of Directors can decide to create Committees (and determine the composition and powers thereof), which carry out their activity under its responsibility, but it cannot delegate the powers that are attributed to it by law or the articles of association or reduce or limit the powers of the Board of Directors. The Board of Directors can grant special mandates to one or more of its members for one or more specific purposes.
CORPORATE GOVERNANCE Board of Directors
FIGURES ON THE BOARD OF DIRECTORS
In 2025, the Board of Directors met 14 times with an average attendance rate of 98.6%. The following people participated in the Board meetings: • the Directors; • the Secretary of the Board; • one representative of the Central Social and Economic Committee in an advisory capacity, except in the case of Board meetings organized without the executive;
— — —
• frequently, the CEO and members of the Executive Committee; • from time to time, the Company’s Statutory Auditors, functional managers and employees. Since the start of 2026, and up to the date of this Universal Registration Document, the Board of Directors has met five times, including to review the annual financial statements for the 2025 fiscal year.
1|
|
2|
|
2.2.3
3|
|
Organization of the work of the Board of Directors and the Committees
The Board of Directors met 14 times in 2025 and worked on: • financial matters (review and approval of the annual and half-yearly financial statements and associated press releases, approval of forecast management documents, budget); • strategic issues, including the approval of the Group’s Medium-Term Plan – 2025-2029, changes in the organization of Interventional Radiology business, and work on the profitability of Diagnostic Imaging business, external and divestment transactions growth transactions; • monitoring the Group’s main challenges, in particular monitoring the situation at the Raleigh production site and its impact on the Group’s results, as well as monitoring its main performance indicators; • monitoring of the Company’s risks, including topics related to cybersecurity and information systems; • matters related to the compensation and appointments of corporate officers (executive and non-executive), including in particular decisions following changes within General Management, the appointment of an Acting Chief Executive Officer, and the process of selecting a new Chief Executive Officer; • the implementation of the Corporate Sustainability Reporting Directive (CSRD), including in particular the proposal for the appointment of Sustainability Commissioners and the validation of the main steps in the implementation of CSRD reporting (including the validation of the dual materiality analysis);
• matters relating to the Company’s social and environmental responsibility (taking into account the specific context of the implementation of the CSRD, including the Group’s Climate Strategy). The organization of governance relating to CSR topics is presented in the Sustainability Statement, section 5.1.2.1 Role of governance bodies; • matters relating to governance, including in particular the Board’s approval, at its meeting of September 22, 2025, of an amended version of the Internal Regulations to reflect the changes to the articles of association adopted by the General Meeting of May 23, 2025. These changes concern in particular the duration of terms of office, the meeting and voting procedures, the ability to adapt the articles of association, and the strengthening of the rules on confidentiality and inside information. They are in addition to the review of the annual assessment of the work of the Board and its Committees, which led to operating adjustments (meeting frequency, Committee composition and organization, agenda structuring).
4|
|
5|
|
6|
|
7|
|
The Board of Directors relies on the work of four Committees: the Strategy and Innovation Committee, the Appointments and Compensation Committee, the Audit Committee, and the Ethics, Governance, and CSR Committee. The Committees are forums for analysis and consideration to prepare for the discussions of the Board of Directors. They issue opinions and recommendations but are not decision-making bodies. They report on their work at each meeting of the Board of Directors. The Directors have a digital platform for secure access to the documents necessary to perform their duties for the Board of Directors and its Committees.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
55
CORPORATE GOVERNANCE Board of Directors
COMPOSITION OF THE COMMITTEES AT DECEMBER 31, 2025
Independent Director.
2.2.3.1
Audit Committee
The Committee met four times in 2025. It is chaired by Michèle Lesieur, Independent Director, and has been composed of four members since May 23, 2025. The Internal Regulations of the Board of Directors set the minimum number of Independent Directors on the Committee and provide that the Chairperson of the Audit Committee must be an Independent Director. Note that the Afep-Medef Code recommends that at least two thirds of the Committee’s members should be Independent Directors. This Committee composition rule was not adopted because of the significant proportion of members representing the Shareholder Agreement on the Board. With two Independent Directors, the Audit Committee is 50% independent. In accordance with article L. 823-19 of the French Commercial Code, the Audit Committee, under the sole collective responsibility of the Board’s members, oversees issues relating to (i) the preparation and examination of the parent-company financial statements and, where applicable, the consolidated financial statements; (ii) the independence and objectivity of the Statutory Auditors; and (iii) the effectiveness of the internal control, audit, and risk management systems. It makes a recommendation to the Board of Directors on the Statutory Auditors, whose appointment and reappointment will be proposed to the General Meeting. The Committee hears from the CEO, the CFO, and the Statutory Auditors. It also regularly heard from the Director of Internal Control, the Heads of Internal Audit and Internal Control, and the Head of Risks. Pursuant to Order No. 2023-1142 of December 6, 2023, transposing the European Corporate Sustainability Reporting Directive (CSRD), the Audit Committee was entrusted with the task of reviewing the process for preparing and certifying sustainability information. For these missions, the Audit Committee organizes its work in conjunction with the Ethics, Governance, and CSR Committee.
In 2025, the Committee devoted its meetings in particular to: • reviewing the Company’s consolidated financial statements; • reviewing the Company’s sustainability report; • reviewing financial communications; • internal audit topics (review of the previous year’s internal audit, follow-up on the audit recommendations, and presentation of internal audit reports); • development and improvement of internal control; • analysis and control of the Group’s risks; • the Statutory Auditors’ and Sustainability Auditors’ audits and reports and the examination of their independence. The Audit Committee attendance rate in 2025 was 100%.
2.2.3.2
Strategy and Innovation Committee
This Committee met seven times in 2025. It is chaired by Marc Massiot, a Guerbet family member serving as a NonIndependent Director. The Committee has been composed of six members since May 23, 2025. The mission of the Strategy and Innovation Committee is to prepare the work of the Board of Directors on topics of major strategic interest, in particular the examination of medium-term strategic directions, changes in the competitive environment, the annual budget, the industrial strategy, Innovation and R&D priorities and projects, investment, divestment, cooperation, and external growth operations, stock market financial strategies, and preserving its main financial balances. The agendas notably included: • the 2026-2030 Medium-Term Plan; • the Group’s industrial strategy; • the strategy of the Group’s various product segments; • the Artificial Intelligence strategy; • discussions on innovation topics. The Strategy and Innovation Committee’s meeting attendance rate in 2025 was 100%.
56
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
CORPORATE GOVERNANCE Board of Directors
2.2.3.3
Appointments and Compensation Committee
The Committee met four times in 2025. It was chaired by Pascale Auger, Independent Director, until May 23, 2025. Since May 23, 2025, it has been chaired by Carine Dagommer, a Non-Independent Director belonging to the Guerbet family. Since then, it has been composed of five members. The current proportion of Independent Directors is 50%(1). The Afep-Medef Code’s recommendation of having Independent Directors constitute a majority of the Committee members was therefore applied. However, it should be noted that a Director representing the employees is a member of this Committee, as recommended by the Afep-Medef Code. The role of the Appointments and Compensation Committee is to make recommendations or proposals to the Board of Directors on: • appointment and reappointment of Directors and appointment, dismissal, and compensation of the Chief Executive Officer and the Deputy Chief Executive Officers; • the Group’s compensation policy and long-term compensation policy; • the compensation policy for executive officers;
2.2.3.4
Ethics, Governance, and CSR Committee
The Committee met four times in 2025. It is chaired by Nicolas Louvet, Non-Independent Director, and has been composed of four members since May 23, 2025. This Committee prepares the work of the Board of Directors with regard to ethics, governance, and CSR within the Group. As such, the Committee handles and monitors all issues relating to: • consistency of the Company’s values, actions, and projects with social, legal, and regulatory standards; • management integrity; • definition of and compliance with good governance rules;
• the Company’s articles of association and the Internal Regulations of the Board of Directors; • the CSR strategy and the implementation of CSR action;
2|
|
• the composition of the Board of Directors and its Committees and reviewing aspects of compliance (independence, conflicts of interest, ownership of shares, etc.). In general, this Committee also ensures that the Board and the Board’s Committees are operating effectively.
The Committee specifically:
The agendas covered:
• made recommendations related to changes within General Management, in particular the departure of the Chief Executive Officer, the appointment of an Acting Chief Executive Officer, and the implementation and monitoring of the selection process for a new Chief Executive Officer;
• progress on the Group’s CSR road map (People & Planet);
• in conjunction with the Ethics, Governance, and CSR Committee, established and followed up on the process of recruiting a new Independent Director at the 2026 General Meeting to become Chairperson of the Board of Directors (following the decision of the Chairperson of the Board of Directors to leave office for personal reasons with effect from the end of the General Meeting to be held on May 22, 2026);
1|
|
• prevention of corruption and fraud and compliance with the ethics charter;
• succession planning for the Chief Executive Officer, senior executives, and people holding key positions within the Group.
• in the context of the appointment of a new Chief Executive Officer, reviewed the compensation policy for the Chief Executive Officer (fixed, variable, and long-term components) to ensure that it is in line with market practices;
— — —
• follow-up on the implementation and progression of CSRD regulations within the Group;
3|
|
4|
|
• energy restraint challenges and plans; • assessment of the Group Alert Line; • the composition of the Committees of the Board of Directors, including a review of the expertise on the Board;
5|
|
• a draft amendment to the Internal Regulations; • the proposed amendment to the articles of association (reduction of the term of office); • follow-up on the action plan put in place following the assessment of the Board of Directors and the Committees held in 2023.
6|
|
The Ethics, Governance, and CSR Committee’s meeting attendance rate in 2025 was 100%.
• proposed a performance bonus share issue plan;
7|
|
• revised the succession plan for the CEO and members of the Executive Committee; The Appointments and Compensation Committee’s attendance rate in 2025 was 100%.
(1)
In accordance with the recommendations of the Afep-Medef Code, the Directors representing employees are not included in the calculation of the percentage of Independent Directors on the Appointments and Compensation Committee.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
57
CORPORATE GOVERNANCE Board of Directors
2.2.4
Assessment of the Board of Directors and its Committees
In accordance with the provisions of its Internal Regulations and the Afep-Medef Code, the Board of Directors conducts an annual self-assessment and, every three years, an external assessment. The purpose of this exercise is to assess the Board’s ability to meet the expectations of the Shareholders who have entrusted it with managing the Company by reviewing its composition, organization, and operation, as well as the four committees that it has set up. After the conduct of a formal evaluation by an external service provider in 2023, the Board of Directors conducted a selfassessment of its operations and work this year. It was carried out using an online questionnaire sent by the Corporate Secretary of the Board at the end of the year to the Board members. This detailed questionnaire, with open and closed questions, allows participants to explain their answers and add comments. It covers the operation of the Board of Directors, its work, and the training and responsibilities of the Directors. The self-evaluation includes a review of the past year and the responses to objectives set at the beginning of the year. Lastly, it looks ahead to the coming year with questions about the objectives for the Board and the topics to be explored further. The reporting on this evaluation took place at the Board meeting of January 30, 2026, and within each of the Committees in January and February 2026. The Board’s operation and governance practices were assessed as satisfactory. Among the strengths identified were the changes made to governance: the monthly frequency of Board meetings, enabling better monitoring of the Group’s activity in a fiscal year that was marked by operational events having a significant financial impact on the Group and requiring greater monitoring of the Board of Directors; strengthened collegiality during discussions and decisions; and an increase in the Board’s added value for management, reinforced by the new composition of the Board of Directors (fewer Directors and the addition of two new Independent Directors with recognized experience in key areas for the Company). The following were also highlighted: the focus of the work of the Committees on key topics for the Company (fostered by the Committees adopting a more limited
58
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
composition and reducing the number of meetings), the strong involvement of the Chairperson of the Board and of the Committee Chairpersons, and recognition of the contribution of the Board’s secretariat. In 2026, the Directors want to continue to focus their work on key and strategic issues for the Group and improve the process for monitoring the decisions of the Board of Directors. In the internal self-assessment questionnaire, the Directors also identified topics to be addressed and dealt with: • monitoring the Group’s financial position and financing; • monitoring the implementation of the Group’s development strategy and the improvement of the profitability of its various business segments; • reviewing industrial strategy; • monitoring major risks relating to the Group’s challenges; • issues relating to the operation of the Board of Directors, with particular consideration given to the frequency of meetings of the Board of Directors and the Committees in a context of the Group’s strategy stabilizing, and the appointment and renewal of directorships in 2026 and 2027.
Assessment of the Committees For the fifth year, each Board Committee conducted its own self-assessment using specific questionnaires sent to the members of each Committee. In general, Director attendance at Committee meetings is very high (between 96% and 100% in 2025). Each Committee member has been particularly active and effective, contributing according to his or her expertise. The self-assessment of each Committee indicates a high level of satisfaction with the appropriateness of the Committees’ composition, with regard to both the number of members and expertise and the allocation of roles. The role of the Strategy and Innovation Committee has been greatly strengthened in terms of both the number of members and the strategic topics addressed. The Directors then outlined the priority themes to be explored by each Committee.
CORPORATE GOVERNANCE General management
2.3
GENERAL MANAGEMENT
2.3.1
Chief Executive Officer
From September 22, 2025, Jérôme Estampes served as Chief Executive Officer, a position separate from that of Chairperson of the Board of Directors. He succeeded David Hale, who had held this position since January 1, 2020.
Post-closing events At its meeting on January 28, 2026, the Board of Directors, on the recommendation of the Appointments and Compensation Committee, decided to appoint Karim Boussebaa as Chief Executive Officer of the Guerbet Group, with effect from February 2, 2026. Karim Boussebaa’s appointment was announced in a press release issued on January 28, 2026.
2.3.2
In accordance with the provisions of the French Commercial Code and the Company’s articles of association, Guerbet’s CEO is appointed by the Board of Directors on the proposal of the Appointments and Compensation Committee. This officer may be dismissed at any time by the Board of Directors. Pursuant to article L. 225-56 of the French Commercial Code, the CEO has the broadest powers to act in all circumstances on the Company’s behalf. The CEO’s powers are exercised within the scope of the corporate purposes and subject to those powers expressly granted to General Meetings of Shareholders and to the Board of Directors by law. The CEO represents the Company in its relations with third parties. The provisions relating to the CEO’s compensation, detailing the rules and principles for determining the CEO’s compensation, as well as the compensation paid and awarded during the 2025 fiscal year are specified in section 2.4 of this report.
Deputy CEO – Chief Pharmacist
On the proposal of the CEO, the Board of Directors may appoint a Deputy CEO to assist in the CEO’s duties. Pursuant to articles L. 5124-2 and R. 5124-34 of the French Public Health Code, the Company has a Chief Pharmacist with the role of Deputy CEO, whose duties are performed with the same authority as the CEO with respect to third parties. In accordance with the provisions of the law on simplification, clarification, and modernization of corporate law of July 19, 2019, amending article L. 225-53 of the French Commercial Code, article 14 of the Company’s articles of association was amended to specify that in the event of the appointment of a Deputy CEO, the Board of Directors will determine a selection process that guarantees, until its completion, the presence of at least one person of each sex among the candidates.
— — —
1|
|
2|
|
3|
|
This officer may be dismissed at any time by the Board of Directors. Philippe Bourrinet was appointed Deputy Chief Executive Officer – Chief Pharmacist by the Board of Directors on March 24, 2021. The Deputy CEO receives compensation for performing the duties of Chief Pharmacist. Philippe Bourrinet has an employment contract for which he receives compensation as Head of Development and Medical and Regulatory Affairs. The provisions relating to the Deputy CEO’s compensation, detailing the rules and principles for determining the CEO’s compensation, as well as the compensation paid and awarded during the 2025 fiscal year are specified in section 2.4 of this report.
4|
|
5|
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
59
CORPORATE GOVERNANCE General management
2.3.3
Executive Committee
Guerbet’s Executive Committee is chaired by the Chief Executive Officer and includes the Directors of the main operational and financial functions of Guerbet. The Executive Committee meets once a month. This body supports the Chief Executive Officer in implementing the strategy defined by the Board of Directors and provides operational guidance for decision-making. Its main tasks are as follows: • determining the Group’s budget lines according to the medium-term strategic priorities determined with the Board of Directors;
• guiding and monitoring operational performance; • giving opinions on the Company’s directions and deciding on reallocations of resources if necessary; • managing critical risks. The missions of the Executive Committee on CSR-related topics are presented in the Sustainability Statement (section 5.1.2 CSR Governance). As of December 31, 2025, the members of the Executive Committee are:
• proposing annual qualitative and quantitative objectives to the Board of Directors;
Equality on the Executive Committee Guerbet is committed to applying a gender equality policy in its Executive Committee and more broadly within its senior management. The Executive Committee is currently composed of 44% women and 56% men.
60
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
CORPORATE GOVERNANCE Compensation of corporate officers
2.4
COMPENSATION OF CORPORATE OFFICERS
2.4.1
Compensation policy for corporate officers
The information set forth below is part of the compensation policy for corporate officers established in accordance with article L. 22-10-8 of the French Commercial Code. This policy describes all the components of the fixed, variable, and, where applicable, exceptional compensation of Guerbet’s corporate officers, including its Chairperson of the Board of Directors, its Chief Executive Officer, its Deputy Chief Executive Officer, and its Directors, and explains the decision-making process for its determination, review, and implementation. The payment and award in year N of the variable components of compensation for fiscal year N-1, which are set out below, are conditional on the approval by the Ordinary General Meeting in year N of the components of compensation for the corporate officer in question under the conditions provided for in article L. 22-10-8 of the French Commercial Code. The compensation policy for corporate officers is determined by the Board of Directors on the basis of recommendations made by the Appointments and Compensation Committee and is reviewed annually. Guerbet’s Appointments and Compensation Committee includes no corporate officers and is composed primarily of Independent Directors and one Director representing the employees, in accordance with the recommendations of the Afep-Medef Code. The Committee may call upon external advisors specializing in executive compensation. The Board of Directors ensures that the compensation policy is appropriate for the Company’s strategy and context and aims to promote its performance and competitiveness in the short, medium, and long term. It is based on the following principles: • compliance with the recommendations of the Afep-Medef Code; • consistency with compensation policies within the market in order to remain competitive. Benchmarks are periodically produced to measure compensation levels and structures against panels of comparable companies in the healthcare sector; • respecting the principle of balance between the various components of compensation (annual fixed, annual variable, and multiyear variable) and in light of the compensation policy in force in the Company;
• a concern for attractiveness and retention to attract, motivate, and retain talent, while taking into account the requirements of stakeholders, including Shareholders, in terms of social and environmental responsibility, transparency, and performance;
— — —
• an alignment of performance conditions with the Company’s interests and objectives in terms of sustainable and profitable growth in the short, medium, and long term;
1|
• transparency and clarity of the compensation policy.
|
The Appointments and Compensation Committee ensures that these principles are appropriately applied in its recommendations to the Board of Directors, in terms of determining the compensation policy and its implementation, when the actual amounts of the compensation packages are determined.
|
The compensation policy for corporate officers, especially their variable compensation, is part of the Company’s short-term, medium-term, and long-term strategy. The objectives for the Chief Executive Officer are based on the Company’s mediumterm and long-term strategic plans. The annual variable compensation criteria are the short-term (one year) version of the objectives of the medium-term and long-term strategic plans. The Chairperson of the Board does not receive variable compensation. The Deputy Chief Executive Officer may receive variable compensation under the employment contract and not for the corporate office. The performance criteria for determining multiyear variable compensation are set out in the medium-term and long-term strategic plans. The criteria for awarding compensation are determined in order to be consistent with the corporate interest of Guerbet Group and to help ensure its sustainability. The compensation of corporate officers also depends on their responsibilities, the results achieved, and the work completed. It depends, particularly for the Chief Executive Officer and the Deputy Chief Executive Officer, on the type of duties entrusted to them or on exceptional situations. In addition, to make sure that the compensation is competitive, the principle of comparability is also applied so that the awarded compensation can be compared with the reference market of healthcare. A benchmark was established in 2022 for the Chairperson of the Board of Directors and in 2026 for the Chief Executive Officer. Changes in the compensation of corporate officers are decided in accordance with the labor policy and the compensation policy applicable to all employees, including other executives and employees of the Company.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
2|
3|
|
4|
|
5|
|
6|
|
7|
|
61
CORPORATE GOVERNANCE Compensation of corporate officers
2.4.1.1
Compensation policy for the Chairperson of the Board of Directors
Compensation structure The Chairperson of the Board of Directors receives total compensation consisting of: • fixed compensation for serving as Chairperson; • compensation for serving as a Director; • group welfare insurance and health insurance plans; • a supplementary pension plan. Consistent with the non-executive role and in line with market practices in France, the Chairperson of the Board of Directors does not receive any short-term annual variable compensation or multiyear variable compensation, in cash or in shares, tied to the performance of the Company or the Group and is not part of any long-term incentive plan. In accordance with the recommendations of the Afep-Medef Code, the fixed compensation of the Chairperson of the Board of Directors, a corporate officer, is reviewed periodically. It may be subject to change according to changes in the Company’s scope as well as market compensation trends so that it remains competitive.
Annual fixed compensation The fixed annual compensation of the Chairperson of the Board of Directors is determined in view of market studies and is awarded as payment for the responsibilities inherent in this type of corporate office. Accordingly, the following factors are taken into account in its determination: • the responsibilities and duties specific to this corporate office, as provided for by law and the Internal Regulations of the Board of Directors, which notably involve ensuring that the Company is properly governed and that its governance bodies (Board of Directors and its Committees and the General Meeting of Shareholders) function effectively; • the skills, experience, expertise, and professional profile of the holder of this position; • market benchmarks on compensation granted to a nonexecutive Chairperson in comparable companies of the healthcare market in France. The compensation policy may be changed during the term of office and prior to reappointment if there is a significant change in the Company’s scope and in the responsibilities entailed by this position or if it diverges further away from the
62
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
benchmark market. In such specific situations, the nature of any adjustment to the fixed compensation and the associated reasons are publicly disclosed. For the 2025 fiscal year, the fixed annual compensation of the Chairperson of the Board of Directors was set at €130,000.
ANNUAL FIXED COMPENSATION FOR 2026 On the proposal of the Appointments and Compensation Committee and after deliberation by the Board of Directors on March 11, 2026, maintenance of the annual fixed compensation of the Chairperson of the Board of Directors at €130,000 for the 2026 fiscal year is proposed, subject to approval by the Annual General Meeting called to approve the financial statements for the 2025 fiscal year to be held on May 22, 2026.
Compensation for serving as a Director As a Director, the Chairperson of the Board of Directors receives compensation for this role. The details of this compensation (fixed and variable portions) are described in section 2.4.2 below.
Benefits in kind Group welfare insurance and health insurance plans Since 2015, the Chairperson of the Board of Directors has been a beneficiary under the following plans, subject to the same conditions applicable to all employees of the Group’s French entities: • an “incapacity, disability, or death” benefit plan; • a supplementary health insurance plan.
Supplementary pension plan In accordance with the decision of the Board of Directors on March 27, 2018, the Chairperson of the Board of Directors is covered by Guerbet S.A.’s funded supplementary pension plan (“article 83”) starting in 2018, subject to the same conditions as Guerbet’s executives.
Other components of compensation The Chairperson of the Board of Directors does not have access to a company car. And will not receive severance pay if this appointment is terminated.
CORPORATE GOVERNANCE Compensation of corporate officers
2.4.1.2
Compensation policy for the Chief Executive Officer (executive corporate officer)
Compensation structure The compensation policy for the Chief Executive Officer aims to strike a balance between long-term and short-term performance to promote the Company’s development for all its stakeholders. As such, in order to safeguard their interests, the Company endeavors to maintain consistency between the Chief Executive Officer’s total compensation and the Company’s performance.
The structure of the Chief Executive Officer’s compensation is broken down as follows: • 1/3 fixed annual compensation, not subject to performance conditions; • 1/3 variable annual compensation, subject to performance conditions (100% paid if objectives are achieved AND not exceeded); • 1/3 multiyear variable compensation, subject to performance conditions.
— — —
1|
|
2|
|
3|
|
Annual fixed compensation The Chief Executive Officer’s annual fixed compensation is awarded as payment for the responsibilities inherent in such a position. The following factors are among those considered: • the level and complexity of the duties and responsibilities attributed to this position; • the skills, experience, expertise, and professional profile of the holder of the position; • market analyses and studies on the compensation of international executives in comparable companies in the healthcare industry with their head office in France to ensure attractive, competitive compensation levels. For the 2025 fiscal year, the Chief Executive Officer’s annual fixed compensation was maintained at €469,500.
ANNUAL FIXED COMPENSATION FOR 2026 On the proposal of the Appointments and Compensation Committee and following the deliberations of the Board of Directors on March 11, 2026, it is proposed to maintain the fixed annual compensation of the Chief Executive Officer for the 2026 fiscal year at €560,000 gross, subject to the approval of the Annual General Meeting called to approve the accounts for the 2025 fiscal year, which will be held on May 22, 2026.
Annual variable compensation Calculation LThe Chief Executive Officer’s annual variable compensation is intended to encourage the achievement of the annual performance objectives determined by the Board of Directors in line with the implementation of the Company’s strategy. The amount of this variable compensation set at between 0% and 150% of the fixed annual remuneration is calculated in proportion to achievement of the objectives. Provided that all the applicable objectives are achieved, variable compensation equals 100% of the annual fixed compensation. If the objectives are exceeded, it may amount to a maximum of 150% of the annual fixed compensation. Its determination is based on quantitative, financial and nonfinancial objectives tied to the progress of key projects for the Group's development, as well as qualitative criteria linked to the Group's strategic challenges.
4|
|
5|
|
6|
|
7|
|
The quantitative objectives related to variable compensation are as follows: • business performance (sales, EBITDA, free cash flow) and progress on Guerbet’s key and strategic projects; • Corporate Social Responsibility with the objectives of achieving a Safety Index (including a reduction in the number of incidents recorded at the Group level); • reducing relative energy and water consumption; • the financial performance objectives based on financial indicators are determined in a specific manner on the basis of the budget pre-approved by the Board of Directors but are not made public due to operational confidentiality.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
63
CORPORATE GOVERNANCE Compensation of corporate officers
The variable annual compensation is calculated and set by the Board of Directors following the close of the fiscal year to which it applies. On the recommendation of the Appointments and Compensation Committee, the Board of Directors determines the various objectives, their weightings, and the expected performance levels. It thus sets: • the trigger threshold below which no variable compensation is paid; • the variable compensation target level, corresponding to the amount due when each objective is achieved; and • the criteria for assessing quantitative and qualitative performance. Accordingly: • 0% of the premium is paid if the achievement of the objectives is below a minimum threshold; • 100% of the premium is paid if the objectives are achieved; • 150% of the premium may be paid if these objectives are exceeded.
Payment condition In accordance with French law, payment of the compensation is subject to approval at the Ordinary General Meeting.
Appointment to or termination of office If a new CEO is appointed or the existing CEO’s appointment is terminated during the course of a year, the same principles as above will apply on a pro-rata basis for the period during which the CEO in question actually holds the office.
2026 OBJECTIVES The Chief Executive Officer’s variable compensation for 2026 will be based on quantitative, financial, and non-financial objectives tied to the progress of key projects for the Group’s development. The details of the performance conditions are as follows:
- company performance (sales, EBITDA, free cash flow);
- the progress of the Company’s key and strategic projects;
- corporate Social Responsibility with the objectives of achieving a Safety Index (including a reduction in the number of incidents recorded at the Group level), reducing relative energy consumption.
Multiyear variable compensation Objective In 2016, Guerbet’s Board of Directors introduced the issue of performance shares in the Group’s compensation policy. The Board of Directors considers that this mechanism, which also applies to other key positions within the Company, is
64
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
particularly suited to the position of Chief Executive Officer in view of the role’s expected level of direct contribution to the Company’s medium-term and long-term performance in line with the objectives communicated to the market. This compensation helps to increase the corporate officer’s motivation and loyalty while aligning the corporate officer’s interests with those of the Company’s Shareholders and its corporate interest.
System and conditions Guerbet’s multiyear compensation system currently consists solely of the issue of performance shares. The maximum number of performance shares that may be awarded is equal to 100% of the Chief Executive Officer’s annual fixed compensation calculated on the basis of the market price on the date awarded. On the recommendation of the Appointments and Compensation Committee, the Board of Directors defines the performance conditions pertaining to compensation in performance shares for all beneficiaries of Guerbet and its subsidiaries throughout the world. Failure to meet the performance conditions over the assessment period results in the loss of all or part of the initial issue. These awards are also subject to a condition of presence in the Group at the end of the vesting period and entail an obligation for the Chief Executive Officer to hold these shares until the end of the term of office (see below). On the proposal of the Appointments and Compensation Committee, the Board of Directors validates the achievement of the defined criteria at the end of the vesting period.
Compulsory holding period Pursuant to the provisions of article L. 225-197-1 of the French Commercial Code and as determined by the Board of Directors, the CEO holds 25% of the issued shares in registered form for their entire term of office. In the event of retirement upon reaching the legal retirement age before the end of the performance share vesting period, the CEO continues to benefit from the performance shares initially issued but remains subject to the other conditions of the plan, including performance conditions. In the event of a departure from the Group for reasons other than retirement, the CEO loses the benefit of the issued performance shares.
Welcome compensation Welcome compensation may be granted to a new Chief Executive Officer arriving from a company outside the Group. This is intended to compensate for the loss of benefits previously enjoyed. This compensation and its payment are disclosed in the Company’s annual report. It may take several forms. In particular, it may be granted in the form of shares, of which 20% fully vested must be held in registered form until leaving office.
Exceptional compensation Exceptional compensation may also be awarded in exceptional circumstances.
CORPORATE GOVERNANCE Compensation of corporate officers
Benefits in kind Group welfare insurance and health insurance plans Under the conditions applicable to all employees of the Group’s French entities, the Chief Executive Officer is covered by the following: • an “incapacity, disability, or death” benefit plan; • a supplementary health insurance plan.
US 401K pension plan The Chief Executive Officer receives a gross annual payment of €40,050 to allow contributions to a US 401K pension plan.
Unemployment insurance coverage Guerbet has taken out a private unemployment insurance policy with the Association pour la garantie sociale des chefs et dirigeants d’entreprises – GSC (French association of unemployment insurance for corporate officers) enabling the Chief Executive Officer to receive compensation in the event of lost employment.
Company car The Chief Executive Officer has use of a company vehicle.
Legal and tax assistance If necessary, the Chief Executive Officer may receive assistance for the preparation of personal tax returns with French and foreign authorities (for example, US authorities).
Accommodation and relocation The Chief Executive Officer is reimbursed for the costs of temporary accommodation in France for a period of 3 to 6 months, a contribution for the search for accommodation in France, and a contribution to their relocation and accommodation costs from the date of moving into a permanent address in France.
Other benefits in kind The Chief Executive Officer is reimbursed for travel expenses and professional expenses in accordance with the Company’s internal policy, and for Professional Civil Liability insurance.
Compensation for serving as a Director The Chief Executive Officer, who is also a Director, receives compensation for that role, including for participating in meetings of the Board of Directors. Currently, the Chief Executive Officer is not a Director and therefore does not receive any compensation in this respect.
Non-compete indemnity Provided that they have held office for a minimum period of 2 years, in return for a non-compete obligation (it being specified that the Company may waive said obligation within one month of departure, in which case no indemnity will be due), the Chief Executive Officer may receive, as of the date of departure from office and for 12 months, a gross monthly indemnity equal to 50% of their average gross compensation (including fixed compensation and variable compensation) during the 12 months preceding the effective date of departure from office.
Compensation upon leaving office The Chief Executive Officer has no commitment from the Company pertaining to compensation or benefits owed if the role is ended or changed.
2.4.1.3
Compensation policy for the Deputy Chief Executive Officer (Group Chief Pharmacist)
— — —
Annual fixed compensation of the Deputy Chief Executive Officer, Chief Pharmacist The Deputy Chief Executive Officer receives “Chief Pharmacist” compensation for serving in this role for Guerbet Group. The Appointments and Compensation Committee proposes to the Board of Directors the amount of the Chief Pharmacist premium for the Deputy Chief Executive Officer, which is then submitted to the General Meeting. The Deputy Chief Executive Officer may also be an employee of the Company with an employment contract for the position held. In that case, the Deputy Chief Executive Officer receives annual fixed compensation and annual variable compensation according to the conditions in force for Group employees.
1|
|
2|
|
3|
|
Compensation for 2026 On the proposal of the Appointments and Compensation Committee and after deliberation by the Board of Directors on March 11, 2026, the annual fixed compensation of the Deputy Chief Executive Officer – Chief Pharmacist – for the 2025 fiscal year is set at €11,500, subject to approval by the Annual General Meeting called to approve the financial statements for the 2025 fiscal year to be held on May 22, 2026.
Multiyear variable compensation
4|
|
5|
|
The Deputy Chief Executive Officer does not receive multiyear variable compensation.
Compensation for serving as a Director The Deputy Chief Executive Officer, who is also a Director, receives compensation for that role, including for participating in meetings of the Board of Directors. Currently, the Deputy Chief Executive Officer is not a Director and therefore does not receive any compensation in this respect.
6|
|
7|
|
Compensation upon leaving office The Deputy Chief Executive Officer has no commitment from the Company pertaining to compensation or benefits owed if the role is ended or changed.
Exceptional compensation Exceptional compensation may also be awarded in exceptional circumstances.
Other components of compensation The Deputy Chief Executive Officer does not receive any other form of compensation for this role.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
65
CORPORATE GOVERNANCE Compensation of corporate officers
2.4.2
Compensation of the Chairperson of the Board of Directors, Hugues Lecat
2.4.2.1
Summary of compensation of the Chairperson of the Board of Directors, Hugues Lecat
(in €)
Compensation awarded for the fiscal year (including social security contributions and benefits in kind) Compensation for serving as a Director(a) TOTAL COMPENSATION
2025
2024
130,000
83,925
56,600 186,600 (b)
30,334 114,259
(a) Given that Directors’ compensation is considered investment income, it is not subject to social security contributions. (b) Amount proposed for a vote at the General Meeting of Shareholders of May 22, 2026.
2.4.2.2
Details of compensation of the Chairperson of the Board of Directors, Hugues Lecat Due for the fiscal year
(in €)
Fixed compensation as Chairperson of the Board of Directors (including social security contributions) Compensation as a Director(a) BENEFITS IN KIND(b) TOTAL COMPENSATION
Paid during the fiscal year
2025
2024
2025
2024
130,000
78,629
130,000
78,629
56,600 8,759
30,334 5,296
30,334 8,759
— 5,296
195,359 (c)
114,259
169,093
83,925
(a) Given that Directors’ compensation is considered investment income, it is not subject to social security contributions. (b) The Chairperson of the Board of Directors has health coverage and a welfare insurance policy. Contributions paid by Guerbet in 2025 totaled €2,909. The Chairperson is also covered by the “article 83” funded pension plan. Contributions for 2025 totaled €5,850. (c) Amount proposed for a vote at the General Meeting of Shareholders of May 22, 2026.
66
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
CORPORATE GOVERNANCE Compensation of corporate officers
2.4.2.3
Components of compensation paid or awarded for the 2025 fiscal year (ex-post vote at the General Meeting of May 22, 2026)
Components of compensation submitted to a vote
2025 fixed compensation
Amounts paid during the past fiscal year
Amounts granted for the past fiscal year or book valuation
€130,000
€130,000
Directorship compensation
€30,334
Benefits of any kind – Welfare insurance and mutual health insurance
€2,909
Benefits of any kind – Supplementary pension
€5,850
Comments
Section 2.4.1.1 Compensation policy for the Chairperson of the Board of Directors. The amount was determined based on: • the responsibilities and duties specific to this corporate office, as provided for by law and the Internal Regulations of the Board of Directors, which notably involve ensuring that the Company is properly governed and that its governance bodies (Board of Directors and its Committees and the General Meeting of Shareholders) function effectively; • the skills, experience, expertise, and professional profile of the holder of this position; • market benchmarks on compensation granted to a nonexecutive Chairperson in comparable companies of the healthcare market in France. The last benchmarking was in 2022. Section 2.4.5 Directors’ compensation.
€56,600
The Directors’ compensation consists of a fixed portion and a variable portion. The variable portion is the main part of the Directors’ compensation. €2,909
1|
|
2|
|
3|
|
Section 2.4.1.1 Compensation policy for the Chairperson of the Board of Directors. Contributions paid by Guerbet for mutual health insurance and welfare insurance. The Chairperson has health coverage and a welfare insurance policy, taken out by Guerbet, under the same conditions as for Guerbet employees. The contributions paid by Guerbet totaled €2,909 in 2025, of which €1,444 for welfare insurance and €1,465 for mutual health insurance.
€5,850
Section 2.4.1.1 Compensation policy for the Chairperson of the Board of Directors. Hugues Lecat is covered by the “article 83” funded pension plan, a mandatory Group insurance policy for the executive category. Contributions for 2025 totaled €5,850.
2.4.2.4
— — —
4|
|
5|
|
6|
|
Summary of benefits of the Chairperson of the Board of Directors
TABLE 11 ACCORDING TO THE AFEP-MEDEF CODE RECOMMENDATIONS AND AMF POSITION-RECOMMENDATION NO. 2009-16
Chairperson of the Board of Directors
Employment contract
Hugues Lecat Start of term of office: May 24, 2024
Yes
7|
|
Compensation or benefits owed or liable to be owed following a termination or change of duties
Supplementary pension plan
No
Yes
×
×
No
Yes
Compensation relating to a non-compete clause
No
×
Yes
No
×
End date: at the close of the 2030 General Meeting called to approve the 2029 financial statements
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
67
CORPORATE GOVERNANCE Compensation of corporate officers
2.4.3
Compensation of the Chief Executive Officer, David Hale, from January 1 to September 22, 2025
2.4.3.1
Summary of compensation of the Chief Executive Officer, David Hale
(in €)
Compensation due for the fiscal year (including payroll taxes)
2025
2024
(a)
839,390
389,060
Multiyear compensation due: • Value of performance shares awarded during the fiscal year
—
—
— (b)
451,546
—
916,235
286,315 675,375
336,072 2,543,243
• Value of performance shares awarded previously • Value of performance shares distributed during the fiscal year TOTAL (a) Including the annual variable compensation to be submitted to a vote at the General Meeting of Shareholders of May 22, 2026. (b) Valuation based on the market price on the day before the issue dates (€35.20).
2.4.3.2
Details of compensation of the Chief Executive Officer, David Hale Due for the fiscal year
(in €)
Fixed compensation (including social security contributions) Variable compensation (including social security contributions)
Paid during the fiscal year
2025
2024
2025
2024
341,455
469,500
341,455
469,500
—
310,848
310,848
469,500
Exceptional compensation (including payroll taxes) BENEFITS IN KIND(b)
— 47,605
— 59,042
— 47,605
— 59,042
TOTAL COMPENSATION
389,060
839,390
699,908
998,042
(a) Gross amount submitted to a vote at the General Meeting of Shareholders of May 22, 202-. (b) LDavid Hale received €47,605 in benefits in kind in 2025. These include: • the same supplementary health and death insurance system as Group employees in France: €1,433; • the same welfare insurance and health insurance plan as Group employees in France: €3,686; • GSC unemployment insurance: €24,831; • a company car: €5,314; • the “article 83” funded pension plan: €12,340.
2.4.3.3
Performance shares granted to the Chief Executive Officer during the 2025 fiscal year
Chief Executive Officer
David Hale
68
GUERBET
Plan date (Board of Directors)
Number of shares issued during the fiscal year
Value of shares (in €)
Acquisition date
Availability date
Performance condition
N/A
—
€—
N/A
N/A
N/A
2025 UNIVERSAL REGISTRATION DOCUMENT
CORPORATE GOVERNANCE Compensation of corporate officers
2.4.3.4
Components of compensation paid or awarded for the 2025 fiscal year (ex-post vote at the General Meeting of May 22, 2026)
Components of compensation submitted to a vote
Amounts paid during the past fiscal year
Amounts granted for the past fiscal year or book valuation
Fixed compensation
€341,455
€341,455
Annual variable compensation
€310,848
€0
Comments
Section 2.4.1.2 Compensation policy for the Chief Executive Officer (executive corporate officer). The following factors are considered in determining the fixed compensation: • the level and complexity of the duties and responsibilities attributed to this position; • the skills, experience, expertise, and professional profile of the holder of the position; • market analyses and studies on the compensation of international executives in comparable companies in the healthcare industry in France to ensure attractive, competitive compensation levels. Section 2.4.1.2 Compensation policy for the Chief Executive Officer (executive corporate officer). The variable compensation for this position for 2024 was based on quantitative criteria (gross margin, EBITDA, free cash flow, and several CSR criteria) and qualitative criteria (progress on projects related to the integration of acquisitions and progress on business development and licensing projects). These criteria were aligned with the Company’s objectives. For confidentiality reasons, the level of achievement required for the quantitative criteria and the details of the qualitative criteria, although precisely pre-established, cannot be disclosed.
Multiyear variable compensation
€286,315
€0
€47,605
€47,605
1|
|
2|
|
3|
|
4|
|
Section 2.4.1.2 Compensation policy for the Chief Executive Officer (executive corporate officer). Performance shares awarded in 2024 During the 2024 fiscal year, 12,828 shares were issued to the Chief Executive Officer.
Benefits of any kind
— — —
5|
|
Section 2.4.1.2 Compensation policy for the Chief Executive Officer (executive corporate officer). David Hale received €47,605 in benefits in kind in 2025. These include: • the same supplementary health and death insurance system as Group employees in France: €1,433; • the same welfare insurance and health insurance plan as Group employees in France: €3,686; • GSC unemployment insurance: €24,831; • a company car: €5,314; • a supplementary pension.
6|
|
7|
|
David Hale was covered by the “article 83” funded pension plan, a mandatory Group insurance policy for the executive category. Contributions are based on the annual gross compensation of policyholders for the insurance period in question, limited to Social Security bracket C. The monthly contribution rate is exclusively for the employer and is equal to 4.5% of the monthly compensation. There are no tax charges associated with the policies. Contributions for 2025 totaled €12,340.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
69
CORPORATE GOVERNANCE Compensation of corporate officers
2.4.3.5
Summary of benefits of the Chief Executive Officer
TABLE 11 ACCORDING TO THE AFEP-MEDEF CODE RECOMMENDATIONS AND AMF POSITION-RECOMMENDATION NO. 2009-16
Employment contract Chief Executive Officer
Yes
David Hale
Compensation or benefits owed or liable to be owed following a termination or change of duties
Supplementary pension plan
No
Yes
×
×
No
Yes
Compensation relating to a non-compete clause
No
Yes
No
×
×
Start of term of office: January 1, 2020
2.4.4
Compensation of the Acting Chief Executive Officer, Jérôme Estampes, from September 22 to December 31, 2025
At its meeting of September 22, 2025, the Board of Directors of the Company decided to appoint Jérôme Estampes, with immediate effect, as Acting Chief Executive Officer, to steer the process of appointing a Chief Executive Officer.
2.4.4.1
Given the temporary nature of the assignment entrusted to Jérôme Estampes, his employment contract for his role as Chief Financial Officer, IT, Business Development and Licensing was maintained for the duration of his term of office as Acting Chief Executive Officer.
Summary of compensation of the Acting Chief Executive Officer, Jérôme Estampes 2025
2024
21,273 (a)
—
(in €)
Compensation due for the fiscal year (including payroll taxes) Multiyear compensation due: • Value of performance shares awarded during the fiscal year • Value of performance shares awarded previously • Value of performance shares distributed during the fiscal year TOTAL
2.4.4.2
—
—
— (b)
—
—
—
— 21,273
— —
Details of compensation awarded to Jérôme Estampes, Acting Chief Executive Officer Due for the fiscal year
Paid during the fiscal year
2025
2024
2025
2024
21,273
—
21,273
—
— (a)
—
—
—
Exceptional compensation (including payroll taxes) BENEFITS IN KIND(b)
99,616 —
— —
— —
— —
TOTAL COMPENSATION
120,889
—
21,273
—
(in €)
Fixed compensation (including social security contributions) Variable compensation (including social security contributions)
(a) LThe Acting Chief Executive Officer does not receive any variable compensation, in accordance with the decision of the Board of Directors of September 22, 2025.
2.4.4.3
Performance shares granted to the Acting Chief Executive Officer during the 2025 fiscal year
Chief Executive Officer
Jérôme Estampes
70
GUERBET
Plan date (Board of Directors)
Number of shares issued during the fiscal year
Value of shares (in €)(a)
Acquisition date
Availability date
Performance condition
—
—
€—
—
—
—%
2025 UNIVERSAL REGISTRATION DOCUMENT
CORPORATE GOVERNANCE Compensation of corporate officers
2.4.4.4
Components of compensation paid or awarded for the 2025 fiscal year (ex-post vote at the General Meeting of May 22, 2026)
Components of compensation submitted to a vote
Amounts paid during the past fiscal year
Amounts granted for the past fiscal year or book valuation
€21,273
€21,273
Annual variable compensation
€—
€—
Multiyear variable compensation
€—
€—
Exceptional compensation
€—
€99,616
Fixed compensation
Comments
Jérôme Estampes’ fixed annual compensation for his corporate office amounted to €78,000, i.e. €21,273 pro rata for the period from September 22 to December 31, 2025. In accordance with the decision of the Board of Directors of September 22, 2025, Jérôme Estampes did not receive any annual variable compensation for his term of office as Chief Executive Officer. In accordance with the decision of the Board of Directors of September 22, 2025, Jérôme Estampes did not receive any multi-year variable compensation for his term of office as Chief Executive Officer. In accordance with the decision of the Board of Directors of September 22, 2025, Jérôme Estampes receives exceptional compensation, of an amount decided by the Board of Directors.
— — —
1|
|
2|
|
On January 28, 2026, the Board of Directors decided to grant €99,616 in exceptional compensation to Jérôme Estampes for his term of office as Acting Chief Executive Officer. Benefits of any kind
2.4.4.5
€—
€—
There are no other benefits associated with the office of Chief Executive Officer (benefits in kind and specifically no compensation related to taking up or leaving office).
3|
|
Summary of benefits of the Acting Chief Executive Officer
4|
|
TABLE 11 ACCORDING TO THE AFEP-MEDEF CODE RECOMMENDATIONS AND AMF POSITION-RECOMMENDATION NO. 2009-16
Employment contract Chief Executive Officer
Jérôme Estampes
Yes
No
Compensation or benefits owed or liable to be owed following a termination or change of duties
Supplementary pension plan Yes
×
No
Yes
×
Compensation relating to a non-compete clause
No
Yes
×
5|
|
No
×
Start of term of office: September 22, 2025
2.4.5
6|
|
Compensation of the Deputy Chief Executive Officer, Philippe Bourrinet
Philippe Bourrinet has been Deputy Chief Executive Officer since March 24, 2021. The information relating to Philippe Bourrinet’s compensation described in this section 2.4.4 provides a breakdown of the elements received in respect of his corporate office, described in section 2.4.1.3 Compensation policy for the Deputy Chief Executive Officer (Group Chief Pharmacist).
He receives compensation (annual fixed, annual variable) as an employee for his role as Senior Vice President of Development, Medical, and Regulatory Affairs for Guerbet Group. Given that these types of compensation are received under an employment contract and not for the corporate office, they are not detailed in the tables below.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
7|
|
71
CORPORATE GOVERNANCE Compensation of corporate officers
2.4.5.1
Summary of compensation of Philippe Bourrinet, Deputy Chief Executive Officer 2025
2024
Compensation for the corporate office (including social security contributions)
11,500
11,500
Value of performance shares distributed during the fiscal year
— 11,500
— 11,500
(in €)
TOTAL
2.4.5.2
Details of compensation awarded to Philippe Bourrinet, Deputy Chief Executive Officer Due for the fiscal year 2025
2025
2024
11,500 (a) 11,500
11,500 11,500
11,500 11,500
11,500 11,500
(in €)
Compensation for the corporate office (including social security contributions) TOTAL COMPENSATION
Amounts paid during the fiscal year 2024
(a) Theoretical annual premium for the office.
2.4.5.3
Components of compensation paid or awarded for the 2025 fiscal year (ex-post vote at the General Meeting of May 22, 2026)
Components of compensation submitted to a vote
Compensation for the office of Deputy CEO (Chief Pharmacist)
2.4.5.4
Amounts paid during the past fiscal year
Amounts granted for the past fiscal year or book valuation
€11,500
€11,500
Comments
Section 2.4.1.3 Compensation policy for the Deputy Chief Executive Officer (Group Chief Pharmacist). The Deputy Chief Executive Officer receives a “Chief Pharmacist” premium for the responsibilities as Chief Pharmacist for Guerbet Group. On the proposal of the Appointments and Compensation Committee, the Chief Pharmacist’s premium for Deputy CEO has been set at €11,500 gross for 2025. The Board of Directors, on the proposal of the Appointments and Compensation Committee, shall submit to the General Meeting the proposal to maintain this premium at €11,500 for 2026.
Summary of benefits of the Deputy Chief Executive Officer
TABLE 11 ACCORDING TO THE AFEP-MEDEF CODE RECOMMENDATIONS AND AMF POSITION-RECOMMENDATION NO. 2009-16
Deputy Chief Executive Officer
Philippe Bourrinet
Employment contract Yes
No
×
Start of term of office: March 24, 2021
72
GUERBET
Compensation or benefits owed or liable to be owed following a termination or change of office
Supplementary pension plan
2025 UNIVERSAL REGISTRATION DOCUMENT
Yes
×
No
Yes
Compensation relating to a non-compete clause No
×
Yes
No
×
CORPORATE GOVERNANCE Compensation of corporate officers
2.4.6
Directors’ compensation
The compensation policy aims to compensate Directors for their commitment to corporate governance. It incorporates an identical fixed portion for all Directors and a variable portion according to meeting attendance criteria.
total amount of €340,000, composed of a fixed portion and a predominantly variable portion calculated according to the participation of each member in their Committee meetings.
As is the case for the corporate officers, changes in the Directors’ compensation are decided in accordance with the labor and compensation policy applicable to all employees.
The Chairperson of the Board of Directors and the Chairperson of each of the Committees receive a higher fixed portion, justified by the workload and additional responsibility that this role entails.
At the General Meeting scheduled for May 22, 2026, the Shareholders will be asked to approve the compensation granted to the Directors for the 2025 fiscal year for a maximum
Marie de la Simone and Jean-Sébastien Raynaud, Directors representing the employees, do not receive compensation for their mandate.
— — —
1|
|
AMOUNT OF COMPENSATION TO BE DISTRIBUTED FOR 2025 FOR SERVING AS A DIRECTOR Annual fixed portion
Variable portion
Net total
Hugues LECAT – Chairperson of the Board
€22,400
€34,200
€56,600
Pascale AUGER
€6,333
€6,171
€12,505
Carine DAGOMMER
€14,200
€22,757
€36,957
Director name
Marie DE LA SIMONE
€—
€—
€—
Éric DRAPÉ
€10,133
€12,900
€23,033
Mark FOUQUET
€4,333
€6,943
€11,276
Éric GUERBET
€12,800
€19,543
€32,343
Didier IZABEL
€6,333
€7,071
€13,405
Céline LAMORT
€12,800
€19,543
€32,343
Michèle LESIEUR
€10,133
€12,857
€22,990
Nicolas LOUVET
€14,400
€21,857
€36,257
Marc MASSIOT
€12,800
€18,171
€30,971
Claire MASSIOT-JOUAULT
€4,333
€5,829
€10,162
Jean-Sébastien RAYNAUD TOTAL
€— 130,998
€— 187,842
€— 318,842
2.4.7
Equity ratios
2.4.7.1
Data used
2|
|
3|
|
4|
|
5|
|
6|
|
The data used to determine the ratios calculated on the average and median salary include the following items: salary (including raises for continued service and long-service awards)
- objective bonus paid (year N-1) + benefits in kind + compensation for the activity of Director + performance shares
for officers and employees. All items are in gross amounts. For employees who joined during the year and for part-time employees, the gross amounts have been adjusted to 100%. Population: employees on a permanent contract with Guerbet S.A., excluding employees whose 100% gross salary is less than €18,000 (e.g. long-term illness or suspension of activity).
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
7|
|
73
CORPORATE GOVERNANCE Compensation of corporate officers
2.4.7.2
Ratio calculated on average salaries
Year
2025
2024
2023
2022
2021
Chief Executive Officer (David Hale)
9.47
15.47
13.03
18.35
15.85
Chief Executive Officer (Jérôme Estampes) Chairperson of the Board of Directors (Hugues Lecat)(a) Chairperson of the Board of Directors (Didier Izabel)(b) Chairperson of the Board of Directors (Marie-Claire Janailhac-Fritsch)(b)
5.85
1.40
2.69
2.81
0.18
0.19
0.17
0.86
1.30 1.46
Deputy Chief Executive Officer (since 2021)
0.18
1.80
Deputy Chief Executive Officer (2016-2021)(c)
0.04
(a) Hugues Lecat was appointed Chairperson of the Board of Directors on May 24, 2024, replacing Didier Izabel. (b) Didier Izabel was appointed Chairperson of the Board of Directors on May 26, 2023, replacing Marie-Claire Janailhac-Fritsch. (c) The Deputy Chief Executive Officer’s compensation of €11,500 for this role and the multiyear variable compensation are included.
Chief Executive Officer: In 2024, the change in David Hale’s ratio (15.47 versus 13.03 in 2023) can be explained by the payment of a higher annual variable compensation in 2024 compared with 2023. This payment is aligned with the Company’s objectives and was validated by the 2024 General Meeting.
Outgoing Chairperson of the Board of Directors (D. Izabel): The 2024 ratio (1.46 versus 1.80 in 2023) needs to be put into perspective due to the end of Didier Izabel’s term of office on May 24, 2024. Deputy Chief Executive Officer: The Deputy Chief Operating Officer’s ratio was stable (0.18 in 2023).
Chairperson of the Board of Directors (H. Lecat): The 2024 ratio (1.30 in 2024) is explained by the taking up of office on May 24, 2024.
2.4.7.3
Ratio calculated on median salaries 2025
2024
2023
2022
2021
Chief Executive Officer (David Hale)
12.18
18.98
15.84
22.09
18.93
Chief Executive Officer (Jérôme Estampes) Chairperson of the Board of Directors (Hugues Lecat) Chairperson of the Board of Directors (Didier Izabel) Chairperson of the Board of Directors (Marie-Claire Janailhac-Fritsch)
7.53
1.70
3.24
3.36
0.22
0.23
0.21
Year
1.11
Deputy Chief Executive Officer (since 2021)
1.59 1.79
0.22
2.19
Deputy Chief Executive Officer (2016-2021)(a)
0.05
(a) For the Deputy Chief Executive Officer, only compensation for his corporate office, amounting to €11,500, is included.
Chief Executive Officer: In 2024, the change in David Hale’s ratio (18.98 in 2024 versus 15.84 in 2023) can be explained by the payment of a higher annual variable remuneration in 2024 than in 2023. Chairperson of the Board of Directors (H. Lecat): The ratio of the current Chairperson of the Board of Directors is pro rata to his appointment during the year 2024 (May 24, 2024).
74
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
Outgoing Chairperson of the Board of Directors (D. Izabel): The 2024 ratio (1.79 versus 2.19 in 2023) is explained by the term of office that ended on May 24, 2024. Deputy Chief Executive Officer: Philippe Bourrinet’s 2024 ratio (0.22) was stable compared with previous years.
CORPORATE GOVERNANCE Compensation of corporate officers
2.4.8
Annual changes in compensation and company performance Rate of change 2025
2024
2023
2022
2021
-28.4%
22.2%
-26.4%
19.3%
NS*
—%
—%
-22.5%
NS*
Didier Izabel (Chairperson of the Board)(b)(c)
NS*
-16.6%
Marie-Claire Janailhac-Fritsch(d) Philippe Bourrinet(e)
—%
—%
NS* -46.0%
—%
—%
—%
David Hale Yves L’Épine Hugues Lecat(a)
—%
—%
-1.5% 12.5%
-1.3% NS*
Pierre André (term ended)(f)
—%
NS*
Marion Barbier (end of term in 2021)
—%
-4.2%
Mark Fouquet
3.1%
-3.4%
-3.4%
11.5%
4.0%
Éric Guerbet
11.5%
-8.0%
-7.4%
28.6%
5.0%
NS
—%
—%
4.0%
31.6%
26.7%
Didier Izabel (Director)(c)
4.7%
Céline Lamort
11.5%
-11.5%
Nicolas Louvet
12.0%
-18.5%
8.0%
8.7%
—%
Claire Massiot-Jouault
21.9%
-26.1%
-14.8%
3.8%
—%
Thibault Viort
-65.1%
12.1%
-5.7%
16.7%
3.4%
Carine Dagommer
7.0%
23.5%
155.0%
NS*
Marc Massiot
24.5%
21.1%
39.0%
NS*
Pascale Auger Guerbet S.A. – Average(g)
112.0% 5.6%
NS* 2.4%
3.6%
3.0%
-2.8%
(g)
3.3%
2.0%
2.6%
2.2%
-0.7%
-31.1%
20.9%
-4.1%
-1.9%
4.3%
Guerbet S.A. – Median EBITDA REVENUE
-6.5%
7.1%
4.3%
2.9%
2.8%
OPERATING INCOME
-277.9%
28.2%
312.9%
-146.9%
-7.6%
NET INCOME
-936.5%
-39.3%
153.9%
-226.0%
78.9%
Comments: The Directors representing the employees do not receive compensation for this office and are therefore not included in this table. Amounts paid: annual gross (including fixed + variable compensation + Directors’ compensation + benefits in kind + exceptional compensation + miscellaneous bonuses + overtime, etc.). (a) Appointed Chairperson of the Board of Directors: May 24, 2024. (b) End of term: May 24, 2024. (c) Appointed Chairperson of the Board of Directors: May 26, 2023. (d) End of term: May 26, 2023. (e) Appointed Deputy CEO on March 24, 2021. This includes compensation of €11,500 for his corporate office. (f) End of term: March 24, 2021. (g) Selected population: Permanent employees of Guerbet S.A. who are part of the staff on December 31 of each year. Excluding expatriate employees, employees whose gross annual salary is less than €18 K (long-term illness, suspension of activity).
- NS: Not significant.
Chief Executive Officer: David Hale’s compensation increased by 22.2%. In 2024, the payment of the higher annual variable remuneration than in 2023 explains this change. David Hale’s fixed compensation remained unchanged. Chairperson of the Board of Directors (H. Lecat): The change in Hugues Lecat’s compensation is not significant due to his taking up the position in 2024.
— — —
1|
|
2|
|
3|
|
4|
|
5|
|
6|
|
7|
|
Deputy Chief Executive Officer: In 2023, Philippe Bourrinet’s compensation as Deputy CEO was identical to his 2022 compensation. Between 2023 and 2024, the upward trend in the median and average salaries of Guerbet S.A. employees was due to changes in the compensation structure, resulting from the arrival of new employees, salary increases, and 2024 bonuses.
Outgoing Chairperson of the Board of Directors (D. Izabel): Didier Izabel’s compensation decreased by 16.6% between 2023 and 2024, due to the end of his term of office as Chairperson of the Board of Directors in May 2024.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
75
CORPORATE GOVERNANCE Compensation of corporate officers
2.4.9
Commitments made to corporate officers when taking up, changing, or terminating their duties
Not applicable.
2.4.10 Plans for the allocation of purchase options to corporate officers 2.4.10.1 Options awarded in 2025 N/A.
2.4.10.2 Options exercised in 2025 N/A.
2.4.10.3 Options not exercised at December 31, 2025 N/A.
2.4.10.4 Allocation and distribution of performance shares to executive officers Details of the performance shares issued to executive officers
2021 plan
2022 plan
2023 plan
General Meeting date
May 29, 2020
May 20, 2022
May 20, 2023 May 26, 2024 May 26, 2024
Board meeting date
March 24, 2021 September 21, 2022 May 09, 2023 June 21, 2024
November 25, 2025
Share issue date
May 01, 2021
September 22, 2022 July 01, 2023
July 01, 2024
February 17, 2026
Distribution date 2021 FISCAL YEAR
May 01, 2024
September 22, 2025 July 01, 2026
July 01, 2027
April 30, 2028
2024 plan
2025 plan
Total number of performance shares distributed to executive officers under each of the plans: • David Hale
15,200
• Share issue date
May 1, 2021
2022 FISCAL YEAR Total number of performance shares distributed to executive officers under each of the plans: • David Hale
25,000
• Share issue date
September 21, 2022
2023 FISCAL YEAR Total number of performance shares distributed to executive officers under each of the plans: • David Hale
28,455
• Share issue date
July 01, 2023
2024 FISCAL YEAR Total number of performance shares distributed to executive officers under each of the plans: • David Hale
12,828
• Share issue date
July 1, 2024
2025 FISCAL YEAR Total number of performance shares distributed to executive officers under each of the plans:
76
• Karim Boussebaa
20,000
• Share issue date
February 17, 2026
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
CORPORATE GOVERNANCE Exceptions to the Afep-Medef Code
2.5
EXCEPTIONS TO THE AFEP-MEDEF CODE
In accordance with article L. 225-37-4-8° of the French Commercial Code, the table below lists the Afep-Medef Code’s provisions that have not been adopted and the reasons why. Topic
Afep-Medef Code
Guerbet situation/Comments
Combination of corporate office and employment contract
When an employee becomes a corporate officer of the company, this terminates their employment contract with the company or a Group company
On September 22, 2025, the Board of Directors decided to appoint Jérôme Estampes, Group Chief Financial Officer since 2019, as Acting Chief Executive Officer. At the same time, the Board of Directors launched a recruitment process for a new Chief Executive Officer. Given the temporary nature of his assignment, it was decided that Jérôme Estampes’s employment contract as Chief Financial Officer should be maintained, and the combination of his employment contract with corporate office should be authorized.
Chairperson of the Appointments and Compensation Committee
Composition of the Audit Committee
Article 23 of the Afep-Medef Code Position of Chairperson of Note that the Afep-Medef Code’s recommendation that the Chairperson of the the Committee should be Appointments and Compensation Committee should be an Independent held by an independent Director has not been adopted. The Board of Directors considers that this member function may be performed by a Director representing the majority Shareholder in view of the composition of this Committee (two Independent Directors and Articles 16 and 17 of the Afep-Medef Code one Director representing the employees) and the fact that Carine Dagommer does not hold any salaried position within the Company. Two thirds independent Note that the Board’s Internal Regulations, setting the minimum number of members independent members of the Audit Committee at one half, deviate from the Afep-Medef Code’s recommendation that at least two thirds of the Committee Article 15 of the Afep-Medef Code members should be Independent Directors. This Committee composition rule was introduced due to the majority proportion of members representing the Shareholder Agreement on the Board. However, the proportion of independent members of the Audit Committee is 50%.
— — —
1|
|
2|
|
3|
|
4|
|
5|
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
77
CORPORATE GOVERNANCE Agreements referred to in article L. 225-37-4-2° of the French Commercial Code
2.6
AGREEMENTS REFERRED TO IN ARTICLE L. 225-37-4-2° OF THE FRENCH COMMERCIAL CODE
During the fiscal year ending December 31, 2025, several agreements falling within the scope of article L. 225-38 of the French Commercial Code were entered into, in particular settlement agreements with executives or Directors and a service agreement entered into with a company managed by a Director. These agreements were previously authorized by the Board of Directors and are in line with the Company’s corporate interests. Details of these agreements can be found in the Statutory Auditors’ special report presented to the Annual General Meeting called to approve the financial statements for the fiscal year ending December 31, 2025.
2.7
DELEGATIONS OF AUTHORITY REGARDING CAPITAL INCREASES
A summary table is provided in section 3.6.11 of the currently valid delegations granted by the General Shareholders’ Meeting in the area of capital increases, pursuant to articles L. 225-129-1 and L. 225-129-2, and showing the use made of these delegations during the 2025 financial year.
2.8
PROVISIONS IN THE ARTICLES OF ASSOCIATION RELATING TO GENERAL MEETINGS
There are no specific provisions in the articles of association on the participation of Shareholders in General Meetings. General Meetings are convened and held, and resolutions are adopted, in accordance with the conditions set by law. However, a double voting right is granted to shares that have been registered for at least two years.
The General Meeting, deliberating under the quorum and majority conditions required for Extraordinary General Meetings, has sole authority to decide on amendments to the articles of association. The Company’s articles of association pertaining to General Meetings are as follows:
Article 19 – Notices of Meetings – Meetings – Access to General Meetings Shareholders’ Meetings are called under the conditions set by law. They are held at the head office or at any other location indicated in the notice of meeting. Any Shareholder who can prove their capacity as such is entitled, regardless of the number of shares that they own, to attend Meetings and participate in the deliberations, in person or by proxy, or to vote by mail, under the applicable legal and regulatory conditions. However, to exercise this right, either the shares must be held in a registered account, by the Shareholder or a registered intermediary, as referred to in article L. 228-1 of the French
78
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
Commercial Code, or a certificate of registration in the account of an authorized financial intermediary attesting to the unavailability of shares held in bearer form must be deposited, at the locations indicated in the notice of meeting, at least three (3) days before the General Meeting. Note that any Shareholder may also participate in General Meetings by videoconference call or using electronic telecommunication or remote transmission media, subject to the qualifications and conditions set by the current laws and regulations, if this is permitted by the Board of Directors when the General Meeting in question is called. Such a Shareholder shall be deemed to be present at this Meeting for the calculation of the quorum and the majority.
CORPORATE GOVERNANCE Provisions in the articles of association relating to General Meetings
Article 20 – Voting right The voting rights attached to shares are proportional to the percentage of the share capital that they represent, except in cases where shares are disqualified for voting purposes as provided for by law. However, a double voting right shall be awarded to Shareholders for all fully paid-up shares that they have held registered in their name for at least two years, on presentation of proof. In the event of a capital increase through the capitalization of reserves, profits, or issue premiums, this double voting right shall be granted upon issuance of the new free shares to
Shareholders based on the existing shares for which they already enjoy this right. The voting right belongs to the beneficial owner in Ordinary General Meetings and to the bare owner in Extraordinary General Meetings, with the exception of shares that are the subject of a collective holding commitment subscribed for the application of article 787-B of the French General Tax Code and are a gift with beneficial ownership. In that case, the beneficial owner’s voting right is limited to decisions concerning the allocation of profits.
— — —
1|
|
Article 21 – Authority – Quorum – Majority for General Meetings The authority of the Ordinary and Extraordinary General Meetings is the authority provided for by law. The Ordinary General Meeting deliberates validly only if the Shareholders present or represented or having voted by mail hold at least, as of the first notice of meeting, one fifth of the shares having a voting right. On the second notice of meeting, no quorum is required. The Extraordinary General Meeting deliberates validly only if the Shareholders present or represented or having voted by
mail hold at least, as of the first notice of meeting, one fourth or, as of the second notice of meeting, one fifth of the shares having a voting right.
2|
|
The Ordinary General Meeting rules by a majority of the votes of the Shareholders present, represented, or having voted by mail. The Extraordinary General Meeting rules by a two-thirds majority of the votes of the Shareholders present, represented, or having voted by mail.
3|
|
4|
|
5|
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
79
CORPORATE GOVERNANCE Factors that could have an impact in the event of a takeover or exchange offer referred to in article L. 225-37-5 of the French Commercial Code
2.9
FACTORS THAT COULD HAVE AN IMPACT IN THE EVENT OF A TAKEOVER OR EXCHANGE OFFER REFERRED TO IN ARTICLE L. 225-37-5 OF THE FRENCH COMMERCIAL CODE
Information that could have an impact in the event of a takeover or exchange offer must be included in the corporate governance report in accordance with article L. 225-37-5 of the French Commercial Code. The table below indicates the section that readers should refer to for each type of information.
Type of information
Section of the Universal Registration Document
1o
The Company’s capital structure.
Capital and shareholding – 3.4
2o
The restrictions in the articles of association on the exercise of voting rights and transfers of shares or the clauses of agreements brought to the attention of the Company pursuant to article L. 233-11.
Corporate governance – 2.8
There are no such restrictions in Guerbet’s articles of association. The provisions of the articles of association relating to General Meetings are set out in this document.
and Capital and shareholding – 3.6.1
A Shareholder Agreement is in force. 3o 4o 5o 6o 7o 8o 9o
10o
Direct or indirect holdings in the Company’s capital of which it is aware pursuant to articles L. 233-7 and L. 233-12. The list of holders of any share with special control rights and a description of such rights. There are no such shares in Guerbet’s capital. Control mechanisms provided for in a potential employee shareholding system when control rights are not exercised by the employees. Shareholder agreements of which the Company is aware and potentially resulting in restrictions on the transfer of shares and the exercise of voting rights. Rules applicable to the appointment and replacement of members of the Board of Directors and to amendments to the Company’s articles of association. The powers of the Board of Directors, in particular with regard to share issuance or buybacks. Agreements entered into by the Company that are amended or terminated in the event of a change in the company’s control, except where such disclosure could cause serious harm to its interests, apart from cases of legal obligation of disclosure. The Group’s financing contracts contain change of control clauses. Agreements providing for the payment of compensation to members of the Board of Directors or employees in the event of their resignation or dismissal without real and serious cause or if their employment were to be terminated as a result of a takeover or exchange offer. No such agreement exists.
80
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
Capital and shareholding – 3.6.4 N/A Capital and shareholding – 3.6.3 Capital and shareholding – 3.6.1 Corporate governance – 2.2 Capital and shareholding – 3.6.10 N/A
N/A
— — —
1|
|
2|
|
CAPITAL AND
3|
|
SHAREHOLDING STRUCTURE
4|
|
3.1
STOCK MARKET DATA
82
3.2
RELATIONS WITH THE FINANCIAL COMMUNITY
83
3.6.3 Control mechanisms provided for a potential employee shareholding system when the control rights are not exercised by the employees
86
3.6.4 Threshold crossings
86
3.6.5 Transactions by executive officers and related parties
86
3.6.6 Trades by non-executive employees
86
3.6.7 Performance share plans
86
84
3.6.8 Stock option plans for the 2025 fiscal year
88
3.4.1 Breakdown of capital
84 84
3.6.9 Limitation of the risk of undue control by the majority Shareholder
88
3.4.2 Change in the breakdown of the share capital and voting rights over the last three years
3.6.10 Powers of the Board of Directors to issue and buy back shares
88
3.5
SHARE BUYBACK PROGRAM
85
3.6.11 Summary of granted delegations with a potential impact on the share capital
89
3.6
ADDITIONAL INFORMATION ABOUT THE CAPITAL
85
3.6.12 Provisions in the articles of association on shares
90
3.3 3.4
DISTRIBUTED DIVIDENDS SHAREHOLDING STRUCTURE
83
3.6.1 Shareholder agreement
85
3.6.2 Share lock-in commitments through “Dutreil” agreements
85
GUERBET
5|
|
2025 UNIVERSAL REGISTRATION DOCUMENT
6|
|
7|
|
81
CAPITAL AND SHAREHOLDING STRUCTURE Stock market data
3.1
STOCK MARKET DATA
Guerbet shares are traded on Euronext Paris – Segment B under ISIN code FR0000032526. Based on the closing price of €14.30 at December 31, 2025, Guerbet’s market capitalization is €181 million. SHARE PRICE PERFORMANCE IN 2025(a)
(a) Based on daily closing prices.
Data on the share price and monthly transactions for 2025
82
Highest price in a trading session (in €)
Lowest price in a trading session (in €)
Number of shares traded
Capital traded
January
28.7
26.1
290,840
7.96
February
27.8
24.7
283,225
7.39
March
28.2
18.3
499,200
11.58
April
20.8
17.4
435,482
8.35
May
21.6
19.3
222,545
4.54
June
22.6
19.9
450,664
9.69
July
23.7
21.0
273,846
6.13
August
23.1
20.0
242,278
5.17
September
20.6
12.7
1,109,046
15.78
October
16.3
13.1
353,551
5.13
November
18.3
14.6
220,571
3.62
December
18.2
11.2
435,855
6.05
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
(in millions of €)
CAPITAL AND SHAREHOLDING STRUCTURE Distributed dividends
3.2
RELATIONS WITH THE FINANCIAL COMMUNITY
The Finance Division is an interface between the Group and the financial community consisting of individual Shareholders, institutional investors, holdings, and financial analysts. It aims to provide all these market players with clear, rigorous, transparent information in real time so as to keep them informed of the Group’s strategy, products, activity, financial results, and medium-term financial objectives and the means to achieve them.
Guerbet’s website at www.guerbet.com has a specific “Investors” section for its Shareholders and the financial community. It provides information about the company and in particular: • the Universal Registration Document, including the annual financial report; • all publications, financial presentations, and press releases (“Presentations, Reports, and Regulated Information” section);
— — —
• information relating to the General Meeting (“General Meeting” section).
1|
2026 financial calendar
|
Event
Date
Publication of 2025 full-year revenue
February 5, 2026
Presentation of consolidated financial statements – 2025 fiscal year
March 11, 2026
Publication of Q1 2026 revenue
April 23, 2026
Annual General Meeting of Shareholders for the 2025 fiscal year
May 22, 2026
Publication of Q2 2026 revenue
2|
|
July 23, 2026
Presentation of half-year consolidated financial statements at June 30, 2026
September 15, 2026
Publication of Q3 2026 revenue
3|
|
October 22, 2026
All publications will be released after the close of Euronext Paris.
4|
|
The Guerbet Group contact person for financial information and investor relations is: Jérôme Estampes – Chief Financial Officer Telephone: +33 (0) 1 45 91 50 69 Email: [email protected]
5|
|
3.3
DISTRIBUTED DIVIDENDS
Dividends paid over the past three years
6|
|
Amount distributed
Gross dividend per share(a)
2022
6,320,558
0.50
2023
6,320,558
0.50
2024
—
—
Fiscal year (in €)
7|
|
(a) Before taxes and social security contributions.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
83
CAPITAL AND SHAREHOLDING STRUCTURE Shareholding structure
3.4
SHAREHOLDING STRUCTURE
3.4.1
Breakdown of capital
At December 31, 2025, the share capital amounted to €12,641,115 divided into 12,641,115 fully paid-up shares with a par value of €1 each. None of these 12,641,115 shares are pledged. At December 31, 2025, the share capital breaks down as follows:
3.4.2
Change in the breakdown of the share capital and voting rights over the last three years
The breakdown of the share capital presented below corresponds to the shares and voting rights for Ordinary General Meetings. There is little difference compared with the breakdown of the share capital for Extraordinary General Meetings. This difference is due to divisions of ownership resulting from the gifting of shares within the Guerbet family whose beneficial owners and bare owners do not belong to the same category of Shareholders. December 31, 2025
Number of shares
Guerbet family agreement Other registered Shareholders – Guerbet family Current & former employees and mutual funds Other registered Shareholders – excluding Guerbet family
December 31, 2024
Number of shares
% of share capital
% of voting rights(a)
6,671,726
December 31, 2023
Number of shares
% of share capital
% of voting rights(a)
52.78
67.41 6,725,523
53.2
67.71 6,731,769
195,025
1.54
1.973
198,139
1.57
2
491,162
3.89
4.53
429,922
3.4
176,490
1.4
1.713
172,420
1.36
Treasury shares
25,992
(b)
Floating shares TOTAL
5,080,720 12,641,115
0.21
— 37,615
(b)
40.19 100
24.374 5,077,496 100 12,641,115
Number % of share of shares capital
% of voting rights(a)
53.25
64.8
201,884
1.6
2.23
4.23
462,429
3.66
4.69
1.7
185,939
1.47
2
0.3
— 63,222
(b)
0.5
—
40.17 100
24.36 4,995,872 100 12,641,115
39.52 100
26.28 100
(a) The breakdown of voting rights is presented in terms of effective voting rights. The number of theoretical voting rights was 19,800,628 at December 31, 2025, 19,810,649 at December 31, 2024, and 18,188,997 at December 31, 2023, assuming that each treasury share grants entitlement to one voting right. (b) This includes treasury shares held under the liquidity contract set up on March 9, 2022.
84
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
CAPITAL AND SHAREHOLDING STRUCTURE Additional information about the capital
3.5
SHARE BUYBACK PROGRAM
To promote trading liquidity, listing regularity for the Group’s shares and in order to avoid share price fluctuations not warranted by market trends, Guerbet has transferred the liquidity agreement entered into on March 9, 2022 with Exane BNP Paribas to Natixis ODDO BHF to trade on the Group’s behalf on the Euronext Paris regulated market.
This new contract was implemented on February 3, 2025. Guerbet may terminate the contract at any time without notice. It may be automatically renewed for successive periods of 12 months. On February 3, 2025, at the start of trading, the resources allocated by Guerbet for implementation of the liquidity contract totaled 10,996 shares and €340,084 in cash.
— — —
Trades during the 2025 fiscal year under the liquidity contract Under the liquidity contract entrusted to Natixis ODDO BHF by Guerbet, the following assets appeared in the liquidity account as of the settlement date of December 31, 2025:
During 2025, a total of:
• 9,995 Guerbet shares;
• 233,037 shares were sold for €4,516,389 (2,266 trades).
• 232,036 shares were purchased for €4,522,191 (2,426 trades);
2|
• €334,282.
|
3.6
ADDITIONAL INFORMATION ABOUT THE CAPITAL
3.6.1
Shareholder agreement
An agreement mainly binding family Shareholders was signed on November 16, 2002. This agreement was published by the Conseil du marché financier (CMF) on December 13, 2002, under number 202C1653. It was updated in September 2013, particularly to take into account Guerbet’s current form of governance (French public limited company with a Board of Directors). The updated version of the agreement was duly transmitted to the Autorité des marchés financiers (AMF). Its purpose is principally “to act as market makers for the group of Shareholders, who are mainly of family origin, to
3.6.2
3|
|
organize trading of the Guerbet shares that each of the members owns and may own in the future and to ensure the cohesiveness and representativeness of the Group that they form within the framework of the current laws and regulations”, and also “to involve the signatories to the agreement in the Company’s development plans, coordinate sales of shares, actively participate in the selection of any new Guerbet partners, and suggest the appointment of new members of Guerbet’s Board of Directors.”
5|
Share lock-in commitments through “Dutreil” agreements
Registration date
Type of collective share lock-in commitment
Duration
December 30, 2015
Inheritance
Commitment withdrawn effective August 21, 2022
June 21, 2022
Donation
Two-year collective commitment followed by four-year individual commitment
June 21, 2022
Inheritance
Two years, then automatic renewal indefinitely
(2)
4|
|
|
The collective share lock-in commitments within the scope of article 787-B of the French General Tax Code(1) are as follows(2):
(1)
1|
|
6|
|
7|
|
Article 787-B of the French general tax code provides that “the shares of companies having industrial operations benefit from a 75% inheritance tax exemption if the shares are covered by a collective share lock-in commitment.” The share lock-in commitments pertain to a minimum of 20% of the percentage of the share capital covered by the agreement on its signing date and a minimum of 20% of the percentage of voting rights covered on its signing date.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
85
CAPITAL AND SHAREHOLDING STRUCTURE Additional information about the capital
3.6.3
Control mechanisms provided for a potential employee shareholding system when the control rights are not exercised by the employees
N/A.
3.6.4
Threshold crossings
To the best of the Company’s knowledge, two of the registered Shareholders crossed the thresholds set by law for the number of shares and/or voting rights held. Ordinary General Meeting
Extraordinary General Meeting
Shareholder
Shares
Voting rights
Shares
Voting rights
Hakea(a)
14.63%
18.67%
14.63%
18.67%
SC Guerbet Fron(a)
6.51%
8.29%
6.51%
8.29%
(a) Member holding companies of the family Shareholder agreement.
3.6.5
Transactions by executive officers and related parties
N/A.
3.6.6
Trades by non-executive employees
3.6.6.1
Options granted to non-executive employees in 2025
N/A.
3.6.6.2
Options exercised by non-executive employees in 2025
N/A.
3.6.6.3
Options not exercised by non-executive employees at December 31, 2025
No stock options remain to be exercised as of the end of the 2025 fiscal year.
3.6.7
Performance share plans
Several performance share plans have been implemented. The performance share plans still in effect are described in detail below and in the notes to the consolidated and individual financial statements (see Financial statements and related notes).
86
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
In November 2025, “Plan 8”, a new share issue plan involving 169,133 shares, was set up.
CAPITAL AND SHAREHOLDING STRUCTURE Additional information about the capital
- Plan 6 (2023): On May 9, 2023, the Board of Directors approved a performance share issue plan for certain employees and officers of the Company and its French and foreign subsidiaries. PLAN 6 (2023) – DECISION OF THE BOARD OF DIRECTORS OF MAY 9, 2023 (IN EFFECT) PLAN 6 SUMMARY (2023) Date of the Extraordinary General Meeting:
May 26, 2023
Board meeting date:
May 9, 2023
Vesting period/conditions:
Issue period of three years from July 1, 2023.
— — —
Vesting of the issued shares is subject to a condition of presence at the end of the issue period and the fulfillment of collective performance criteria. The vested shares will be available without any holding period. However, the Chief Executive Officer must retain 20% of the vested shares in registered form until leaving office. Share issue date:
July 1, 2023
Shares initially issued:
110,599 shares
• of which issued to the top 10 recipients: Share issue price:
62,283 shares €17.00(a)
1|
|
2|
|
2025 fiscal year Number of pending share issues at December 31, 2025: Value of pending share issues at December 31, 2025:
37,678 shares €467 k(b)
3|
|
(a) Opening price on issue date. (b) IFRS 2 unit fair value at December 31, 2025.
- Plan 7 (2024): On May 24, 2024, the Board of Directors approved a performance share issue plan for certain employees and officers of the Company and its French and foreign subsidiaries.
4|
|
PLAN 7 (2024) – DECISION OF THE BOARD OF DIRECTORS OF MAY 24, 2024 (IN EFFECT) PLAN 7 SUMMARY (2024)
5|
Date of the Extraordinary General Meeting:
May 24, 2024
Board meeting date:
May 24, 2024
Vesting period/conditions:
Issue period of three years from July 1, 2024.
|
Vesting of the issued shares is subject to a condition of presence at the end of the issue period and the fulfillment of collective performance criteria. The vested shares will be available without any holding period. However, the Chief Executive Officer must retain 20% of the vested shares in registered form until leaving office. Share issue date:
July 1, 2024
Shares initially issued:
76,867 shares
• of which issued to the top 10 recipients: Share issue price:
33,228 shares €35.20(a)
6|
|
7|
|
2025 fiscal year Number of pending share issues at December 31, 2025: Value of pending share issues at December 31, 2025:
28,897 shares €683 k(b)
(a) Opening price on issue date. (b) IFRS 2 unit fair value at December 31, 2025.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
87
CAPITAL AND SHAREHOLDING STRUCTURE Additional information about the capital
- Plan 8 (2025): On November 25, 2025, the Board of Directors approved a performance share issue plan for certain employees and officers of the Company and its French and foreign subsidiaries. PLAN 8 (2025) – DECISION OF THE BOARD OF DIRECTORS OF NOVEMBER 25, 2025 (IN EFFECT) PLAN 8 SUMMARY (2025) Date of the Extraordinary General Meeting:
May 24, 2024
Board meeting date:
November 25, 2025
Vesting period/conditions:
Issue period of 28 months from November 25, 2025. Vesting of the issued shares is subject to a condition of presence at the end of the issue period and the fulfillment of collective performance criteria. The vested shares will be available without any holding period. However, the Chief Executive Officer must retain 25% of the vested shares in registered form until leaving office.
Share issue date:
Under review
Shares initially issued:
Under review
• of which issued to the top 10 recipients: Share issue price:
€13.64(a)
2025 fiscal year Number of pending share issues at December 31, 2025: Value of pending share issues at December 31, 2025:
169,133 shares —
(a) Opening price on issue date. (b) IFRS 2 unit fair value at December 31, 2025.
3.6.8
Stock option plans for the 2025 fiscal year
See note 22 Free share allocation plan in the individual financial statements and notes (section 6.3.2).
3.6.9
Limitation of the risk of undue control by the majority Shareholder
The Company has taken measures to limit the risk of undue control by the majority Shareholder by separating the positions of Chairperson of the Board of Directors and Chief Executive Officer and by ensuring that these positions are held by people from outside the Guerbet family.
3.6.10 Powers of the Board of Directors to issue and buy back shares On May 23, 2025, the General Meeting renewed the authorization for the Board of Directors for 18 months to implement a program to buy back a number of Company shares, which are not to exceed (i) 10% of the total number of shares making up the share capital or (ii) 5% of the total number of shares making up the share capital if they are shares acquired by the Company in view of their holding and their tendering for payment or exchange in connection with a
88
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
merger, demerger, or contribution, with the understanding that acquisitions carried out by the Company may not in any case result in the Company holding more than 10% of the shares making up its share capital at any time whatsoever. The Executive Committee decided to use this delegation of authority in connection with a liquidity contract.
CAPITAL AND SHAREHOLDING STRUCTURE Additional information about the capital
3.6.11 Summary of granted delegations with a potential impact on the share capital Purpose of delegation
Maximum nominal amount
Duration of authorization
Expiration
Delegation of authority to the Board of Directors to increase the share capital by capitalization of reserves, profits, or premiums or any other sum eligible for capitalization
€2,515,000
26 months
July 24, 2026
Delegation of authority to the Board of Directors to increase the share capital by issuing, with preferential subscription rights, shares and/or debt securities giving access to new shares
Capital increases: €6,295,000(a) Debt security issues: €200,000,000(b)
26 months
July 24, 2026
Delegation of authority to the Board of Directors to increase the share capital by issuing, with cancellation of preferential subscription rights, shares, and/or debt securities giving access to new shares, with a mandatory priority period, through public offerings other than those referred to in article L. 411-2 of the French Monetary and Financial Code
Capital increases: €1,255,000(a)(c) Debt security issues: €200,000,000(b)
26 months
July 24, 2026
Delegation of authority to the Board of Directors to increase the share capital by issuing, with cancellation of preferential subscription rights, shares, and/or debt securities giving access to new shares, with an optional priority period, through public offerings other than those referred to in article L. 411-2 of the French Monetary and Financial Code
Capital increases: €1,255,000(a)(c) Debt security issues: €200,000,000(b)
26 months
July 24, 2026
Delegation of authority to the Board of Directors to increase the share capital by issuing, with cancellation of preferential subscription rights, shares and/or debt securities giving access to new shares through public offerings referred to in article L. 411-2 (1) of the French Monetary and Financial Code
Capital increases: €1,255,000(a)(c) Debt security issues: €200,000,000(b)
26 months
July 24, 2026
Authorization for the Board of Directors, in the event of an issue with cancellation of preferential subscription rights through public offerings, including public offerings referred to in article L. 411-2 (1) of the French Monetary and Financial Code, to fix the issue price in the manner specified by the General Meeting, within the limit of 10% of the capital per year Authorization for the Board of Directors to increase the amount of issues with or without preferential subscription rights
Capital increases: €1,255,000(a)(c) Debt security issues: €200,000,000(b)
26 months
Limit provided for in the applicable regulations (currently 15% of the initial issue)(a)
26 months
Delegation of authority to the Board of Directors to increase the share capital by issuing shares in consideration of contributions in kind within the limit of 10% of the share capital
Capital increases: €1,255,000(a) Debt security issues: €200,000,000(b)
26 months
Delegation of authority to the Board of Directors to increase the share capital with cancellation of the preferential subscription right by issuing shares of the Company reserved for members of a company savings plan
€250,000(a)
26 months
July 24, 2026
Authorization granted to the Board of Directors to issue performance shares freely to certain employees and officers of the Company and its affiliates
2% of share capital
24 months
May 24, 2026
— — —
1|
|
2|
|
3|
|
July 24, 2026
4|
|
July 24, 2026
5|
|
July 24, 2026
6|
|
7|
|
(a) Delegation subject to the overall limit for capital increases of €6,295,000 (approximately 49.9% of capital). (b) Delegation subject to the overall limit for debt security issues of €200,000,000. (c) A sub-limit of €1,255,000 (approximately 9.9% of capital) applies to these delegations.
No granted authorizations were used during the 2025 fiscal year. At the General Meeting of May 22, 2026, the Shareholders will be asked to renew the financial delegations mentioned above.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
89
CAPITAL AND SHAREHOLDING STRUCTURE Additional information about the capital
3.6.12 Provisions in the articles of association on shares 3.6.12.1 Identifiable bearer shares (article 8) The company is entitled, at any time, to ask the organization responsible for clearing the securities, under the conditions and according to the legal procedures in force, for information concerning the identity of holders of securities that immediately or ultimately grant a right to vote at its Shareholder Meetings and the quantity of securities that each of them holds and, where appropriate, any restrictions to which the securities may be subject.
3.6.12.2 Declaration of threshold crossings The company’s articles of association do not provide for any additional disclosure obligations if the fraction of the share capital or voting rights held by a Shareholder represents less than one twentieth of the total, as mentioned in article L. 233-7-1 of the French Commercial Code.
3.6.12.3 Actions necessary to modify Shareholders’ rights The Group has not laid down any provisions that are stricter than those imposed by the law.
90
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
— — —
1|
|
2|
|
MANAGEMENT
3|
|
REPORT
4|
|
4.1
ANALYSIS OF THE GROUP’S ACTIVITY AND RESULTS
92
4.7
4.1.1 Presentation of reported revenue
92
4.7.1 Risk management and insurance
97
4.1.2 Revenue analysis
92
4.7.2 Internal Control
100
4.1.3 Results
93
4.7.3 Internal Audit
101
4.1.4 Analysis of the results
93
4.1.5 Financial position
94
4.8
102
4.1.6 Analysis of the financial position
94
4.8.1 Strategic risks
103
4.1.7 Outlook
94
4.8.2 Operational risks
106
4.2
96
4.9
109
MAJOR EVENTS SINCE THE START OF THE 2026 FISCAL YEAR
RISK MANAGEMENT, INTERNAL CONTROL, AND INTERNAL AUDIT
RISK FACTORS
OTHER LEGAL INFORMATION
97
4.9.1 Guerbet S.A.’s results for the last five fiscal years
109 110
4.3
CONSOLIDATED COMPANIES
96
4.9.2 Information regarding the breakdown of Guerbet S.A.’s trade payables and trade receivables by due date
4.4
RESULTS OF SUBSIDIARIES HELD BY GUERBET S.A.
96
4.9.3 Information on the acquisition of participating and controlling interests (article L. 233-6 of the French Commercial Code)
110
COMPANIES DIRECTLY OR INDIRECTLY CONTROLLED BY GUERBET S.A.
96
4.9.4 Information on related-party agreements (article L. 225-38 of the French Commercial Code)
111
4.5
112
TRANSACTIONS IN TREASURY SHARES OF GUERBET S.A.
97
4.9.5 Other information from the management report contained in other sections of the Universal Registration Document
4.6
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
5|
|
6|
|
7|
|
91
MANAGEMENT REPORT Analysis of the Group’s activity and results
4.1
ANALYSIS OF THE GROUP’S ACTIVITY AND RESULTS
4.1.1
Presentation of reported revenue
IFRS (in thousands of €)
Revenue
2024
786,443
841,093
Divested businesses (Accurate et urology)
1,876
4,152
Breakdown of revenue by geographic region
2025
2024
EMEA
43.8%
42.1%
Americas
29.7%
30.5%
Asia
26.5%
27.4%
2025
2024
X-ray
54.4%
56.9%
MRI TOTAL DIAGNOSTIC IMAGING
32.1% 86.5%
31.2% 88.1%
INTERVENTIONAL RADIOLOGY
13.5%
11.9%
Breakdown of revenue by product range
4.1.2
Revenue analysis
The Group saw a 6.5% decline in its sales in 2025 to €786.4 million. At constant exchange rates (CER)(1), this decline is reduced to 3.8%, incorporating an unfavourable currency effect of €22.8 million due to the depreciation of the US dollar, the Brazilian real and Asian currencies (mainly the South Korean won and the Chinese yuan). At CER and on a like-for-like basis(2), revenue fell by 3.5% in 2025. This decrease, which slightly exceeds the forecast range announced on December 2 (between -4% and -5%), reflects contrasting trends: a 5.4% fall in business at CER and on a likefor-like basis in the first half of the year, linked to the contraction in sales in France, which was followed by an increase of 2.6% in the third quarter, and then a decline of 5.6% in the fourth quarter, impacted by the situation at the Raleigh industrial site in North Carolina in the United States. In EMEA, full-year sales came to €343.7 million, down 2.5% at CER and on a like-for-like basis. The region saw growth of 7.6% excluding France, where volumes suffered from the rapid switch in the mix (from single dose to larger vials) following supply chain reform. In the fourth quarter alone, which saw a return to growth in France, revenue in EMEA came to €87.9 million, a decrease of 3.2% at CER and on a like-forlike basis. In the Americas, revenue came to €233.0 million in 2025, a decrease of 3.8% at CER and on a like-for-like basis. This factors in a contraction of 8.6% in the fourth quarter as a result
(1)
(2)
92
2025
of the delayed release of batches produced at the Raleigh site and the plan to bring the site into compliance with the recommendations of the Food and Drug Administration (FDA). In Asia, full-year sales amounted to €207.9 million, down 4.8% at CER and on a like-for-like basis (-6.1% in the fourth quarter), linked in particular to the loss of a customer by Guerbet's distributor in Vietnam. In Diagnostic Imaging, full-year revenue came to €678.2 million, a decrease of 5.3% at CER and on a like-forlike basis, incorporating a contraction of 9.1% in the fourth quarter. • Sales in the MRI division were down by 1.9% over the year at CER and on a like-for-like basis, with a more acute decline in the fourth quarter (-12.5%) due to the situation at the Raleigh site. • Sales in the X-ray division were down 7.2% at CER and on a like-for-like basis in 2025 (-7.2% also in the fourth quarter), linked to lower volumes of Xenetix® and Optiray®, mainly in France. In Interventional Imaging, revenue reached €106.3 million for the year, an increase of 9.7% at CER and on a like-for-like basis. This increase, which factors in a further acceleration in the fourth quarter (+20.4%), was fuelled by solid momentum in volumes and prices for Lipiodol®, particularly in vascular embolization.
At constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year. Excluding the urology and Accurate businesses (including sales made in 2025 from inventories of components and finished products), which were sold in July 2024 and January 2025 respectively.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
MANAGEMENT REPORT Analysis of the Group’s activity and results
4.1.3
Results 2025
2024 % of revenue
IFRS (in thousands of €)
% of revenue
- Revenue
786,443
100
841,093
100
- Royalties
7,357
0.9
3,699
0.4
- Other operating income
5,519
0.7
7,677
0.9
- Purchased consumed and change in inventories
(199,297)
(25.3)
(189,263)
(22.5)
- External expenses
(238,567)
(30.3)
(255,029)
(30.3)
- Staff-related costs
(254,255)
(32.3)
(273,980)
(32.6)
+/- Other operating income and expenses
(8,157)
(1.0)
1,623
0.2
- Taxes EBITDA(a)
(16,783) 82,261
(2.1) 10.5
(16,400) 119,419
(1.9) 14.2
- Depreciation, amortization, impairment and provisions OPERATING RESULT
(170,424) (88,164)
(21.7) (11.2)
(69,849) 49,570
(8.3) 5.9
- Net financial expenses +/- Foreign exchange gains or losses and other financial income/ expenses
(19,435)
(2.5)
(22,290)
(2.7)
(1,980)
(0.3)
(7,933)
(0.9)
+/- Tax expense NET RESULT
(3,076) (112,654)
(0.4) (14.3)
(5,881) 13,467
(0.7) 1.6
— — —
1|
|
2|
|
3|
|
(a) EBITDA = Operating income + net amortization, depreciation, impairment and provisions.
4.1.4
Analysis of the results 4|
|
In 2025, the Group generated an EBITDA margin rate representing 10.5% of revenue. Excluding non-recurring costs related to the optimization of the operating plan and the change in the sales model which totaled -€12.2 million (vs. -€6.0 million in 2024), the restated margin rate was 12.0%, at the high end of the adjusted range communicated on December 2 (between 10.5% and 12%), compared with 14.9% in 2024. The fall in profitability is due to the decline in activity and pressure on prices, particularly in the United States where margins were penalized by the unfavorable increase in the weight of distributors in the customer mix. At the same time, the Group maintained good cost discipline, with a decrease in personnel expenses (-7.2%) and external expenses (-6.5%).
The Group made an operating loss for the year of -€88.2 million, after the recognition of €170.4 million in depreciation, amortization and provisions. This includes in particular a non-recurring impairment of €86 million recorded in relation to the current situation at the Raleigh site following the impairment tests carried out during the year, as well as a provision of €10 million relating to the future destruction of certain inventories at the Raleigh site. These two accounting items have no impact on the Group's cash generation. After taking into account lower financial expenses (-12.8%) of €19.4 million, and foreign exchange losses (€2.0 million) and tax (€3.1 million), the Group made a net loss of -€112.7 million, compared with a profit of €13.5 million in 2024.
5|
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
93
MANAGEMENT REPORT Analysis of the Group’s activity and results
4.1.5
Financial position
IFRS (in thousands of €)
CASH FLOW AFTER FINANCE COSTS AND TAXES Change in working capital requirements, of which:
2025
2024
60,298
86,315
5,176
(12,252)
• change in inventories
(18,581)
(6,568)
• change in trade receivables
27,303
(27,348)
• change in trade payables
(7,039)
1,885
• change in other assets and liabilities
3,494
19,779
(44,932)
(58,240)
—
(6,305)
FREE CASH FLOW(b)
(1,351) 19,191
(84,047) (9,122)
NET DEBT(c)
325,697
344,888
Gross investments restated for debts on fixed assets Dividends paid Other(a)
(a) Mainly consisting of tax, the impact of changes in exchange rates, sales of fixed assets, and the capital increases presented in detail in the consolidated cash flow statement. (b) The free cash flow is equal to the difference between the surplus operating cash flow and investment expenditure. It explains any increase or decrease in the net debt. (c) The net debt is calculated by adding up current and non-current financial debts and subtracting cash and cash equivalents.
4.1.6
Analysis of the financial position
On the balance sheet, Shareholders’ equity stood at €267 million at December 31, 2025, compared with €394 million a year earlier. Free cash flow (FCF) was positive for the year at €19.2 million (versus -€9.1 million in 2024), driven by a significant improvement in working capital requirements (WCR), thanks in particular to the optimization of the average days sales outstanding (DSO).
4.1.7
At the Raleigh industrial site, the remediation plan initiated in the fourth quarter of 2025 is continuing with a new management team in place and the support of external experts. The corrective actions undertaken, including the modernization of equipment and processes, aim to respond as quickly as possible to the FDA's requests, and thus allow a return to a normative release rate for batches produced at the plant. The batch release rate has increased compared to the fourth quarter of 2025 and will continue to increase throughout the 2026 fiscal year.
94
This covenant applies to the bank debt and bonds negotiated in 2023.
GUERBET
In order to support Guerbet Group’s long-term development, the Board of Directors will propose at the General Shareholders’ Meeting of May 22, 2026 that no dividends be distributed to Shareholders in respect of the 2025 fiscal year.
Outlook
Update on the Raleigh site and significant negative impact expected in 2026 on revenue, profitability, cash generation and group indebtedness
(1)
Net debt came to €325.7 million (vs. €344.9 million in 2024), i.e. financial leverage(1) (net debt/EBITDA) of 4.0x (compared with 2.9x in 2024), below the ceiling of 4.8x set in December 2025 under the waiver obtained by the Group for its covenant from its lenders.
2025 UNIVERSAL REGISTRATION DOCUMENT
The Raleigh site plans to be ready for a new FDA inspection by the end of fiscal 2026. It expects to return to a normative release rate by the end of 2026, allowing Guerbet to operate under normal conditions in full-year 2027. The Group anticipates a significant negative financial impact in 2026 from the situation in Raleigh: • On activity mainly in North America and Latin America; • On profitability, due to expenses related to the compliance plan, the increase in unit costs caused by a lower level of production, and inventory destruction costs; • On cash generation, with free cash flow expected to be negative for the year and net debt expected to increase.
MANAGEMENT REPORT Analysis of the Group’s activity and results
Guerbet draws attention to the probable risk of non-compliance with the net financial debt to EBITDA ratio of 3.5x tested on June 30, 2026 under the terms of the €350 million syndicated credit agreement and the €50 million EuroPP bond issue agreement and €50 million Relance bond issue agreement. If this non-compliance materializes, it would give lenders the right, subject to certain majorities being reached, to declare their debt due and payable in advance from the second half of 2026. The Board of Directors has approved the Group's consolidated financial statements today in accordance with the going concern principle. The audit procedures on the consolidated financial statements have been carried out and the auditors' report, which will mention a significant uncertainty related to the going concern assumption due to the probable risk of non-compliance with the debt ratio mentioned above, is currently being issued. The going concern assumption is therefore based on the assumption that a waiver will be obtained from the lenders. If this assumption is not met, the going concern assumption used for the financial statements as of December 31, 2025 may not be appropriate. Guerbet is confident in its ability to find a satisfactory solution within a timeframe that is compatible with its contractual commitments.
Pursuing its transformation plan and strategic priorities Guerbet's teams remain fully committed to implementing the transformation plan launched in autumn 2025, aimed at strengthening sales momentum and restoring long-term profitability. This plan is based on three strategic priorities:
• Strengthen operational efficiency in Diagnostic Imaging by improving the competitiveness of the X-ray activity – in particular by streamlining the reference portfolio, promoting multi-dose (large) vials and optimizing industrial processes – while continuing to gain market share in MRI thanks to the Dotarem®/Elucirem™ franchise, with a rampup for the latter through geographical expansion and new indications. • Support the strong momentum in Interventional Radiology (average full-year growth of +16.1% since 2012) by capitalizing on the positioning of Lipiodol® as the reference treatment for HCC (liver cancer), the growth in its use for vascular embolization, and the potential of Lipiojoint in the management of osteoarthritis. • Improve productivity and cash generation by focusing on the twin aims of reducing fixed costs by implementing a plan to completely overhaul the support functions across the Group's entire geographical scope, improving commercial and industrial efficiency and strengthening the financial structure through cash generation, based on rigorous management of working capital requirements (control of payment deadlines, optimization of inventories) and strict control of purchases. The full effect of this transformation plan is expected to be visible in fiscal 2027. The implementation of these measures in the French scope will be subject to consultation with the employee representative bodies for projects falling within their remit.
— — —
1|
|
2|
|
3|
|
In this environment, the Group will communicate its 2026 targets at the latest when it presents its first-half revenue on July 23, 2026. The detailed presentation of the 2025 annual results is available in the Investors section of the Company’s website: https://www.guerbet.com/investors.
4|
|
5|
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
95
MANAGEMENT REPORT Major events since the start of the 2026 fiscal year
4.2
MAJOR EVENTS SINCE THE START OF THE 2026 FISCAL YEAR
Governance At its meeting on January 28, 2026, the Board of Directors, on the recommendation of the Appointments and Compensation Committee, decided to appoint Karim Boussebaa as Chief Executive Officer of the Guerbet Group, with effect from February 2, 2026. On the same date, Jérôme Estampes resumed his duties as Group Chief Financial Officer and Senior Vice President Business Development and Licensing.
Karim Boussebaa’s appointment was announced in a press release issued on January 28, 2026. On March 11, 2026, Guerbet announced the appointment, at the Board of Directors meeting, of Antoine Fady as non-voting Director with immediate effect. The appointment of Mr. Fady as Director will be submitted to the General Meeting of May 22, 2026, for approval. Following this General Meeting, a proposal will be made to the Board of Directors of Guerbet to appoint Antoine Fady as Chairperson, replacing Jean-Hugues Lecat.
Geopolitical tensions Guerbet is closely monitoring the situation in the Middle East with respect to potential indirect consequences that could impact the economic environment in which it operates (cost of raw materials, supply costs, costs of transport and its products etc.).
4.3
Given that the Company has no direct interests in the conflict zones, it believes that the situation will have limited effects on its operations and financial performance in future periods.
CONSOLIDATED COMPANIES
The consolidated companies are listed in note 30 to the consolidated financial statements in section 6.1.
4.4
RESULTS OF SUBSIDIARIES HELD BY GUERBET S.A.
The results of the subsidiaries controlled by Guerbet S.A. are presented in note 29 to the Guerbet S.A. financial statements in section 6.3.
4.5
COMPANIES DIRECTLY OR INDIRECTLY CONTROLLED BY GUERBET S.A.
The companies controlled directly or indirectly by Guerbet S.A. within the meaning of article L. 233-3 of the French Commercial Code and the stake in the Company’s capital held by them (treasury shares) are listed in note 29 to the Guerbet S.A. financial statements in section 6.3.
96
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
MANAGEMENT REPORT Risk management, internal control, and internal audit
4.6
TRANSACTIONS IN TREASURY SHARES OF GUERBET S.A.
Number of shares purchased and sold during the fiscal year: • Number of shares purchased during the fiscal year under the liquidity contract entrusted to BNP Paribas by Guerbet: 9,995 (see section 3.5 Share buyback program); • Number of shares sold during the fiscal year: none.
Number of shares registered in Guerbet S.A.’s name at the close of the fiscal year and their value measured at the purchase price as well as their nominal value: • Number of shares registered in the Company’s name at the close of the fiscal year: 25,992 (see section 3.4 Shareholding structure);
— — —
• Value measured at the purchase price: €483k; • Nominal value: €1; • Fraction of the capital that they represent: 0.21% (see section 3.4 Shareholding structure).
1|
|
Authorization to buy back shares and the conditions under which the shares were bought back and used during the last fiscal year ended: see section 3.5 Share buyback program.
2|
|
4.7
RISK MANAGEMENT, INTERNAL CONTROL, AND INTERNAL AUDIT
4.7.1
Risk management and insurance
In a constantly changing environment, risk management is an essential asset to ensure the sustainability of the Group’s activities. According to the AMF definition, risk represents the possibility of an event occurring that has consequences that may affect the persons, assets, objectives, environment, or reputation of a company. The risk management carried out by Guerbet aims to identify, assess, and mitigate these risks in order to ensure a level of control that is consistent with its objectives, customers, locations, and the needs of the Group. At Guerbet, we integrate a risk vision at all organizational levels through a cultural transformation axis to facilitate informed risk-taking within the organization.
3|
|
Risk management policy Guerbet’s global risk management system enables risk management in three stages:
4|
|
- Identification: Identification involves recognizing the responsibility of each individual and is part of an ongoing process to centralize major risks via the Risk and Insurance function; The risk assessment process is formalized annually by the Group Risk Manager through a process of interviews and management of actions. The objective is to assess a risk with regard to its impacts and its probability of occurrence;
- Risk management: The risks identified and analyzed in this way are then managed via action plans based on strategies such as avoidance, reduction, transfer (via the insurance market, for example), or acceptance. All these risks are the responsibility of the Executive Committee.
GUERBET
5|
|
- Risk analysis:
2025 UNIVERSAL REGISTRATION DOCUMENT
6|
|
7|
|
97
MANAGEMENT REPORT Risk management, internal control, and internal audit
Organization of the risk management system Guerbet has reorganized its Risk Management model to adapt it to internal developments and the external environment. The Risk and Insurance function, which now reports to General Management, supplements the internal audit, internal control, anti-corruption, and third-party evaluation functions in support of operational and support activities.
Organized according to the three control lines model, the risk management system is now in line with the various governing bodies and the Audit Committee. The roles and responsibilities are clearly established and clarified on the three lines of control in order to allow a broad dissemination of the risk management culture within Guerbet.
FUNCTIONS PARTICIPATING IN THE OVERALL CONTROL SYSTEM FOR RISKS
First line of control
Third line of control
This first line is made up of the various support departments (Human Resources, Purchasing, Finance, Legal, Compliance, Quality, etc.), responsible for steering and supporting operational management in its routine controls of activities (detection, security, training).
The third line of control is carried out by internal audit.
Second line of control This line includes all the departments that oversee risks and support the first line of control, directly involved in day-to-day operations and risk management. These include units responsible for field expertise and functions dedicated to coordinating the risk management system (risk management & insurance, internal control, compliance, etc.).
98
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
Internal audit is an independent function that reports to Executive Management and the Audit Committee. It acts within the framework of an audit plan drawn up annually and approved by the same Committee.
MANAGEMENT REPORT Risk management, internal control, and internal audit
Risk management at subsidiary level
Information on major insurance programs
The General Managers of the subsidiaries and local correspondents are responsible for managing decentralized risks. This strategy, which is as close as possible to the risks associated with local activities and realities, enables better detection of risks and proposes action plans to control them.
Information relating to Guerbet’s insurance programs is provided for information purposes only so as to present the scope of coverage that will protect our Group in 2025. The Group program adapts to changes in Guerbet and its environment, taking into account changes in the insurance and reinsurance market.
Insurance program Guerbet has a comprehensive insurance policy aimed at protecting people and their assets in the course of its activities. It is associated with the identification of existing and emerging risks via the Risk Manager in collaboration with the various departments that make up Guerbet. Guerbet’s insurance policy involves monitoring risk prevention measures by the support departments and operational management.
International programs In order to cover the main risks identified, Guerbet has implemented a global group insurance program to cover its activities in a consistent manner. Programs such as “Property Damage and Consequential Losses”, “Goods Carried”, “Civil Liability”, and “Corporate Officer Liability” are arranged through insurance brokers. These programs are deployed from France and arranged with renowned international insurers, thus guaranteeing a uniform level of coverage. The Group also takes out insurance in compliance with local regulations, such as:
The structure of these programs, along with its limits, coverage, and exclusions, aligns with market practices and Guerbet’s needs.
— — —
Civil & environmental liability Guerbet’s Civil & Environmental Liability insurance aims to protect the Group against the financial consequences resulting from personal injury or property damage caused by its business or its products to a third party.
1|
|
Property damage and consequential losses The purpose of this insurance is to protect the Group’s assets against risks such as fire, natural events, and associated consequential losses. This program consists of limits, deductibles and exclusions in accordance with the practices applied by the insurance market at the date of publication of this document.
2|
|
3|
|
Goods carried This insurance covers Guerbet’s property against various risks that may occur during their transit (by road, sea, or air) by professional carriers anywhere in the world.
4|
|
• car insurance; • civil liability insurance related to clinical trials; • construction insurance (all construction site risks, structural damage, etc.).
5|
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
99
MANAGEMENT REPORT Risk management, internal control, and internal audit
4.7.2
Internal Control
Definition
Work
Internal control is a process implemented by the Board of Directors, the Executive Committee, and the Group’s officers as well as all employees so that there is reasonable assurance of achieving the objectives relating to:
In 2025, the Internal Control function continued its work within the Group, particularly on the following topics:
• effectiveness and efficiency of internal processes;
• the performance of second-level controls on the Purchasing, Sales, and Business Expenses processes in particular;
• reliability of financial information; • compliance with applicable laws and regulations; • safeguarding assets and preventing fraud. Internal control contributes to risk management but cannot guarantee that all risks are completely eliminated or controlled.
• the implementation of a self-assessment campaign within the Group’s scope of the application of controls on the management of supplier databases; • development of data analysis reports for our ERP system to support our internal control approaches;
Objective
• coordinating the annual review of access to critical information systems;
The objectives of the Internal Control function are to:
• operational support for the automation of certain controls in our ERP system.
• structure, build and maintain the Group’s risk management system, in accordance with the Internal Control charter approved by the Chief Executive Officer and the Audit Committee, and inspired by the COSO framework; • analyze the main processes with the managers concerned to develop internal control frameworks; • support managers in drafting the Group’s policies and procedures; • maintain a document base accessible to all employees, containing key policies, procedures, and Internal Control standards; • manage the Group’s signature delegation system; • coordinate a network of representatives to promote Internal Control and implement frameworks within the Group’s main entities, ensuring the existence and effectiveness of controls; • conduct self-assessment campaigns.
Organization The Internal Control function reports to the Audit, Risk, Internal Control, and Ethics Division, which reports to the Chief Executive Officer. It is supported by a network of specialists at different levels: • the managers of functions/entities/plants within the Group, who are responsible for implementing internal control within their scope of responsibility; • the Financial Controllers and the Internal Control specialists, who coordinate the implementation of internal control within their scope of responsibility and then report on the progress to Group Internal Control.
100
• regular updating of the Group’s key policies and procedures with the relevant departments;
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
A 2024 review and the 2025 outlook of the Internal Control activity were presented to the Audit Committee in the first quarter of 2025.
Procedures for preparing and processing financial and accounting information Guerbet’s consolidated financial statements are prepared in accordance with international financial reporting standards (IFRS). The Administrative and Financial Division is responsible for preparing the financial statements. According to a schedule and consolidation instructions sent to the entities by the Administrative and Finance Division, the entities prepare a consolidated monthly report using a single software program. At each accounting close, the accounting teams review the accounts, and the Financial Controllers analyze and explain variances in the results from one period to the next and divergences from the budget. At the quarterly closing of the accounts, the Audit Committee reviews the accounts. This process is supplemented by the Statutory Auditors’ operations and certification work for the individual annual financial statements and the consolidated half-year and annual financial statements.
MANAGEMENT REPORT Risk management, internal control, and internal audit
4.7.3
Internal Audit
Within the Group, Internal Audit provides an independent and objective assessment of the effectiveness of the control systems in place in relation to the main risks identified in the Company. Internal Audit governance is defined in an Internal Audit Charter approved by the Chief Executive Officer and the Audit Committee. This charter specifies the duties, areas of operation, and responsibilities of Internal Audit and the methodologies used to carry out Internal Audit tasks. Internal Audit’s scope of responsibility covers all Group operations, functions, and legal entities. Internal Audit reports to the Audit, Risk, Internal Control, and Ethics Division, which reports directly to the Chief Executive Officer and communicates regularly with the Audit Committee. This organizational structure supports the necessary independence of Internal Audit within the organization while promoting coordination with the Internal Control and Risk Management departments, which contribute to the control of risks within the Group scope. The Internal Audit team consists of a Head of Internal Audit and two Internal Auditors, all reporting directly to the Director of Audit, Risk, Internal Control, and Ethics. Through its work and recommendations, Internal Audit helps to improve the organization’s overall performance by regularly and methodically assessing the risk control and governance processes.
The Internal Audit plan is presented each year to the Audit Committee, which reviews it, adjusts it if necessary, and issues a positive opinion before it is deployed. This annual internal audit plan is based on the risks identified at the Group level and on various information gathered during interviews with members of the Executive Committee or the Group’s sector experts. The audit plan for 2026 was approved at the Audit Committee meeting on November 21, 2025. Audit reports detailing the recommendations specific to each mission are drafted and circulated to the individuals concerned and to the Executive Committee members responsible for the audited activities. An oral presentation is provided at Audit Committee meetings, and the reports are made available to Audit Committee members. The Audit Committee monitors the progress of the implementation of the action plans relating to the audits performed.
— — —
1|
|
2|
|
In 2025, the Director of Audit, Risk, Internal Control, and Ethics and the Internal Audit Manager gave presentations at four Audit Committee meetings, including: • the report on Internal Audit activities for 2024 and the outlook for 2025;
3|
|
• a summary of internal audit findings. In 2025, these findings pertained to audits of sales entities and shared service centers in 2024 and 2025; • regular monitoring of progress on action plans following the audits;
4|
|
• the proposed internal audit plan for 2026.
5|
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
101
MANAGEMENT REPORT Risk factors
4.8
RISK FACTORS
With the support of the Group’s operational departments and support departments, Risk Management drew up a risk framework and then assessed the 20 risks likely to affect the Group’s performance. Each risk was: • described by specifying a feared scenario; • evaluated according to scoring criteria previously approved by Management and consisting of: • the scale of consequences via a prism of eight impacts, • a frequency scale, • detection, prevention and protection capacity in order to reduce the impact or frequency of the risk; • constructed by identifying existing action plans or plans to be implemented. The risks to which the Company is exposed are identified, assessed, and ranked through a risk management information system. The Risk Manager conducts an annual risk review with the risk “sponsors” in order to monitor and update them.
The risk map, which consolidates the Group’s major risks, is established and updated annually. This matrix is presented to the Group Executive Committee and the Audit Committee. As of the date of publication of this Universal Registration Document, there were eight risks that could affect the Group’s business, results, or reputation. These eight risks are classified according to two themes: • strategic; • operational. For the purposes of this document, these risks are presented without a hierarchy taking into account the net risk rating (gross risk less the effectiveness of the control plans). It is noted that beyond the eight risks listed below, Guerbet may be exposed to other non-specific risks, or risks of which it is not aware, or whose potential consequences could be underestimated, or whose realization is not considered, at the date of publication of this Universal Registration Document, likely to have a material adverse impact on Guerbet, its business, financial position, reputation, or strategies.
The table below shows the eight main major risks identified for the 2025 fiscal year, taking into account the control measures put in place by the Group:
Category
Risk description
Risks associated with the consequences of a high level of debt associated with an event impacting business continuity Strategic risks
Operational risks
102
GUERBET
Change versus 2024
New
Criticality Control level
Page
●●●●
●●
102
Risks relating to the consequences of inflation
≈
●●●
●●●
103
Risks relating to the consequences of global warming
≈
●●●●
●●
103
Information system and cybersecurity risks
↘
●●●●
●
104
Market risks
≈
●●●●
●●●
104
Purchasing and subcontracting risks
≈
●●●
●●
105
Environmental and safety risks
≈
●●●●
●●
106
Risks relating to product quality and safety
↘
●●●●
●●
107
Risks associated with the impact of geopolitical tensions in the Middle East, Ukraine, and Taiwan
≈
●●●
●●
107
2025 UNIVERSAL REGISTRATION DOCUMENT
MANAGEMENT REPORT Risk factors
4.8.1
Strategic risks Risks associated with the consequences of a high level of debt associated with an event impacting business continuity
Description of risks
Control actions
As part of the approval of the Guerbet group’s consolidated financial statements, the Company reviewed its liquidity risk. As at December 31, 2025, the Guerbet Group had a net financial debt-to-EBITDA ratio under the financing documentation of 4x below the 4.8x ceiling obtained under a waiver from its financial partners. Nevertheless, it appears that the expected negative free cash flow in the 2026 fiscal year and an increase in expected net financial debt lead to the Guerbet Group being exposed to a risk linked to the consequences of a high level of debt combined with the occurrence of an event impacting the business continuity of a critical site or function. Such an event, whether of industrial, regulatory, quality or operational origin, may temporarily affect the Group’s ability to produce, distribute its products or generate the expected cash flows. In this respect, the Guerbet Group anticipates a significant negative impact of the situation in Raleigh on the financial situation in 2026. In this context, a significant deterioration in operating or financial performance could increase the Group’s sensitivity to compliance with its financial commitments, particularly with regard to the covenants attached to certain financing agreements. The Company may therefore no longer be able to realize its assets or settle its liabilities in the normal course of its business.
In order to limit the probability of this risk occurring and mitigate its potential impacts, in particular the financial risk associated with non-compliance with covenants, the Guerbet Group is implementing several control systems, based in particular on the transformation plan initiated in fall 2025.
In this regard, there is a probable risk of non-compliance with the net financial debt to EBITDA ratio of 3.5x tested at June 30, 2026 under the terms of the €350 million syndicated loan agreement and the €50 million EuroPP and the €50 million Relance bond issue agreements. If this non-compliance materializes, subject to the attainment of certain majorities, this would confer on the lenders the right to declare prematuring of the debt owed to them from the second half of 2026. Accordingly, the going concern principle described above is based on the assumption of obtaining a new waiver from the lenders. If this assumption were not met, the going concern principle used to approve the financial statements for the year ended December 31, 2025, may not be appropriate. As a result, there is significant uncertainty related to going concern due to the probable risk of non-compliance with the debt ratio mentioned above.
The Group therefore relies on business continuity and recovery plans in order to reduce the operational and financial impacts of a significant business interruption. These measures help preserve the Group’s ability to maintain its essential activities and limit operating losses. The Group also ensures close financial management, based on regular monitoring of key performance and liquidity indicators, incorporating forward-looking analyses. This management aims to anticipate situations of financial stress and to identify available adjustment levers in advance. The Group also maintains regular dialogue with its financial partners, promoting early and concerted management of its financing structure in the event of exceptional events. This approach helps to strengthen the Group’s financial resilience. Lastly, this risk is subject to specific monitoring as part of risk governance, particularly during the annual risk mapping reviews presented to the management and control bodies. The associated control actions are monitored and adapted according to changes in the operational, regulatory, and financial context.
— — —
1|
|
2|
|
3|
|
4|
|
5|
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
103
MANAGEMENT REPORT Risk factors
Risks relating to the consequences of inflation Description of risks
Control actions
Since the post-pandemic reopening, inflation has been largely driven by rising energy prices. This phenomenon, already amplified by the Russian-Ukrainian conflict as early as 2022, had led to high volatility in industrial costs in the eurozone.
In 2024, the impact of this phenomenon decreased significantly thanks in particular to a return to global production favoring sourcing for some of the materials required for Guerbet’s activity.
In 2025, tensions on the energy markets remain significant. The pressure on prices is the result of structural factors: recovery in global demand, persistent production constraints, and disruptions in supply chains, combined with an energy transition that is temporarily increasing the volatility of traditional markets. Moreover, geopolitical tensions in several producing regions continue to fuel risks of supply disruption, which plays a role in keeping energy inflation above pre-pandemic levels.
In 2025, global growth remains moderate in a context of economic slowdown and a high level of uncertainty. The IMF projections point to a slight deceleration in global activity due to an environment marked by increased trade fragmentation and persistent geopolitical tensions. In this context, cost control remains a central issue. This is ensured in particular by the actions taken with our suppliers, including contract reviews, ongoing negotiations with our strategic suppliers, and maintaining long-term relationships that constitute an essential lever for securing supplies and optimizing our economic performance.
Risks relating to the consequences of global warming Description of risks
Control actions
Climate change brings about physical and transition issues such as:
A summary of the risks and opportunities that could have a significant impact on the Group is presented in section 5.2.1.3 Physical and transition risks.
• physical risks for our industrial plants and main suppliers in our supply chain due to acute weather phenomena (such as heatwaves, natural disasters, flooding) or chronic weather phenomena (changes in temperature, etc.) and the financial impact of these risks; • transition risks related to the scarcity of resources, the strengthening of market requirements and regulations, reputational issues related to the expectations of internal and external stakeholders, and the financial impact of these risks in the short, medium, and long term. Guerbet stepped up its climate risk assessment as part of the preparation of the “Climate Strategy” on physical and transition risks. Physical risks were analyzed for all of our industrial plants and for key suppliers. This assessment was performed using an analytical tool to measure the exposure of assets to climate risk, assess the vulnerability of activities, and define the risk mitigation strategy. This analysis was refined by incorporating a financial estimate of the main risks and opportunities.
104
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
This summary identifies the main risks and opportunities that could have an impact on activities, the supply chain, costs, and competitiveness. This is why Guerbet has implemented action plans such as measures to reduce energy consumption, optimize processes, and control waste. Guerbet has formalized its decarbonization Cf. section 5.2.1 Climate – ESRS E1.
ambition.
A decarbonization roadmap including industrial projects is included in the five-year medium-term plans. This includes dedicated OPEX and CAPEX. Physical risks are addressed as part of emergency procedures at plants that may be subject to the risk of hurricanes. Industrial plants are adapting their lead times and inventory to cope with any production plant or supplier disruption. Note that all these actions are integrated into the business continuity program of the Group and the industrial plants.
MANAGEMENT REPORT Risk factors
Information system and cybersecurity risks Description of risks
Control actions
The Group remains exposed to the risk of failure of its information systems in the event of a malfunction, malicious act, or cyberattack. The materialization of this risk could result in the loss or corruption of sensitive data, particularly relating to products, customers or financial data, as well as the temporary or total unavailability of certain strategic systems, disrupting business processes.
In order to reduce the risk of cyberattacks, the Group has implemented a strengthened set of measures designed to protect its sensitive data and increase the resilience of its information systems. These actions include securing servers, whether hosted on-site or with external service providers, streamlining and gradual centralization of IT infrastructures, as well as the regular implementation and testing of business continuity plans. In addition, vulnerability audits are conducted on a recurring basis in order to identify, monitor and correct potential weaknesses.
Since 2020, Guerbet has seen an increase in attacks, particularly phishing campaigns, in an environment marked by the general intensification of cyber threats and changes in working methods. In 2025, the cyber landscape is becoming even more complex: attacks are becoming more sophisticated, including cybercriminals’ use of artificial intelligence to automate intrusions, perfect phishing attempts, and develop attack tools that are more difficult to detect.
In 2022, the Information Systems Division stepped up cyber risk awareness initiatives, in particular those related to phishing attempts. Educational campaigns, supplemented by the periodic sending of test emails, are carried out with all employees. These actions make it possible to assess the level of vigilance and strengthen the ability of the teams to identify and report fraudulent messages. Network traffic protection and monitoring tools are also frequently updated to maintain an optimal level of security. The architecture of the Active Directory has been strengthened to limit the risk of intrusion and improve access segmentation. Lastly, multi-factor authentication has been extended to all users, providing an additional layer of security for access to the Group’s resources.
— — —
1|
|
2|
|
3|
|
4|
|
Market risks Description of risks
Control actions
Guerbet is exposed to risk on the Chinese market through a state policy on centralized purchasing.
In order to protect itself against this risk, the Group has previously put in place a series of reflections and measures to consolidate its positioning and to be fully able to supply the Chinese market subject to the VBP to the required capacity.
VBP (Volume-Based Procurement) is a large-volume purchasing policy implemented in 2018 by the Chinese government to reduce the costs of medicines and medical devices. It allows the Chinese government to negotiate directly with manufacturers, thereby obtaining reduced prices through large-scale orders for public hospitals.
5|
|
6|
|
This government purchasing mechanism was mobilized for a product in the Guerbet range for the first time in October 2024, and was rolled out in 2025 with its application to a second product.
7|
|
This type of practice can, in the extreme, lead to increased competition, vulnerability to changes in government policy or fluctuations in public demand, and margin erosion. However, this risk may represent an opportunity for Guerbet to secure and extend its local positioning over the two years following the awarding of the tender.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
105
MANAGEMENT REPORT Risk factors
4.8.2
Operational risks Purchasing and subcontracting risks
Description of risks
Control actions
The risks materialize through scenarios involving the failure of a key service provider, which could lead to a disruption in the supply of raw materials, strategic packaging components, or materials used to manufacture medical equipment.
The Purchasing Department, in close collaboration with the support and operational functions, assesses the performance of our suppliers and subcontractors several times a year using the “Pestel” method. This multicriteria method allows performance to be evaluated in terms of reliability, meeting deadlines, quality, HSE, and costs.
These risks could also materialize through the discontinuation of a service, impacting the production or sale of Guerbet products. Since 2020, the global economy has been facing major disruptions (pandemic, logistical tensions, shortages of certain raw materials), in addition to the consequences of the war in Ukraine. In 2025, although these factors continued to impact certain supply chains, our suppliers, contractors, and subcontractors were able to maintain their level of service, ensuring the continuity of Guerbet’s business.
There is an associated action plan incorporating priority management, taking into account the availability of technical resources. This plan is reviewed quarterly with the plants involved and the Industrial Operations Division. An additional review is conducted with the support departments (Purchasing, Quality, HSE, and the Industrial Division). In addition, Guerbet has consolidated its selection process for service providers, taking into account the Group’s values as reflected in the “supplier code of conduct”. This code, appended to contracts, formalizes the expectations with which suppliers and their subcontractors must comply in terms of, in particular, the environment. This is covered in section 5.3.2.2 Responsible purchasing and human rights commitments in the sustainability state. Strategic service providers are also included in an audit plan drawn up and implemented annually to secure our purchases and physical flows. Negotiations are conducted to obtain medium- and long-term supply agreements. A plan to qualify a second source for strategic raw materials is implemented based on available technical resources. Guerbet trains its employees in the management and control of subcontractors. A review of the financial data of our key suppliers has been added to our risk analysis approach. Guerbet has conducted “Market” trend analyses to refine its strategic positioning. Guerbet has reviewed the order lead times for high-demand raw materials, while revising its inventory strategy to pre-empt any delays. Lastly, air freight is the variable that allows us to make any necessary adjustments to deliver to our customers on time.
106
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
MANAGEMENT REPORT Risk factors
Environmental and safety risks Description of risks
Control actions
The production of active chemical ingredients for contrast media entails various safety and environmental risks. These risks, especially the risks of fire, chemical exposure, and environmental pollution, are due to the dangers inherent in the use of certain raw materials, solvents, and reagents. But also the implementation of industrial processes to transform them into active ingredients as well as the treatment of waste from production.
The industrial plants roll out vital safety procedures (work permits, lockouts, fire permits, confined spaces, etc.) to reinforce accident prevention. As such, our production sites are regularly inspected by the authorities, which helps to develop our excellence in occupational health, safety, and the environment.
Guerbet’s production activity is carried out at seven different industrial plants. The three active ingredient production plants (Lanester, Marans, and Dublin) have the Seveso classification and are therefore subject to the European Union’s Seveso Directive. If these operating risks were to materialize, they could harm people and property, pollute the environment, lead to plant shutdowns, and, in some cases, make the Group liable for civil and/or criminal penalties and the payment of damages.
To control these risks, the Group deploys a policy and develops a system for Health, Safety, and Environment (HSE) management. Guerbet has defined HSE objectives throughout the Group, especially at the industrial plant level. The Group gives top priority to the safety of its employees. To this end, considerable human and material resources are deployed. At each establishment, the plant director, who is responsible for implementing the HSE policy, appoints a dedicated manager. The administrative authorities work with the plants to define the objectives to be achieved in terms of environmental performance (discharge thresholds, supervision of activities). The Group takes measures to ensure that the targets are reached. HSE risk analyses (including analyses of risks relating to processes in active ingredient production plants) and audits identify the necessary means for continuous improvement of operational safety management.
— — —
1|
|
2|
|
3|
|
The HSE objectives resulting from risk analyses and audits are documented in regularly monitored action plans. The Group and the plants organize HSE training programs rolled out to all staff. The Group has also developed a system for reporting all HSE events incorporating a systematic search for root causes, including analysis of the human factor.
4|
|
To strengthen our HSE management system, Guerbet has digitalized the main processes of its guidelines: • accident and incident reporting; • risk analysis; • HSE awareness meetings; • field safety visits; • feedback on hazardous situations and ideas for improvement; • monitoring of preventive and corrective actions. Digitalization started in 2024 continued in 2025 to strengthen our management system with better flexibility, responsiveness, and monitoring. The chemical plants also continued and accelerated the process risk analyses based on the HAZOP (Hazard Operation) method for greater reliability.
5|
|
6|
|
7|
|
In 2025, days dedicated to HSE topics raised employee safety and environmental awareness (safe behavior, fire safety, prevention, climate, etc.). These days are important times for group exchanges to reinforce the safety culture.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
107
MANAGEMENT REPORT Risk factors
Risks relating to product quality and safety Description of risks
Control actions
Product quality and safety are major commitments of the Group, in order to deliver customer satisfaction and patient protection. The Group is aware of the challenges associated with the use of its medicinal products and medical devices, so its pays the closest attention to the control of risks likely to incur its liability. Such events may generate significant financial, legal or reputational consequences.
The system put in place is based in particular on:
In order to prevent and limit these risks, the Group implements a structured and consistent system covering the entire lifecycle of its products.
• Rigorous and continuous control of manufacturing and distribution processes, based on high industrial standards, regular audits, and continuous improvement programs; • A robust drug safety and medical device safety monitoring system, guaranteeing that any adverse event related to the use of its products is collected, analyzed and systematically declared to the competent authorities, in compliance with national and international regulatory obligations; • The design, development and marketing of products whose efficacy and safety are demonstrated on the basis of trials, quality controls and tests in accordance with good practices and the legislative frameworks in force. This structure means that the Group ensures that each of its products meets the strictest requirements in terms of quality, performance and safety. This approach contributes to building long-term trust among patients, healthcare professionals, partners and authorities, and is fully in line with the Group’s commitments in terms of responsibility and compliance.
Risks associated with the impact of geopolitical tensions in the Middle East, Ukraine, and Taiwan Description of risks
Control actions
Due to its international positioning, Guerbet is faced with several geopolitical and economic factors that could, at the extreme, generate instability in the market for contrast media and related medical devices.
In order to navigate this complex and uncertain environment, Guerbet has adopted proactive sourcing and supply-chain strategies. Guerbet’s strategies have helped offset the increase in production costs due to higher commodity and energy prices and also supply chain disruptions. Similarly, Guerbet monitors global geopolitical developments and adjusts its industrial and commercial strategies accordingly, taking into account tensions such as the Israeli-Palestinian conflict or the China-Taiwan tensions, which may complicate access to Asian markets and require a reorganization of supply chains. Finally, current and future protectionist trade policies are analyzed and integrated into Guerbet’s industrial and commercial strategy to control import costs and strengthen compliance in response to an unstable regulatory environment.
108
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
MANAGEMENT REPORT Other legal information
4.9
OTHER LEGAL INFORMATION
4.9.1
Guerbet S.A.’s results for the last five fiscal years 2025
2024
2023
2022
2021
Share capital
12,641,115
12,641,115
12,641,115
12,641,115
12,641,115
Number of existing common shares
12,641,115
12,641,115
12,641,115
12,641,115
12,641,115
—
—
—
—
—
• Through bond conversions
—
—
—
—
—
• Through exercise of subscriptions rights OPERATIONS AND RESULTS OF THE FISCAL YEAR
—
—
—
—
—
(in €)
CAPITAL AT YEAR-END
Number of existing preferred (non-voting) shares
— — —
Maximum number of future shares to be created
Revenue excluding taxes with various services and products Result before tax, employee profit sharing, depreciation and amortization, and provisions Profit tax Employee profit sharing due for the fiscal year Result after tax, employee profit sharing, depreciation and amortization, and provisions Distributed result EARNINGS PER SHARE
477,883,589 541,061,080 534,288,345 482,114,693 468,989,125
1|
|
2|
|
67,859,781
51,246,360
66,517,604
69,244,672
39,790,993
(5,006,231)
(2,898,449)
4,098,617
2,687,458
(7,291,843)
658,969
780,618
710,181
527,161
484,823
(61,154,633)
27,915,965
18,585,937
(77,407,478)
19,497,207
— (a)
—
6,320,558
6,320,558
10,744,948
Result after taxes and employee profit sharing but before depreciation, amortization, and provisions Result after tax, employee profit sharing, depreciation and amortization, and provisions
5.71
4.22
4.88
5.22
3.69
(4.84)
2.21
1.54
(6.12)
1.54
Diluted net income
(8.91)
1.75
1.07
(3.25)
2.58
Gross dividend per share EMPLOYEES
—
(a)
—
0.50
0.50
0.85
Number of employees at December 31
1,048
1,046
1,038
1,074
1,060
Total wages
65,521,192
69,700,924
70,440,021
64,215,637
66,555,651
Total payroll taxes
31,106,256
34,834,991
37,506,756
32,393,613
31,181,601
3|
|
4|
|
5|
|
6|
|
(a) This amount will be subject to the approval of the Shareholders of the General Meeting of May 22, 2026, called to approve the financial statements for the 2024 fiscal year 2025.
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
109
MANAGEMENT REPORT Other legal information
4.9.2
Information regarding the breakdown of Guerbet S.A.’s trade payables and trade receivables by due date
Pursuant to the provisions of article D. 441-6 of the French Commercial Code and Decree No. 2021-211 of February 24, 2021, the breakdown of the balance of trade payables and receivables of Guerbet S.A. as at December 31, 2025 is as follows: INVOICES RECEIVED OUTSTANDING AT THE CLOSING DATE OF THE FINANCIAL YEAR THAT HAS ENDED 0 day
1 to 30 days
31 to 60 days
61 to 90 days
91 days or more
Total (1 day or more)
1,986
144
55
20
410
629
18,625 INVOICES RELATING TO DISPUTED RECEIVABLES OR BAD DEBTS
2,466
1,194
45
(705)
3,511
LATE PAYMENT RANGES Number of invoices involved Total amount, including taxes, of these invoices (in thousands of €)
Number of invoices excluded
—
Total amount, excluding taxes, of excluded invoices
—
(in thousands of €)
REFERENCE PAYMENT PERIODS USED (CONTRACTUAL OR STATUTORY PERIOD – ART. L. 441-6 OR ART. L. 443-1 OF THE FRENCH COMMERCIAL CODE) Payment periods used to calculate late payments
Contractual periods:
0 to 60 days
INVOICES ISSUED OUTSTANDING AT THE CLOSING DATE OF THE FINANCIAL YEAR THAT HAS ENDED 0 day
1 to 30 days
31 to 60 days
61 to 90 days
91 days or more
Total (1 day or more)
289
25
8
3
13
49
19,100 INVOICES RELATING TO DISPUTED RECEIVABLES OR BAD DEBTS
2,146
509
7
755
3,417
LATE PAYMENT RANGES Number of invoices involved Total amount, including taxes, of these invoices (in thousands of €)
Number of invoices involved
2
Total amount, including taxes, of these invoices
1.1
(in thousands of €)
REFERENCE PAYMENT PERIODS USED (CONTRACTUAL OR STATUTORY PERIOD – ART. L. 441-6 OR ART. L. 443-1 OF THE FRENCH COMMERCIAL CODE) Payment periods used to calculate late payments
4.9.3
GUERBET
0 to 60 days
Information on the acquisition of participating and controlling interests (article L. 233-6 of the French Commercial Code)
N/A.
110
Contractual periods:
2025 UNIVERSAL REGISTRATION DOCUMENT
MANAGEMENT REPORT Other legal information
4.9.4
Information on related-party agreements (article L. 225-38 of the French Commercial Code)
4.9.4.1
Agreements entered into during the financial year ended December 31, 2025
Agreement entered into on April 5, 2025 between Pascale Auger and Guerbet in connection with her resignation from her office as Director • On April 4, 2025, the Board of Directors authorised the execution of a settlement agreement between Guerbet and Pascale Auger in order to amicably and definitively resolve the terms and conditions of her resignation. The agreement provides for (i) an irrevocable and mutual waiver of any claim or legal action related to the cessation of her duties, (ii) standard confidentiality and non-disparagement provisions for a period of five years from the signing of the agreement, and (iii) the resignation of Pascale Auger from her office as Director on the date of execution of the settlement agreement, with effect as of the date of the Shareholders’ Meeting approving the financial statements for the 2024 financial year, held on May 23, 2025. • The agreement provides for the payment by the Company to Pascale Auger, as from the effective date of her resignation, of a lump-sum, final and comprehensive settlement indemnity, in full and final discharge, amounting to €35,000 gross before any deductions. It is also specified that Pascale Auger will receive the remuneration due to her in respect of her duties as Director for the 2024 and 2025 financial years up to the date of the Shareholders’ Meeting approving the 2024 financial statements. • The settlement agreement is in the corporate interest of the Company, as it protects the Company from any potential litigation and is aligned with its intention to renew its governance.
Agreement entered into on September 25, 2025 between MVE SAS, a company owned and managed by Éric Drapé – Director, and Guerbet • On September 22, 2025, the Board of Directors authorised the execution of a service agreement with MVE SAS, a company owned and managed by Éric Drapé, Director. The agreement covers the provision of advisory and support services for the implementation of actions aimed at improving operational performance within industrial operations and the supply chain.
• The agreement provides for a payment of €3,000 excluding VAT per actual day of services rendered, up to a maximum amount of €60,000 excluding VAT. • The execution of this agreement is in the corporate interest of the Company as it enables Guerbet to benefit from the recognised expertise and competencies of the service provider in the field of technical operations.
Settlement agreement entered into on October 8, 2025 between David Hale and Guerbet following the decision of the Board of Directors on September 22, 2025 to terminate his duties as Chief Executive Officer • The settlement agreement was submitted by the Company to the related-party agreements procedure provided for under articles L. 225-38 et seq. of the French Commercial Code. In this context, the agreement will be submitted to the approval of the Shareholders at the next Annual General Meeting to be held on May 22, 2026. • The purpose of the agreement is to prevent, through each party’s irrevocable waiver of any disputes between them, all claims—whether existing, potential, current or future—that could arise between the Company and David Hale in relation to his departure, in consideration of mutual concessions and without any admission of liability by either party.
— — —
1|
|
2|
|
3|
|
4|
|
• The agreement provides for a total amount of €360,000, including €350,000 gross in consideration for a noncompete undertaking and €10,000 excluding VAT for miscellaneous expenses borne by the Company. • The Board of Directors considered that the execution of the agreement enables the Company to preserve its interests in the context of the departure of its executive (i) by extinguishing any potential disputes and (ii) by protecting the Company against competitive activities by its former Chief Executive Officer.
4.9.4.2
Agreements entered into previously, but the effects of which continued during the past financial year
5|
|
6|
|
7|
|
N/A.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
111
MANAGEMENT REPORT Other legal information
4.9.5
Other information from the management report contained in other sections of the Universal Registration Document
Apart from the information already presented in this chapter, the Guerbet Group discloses other information that must be included in the management report in accordance with the French Commercial Code. The table below indicates the section that the reader should refer to for each type of information. Type of information
Associated section of the Universal Registration Document
Research and development activity
The Guerbet Group – p. 27 to 33
Issue of performance shares and stock options to executive officers Issue of performance shares and stock options
Corporate governance – p. 76
Equity stakes acquired during the fiscal year
The Guerbet Group – p. 34 to 35
Compensation of executive officers:
Corporate governance – p. 61 to 77
• Information on compensation • Information on pension commitments Holders of capital and voting rights
Capital and shareholding structure – p. 84
Employee shareholdings
Capital and shareholding structure – p. 84
Amount of dividends paid out in respect of the three previous fiscal years Total non-deductible expenses referred to in article 39-4 of the French General Tax Code
Capital and shareholding structure – p. 83
Employee, environmental and social data Measures to encourage citizen involvement in local democracy (L. 22-10-35, 3°)
Sustainability statement – p. 113 to 203 Sustainability statement – p. 161
Information on key intangible assets, their significance to the business model, and how they contribute to value creation for the Company (L. 232-1, II, 7° et L. 22-10-35, al. 5)
112
Capital and shareholding structure – p. 86 to 91
Financial statements and related notes – p. 271
Guerbet complies with the legal provisions set forth in article L. 2123-1 and following of the French General Code of Local Authorities. The Guerbet Group – p. 14 to 15 Sustainability statement – p. 149 to 162
Impact of the Company’s activities on the fight against tax evasion (L.22-10-35, 1°) Measures to foster ties between the Nation and its armed forces, as well as initiatives to support engagement in the National Guard reserves (L. 22-10-35, 2°)
Sustainability statement – p. 182
Specific information for companies operating at least one site classed Seveso “high threshold” (L. 232-1-1)
Sustainability statement – p. 164 to 176
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
N/A
— — —
1|
|
SUSTAINABILITY
2|
|
STATEMENT 3|
|
5.1
114
5.5
5.1.1 Business model, value chain and CSR strategy
GENERAL INFORMATION
114
5.5.1 Background
ENVIRONMENTAL TAXONOMY
178
5.1.2 CSR governance
116
5.5.2 CSR strategy and eligible activities
179
5.1.3 Core policies and mechanisms of the CSR strategy
117
5.5.3 Eligible financial metrics
179
5.1.4 Stakeholders
121
5.5.4 Aligned financial metrics
181
5.1.5 Due diligence
124
5.5.5 Conclusion and outlook
183
5.1.6 Impacts, risks and opportunities
125
5.1.7 General basis for establishing the sustainability statements – BP-1
127
5.6
184
METHODOLOGIES AND SPECIAL CIRCUMSTANCES
178
5.6.1 Scopes and exclusions
184 184
129
5.6.2 Data collection systems and processes
5.2.1 Climate – ESRS E1
130
5.6.3 Engagement of external third parties
184
5.2.2 Control of discharges – ESRS E2
142
5.6.4 Other special circumstances
185
5.2.3 Preservation of water resources – ESRS E3
144
5.6.5 Changes since the previous fiscal year
185
5.2.4 Favoring the circular economy – ESRS E5
146
5.6.6 List of data points in cross-cutting and thematic standards derived from other EU legislation (ESRS 2 IRO-2, appendix B)
185
5.3
5.2
PLANET (ENVIRONMENTAL DATA)
PEOPLE (SOCIAL DATA)
149
5.3.1 Guerbet employees – ESRS S1
150
5.3.2 Workers in the value chain – ESRS S2
163
5.3.3 Local communities – ESRS S3
165
5.3.4 Commitment and responsibility in healthcare – ESRS S4
167
5.4
172
BUSINESS CONDUCT INFORMATION – ESRS G1
5.4.1 Corporate culture
172
5.4.2 Business ethics
173
4|
|
5|
|
6|
|
7|
|
5.7
CSRD ANNEX
195
5.7.1 Specific definitions
195
5.7.2 Environmental taxonomy tables
200
5.7.3 Glossary
202
5.8
203
REPORT ON THE CERTIFICATION OF SUSTAINABILITY INFORMATION AND VERIFICATION OF THE DISCLOSURE REQUIREMENTS UNDER ARTICLE 8 OF REGULATION (EU) 2020/852
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
113
SUSTAINABILITY STATEMENT General information
5.1
GENERAL INFORMATION
5.1.1
BUSINESS MODEL, VALUE CHAIN AND CSR STRATEGY
114
5.1.2
CSR GOVERNANCE
116
5.1.2.1 Role of governance bodies
116
5.1.2.2 Information sent to the governance bodies
117
5.1.2.3 CSR criteria in variable compensation
117
5.1.3
117
CORE POLICIES AND MECHANISMS OF THE CSR STRATEGY
5.1.3.1 Ethics Charter
117
5.1.3.2 GuerbetEthicsAlertLine whistleblowing system
117
5.1.3.3 HSE policy
118
5.1.3.4 Responsible purchasing approach
119
5.1.3.5 Integrating the SDGs into the CSR strategy
120
5.1.1
5.1.4
STAKEHOLDERS
121
5.1.5
DUE DILIGENCE
124
5.1.6
IMPACTS, RISKS AND OPPORTUNITIES
125
5.1.6.1 Double materiality assessment methodology
125
5.1.6.2 Link to the strategy and the business model
127
5.1.6.3 Integration into the overall risk management process
127
5.1.6.4 IRO-2 – ESRS disclosure requirements covered by corporate sustainability statements
127
5.1.7
127
GENERAL BASIS FOR ESTABLISHING THE SUSTAINABILITY STATEMENTS – BP-1
Business model, value chain and CSR strategy(1)
Business model and value chain The business model is presented in chapter 1. The Guerbet Group. Its value chain is presented below:
CSR commitment integrated into our strategy Guerbet’s strategic roadmap and business model incorporates sustainability matters from the Corporate Sustainability Reporting Directive (CSRD(2)), known as ESRS(3):
- Strengthen leadership in magnetic resonance imaging (MRI);
- Develop Interventional Radiology by capitalizing on the potential of Lipiodol®;
- Enhance Operational Excellence;
- Explore new growth drivers.
(1) (2) (3)
114
Guerbet’s products and innovations demonstrate the Company’s commitment to integrating environmental and social issues into its business model and its strategy. In this context, Guerbet’s innovation is designed to reduce environmental impact and respond to the recommendations of the authorities, in particular by reducing the quantity of gadolinium. Guerbet’s commitment to corporate social responsibility (CSR) is consistent with the Company’s founding values. This commitment supports the implementation of the corporate purpose, mission and strategy. CSR thus constitutes a real lever for value creation, contributing to the Company’s overall performance and strengthening its ability to differentiate itself in its market.
CSR: corporate social responsibility. CSRD: Corporate Sustainability Reporting Directive. ESRS (European Sustainability Reporting Standards): set of standards and indicators defined as part of the CSRD.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
SUSTAINABILITY STATEMENT General information
The CSR strategy and associated objectives support this Group strategy. They are built around impacts, risks and opportunities (IRO).
The IROs were defined as part of the double materiality assessment(1), which incorporates the interests of stakeholders. This analysis is approved by the Board of Directors, whose members are called upon to engage in in-depth discussions with professionals on innovation issues.
CSR strategy
— — —
1|
|
2|
|
3|
|
4|
|
5|
|
6|
|
7|
|
(1)
Double materiality involves examining two dimensions: financial materiality and impact materiality.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
115
SUSTAINABILITY STATEMENT General information
The other components of the business model listed in the CSRD are presented in various sections summarized below. Other components of the business model
Sections
Principal markets
Our international footprint/1.3.2 Markets
Number of employees by geographical area
5.3.1 Guerbet employees – ESRS S1
Revenue
In figures
Evaluation of products, services, markets and customers
5.1.6.1 Double materiality assessment methodology
Dialogue with stakeholders
5.1.4 Stakeholders
5.1.2
CSR governance
5.1.2.1
Role of governance bodies
Guerbet operates with governance structured around two main bodies: the Board of Directors and the Executive Committee. Regarding governance, the CSRD Directive covers administrative, management and supervisory bodies. For Guerbet, this is the Board of Directors and its specialized Committees. The composition, roles and responsibilities of Guerbet’s governance bodies are described in chapter 2 Corporate governance. This section details CSR governance. CSR GOVERNANCE
116
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
DIVERSITY OF GOVERNANCE BODIES
SUSTAINABILITY STATEMENT General information
CSR expertise of governance bodies The competencies of the Board of Directors are described in section 2.2.1.6 Training and orientation of Directors.
• review of the material matters and IRO by the Audit Committee. The impact, risk and opportunity assessment is updated annually, or if there is a significant event;
In 2025, Directors received CSR training.
• validation by the Board of Directors in accordance with the double materiality assessment methodology (section 5.1.6.1);
The members of the Executive Committee and the Board of Directors were made aware of the CSRD and the double materiality assessment, via dedicated presentations and meetings.
• a review of the financial and strategic arrangements in connection with the IROs is carried out at least twice a year, in line with the preparation of the annual budgets and Medium-Term Plans.
Operational CSR organization
5.1.2.3
The objectives defined by Guerbet in relation to these impacts, risks and opportunities are approved by the Executive Committee and the Board of Directors. At Guerbet, the HSE(1) & CSR Department reports to the Technical Operations Director and the Human Resources Director, who are members of the Executive Committee. In 2025, Guerbet strengthened its commitment by creating a CSR network for each department, each responsible for implementing the People & Planet commitment for its scope, under the guidance of the HSE & CSR Department.
CSR criteria in variable compensation
Guerbet’s CSR commitments are integrated into performance through recognition and compensation policies. The variable compensation of the Chief Executive Officer (detailed in section 2.4.3 Compensation of the Chief Executive Officer) and of the Executive Committee includes CSR objectives, monitored monthly, defined by the relevant Committees.
• individual variable compensation linked to carbon, water and safety objectives for managers and a specific CSR objective for certain key contributors;
Information sent to the governance bodies
• profit-sharing agreement on safety objectives, for employees in France;
Guerbet’s governance bodies ensure regular and structured monitoring of CSR information: • progress of roadmaps, in decarbonization trajectories;
particular
water
and
1|
|
2|
|
Employees are also involved in achieving CSR objectives through several mechanisms: • share allocation plans linked to carbon objectives, intended for certain employees and managers;
5.1.2.2
— — —
3|
|
4|
|
• awards system that incorporates behavioral principles, in line with Guerbet’s strategic ambitions (see 5.4.1 Corporate culture).
5|
|
5.1.3
Core policies and mechanisms of the CSR strategy
5.1.3.1
Ethics Charter The Charter embodies the Group’s ethical principles and guides decisions on a daily basis. It is a benchmark policy, essential to the Company’s reputation and the management of material impacts, risks and opportunities.
Its update is coordinated by the Audit, Risk, Internal Control and Ethics Director, in consultation with the Executive Committee and the Directors concerned, and sent to the Chief Executive Officer and the members of the Board of Directors. The Executive Committee is responsible for the dissemination and application of the Ethics Charter within the Group, with the support of internal resources (managers, advisers, experts).
Updated in 2024, it was distributed via an internal communication plan and a multilingual e-learning module that was rolled out to all employees in 2025.
6|
|
The Ethics Charter, based on five pillars, comes under the regulatory frameworks applicable to Guerbet.
5.1.3.2
GuerbetEthicsAlertLine whistleblowing system
7|
|
Guerbet encourages its employees and external stakeholders to report any events that are contrary to its ethical principles and applicable laws and regulations. These reports may be made by employees to their line manager, designated contact persons or through a dedicated whistleblowing platform, GuerbetEthicsAlertLine. This platform is also accessible to stakeholders externally via this link: https:// report.whistleb.com/en/GuerbetEthicsAlertLine.
The Ethics Charter applies to all employees, including temporary employees and external partners. It is supplemented by specific policies.
(1)
HSE: Health, Safety, Environment.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
117
SUSTAINABILITY STATEMENT General information
This secure platform is independent of the IT network, and it is used to confidentially collect, record and investigate any professional alert declared anonymously or otherwise.
This platform is included by default in the list of applications available to employees and communicated on the corporate social network Guerbet Inside.
All messages received are handled under the responsibility of the two Group contacts in order to coordinate analyses, admissibility, investigations, confidentiality and any corrective actions (including sanctions).
A report on the functioning of the whistleblowing system, the associated escalations and the effectiveness of the system is presented to the Ethics Committee and the Board of Directors annually.
The e-learning module on the Ethics Charter covers this whistleblowing system.
Subjects covered
- Respecting our employees
• Health hand safety of people • Diversity and combating discrimination • Combating harassment • Social dialogue
• 5.3.1.3 Health and safety • 5.3.1.7 Diversity and inclusion • 5.3.1.4 Quality of life at work and working conditions • 5.3.1.1 Impact management and dialogue process
- Respecting patients and • Product quality and safety healthcare professionals • Product information • Interactions with healthcare professionals • Interactions with patient organizations • Commercial and fair competition law
- Acting with integrity in business affairs • Anti-corruption and conflicts of interest • Responsible purchasing • Representation of interests
• 5.3.4.3 Product quality and safety for patients and healthcare professionals • 5.3.4.1 Impact management and dialogue process
- Respecting the Company
• Protecting the Group’s assets • External communication • Protecting personal data
• 4.8 Risk factors and risks presented in the Sustainability Statement • 5.1.4 Stakeholders • 5.4.2.4 Protection of personal data
- Protecting the environment
• Controlling and reducing our environmental impacts • Combating climate change
• 5.2 Planet (environmental data) • 5.2.1 Climate – ESRS E1
5.1.3.3
HSE policy
The Group has developed a HSE policy, which reflects its commitment to protecting the environment, health and safety of its employees and stakeholders. This policy applies to the entire Group and is structured around the following six commitments:
- providing sufficient and appropriate means to continuously improve safety and reduce environmental impacts for all activities;
- promoting and strengthening the safety culture in all sectors, through appropriate training, a determined management commitment and appropriate visual management;
- recognizing good practices and good behaviors and sharing experiences;
- complying with applicable regulations wherever Guerbet operates, meeting the expectations of stakeholders (employees, staff representatives, local communities, authorities, suppliers, customers and investors);
118
Correspondence in the Sustainability Statement and the Universal Registration Document
Pillars of the ethics charter
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
• 5.4.2.3 Compliance with competition law • 5.4.2.2 Prevention of corruption and conflicts of interest • 5.4.2.1 Management of supplier relations • 5.4.2.5 Representation of interests
- maintaining heightened vigilance of major risks and deploying prevention policies, particularly at the production and distribution sites;
- considering HSE from the start of any planned development, new product design or process improvement. The Chief Executive Officer is responsible for implementing this policy. The Human Resources Director and the Technical Operations Director, members of the Executive Committee, are in charge of its deployment. The industrial sites have HSE management systems, based on the principles of the ISO 14001 and ISO 45001 standards. In addition, the active ingredient production plant in Dublin is ISO 14001 certified and is the largest contributor to energy and water consumption. The Group conducts regular performance reviews to monitor the progress of actions. Practices are organized on a very regular basis at executive committee level at the industrial sites to raise HSE issues, promoting greater responsiveness and collective commitment.
SUSTAINABILITY STATEMENT General information
The HSE policy is available on the internal document system and on the website. It is applied locally and displayed at industrial sites. It will be updated in 2026, in order to integrate the guidelines linked to the arrival of the Chief Executive Officer and the Technical Operations Director.
- accounting compliance;
5.1.3.4
Responsible purchasing approach
- data safety and integrity;
The Group pursues a responsible purchasing policy. This means that Guerbet only works with suppliers with integrity and respect for the environment. Guerbet promotes its social values to its suppliers and asks them to do the same with their own partners.
Ethical purchasing charter
This approach is included in the Ethics Charter.
Vision “At Guerbet, we are committed every day to improving the diagnosis and prognosis of patients. This commitment goes beyond our products and is embodied in the way we work, starting with our purchasing practices. Our vision is to contribute to the future of health innovation through responsible purchasing. We aspire to build a resilient and transparent purchasing ecosystem that drives innovation while supporting sustainable health. We encourage collaboration and trust by developing a strong network of sustainable partners, sharing our values. Together, we are building a purchasing model that supports Operational Excellence and helps protect people, the planet and the living world.”
Policy The deployment of the responsible purchasing policy is the responsibility of the Purchasing Manager.
- conflicts of interest;
- compliance with the rules of international business ethics;
- protection of personal data and respect for intellectual property;
- reporting problems.
The Group requires all employees involved in purchasing to comply with the principles of the ethical purchasing charter. Each buyer acts with integrity, prevents any conflict of interest and guarantees confidentiality and the protection of intellectual property. They ensure that suppliers apply the code of conduct, including by prohibiting all forms of modern slavery (forced labor, child labor or illegal workers), and promotes sustainable, innovative and value-creating practices.
2|
The responsible purchasing policy is implemented internally by specific training and familiarization with the documentation. Guerbet delivers a buyer skills development program: • responsible purchasing training; The aim of this training and network coordination is to ensure that the teams take ownership of and implement the Group’s vision.
The Director of Purchasing remains the sponsor of responsible purchasing at the Executive Committee.
Responsible purchasing process
• risk analysis; • performance assessment and review;
Guerbet verifies the financial guarantees of suppliers and ensures competitive bidding, which is a hallmark of efficiency:
• dialogue;
• open access to calls for tenders;
• commitment and continuous improvement.
• equal treatment of applicants;
- labor;
- environment;
- fair competition;
- combating corruption;
5|
|
Selection
- human rights;
4|
|
In 2025, a responsible purchasing unit was created to structure and manage the responsible purchasing process.
• selection;
This code is structured around 11 topics:
3|
|
• carbon footprint and decarbonization training.
Guerbet is integrating CSR into its purchasing processes.
The supplier code of conduct sets out Guerbet’s ethical, fair competition and anti-corruption requirements that apply to any entity acting for the Group. This code, which is included in each contract, commits suppliers to respecting these principles and passing them on to their own partners.
1|
|
|
Skills development
Guerbet integrates its ethical, social and environmental values into purchasing processes:
Supplier code of conduct
— — —
• transparent, traceable procedures;
6|
|
7|
|
• consideration of the total cost. Guerbet compares suppliers on the basis of uniform criteria. The CSR criteria represent 10% of the total weight. The Group undertakes to avoid situations of economic dependence and abusive commercial practices.
Risk analysis The Purchasing Department, together with the main internal users, in particular the industrial plants, assesses the performance of its suppliers and strategic subcontractors using the “Pestel” method. This multi-criteria method makes it possible to assess their CSR performance.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
119
SUSTAINABILITY STATEMENT General information
Evaluation, performance review and engagement
5.1.3.5
Guerbet assesses the CSR performance of its strategic suppliers via an internal tool. To strengthen this assessment process, Guerbet plans to set up an external CSR assessment platform. The results will be used to define objectives for improving supplier practices on environmental, social and governance issues.
The Sustainable Development Goals (SDG) define global sustainable development priorities and aspirations for 2030.
Business reviews are held annually with key suppliers: their objective is to deliver quality assessment, support continuous improvement, ensure optimal supply and strengthen existing relationships.
Integrating the SDGs into the CSR strategy
Guerbet contributes positively to 15 of the 17 SDGs through its mission, its strategic roadmap and its People & Planet commitment.
The Group supports certain major partners in implementing progress plans. SDG
Guerbet’s contributions to the SDGs • Guerbet favors permanent contracts for its employees. • Attractive compensation linked to contribution to the success of the Company. • Guerbet Positive volunteer program. • Guerbet Positive volunteer program (food drives).
• Guerbet’s mission: to provide healthcare professionals with the contrast media, medical devices and innovative solutions essential for Diagnostic Imaging and Interventional Radiology to improve patient prognosis and quality of life. • Strategic roadmap to meet medical needs. • The diversity of teams is an asset and represents an opportunity to develop the Group’s sustainable performance, innovation and creativity. Guerbet promotes inclusion, regardless of gender, age, marital status, sexual orientation, disability, national or ethnic origin, or religious or political beliefs, in recruitment and career development. • The Group aims for a balanced representation of women at all levels. • Support for young people: visits to industrial sites for students, presentations at school forums, receiving interns and young people on work-study programs. • • • • •
The Group aims for Operational Excellence and invests to ensure its environmental performance. The company is committed to reducing its environmental footprint across its entire scope of activities. The Group is committed to controlling its processes and emissions while seeking innovation to reduce their impact. The Group has set itself targets to decarbonize and reduce its water consumption. Guerbet seeks to preserve natural resources such as water or raw materials and limit the impact of its activities until the end of life of its products.
• The Group operates a high-added value business. • Guerbet is committed to ensuring compliance with the fundamental conventions of the International Labor Organization (ILO). The Group has set safety objectives. • Guerbet incorporates human rights into its internal policies such as its ethics charter, its responsible purchasing policy, and via its secure whistleblowing platform. • The Group strives for Operational Excellence. It pursues its industrial investment program and the development of its network in order to guarantee the safety and compliance of operations, the quality of its products and services for patients and healthcare professionals, the reliability of supply, and environmental performance. • Guerbet aims to be a trusted partner for all its stakeholders. • The Group conducts its business with ethics and integrity, two essential principles for establishing and maintaining credibility. • Through its Guerbet Positive volunteer program, the Group enables employees to make concrete commitments for associations and causes in line with the Company’s values.
120
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
SUSTAINABILITY STATEMENT General information
5.1.4
Stakeholders
Guerbet maintains an open and transparent dialogue with its stakeholders, a key aspect of its sustainability strategy. This dialogue makes it possible to understand their expectations and to share initiatives and challenges. It contributes to sustainable performance by promoting the identification of new opportunities and the acceleration of innovation. OUR STAKEHOLDERS
— — —
1|
|
2|
|
3|
|
4|
|
STRONG RECOGNITION OF STAKEHOLDERS Organization
Context
EthiFinance: non-financial rating agency for companies listed on European markets.
2023
2024
2025
Gold level 76/100
Gold level 77/100
GOLD LEVEL SINCE 2023 ↗ 77/100
Comments
5|
|
2023 and 2024 ratings updated to take into account changes to the EthiFinance framework.
6|
|
CDP(a) identifies the world’s most active companies in terms of climate and water conservation.
= Climate B
= Climate B
= CLIMATE B
Water B
Water B
WATER B
Committed level
SILVER LEVEL ↗ 71/100
A++ Drug: 90/100 MD: 88/100
WINNER
EcoVadis(b) assesses the CSR performance of companies.
CAHPP(c) assesses the CSR performance of companies.
A++ 90/100 & 85/100
↗ A++
DRUG: 84/100 MD: 88/100
7|
|
Guerbet reached second place in the drug category in 2025, with a score of A++ (ranking from D to A++).
(a) CDP: non-profit organization that identifies the world’s most active companies in the fight against climate change. (b) https://recognition.ecovadis.com/Rn7tVSVyMU6rugwmVZwWMw. (c) Purchasing center for private and public hospitals that supports 3,300 healthcare facilities in purchasing.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
121
SUSTAINABILITY STATEMENT General information
EcoVadis Silver Medal Guerbet was awarded EcoVadis Silver Medal status(1), a distinction that places us in the top 15% of companies. This recognition highlights the commitment and the maturity of our sustainability approach and the effective integration of environmental, social and ethical issues into our practices, throughout our value chain.
Top 15% of the most committed companies.
External controls Guerbet’s People & Planet commitment is inspired by international standards, initiatives, and principles: Science-Based Targets initiative (SBTi)(a)
The Science Based Targets initiative (SBTi) encourages ambitious climate action in the private sector by allowing companies to set science-based emissions reduction targets aligned with the Paris Agreement.
ISO 14001
ISO 14001 is an internationally recognized standard that establishes the requirements for an environmental management system. It helps organizations improve their environmental performance.
These are greenhouse gas emission reduction objectives that provide organizations with a trajectory aligned with climate science; defining a SBT is integral to a credible climate strategy.
Guerbet’s industrial sites have HSE management systems, based on the principles of the ISO 14001 standard.
Guerbet is committed to a minimum “Well-below 2°C” trajectory.
The active ingredient production site in Dublin is ISO 14001 certified. It is the largest contributor in terms of energy and water consumption.
This trajectory was validated by the SBTi in 2023. The Group joined the list of Companies Taking Action, which are companies active in the fight against global warming.
(a) The Science-Based Targets (SBTi) initiative encourages ambitious climate action in the private sector by allowing companies to set science-based emission reduction targets. https://sciencebasedtargets.org/. These are greenhouse gas emission reduction objectives that provide organizations with a trajectory aligned with climate science. The definition of an SBT is integral to a credible climate strategy.
(1)
122
https://recognition.ecovadis.com/Rn7tVSVyMU6rugwmVZwWMw.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
SUSTAINABILITY STATEMENT General information
Methods of dialogue with stakeholders Guerbet’s People & Planet commitment is regularly communicated to stakeholders, internally and externally, via various media (Universal Registration Document, website, press releases, social networks). The Group also takes into account their expectations through CSR questionnaires, sector reports and benchmarks. The methods for dialogue with stakeholders are detailed in the table below: Stakeholders
Employees
Staff representatives
Healthcare stakeholders and patients
Board of Directors
— — —
Dialogue methods
The Group encourages regular dialogue with its employees: • interactions between managers and employees, performance and development review; • dialogue between sectors, via communities or internal reference persons; • induction programs for new employees; • regular communication by videoconference or via the Guerbet Inside corporate social network.
1|
|
Guerbet strives to foster regular social dialogue, which aims in particular to promote communication between all internal stakeholders: dialogue between social partners and Management and between managers and teams.
2|
|
Guerbet manages its interactions with healthcare actors in strict compliance with local regulations: • participating in conferences, organization of symposia, expert committees and scientific and educational exchanges with healthcare professionals; • carrying out surveys and answering questions.
3|
|
To ensure the Company’s performance and continuation, the Board of Directors maintains regular dialogue with Management and employees, in particular through the presence of an Employee Director and a staff representative, as well as with all stakeholders. The Board of Directors reports on its management to the Shareholders at the General Meetings, where the annual accounts are approved and the major strategic directions are discussed.
4|
|
Shareholders
Guerbet maintains constructive dialogue with the authorities. This regular dialogue is based on accountability and transparency.
5|
|
Institutions
The Group maintains regular dialogue with investors through financial and non-financial communication, participation in forums, and responses to non-financial rating questionnaires. Investors and rating agencies
This dialogue is carried out in strict compliance with the regulatory obligations related to its status as a listed company, in particular with regard to the non-disclosure of inside information.
6|
|
Membership of and participation in clusters, associations and professional unions to share best practices: LEEM, France Chimie, G5 Santé, MedTech In France and French Healthcare. Professional societies
7|
|
The Group develops local relationships and initiatives to support the economic development of the regions where it operates. Local communities
To ensure continuous and transparent dialogue with its suppliers, carriers, subcontractors and business partners, etc., the Group relies on various procedures and processes. Partners
Innovation partners
Guerbet is developing a strategy based on public and/private partnership agreements, collaborations and innovation: networked research programs, start-up research and assessment and targeted strategic partnerships.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
123
SUSTAINABILITY STATEMENT General information
5.1.5
Due diligence
Guerbet has implemented due diligence processes to identify, assess and remedy impacts related to its activities. These processes enable proactive management of CSR impacts, risks and opportunities. The table below lists the sections of the report that relate to the key elements of due vigilance. Elements of due vigilance
Related report sections
a. Integrate due diligence into governance, strategy and the business model
• 5.1.2 CSR governance • 5.1.3 Core policies and mechanisms of the CSR strategy • 5.1.2 CSR governance • 5.1.3 Core policies and mechanisms of the CSR strategy • 5.1.4 Stakeholders • Policies, dialogue processes and channels for raising concerns presented in the thematic ESRS.
b. Collaborate with relevant stakeholders at all stages of the due diligence process
124
c. Identify and assess negative impacts
• 5.1.6 Impacts, risks and opportunities
d. Implement actions to address negative impacts
Actions presented in the paragraphs “Management of negative impacts and channels for raising concerns” of the following sections: • 5.3.1 Guerbet employees – ESRS S1 • 5.3.2 Workers in the value chain – ESRS S2 • 5.3.3 Local communities – ESRS S3 • 5.3.4 Commitment and responsibility in healthcare – ESRS S4 • 5.1.3.2 GuerbetEthicsAlertLine whistleblowing system
e. Monitor the effectiveness of these efforts and communicate
“Metrics and targets” paragraphs presented in the following sections:
GUERBET
• 5.2 Planet (environmental data) • 5.2.1 Climate – ESRS E1 • 5.2.2 Control of discharges – ESRS E2 • 5.2.3 Preservation of water resources – ESRS E3 • 5.2.5 Favoring the circular economy – ESRS E5 • 5.3 People (social data) • 5.3.1 Guerbet employees – ESRS S1 • 5.3.2 Workers in the value chain – ESRS S2 • 5.3.3 Local communities – ESRS S3 • 5.3.4 Commitment and responsibility in healthcare – ESRS S4 • 5.4 Business conduct information – ESRS G1
2025 UNIVERSAL REGISTRATION DOCUMENT
SUSTAINABILITY STATEMENT General information
5.1.6
Impacts, risks and opportunities
5.1.6.1
Double materiality assessment methodology
With the entry into force of the CSRD, companies in Europe must incorporate a double materiality assessment into their sustainability report. Double materiality consists of examining two dimensions: • financial materiality: assessing the risks and opportunities related to sustainability issues in financial performance; • impact materiality: assessing the impact of activities on the environment and stakeholders.
— — —
Guerbet has a procedure describing the method for the double materiality assessment, summarized below:
1|
|
2|
|
3|
|
In 2024, this analysis was conducted by the HSE and CSR team, supported by an external firm and with input from key internal functions. The expectations of the stakeholders were taken into account, thanks to internal knowledge and a document review. In 2025, Guerbet used a benchmark for the sector and indepth analyses conducted internally. Guerbet has considered the time horizons as defined in the CSRD, namely: • Short term (ST): 1–3 years;
The associated IROs have been determined taking into account the Group’s activities and the interests of stakeholders across the value chain: • Upstream: corresponds to everything that happens before the Company’s own operations (activities of suppliers, carriers, subcontractors and innovation partners); • Own operations (OO): concern activities within the Company, under its direct control; • Downstream: concerns everything that happens after own operations, up to the end of life of the products.
• Medium term (MT): 3–5 years;
Assessment process
• Long term (LT): 5 or more years.
The assessment of the IROs was conducted without taking into account the control measures in place, in accordance with the expectations of the CSRD. This is a gross rating.
The HSE and CSR team is responsible for updating the double materiality assessment annually or in the event of substantial changes. The analysis is reviewed at a macro level by the Executive Committee and the Board of Directors. The Statutory Auditors audit the various stages of the analysis (see 5.8 Certification report).
Identification process The Group has identified the impacts, risks and opportunities based on the 37 challenges defined in the CSRD standards. The IROs associated with specific challenges, not covered by the standards, have been identified based on internal knowledge, on the sector guide, and on reference standards (Guiding Principles of the United Nations, the OECD, the ILO fundamental conventions, sector reports, etc.). Several challenges such as quality, product compliance, patient and healthcare professional safety have thus been identified.
(1)
(2)
4|
|
5|
|
6|
|
The impact materiality methodology is based on: • characterization of the impact: on stakeholders, including the planet, negative or positive, proven or potential; • probability: rate of appearance of the impact;
7|
|
• severity of the impact assessed according to three axes: extent, irreversibility and magnitude. The materiality of impact for stakeholders was pre-rated by the external firm, on the basis of a document review (external data from ENCORE(1) and SHDB(2), internal studies available including climate risk analysis) and the firm’s expertise. Priority was given to documentary sources. In 2025, the update was carried out using the sector guide.
ENCORE: Exploring Natural Capital Opportunities, Risks and Exposure, a practical guide for financial institutions – a United Nations Environment Program Finance Initiative https://www.unepfi.org/publications/exploring-natural-capital-opportunities-risks-and-exposure-a-practical-guide-for-financial-institutions/. SHDB: Social Hotspots Database, provides continuous improvement solutions for companies aiming to have a socially responsible supply chain, by equipping them with tools to assess sector-specific risks and opportunities. http://www.socialhotspot.org/.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
125
SUSTAINABILITY STATEMENT General information
The financial materiality methodology is that used in the Group’s overall risk management process: • probability of occurrence;
based on a preliminary rating carried out by the external firm. In 2025, the update was conducted using the Group’s overall risk management process.
• probability of occurrence;
A global consistency review was carried out.
• level of financial risk, • importance of the HSE risk, • extent of reputational risk, • scale of regulatory risk, • magnitude of organizational risk. The financial materiality was determined during workshops conducted with the HSE & CSR team and business contributors,
Following the update of the double materiality assessment, six issues previously considered material in 2024 are now classified as non-material in 2025 in relation to Guerbet’s activities. This update enabled Guerbet to identify: • an opportunity for a market share gain and attracting investors through the climate transition; • a positive impact of contributing to the reduction of the health system’s environmental footprint, in line with the circular economy and resource conservation challenge. These developments are based on in-depth internal analyses, the sector benchmark, and the existing regulatory framework. The six non-material issues are: patient safety in clinical trials, personal data, substances of concern, microplastics, pollution of living organisms, biodiversity and ecosystems.
126
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
Result of the double materiality assessment The summary of the double materiality assessment is presented below, by issue. These IROs are presented as an introduction to the policies and thematic issues in the sustainability statement to facilitate reading and promote reconciliation with the control methods in place (policies, actions, targets and metrics).
Although these issues are not considered material within the meaning of the CSRD, Guerbet acts proactively through internal mechanisms and the deployment of initiatives. For example, the Group’s environmental commitments, policies and actions (life cycle analysis, decarbonization, resource conservation, waste control and sustainable partnership) contribute to preserving biodiversity and living organisms. Additional actions are being implemented: analysis using the WWF Biodiversity Risk Filter tool on these industrial sites that has not identified a significant impact of its operations on endangered species, mapping fauna and flora and restoration of a basin at Dublin, eco-grazing at Marans and Lanester, beehives at Lanester and beehive mentorships at Aulnay, and all the industrial sites and head office applying rational management of green spaces.
SUSTAINABILITY STATEMENT General information
5.1.6.2
Link to the strategy and the business model
In addition to the analysis based on a gross rating, Guerbet produced a net rating, incorporating the existing control measures. This approach allows for better prioritization of sustainability priorities. This analysis makes it possible to define the roadmap, objectives and actions that will strengthen Guerbet’s resilience and reduce environmental and social impacts, all while promoting the policies and initiatives already in place. The business model is geared towards more sustainable and responsible performance, creating environmental, social and societal added value for stakeholders. The current and expected financial effects of impacts, risks and opportunities are not reported this year. The policies and actions presented in this chapter attest to the strategy and resilience of the Group’s business model in relation to the material IROs.
5.1.6.3
Integration into the overall risk management process
The result of this analysis, in conjunction with the control actions already in place, enables the Group to continuously strengthen its CSR roadmaps. The head office teams consolidate CSR data from the information systems or internal files. The indicators are verified by the key contributors and then undergo head office consistency reviews (loopbacks, comparison with previous years, analysis of divergences). If necessary, the teams concerned shed light on any discrepancies and carry out corrections. Guerbet plans to strengthen internal control and sustainability risk assessment processes.
— — —
1|
|
5.1.6.4
IRO-2 – ESRS disclosure requirements covered by corporate sustainability statements
2|
|
Publications targeted by IRO-2, see 5.6.6 List of data points in cross-cutting and thematic standards derived from other EU legislation (ESRS 2 IRO-2, Appendix B).
3|
The main CSR risks have been integrated into the Group’s overall risk management process.
|
The results of the IRO analysis are presented and validated by the Audit Committee of the Board of Directors.
5.1.7
General basis for establishing the sustainability statements – BP-1
The sustainability statement demonstrates the Group’s commitment to going beyond mere regulatory requirements for transparency. It highlights the CSR policies, actions, objectives and results that reflect proactive consideration of the impacts, risks and opportunities, as well as the expectations of the stakeholders.
Sustainability information covers the same scope as the financial statements. Clarification is provided when the information required by the Directive is not available. The sustainability indicators are not subject to validation by an external body (apart from verifications as part of audits of the Sustainability statement).
This chapter is an integral part of the Guerbet Universal Registration Document, in accordance with the regulatory requirements of the CSRD. The list of sustainability statement requirements that have been cross-referenced is presented in the following table: Cross-referenced disclosure requirement
Corresponding section in the URD
Business model and value chain (SBM-1)
Our business model
Governance Information (GOV-1 and GOV-2)
2 Corporate governance
Innovation challenge and contribution to health (ESRS S4) Publication of information on special circumstances and methodologies for calculating indicators (BP-2)
1.5 Innovation, Research and Development
Definitions, methodology and scope of indicators
5.7 CSRD annex
4|
|
5|
|
6|
|
7|
|
5.6 Methodologies and special circumstances
Standards and methodological frameworks applied Other frameworks have been taken into account when establishing the Sustainability statement, such as the GHG protocol(1). No material indicators in addition to those required by the CSRD were reported. (1)
The GHG protocol (Greenhouse Gas Protocol) is a globally recognized set of standards for measuring and reporting greenhouse gas (GHG) emissions in a consistent and transparent manner.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
127
SUSTAINABILITY STATEMENT General information
Consideration of the value chain and sources of uncertainty Stakeholder expectations have been integrated by drawing on the expertise of internal contributors, regular dialogue and mechanisms such as surveys. • For own operations, the stakeholders considered are the employees 5.3.2 Guerbet employees – ESRS S1. • Upstream, these are mainly suppliers, carriers, subcontractors and innovation partners (sections 5.3.3 Workers in the value chain – ESRS S2, 5.2. Planet and 5.4.2.1 Management of supplier relations). • Downstream, the stakeholders include healthcare actors and patients (section 5.3.4 Commitment and responsibility in healthcare – ESRS S4).
Scope of application The presented Sustainability Statement falls within the context of the second year of application of the CSRD provisions, incorporating the adjustments resulting from the “Omnibus” and “Quick Fix” measures. The Group has endeavored to apply the normative requirements of the ESRS, as updated on the date of establishment of the report, based on the information available within the deadlines provided. Some contextual specificities for applying CSRD requirements remain: • the definition of materiality thresholds;
Data provided by third parties, such as waste treatment suppliers, are subject to internal consistency and verification reviews during audits and do not present any uncertainty issues.
• the absence of established practices, in particular to further analyze the impacts, risks and opportunities on the value chain, see 5.1.1 Business model, value chain and CSR strategy (SBM-3) and 5.1.6 Impacts, risks and opportunities (IRO-1);
Assumptions are made to calculate certain indicators. If these are changed, Guerbet will recalculate the reference year using the same methodology.
• the use of estimates and scope limitations applied on a case-by-case basis to certain data (see 5.6.4 Other special circumstances);
Calculation methodologies are presented in section 5.7.1 Specific definitions.
• uncertainties as to the applicability of certain data points and their relevance; • unavailability at the reporting date of certain information required under the ESRS, due to the complexity of collecting or developing such information, including environmental financial effects. The Group will continue to adapt its reporting practices in line with future regulatory developments and the recommendations in place.
The Group is part of a continuous improvement approach in this reporting and communication exercise. Standards
RD
Theme
Comment
Action plan
E5
E5-5
Share of recyclable content in products and their packaging
In 2025, Guerbet initiated mapping to identify the proportion of recycled and recyclable materials in packaging.
This work will be further developed, taking into account the clarifications expected in the revised version of the ESRS.
S1
Share of employees who S1-13 participated in the performance assessment
S1
The Group does not publish metrics associated with adequate wages. Salaries are reviewed S1-10 Adequate wages regularly on the basis of specialized benchmarks in order to ensure the consistency of its practices.
G1
G1
128
GUERBET
G1-6
G1-6
Average payment time
% of on-time payments
The decision was made to consolidate an indicator that best reflects reality. Consolidation on — a limited scope (employees on permanent contracts who arrived before September 15).
The payment period is calculated by comparing trade payables including VAT with purchases for the year excluding VAT. This method leads to a slight overestimation of the indicator.
Discussions will be continued and intensified in 2026 in order to define an approach that fits the Group’s compensation structure.
This work on reliability will With regard to the percentage of payments made continue in the coming years on time, the Group continued its improvement momentum by publishing an initial estimate focusing on strategic suppliers accounting for 30% of expenses.
2025 UNIVERSAL REGISTRATION DOCUMENT
Time horizon
—
—
One to three years
One to three years
SUSTAINABILITY STATEMENT Planet (environmental data)
5.2 5.2.1
PLANET (ENVIRONMENTAL DATA) CLIMATE – ESRS E1
130
5.2.1.1 Governance
130
5.2.1.2 Transition strategy
130
5.2.1.3 Physical and transition risks
133
5.2.1.4 Policy
5.2.3
PRESERVATION OF WATER RESOURCES – ESRS E3
144
5.2.3.1 Policy
144
5.2.3.2 Actions
144
135
5.2.3.3 Metrics and targets
145
5.2.1.5 Actions
135
5.2.1.6 Metrics and targets
137
5.2.4
146
5.2.2
142
CONTROL OF DISCHARGES – ESRS E2
5.2.2.1 Policy
142
5.2.2.2 Actions
142
5.2.2.3 Metrics and targets
143
FAVORING THE CIRCULAR ECONOMY – ESRS E5
5.2.4.1 Policy
146
5.2.4.2 Actions, metrics and targets
146
— — —
1|
|
Five areas of commitment Guerbet is fully aware of the environmental challenges facing the world and pursues its development in a sustainable manner.
This approach is structured around five areas aimed at protecting living organisms:
The Group is committed to reducing its environmental footprint across all its operations, from supply, during production stages, through to customer delivery and to the use and end of life of products.
• circular economy;
2|
|
• decarbonization; • preservation of resources;
3|
|
• sustainable partnership; • control of discharges.
4|
|
5|
|
6|
|
7|
|
The Group’s carbon footprint assessment takes into account all the activities of Guerbet and its partners. The other environmental indicators concern the scope of industrial plants, excluding data from the Lyon plant and administrative and sales units, where the impact is not significant.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
129
SUSTAINABILITY STATEMENT Planet (environmental data)
5.2.1
Climate – ESRS E1
5.2.1.1
Governance
Guerbet’s governance also covers climate issues. The results and progress of Guerbet’s actions are presented to the Executive Committee and the Ethics, Governance and CSR Committee of the Board of Directors.
objectives. It makes it possible to implement strategies and technologies that can be strengthened over time. This objective takes into account: • the Group’s growth strategy; • areas of work identified internally;
The climate is integrated into the Chief Executive Officer’s variable compensation policy.
• innovation and technological developments;
The Group is rolling out climate governance at each level of the Company and in internal decision-making mechanisms: variable compensation, budgets, Medium-Term Plan, etc.
• the use of renewable energies, favoring deployment at our plants rather than the purchase of certificates.
5.2.1.2
Transition strategy
SBTi targets and transition strategy Aware of climate issues and its responsibility, Guerbet has since 2021 been committed to a Well-below 2°C trajectory by 2032. This commitment breaks down as follows for scopes 1, 2 & 3(1):
• partner engagement;
This objective is based on scientific evidence and has been validated by an external body, the SBTi. Thus, Guerbet is part of Companies Taking Action, i.e. companies actively engaged in the fight against global warming. The STBi target covers 100% of the emissions of scopes 1 & 2. It covers 85% for scope 3 in the following emission categories: • purchased goods and services; • fuel and energy activities; • upstream transport and distribution; • waste generated during operation; • downstream routing. BREAKDOWN OF GREENHOUSE GAS (GHG) EMISSIONS
Guerbet has developed a transition strategy and plans to formalize a transition plan, within the meaning of the CSRD, within one to three years. This plan seeks to strengthen Guerbet’s current decarbonization trajectory, which aims to limit warming well-below 2°C compared with pre-industrial temperatures, in line with the recommendations of the Intergovernmental Panel on Climate Change (IPCC). This strategy is implemented within the organization through action plans. The “Well-below 2 °C” objective is aligned with the commitments of many countries under the Paris Agreement. This is a structuring step to accelerate our decarbonization approach before moving towards more ambitious long-term
(1)
130
Guerbet incorporates environmental and climate criteria into its significant industrial investments. Guerbet’s carbon trajectory is updated and presented annually to the General Manager, the Director of Technical Operations and the Ethics, Governance and CSR Committee of the Board of Directors.
Scopes 1, 2 & 3 are greenhouse gas (GHG) emission categories: • Scope 1: emissions directly emitted by the Company’s activities, from fossil fuels. • Scope 2: indirect emissions associated with the production of purchased and consumed energy (electricity and heating/cooling networks); • Scope 3: indirect emissions that are beyond the direct control of the Company, often encompassing activities upstream and downstream of the value chain (purchased products and services, transport and logistics, waste, etc.).
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
SUSTAINABILITY STATEMENT Planet (environmental data)
SCOPE OF GUERBET’S CARBON FOOTPRINT ASSESSMENT
— — —
1|
|
2|
|
SCOPES 1 & 2 ROADMAP
3|
|
4|
|
5|
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
131
SUSTAINABILITY STATEMENT Planet (environmental data)
SCOPE 3 ROADMAP
Guerbet’s climate objectives were set in 2022 with a time horizon of 2032. The transition strategy is presented with a 2030 outlook based on the Medium-Term Plan. It will be updated annually to reflect strategic developments. The Group has chosen 2021 as its reference year, a recent year that is representative of its activities and reflects a carbon maturity that is relevant for monitoring. To define its objectives, the Group took into account the expectations of customers collected via the CSR questionnaires received during calls for tenders, for example.
132
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
Locked-in emissions Locked-in emissions from the consumption of assets have not been treated separately from other emissions.
Resources allocated to action plans The capital expenditure planned over a five-year horizon to support the transition strategy in scopes 1 & 2 amounts to €15.3 million. This expenditure is updated annually.
SUSTAINABILITY STATEMENT Planet (environmental data)
5.2.1.3
Physical and transition risks
In addition to the work carried out on the identification of material impacts, risks and opportunities, the Group carried out a study on its main physical and transition risks in 2022.
Guerbet has relied on low (+1.5 °C) and high (+4 °C) warming scenarios by 2030 and 2040–2050, based on IPCC reports. These time horizons enable a relevant alignment with the Group’s strategic plans. Guerbet conducted a transition risk analysis (scarcity of resources, market requirements, regulations, reputation, etc.) and physical risk analysis for its industrial sites and key suppliers.
Acute
Chronic
The analysis was conducted on the following climatic hazards, by 2030 and 2040-2050: Temperature-related hazards
Wind-related hazards
Water-related hazards
Hazards related
✓ Change in temperature
✓ Changes in wind patterns
✓ Hydrological variability or changes in precipitation patterns and types
× Coastal erosion
✓ Thermal stress
✓ Sea level rises
× Soil degradation
✓ Temperature variability
✓ Water stress
× Soil erosion
× Thawing of permafrost
× Ocean acidification
× Solifluction
✓ Heat waves
× Saline intrusion ✓ Dryness
× Avalanche
✓ Heavy rainfall
× Landslides
✓ Flooding
× Collapse
✓ Cold wave/frost
✓ Cyclones, hurricanes, typhoons × Storms
✓ Forest fires
× Tornados
— — —
1|
|
2|
|
3|
|
× Glacial lake overflow ✓ hazards analyzed.
× hazards not analyzed, as they are less relevant to Guerbet’s activities and the locations of its sites.
Guerbet made an initial estimate of the financial consequences of these risks by including the location of its sites with regard to the climatic hazards identified, as well as the vulnerabilities upstream and downstream of its value chain. This estimate is based in particular on input data such as the value of the sites and the cost of a day of production. Financial plans intended to offset or cover these impacts were not included in these estimates. This analysis, supplemented by a financial rating, identified the main risks and opportunities, the related areas of focus and progress presented below. It did not identify any assets or economic activities incompatible with a decarbonization strategy. These risks can have an impact on activities, supply
chain, costs and competitiveness. The exercise was conducted on gross risks, without taking into account existing adaptation measures. The most exposed sites were identified based on the estimated financial impact for the hazards concerned. To mitigate the consequences of climate change on its activities, Guerbet has implemented action plans such as programs to reduce energy consumption, optimize processes and control waste. In the event of an incident, Guerbet also has business continuity plans incorporating emergency procedures related to physical risks in particular. These business continuity plans take into account identified short-term risks.
4|
|
5|
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
133
SUSTAINABILITY STATEMENT Planet (environmental data)
The sites most exposed to water stress risk are the Dublin, Lanester and Rio sites. SUMMARY OF MATERIAL IROS(1) These studies fed into the analysis of the material climate IROs. IRO type IRO
Y
Market share gain and investor attractiveness through the climate transition
l
Cost optimization through energy efficiency
R
Scope I-
Upstream
OO
Horizon Downstream
l l
Direct and indirect GHG emissions Consequences of extreme weather event on the supply chain and workers
I+
l
ST
MT
LT
l
l
l
l
l
l
l
l
l
l
l
l
l
l
The Group conducted an internal survey to consolidate its customers’ expectations.
(1)
134
Impacts apply to stakeholders, while risks and opportunities relate to Guerbet. The impact, risk and opportunity assessments are raw, i.e. they do not take into account existing means of control (policies, actions, targets and metrics). IRO type: O = opportunity; R = risk; I+ = positive impact; I- = negative impact. Scope: OO = own operation. Horizon: ST = short term; MT: medium term; LT: long term.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
SUSTAINABILITY STATEMENT Planet (environmental data)
5.2.1.4
Policy
The Group followed the following steps to define its Climate Strategy:
— — —
1|
|
TCFD: The Task Force on Climate-related Financial Disclosures is an international working group created in 2015 by the Financial Stability Board to develop a framework for companies to disclose information on financial risks related to climate change in financial economic activities. The analysis according to the TCFD framework has no impact on the reporting according to the ESRS.
Climate change is a major issue for the Group, as it directly and indirectly impacts its business. In this context, the double materiality assessment identified specific IROs, based on the studies performed and changing stakeholder expectations.
5.2.1.5
Actions
In connection with its carbon footprint and its decarbonization objectives, Guerbet is deploying the actions detailed below.
To respond to the Group’s IROs by meeting the challenges of sustainable transformation and performance, Guerbet has defined a Climate Strategy, integrating upstream, downstream and its own operations. This covers the following areas in particular:
In order to reduce the carbon impact of energy consumption and industrial processes, Guerbet has already activated several levers, including:
• adaptation to climate change (e.g. water-cooling systems during heat waves);
• monthly monitoring of energy-related carbon emissions at industrial sites;
• climate change mitigation, by developing a decarbonization trajectory;
• a carbon criterion in the review processes for significant and budgetary investments for the year and over a five-year horizon;
• energy efficiency, with the deployment of less energy-intensive technologies; • deployment of renewable energies, with the installation of solar panels;
Optimizing consumption and industrial processes
• quarterly performance reviews conducted with the Executive Committees of industrial sites and the Technical Operations Department;
• partnerships with suppliers and carriers to reduce emissions.
• organizing regular meetings between trained employees to share best practices and projects.
The objective of these areas is to preserve business continuity and strengthen the Group’s resilience.
Actions were carried out in 2025 on the industrial sites:
To ensure the relevance, implementation and effectiveness of these strategic axes and the resulting actions, a monitoring process is put in place. Guerbet’s climate challenges and the Group’s progress on its objectives are presented to part of the Executive Committee and to the Board of Directors. Guerbet has defined a transition strategy incorporating decarbonization. This is not a dedicated climate policy, as this area is integrated into the People & Planet commitment and into the HSE policy. The CEO and the Technical Operations Director are responsible for its deployment. Employees are made aware of this strategy. The Group regularly communicates externally on its transition strategy. For the sake of transparency and in response to the expectations of its stakeholders, Guerbet has reported information and data on its Climate Strategy, responding to the CDP climate questionnaire.
2|
|
3|
|
4|
|
5|
|
6|
|
• at Lanester: • launch of a project to install an evapo-concentrator (see opposite for focus), • feasibility study underway to recover the site’s waste heat internally and externally, • strengthening the energy management system with a view to ISO 50001 certification,
7|
|
• continuing the recycling of a solvent with a high calorific value to replace the gas in the incinerator; • at Dublin, an authorization and study application for the installation of a wind turbine on site; • at Marans, implementation of a project to reduce the use of a solvent for the synthesis of a chemical intermediate; • at Raleigh: • renovation and optimization of the steam network maintenance program, which has reduced gas consumption and associated greenhouse gas emissions, • renovation of the building roof to improve performance and thermal comfort;
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
135
SUSTAINABILITY STATEMENT Planet (environmental data)
• at Aulnay-sous-Bois: • implementation of a metering plan, installation of new electricity meters, and launch of a call for tenders for energy management software, • renovation of the insulation of the steam condensate pipes.
Focus on the evapo-concentrator installation project • Investment: €7 million • Major contribution to reducing the carbon footprint and the circular economy: • 3,200 tons of recycled ethanol distillates, • 15% reduction in waste produced on site, • reduction of 3,700 tons of CO2e(1): 25% of the Group’s target in scopes 1 & 2. • Creation of non-relocatable jobs •
Winner of DECARB IND France 2030 – Morbihan
• 32% subsidized • This project is fully in line with the People & Planet strategy and the commitment to employment, innovation and ecological transition in France
In 2025, the purchasing team conducted a targeted assessment of decarbonization with strategic suppliers (accounting for approximately 88% of emissions linked to purchases of raw materials and packaging). The objective is to assess, identify and co-construct progress plans, depending on the maturity of the suppliers. Guerbet is continuing to implement a specific CSR action plan with a major partner in Asia, supporting the partner in carrying out a second carbon footprint assessment. The Group is continuing to evaluate and cooperate with its key suppliers to better take into account their decarbonization strategy and innovate together. For example, this allowed Guerbet to substitute an input with a less carbon-intensive material, thus dividing the associated carbon footprint by four.
Decarbonizing our packaging The packaging team has drawn up a 3R (Reduce, Reuse, Recycle) roadmap, inspired by the LEEM (Les Entreprises du médicament) commitment plan. One of the actions is to switch to electronic package leaflets, whenever possible. Mapping of packaging configurations including recycled materials and carbon impact assessment has been drawn up and allows current and future actions to be managed.
Decarbonizing the supply chain Transport accounts for 9% of emissions. The Group is continuing the initiatives implemented in its supply chain, namely: • making sales forecasts more reliable thanks to better knowledge of local markets and investment in statistical forecasting tools: in 2025, the indicator clearly progressed compared with 2024; • developing partnerships with the main carriers and engaging in joint initiatives;
Decarbonizing our supply chain The responsible purchasing policy supports the decarbonization strategy and integrates climate into the processes and tools presented in section 5.1.3. • Policy; • Ethical purchasing charter; • Skills development; • Responsible purchasing process: • selection, • risk analysis, • evaluation and review of performance and commitment. For example, the Group supports two major partners in carrying out their carbon footprint assessment and defining their decarbonization strategy.
136
• following and training in the procedure for air transport including consideration of CO2e; • optimizing the number of product references; • using greener transport for deliveries: • electric vehicle in the São Paulo region (Brazil),
• Supplier code of conduct;
(1)
• integrating environmental performance into the selection process and reporting;
• NGV vehicles between storage and distribution centers (France and Belgium). In connection with these key actions, Guerbet has set targets for the year 2025 and over a five-year horizon: • reduce the proportion of finished products transported by air, in favor of sea transport: there was a reduction between 2024 and 2025; • improve the indicator on the on-time delivery of products ordered. In 2025, the decarbonization trajectory of the supply chain was updated and confirms a reduction of more than 30% in carbon intensity per ton transported by 2029.
CO2e: the CO2 equivalent is a unit of measurement designed to account for the climate effect of various greenhouse gases.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
SUSTAINABILITY STATEMENT Planet (environmental data)
Integrating carbon at the heart of innovation Guerbet is committed to gradually deploying life cycle analyses (LCAs) of new products and strategic references in order to better manage and reduce their environmental footprint, and particularly their carbon footprint. In 2025, Guerbet launched an LCA project for products mobilizing cross-functional teams. This project began with an awareness-raising campaign on environmental footprint assessment and aims to identify and prioritize impact reduction levers.
Engaging employees Guerbet wishes to involve all employees in its Climate Strategy and to this end offers several awareness-raising and engagement mechanisms. Thus, during the People & Planet Weeks held at the head office and several of our industrial sites, workshops were conducted to raise awareness of climate issues:
Optimizing travel Business trips The Group’s travel policy incorporates low-carbon measures, encouraging the use of videoconferencing and public transport, particularly rail transport. The use of electric and hybrid vehicles is encouraged by the Company car policy, in countries where the energy mix is favorable. In France, more than 45% of the vehicles in the fleet in France emit very little. Guerbet exceeds future requirements in France, which will require 35% of new vehicles to emit less than 50 g of CO2/km in 2027.
1|
|
New orders consist exclusively of plug-in electric or hybrid models (< 80 g CO2/km). Only employees with very high travel needs may have mild hybrid vehicles, strictly limited to < 108 g CO2e/km.
2|
Result for France:
|
• at Aulnay and Raleigh, workshops on personal carbon footprint assessment, and Guerbet’s carbon footprint and decarbonization strategy;
• 66% hybrid or electric vehicles (32% in 2024);
• at Rio, a week to raise employee awareness of environmental responsibility.
The Group also has charging stations for electric vehicles at several sites in France. In 2025, 12 new charging points were installed at the Aulnay site.
Communications are regularly shared on the intranet and numerous communication ambassadors aim to engage employees by explaining how they can contribute at their level.
Commuting
In addition, the Group has put in place financial recognition mechanisms that correlate with the achievement of the decarbonization objectives (see section 5.1.2.3 CSR criteria in variable compensation). For example, the Chief Executive Officer and the Director of Technical Operations, both members of the Executive Committee, as well as the Director of Purchasing, have individual objectives associated with their performance on the Group’s climate issues. Guerbet has also incorporated carbon criteria into its bonus share plan (see section 5.1.2.3 CSR criteria in variable compensation).
— — —
• average CO2e: 85 g/km (106 in 2024).
To reduce the impact of commuting, Guerbet promotes active travel and has a teleworking agreement.
3|
|
4|
|
5.2.1.6
Metrics and targets
SBTi target and outcomes CHANGE BROKEN DOWN BY SCOPE (kTCO2e)
Strengthening engagement with partners
5|
|
6|
|
Guerbet is committed to decarbonizing its activities and also helping to reduce the carbon footprint of the healthcare system. This is why the Group has been developing circular economy partnerships with healthcare professionals in France since 2023 (see section 5.2.4 Favoring the circular economy – ESRS E5).
7|
|
Guerbet promotes its approach at conferences and professional events. Guerbet regularly communicates its actions and results to investors, via its financial communications or by participating in responsible investment forums. The merger between financial and non-financial contributes to strengthening the reputation and confidence of Shareholders and to attracting new investors. In addition, Guerbet has CSR indicators, decarbonization, in some of its financing.
including
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
137
SUSTAINABILITY STATEMENT Planet (environmental data)
2021 reference
2025
2024
Absolute GHG emissions for scopes 1 & 2 (tons CO2e) 49,780 50,203 45,350 Absolute GHG emissions for scope 3 (tons CO2e) 190,570 189,691 165,655 The target covers 100% of the emissions of scopes 1 & 2 and covers 85% of scope 3. This objective is built on the basis of stakeholder expectations and scientific evidence. It has been validated by the SBTi. In 2025, scopes 1 & 2 emissions decreased by 10% compared with 2024. This improvement resulted from the implementation of actions at our industrial sites detailed in the paragraph Optimizing consumption and industrial processes, in particular the purchase of green electricity at Dublin and the improvement of the steam production system at Raleigh. scope 3 emissions take into account the entire upstream and downstream value chain (see scope of carbon footprint assessment). They are down by 12.7% compared with 2024. This reduction is achieved thanks to the actions carried out by the teams, particularly in the Transport and Distribution category (actions detailed in the paragraph Minimizing the carbon impact of the supply chain) and by the fall in the Group’s activity, reflected in emissions related to purchased goods and services and capital goods.
2025 target
Target value
% achievement of target
N/A
36,091
32% 2032
N/A
164,843
97% 2032
Comment
Target covering 100% of scopes 1 & 2 Target covering 85% of scope 3
The actions carried out on scopes 1 & 2 make it possible to achieve, by 2025, 31% of the reduction target set for 2032 compared with 2021. On scope 3, the target set for 2032 was almost reached by 2025 (97%), due to the actions taken but also the decline in the Group’s activity. In 2025, the Group carried out a project to digitize its carbon footprint assessment. This resulted in methodological reviews and variations in CO2e emissions in scopes 1, 2 & 3. These methodological changes were also applied to 2021 and 2024.
ESG target and outcomes Guerbet has introduced ESG (Environmental, Social and Governance) criteria into some of its financing. The actions taken to decarbonize emissions linked to the energy consumption of industrial sites, in particular the installation of a solar farm on our Dublin site, the purchase of green electricity via guarantees of origin and energy efficiency, mean that the 2025 target has been exceeded: -6% reduction in emissions versus -4.9% reduction targeted.
2021 reference
2024
2025
2025 target
0.0%
-4.4 %
-6.0%
-4.9%
Absolute GHG emissions for scopes 1 & 2 energy at industrial sites with constant emission factors (% versus 2021)
Target year
Target value
Target year
-9.0%
2028
Guerbet scores B on the CDP questionnaire
Internal carbon pricing
In 2025, Guerbet received a score of B on the CDP questionnaire, on a rating scale from A to D. Responding to this type of questionnaire strengthens the Group’s reputation, builds Shareholder trust, and attracts new investors, but also serves as a driver of continuous improvement.
The Group does not use any carbon pricing mechanism but plans to deploy it in the coming years.
Energy consumption The reduction of relative energy consumption at our industrial sites is one of the criteria used to calculate the variable compensation of the Chief Executive Officer and employees concerned, through our objectives related to scopes 1 & 2. In 2025, energy consumption at our industrial sites was 178,993 MWh, a reduction of 5% in absolute terms compared with 2024. This reduction in consumption is mainly due to actions taken at the Raleigh and Lanester sites to reduce gas consumption: optimization of industrial steam production and strengthening of the energy management system.
GHG absorption and mitigation projects The Group has not implemented any projects aimed at absorbing or storing greenhouse gases. Guerbet does not purchase carbon credits.
138
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
The energy efficiency actions implemented are detailed in the paragraph Optimizing consumption and industrial processes.
SUSTAINABILITY STATEMENT Planet (environmental data)
ENERGY CONSUMPTION AND MIX OF GUERBET’S INDUSTRIAL SITES 2024
2025
- Fuel consumption from coal and coal-based products (MWh)
—
—
- Fuel consumption from crude oil and petroleum products (MWh)
—
—
131,453
121,816
—
—
12,497 143,950
7,703 129,519
76%
72%
- CONSUMPTION FROM NUCLEAR SOURCES (MWh)
22,461
23,823
Share of nuclear sources in total energy consumption
12%
13%
—
—
20,565
23,616
- TOTAL RENEWABLE ENERGY CONSUMPTION(d) (MWh)
1,389 21,953
2,035 25,651
Share of renewable sources in total energy consumption
12%
14%
Share of decarbonized sources in total energy consumption
24%
28%
Share of renewable sources in total electricity consumption
39%
45%
-
Fuel consumption from natural gas (MWh)
-
Fuel consumption from other fossil fuels (MWh)
-
Consumption of electricity, heat, steam and cooling purchased or acquired from fossil sources(a) (MWh)
-
TOTAL FOSSIL ENERGY CONSUMPTION(b) (MWh) Share of fossil fuels in total energy consumption
Fuel consumption from renewable sources(c) (MWh)
- Consumption of electricity, heat, steam, and cooling purchased or acquired from renewable sources (MWh)
- Consumption of self-produced non-fuel renewable energy (MWh)
(e)
Share of decarbonized sources(e) in total electricity consumption TOTAL ENERGY CONSUMPTION(f) (MWh)
78%
87%
188,364
178,993
(a) Consisting of electricity of fossil origin only, from national electricity grids. (b) Total fossil energy consumption (b): sum of lines 1 to 5. (c) Consumption of fuel from renewable sources, including biomass and also including industrial and municipal waste of biological origin, biogas, renewable hydrogen, etc. (d) Total renewable energy consumption: sum of lines 8 to 10. (e) Decarbonized sources: renewable sources and nuclear sources. (f) Total energy consumption: sum of lines 6, 7 and 11.
— — —
1|
|
2|
|
3|
|
4|
|
5|
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
139
SUSTAINABILITY STATEMENT Planet (environmental data)
ELECTRICITY BY SOURCE FOR INDUSTRIAL SITES Total renewable electricity generated and self-consumed on site (MWh) Total steam produced and selfconsumed on site (MWh) Total other heating fluids (excluding steam) produced on site (MWh)
2024
2025
1,389
2,035
118,308 109,635 13,145
12,182
2024
2025
% 2025/ 2024
224
228
2.7%
ENERGY INTENSITY PER NET REVENUE
In 2025, 87% of the electricity consumption of Guerbet’s industrial sites was decarbonized (+9 points versus 2024), reducing the share of fossil energy. This result is linked to a solar farm being installed on the Dublin site, three industrial sites where energy is decarbonized being established in France, green electricity being purchased, and reduction actions being carried out.
Energy intensity relative to net revenue(a) (MWh/€m)
(a) Net revenue reported in section 4.1, Revenue analysis, and in note 4 to the consolidated financial statements.
TOTAL GHG EMISSIONS INTENSITY In 2025, GHG emissions intensity was 268 tons CO2e/€m of revenue. GHG intensity per net revenue
Total location-based GHG emissions per net revenue(a) (tons CO2e/€m)
Total market-based GHG emissions per net revenue(a) (tons CO2e/€m)
2024
2025
% 2025/ 2024
281
268
-4.8 %
285
269
-5.8 %
(a) Net revenue reported in section 4.1, Revenue analysis, and in note 4 to the consolidated financial statements.
Energy intensity increased by 2.5% in 2025 compared with 2024. This is due to a greater fall in revenue than the fall in energy consumption. ENERGY PRODUCTION AT INDUSTRIAL SITES All energy (electricity, steam, other heating fluids) produced at our industrial sites is self-consumed.
GHG intensity decreased between 2024 and 2025 (-5.8%). This result is linked to a significant reduction in energy consumption and greenhouse gas emissions, resulting from the Group’s actions and efforts. All industrial sites have decarbonization objectives.
140
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
SUSTAINABILITY STATEMENT Planet (environmental data)
TOTAL GROUP GHG EMISSIONS (E1-6) 2021 reference
2024
2025
% N/N-1
Gross scope 1 GHG emissions (tons CO2e) Percentage of scope 1 GHG emissions resulting from regulated emissions trading systems (%) SCOPE 2 GHG EMISSIONS
37,539
38,286
37,133
-3%
24%
20.1%
19.7%
-1.7%
Gross location-based scope 2 GHG emissions (tons CO2e)
11,073
8,595
6,967
-7.4%
Gross market-based scope 2 GHG emissions (tons CO2e) SIGNIFICANT SCOPE 3 GHG EMISSIONS
12,241
11,917
8,217
-29.1%
Total indirect gross GHG emissions (scope 3) (tons CO2e)
- Purchased goods and services
190,570
189,691
165,655
-12.7%
122,713
123,925
115,482
-6.8%
- Capital goods
12,590
8,916
2,604
-70.8%
- Activities in the fuel and energy sectors (not included in scopes 1 & 2)
5,143
6,502
5,347
-17.8%
- Upstream transport and distribution
27,384
24,301
19,028
-21.7%
- Waste produced during operation
5,412
5,551
7,687
38.5%
- Business travel
2,296
6,830
6,047
-11.5%
- Employee commuting
SCOPE 1 GHG EMISSIONS
— — —
1|
|
2,440
2,596
2,455
-5.4%
- Upstream leased assets
—
—
—
—%
- Downstream routing
68
3
2
-22.1%
- Transformation of products sold
—
—
—
—%
- Use of products sold
5,449
4,938
2,901
-41.3%
- End-of-life treatment of products sold
7,075
6,072
4,047
-33.4%
- Downstream leased assets
—
—
—
—%
- Excesses
—
—
—
—%
- Investments
—
55
55
—%
TOTAL LOCATION-BASED GHG EMISSIONS (tons CO2e)
239,182
236,572
209,755
-11.3%
TOTAL MARKET-BASED GHG EMISSIONS (tons CO2e)
240,350
239,894
211,005
-12%
2|
|
3|
|
4|
|
5|
TOTAL GHG EMISSIONS
|
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
141
SUSTAINABILITY STATEMENT Planet (environmental data)
5.2.2
Control of discharges – ESRS E2
The Group is committed to controlling its processes and emissions while seeking innovation to reduce their impact. SUMMARY OF MATERIAL IROS IRO type IRO
Y
R
I+
Consequences of water, air and soil contamination in the event of an industrial incident Changes in regulations
With respect to the resources allocated to the management of material impacts and risks, Guerbet will not publish this type of information. In addition, 86% of the Group’s revenue is eligible for the “Pollution prevention and control” objective. The alignment prospects are detailed in section 5, 5.5 Environmental taxonomy.
Policy
The impacts, risks and opportunities relating to the control of discharges are covered by the ethics charter and the five areas of commitment. The Group and its sites apply HSE policies covering the control of discharges.
Horizon
I-
Upstream
OO
Downstream
ST
l
l
l
l
l
l
l
l
Material IROs related to control of discharges have been identified based on Guerbet’s business model. The ENCORE database was used to assess the impacts of discharges on ecosystems. During its double materiality assessment, the Group relied on existing mechanisms promoting dialogue with local stakeholders. Regular exchanges are carried out via site monitoring committees and interactions with local authorities representing the interests of local communities (see section 5.3.3 Local communities – ESRS S3). The Group conducted an internal survey to consolidate its customers’ expectations.
5.2.2.1
Scope
MT
LT
l
The sites take care on a daily basis to control the pollution risks of their operations and associated impacts, to avoid incidents and to control potential impacts. All commitments and policies relating to control of discharges are deployed at the Group’s industrial sites under the responsibility of the Site Directors.
5.2.2.2
Actions
The three active ingredient production sites (Dublin, Lanester, and Marans) are subject to specific requirements through prefectural orders, which set out the technical and operational provisions that must be followed. These orders provide for an intervention plan to be deployed in the event of an incident. Sites are subject to internal and external inspections and controls according to predefined parameters, in order to ensure that industrial safety conditions are respected. Guerbet carries out and revises hazard studies every five years for the Seveso upper tier sites. These include the implementation and monitoring of risk control actions, particularly with regard to the management and reduction of discharges. Guerbet monitors regulatory changes in order to continuously adapt its practices and anticipates future needs through regular investments at its sites. No major incidents requiring operational expenses occurred in 2025.
Controlling discharges into water, air and soil Active pharmaceutical ingredient (API) production sites are key points in terms of risk management, given the specific nature of their activities. These sites based in Europe operate within a demanding regulatory framework such as the Seveso regulation, guaranteeing high standards. They are also subject to local environmental protection regulations, such as the implementation of a safety management system commensurate with the risk of accidents or the regular updating of hazard studies. Each site applies HSE policies, covering in particular: • prevention and control of industrial risks; • controlling environmental impacts on a daily basis and in the event of an accident; • industrial safety culture.
142
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
The release thresholds defined by regulations (Industrial Emissions Directive (IED) and Water Framework Directive (WFD)) are applied by the active ingredient manufacturing sites. These thresholds give rise to numerous measures on parameters covering air emissions, liquid discharges, and the monitoring of groundwater quality. The results are used for operational management of the plants, with alert thresholds enabling rapid detection and proactive correction of any fluctuations. These figures are communicated to local authorities through periodic reports and specific studies (solvent management plan, annual environmental report, annual declaration of pollutant emissions and waste, etc.).
SUSTAINABILITY STATEMENT Planet (environmental data)
The sites implement actions to optimize their processes, reduce their impacts and manage their discharges:
The Group strives to avoid, substitute and reduce the use of these substances with less dangerous alternatives.
• at Dublin, a monitoring and optimization program for the treatment plant is in place to prevent malfunction, improve efficiency, and ensure treatment performance;
For consumable medical devices, the majority are phthalatefree. There are still two references containing them, but by the end of 2026 all products will be free of them.
• the Lanester site optimizes effluent and waste management through efficient in-house facilities: • biological treatment is preferred for biodegradable effluents, • nanofiltration reduces the quantities of effluents incinerated in-house, reduces the use of gas, and increases water recycling through the reuse of treated effluents, • iodine is recycled internally at a dedicated facility, where possible, • volatile organic compounds (VOCs) are captured by a gas washing system connected to the incinerator; • at Marans, the optimization of effluent treatment continues to reduce chemical oxygen demand via the site’s wastewater treatment plant and a chemical treatment facility. The site separates the effluents and recovers some of the solvents externally. The sites carry out groundwater quality measurements to indirectly monitor soil pollution.
The electronic parts of the injection systems comply with RoHS guidelines, which aim to reduce exposure to hazardous substances in products.
5.2.2.3
Metrics and targets
API production sites declare their discharges into water, air and soil each year. These discharges are monitored and measured in accordance with local regulatory requirements and are the targets for the sites. The sites comply with the thresholds set in consultation with the environmental authorities. The following metrics are consolidated for its API sites:
Guerbet received a score of B on the CDP Water questionnaire. This questionnaire includes criteria relating to discharges into water.
Avoiding and reducing substances of concern and very high concern (SVHC) This issue is presented to meet the expectations of stakeholders. Guerbet mapped the issue through the double materiality assessment and concluded that it is not material within the meaning of the CSRD. Substances of concern and very high concern are chemical compounds identified for their potentially serious effects on human health and the environment. These substances are regulated by the REACH regulation(1) of the European Union. The RoHS regulation(2) complements the REACH regulation and aims to limit the use of certain hazardous substances in electrical and electronic equipment. Guerbet organized its activity to comply with the Regulation and ensure its implementation.
(1) (2)
2|
|
3|
|
4|
|
Product recovery at end of life
A pilot project is underway with hospitals and clinics to recover non-injected iodinated products and recycle them (see 5.2.7.2.3 Improving the end of life of products).
1|
|
Discharges into water
In addition, programs to detect and repair fugitive emissions and/or leaks are being implemented in 2025 and 2026 to ensure compliance with thresholds and prevent fugitive VOC emissions.
Guerbet supports the MeGadoRe (Medical Gadolinium Recycling) Chair in collecting unused fractions of contrast media from healthcare facilities.
— — —
Chemical oxygen demand (COD) and total organic carbon (TOC) are key parameters for monitoring effluent quality. They measure the total quantity of organic matter, whether biodegradable or not. 2024
TOC emissions (COD/3) from our API production sites (in tons)
2025
5|
|
6|
|
63
66
The increase between 2024 and 2025 is linked to a change in the mix of effluents treated at the wastewater treatment plant at the Dublin site.
7|
|
Discharges are below the thresholds defined by the locally applicable regulations.
REACH: Registration, Evaluation, Authorization and Restriction of Chemicals. RoHS: Restriction of Hazardous Substances.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
143
SUSTAINABILITY STATEMENT Planet (environmental data)
Discharges into air NOx and NO2 emissions from our industrial API production sites (in tons)
Soil pollution 2024
2025
30
33
Guerbet does not directly track soil pollution indicators as this is not material for its sites. This is because the sites do not spread or inject waste into the soil. This is also consistent with local regulations and site operating licenses, which do not require reporting on soil pollution.
Nitrogen oxides (NOx) are a key indicator for monitoring air release quality. It represents the sum of the quantities of nitric oxide (NO) and nitrogen dioxide (NO2).
The Marans and Lanester sites are subject to groundwater quality monitoring. No threshold breach was noted. The Dublin site monitors the integrity of the buried pipelines.
Discharges from the industrial API production sites are below the thresholds set by applicable local regulations.
5.2.3
In addition, there were no spill incidents leading to discharges or pollution in the soil in 2025.
Preservation of water resources – ESRS E3
The Group aims to make optimal use of natural resources, in particular through actions to reduce water consumption. SUMMARY OF MATERIAL IROS IRO type IRO
Y
Supply chain disruptions in the event of restrictions on water consumption Pressure on water resources Water-related material IROs have been identified based on Guerbet’s business model which requires the use of water for the production of its products. The ENCORE database was used to assess the impacts on ecosystems. During its double materiality assessment, the Group relied on existing mechanisms promoting dialogue with local stakeholders. Regular exchanges are carried out via site monitoring committees and interactions with local authorities representing the interests of local communities. The Group conducted an internal survey to consolidate its customers’ expectations. For resources allocated to material risk and impact management, Guerbet will not publish this type of information for this year.
5.2.3.1
Policy
The Ethics Charter and the HSE policy reflect the Group’s commitment to minimize the environmental impact of its activities. This policy, which applies to the Group’s own operations, is deployed at the Group’s industrial sites under the responsibility of the Site Directors. It includes the challenges of optimizing water consumption, particularly for the sites exposed to the risk of water stress (Lanester, Dublin and Rio de Janeiro). The actions carried out by the sites to control discharges into water are presented in section 5.2.2 Control of discharges – ESRS E2.
144
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
R
I+
Scope I-
l l
5.2.3.2
Horizon
Upstream
OO
Downstream
ST
l
l
l
l
l
l
MT
LT
l
Actions
The sites implement 3R (Reduce, Reuse and Recycle) programs to manage water consumption. The sites, including those exposed to the risk of water stress, implement measures adapted to their specific characteristics: • at Lanester, a working group defines the roadmap for reducing consumption, with studies and actions aimed at optimizing purified water production and recycling water internally. The initiative to reuse water for the cooling of the incinerator, which was awarded the Loire-Bretagne water trophy, is continuing, and the site is participating in a regional working group to share diagnostics and best practices. A study on the recovery of waste heat is underway and could reduce the site’s water consumption by up to 20%, while optimizing energy recovery; • in 2025, the Rio de Janeiro site optimized the cleaning and preparation processes of the production lines, which reduced the associated water consumption. Actions to preserve resources are carried out at the other sites: • at Raleigh, water meters were installed and the equipment wash cycle optimized to reduce water consumption; • at Marans, the optimization of production systems for water for manufacturing reduced water consumption by 20%.
SUSTAINABILITY STATEMENT Planet (environmental data)
5.2.3.3
Metrics and targets
Indicators 2023 (reference year)
Reduction in relative water consumption(a) Total water consumption (m3) of which total water consumption (m3) in areas exposed to water risks (high) Total quantity of water recycled and reused (m3) Total quantity of water stored
2024
2025
% N/N (reference) Objective
Target in some of our financing: • Year 2025: 0.0% -15% • Year 2028: -8.7%
N/A
-16%
-15%
1,025,779
956,145
947,108
-8%
563,415
525,930
505,737
-10%
20,785
23,935
28,080
35%
— — —
1|
|
(m3)
—
—
—
—
change in storage (m3) Intensity: Total water consumption per net revenue(b) (m3/€m)
N/A
N/A
N/A
N/A
1,305
1,137
1,204
-8%
(a) (b) Net revenue reported in section 4.1, Revenue analysis, and in note 4 to the consolidated financial statements. The indicators presented above have not been validated by an external body.
2|
|
Relative water consumption: total water consumption (m3), relative to production.
3|
|
Progress made
Objective
In 2025, water consumption at our industrial sites decreased compared with 2023:
By 2028, Guerbet has set itself a target of reducing relative water consumption by 8.7% compared with 2023, for its own operations. This objective has been introduced into some of its funding. Discussions have taken place with investors to define this objective. It aims to strengthen the Group’s resilience to climate change. It is applied annually and is included in the calculation of the variable compensation of the employees concerned (see 5.1.2.3 CSR criteria in variable compensation).
• by 8% in intensity; • by 15% relative to production; • by 8% in absolute terms. This performance is achieved thanks to the actions implemented at the sites, detailed in the previous paragraph.
4|
|
5|
|
The objective was defined taking into account risks for Guerbet, including water stress affecting three of its sites, as well as medium-term production prospects, but not based on scientific evidence.
6|
|
7|
The CDP Water questionnaire, for which Guerbet received a score of B, also includes water sampling criteria.
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
145
SUSTAINABILITY STATEMENT Planet (environmental data)
5.2.4
Favoring the circular economy – ESRS E5
Guerbet is committed to developing its activities as sustainably as possible, taking circular economy considerations into account. SUMMARY OF MATERIAL IROS IRO type IRO
Y
Market share gain through the circular economy and eco-design Contribution to reducing the environmental footprint of the health system
I+
I-
l
Supply disruptions and rising resource costs
l l
Horizon
OO
Downstream
l
l
l
l
l
l
l
ST
MT
LT
l l l
Material IROs have been identified based on Guerbet’s business model which requires resources and raw materials to manufacture active ingredients, contrast media and medical devices.
5.2.4.2
The importance of the waste theme was assessed taking into account existing production processes and historic waste data. To update its double materiality assessment, the Group relied in particular on an internal survey to consolidate its customers’ expectations and discussions with the authorities. With regard to resource outflows (products and services placed on the market), the evaluation was carried out taking into account the expectations of partners, customers and civil society. The ENCORE database and the United Nations report (Global Waste Management Outlook, UNEP) were used.
The Group implements an innovation approach to processes at its active ingredient production sites, based in particular on:
5.2.4.1
Policy
• the Ethics Charter; • the HSE policy, which aims in particular to reduce environmental impacts from the start of any project; • the Planet commitment centered around eco-design and five areas, four of which favor the circular economy: life cycle analysis, resource conservation, control of discharges and sustainable partnership. These commitments aim to reduce Guerbet’s impact on the environment and increase the resilience of our activities. They are implemented at industrial sites under the responsibility of the Site Directors.
GUERBET
Actions, metrics and targets
5.2.4.2.1 Innovating for more rational use of resources
• the substitution of solvents with others that have less environmental impact; • the use of solvents from regeneration; • prioritizing recycling internally (iodine, solvents). These initiatives, led by the Development teams and the industrial sites, result in concrete actions, such as:
Solvent recycling
Resource use and circular economy IROs are covered by several commitments and policies:
146
R
Scope Upstream
2025 UNIVERSAL REGISTRATION DOCUMENT
• At Dublin, 80% of solvents are recycled internally using dedicated equipment. • At Lanester: • more than 800 tons of effluent from production are now recycled rather than incinerated, which also reduces the footprint of the site by 1,000 tons of CO2e, • a second solvent is externally regenerated, reducing the consumption of virgin resources. • Lanester also optimizes its waste by isolating a solvent with a high calorific value to supply the incinerator, thereby reducing gas consumption: • the evapo-concentrator project will make it possible to recycle up to 3,200 tons of ethanol distillates. • At Marans: the site favors the external recycling of its effluents.
SUSTAINABILITY STATEMENT Planet (environmental data)
Recycling of iodine and active ingredients
Resource inflow metrics and targets
• Lanester and Dublin recover iodine and iodinated active substances from specific facilities.
The resource inflows considered are as follows:
• Iodine is also recovered from recovery channels at the Raleigh, Aulnay-sous-Bois and Rio de Janeiro sites.
• raw substances and chemical, mineral and natural raw materials; • packaging; • electronic equipment.
— — —
Water consumption is detailed in section 5.2.3. 2024
2025
Confidential
Confidential
Confidential
Confidential
Rate of iodine recycled internally at Lanester
95.8%
96.4%
Rate of solvents recycled internally at Dublin
80%
80%
Total weight of technical and biological products and materials used Percentage of organic materials from sustainable sources used to produce company products and services (including packaging)
In 2025, 96.4% of the iodine in effluents and 80% of solvents were recycled at dedicated facilities. To date, Guerbet has not defined objectives relating to the use of resource inflows and wishes to deepen the analysis conducted in the short term to better understand its impacts in terms of resource inflows and, if necessary, define an objective.
5.2.4.2.2 Strengthening eco-design efforts Guerbet aims to strengthen eco-design and circular economy approaches for its new products and those in development, in collaboration with its partners and customers. To support this approach, the Group plans to gradually roll out life cycle assessments (LCAs) for its products. In 2025, the Group initiated a life cycle analysis on several key products. The results are expected in 2026 and will be supplemented by eco-design workshops. This cross-cutting work will make it possible to identify levers for reducing the environmental impacts of products and will feed into Guerbet’s CSR strategy. In 2024, Guerbet received the JFR (Francophone Radiology Days) 2024 Innovation Prize in the Jury Prize category for its product Elucirem™ (more information is provided in the Summary of Product Characteristics (SmPC)(1)). Guerbet injectors have a service life of seven years, comparable to that of other injectors on the market. Although they do not have a repairability index, initiatives are underway to extend their service life. For example, in 2025 a project conducted in São Paulo refurbished 93 injectors, thus avoiding more than two tons of waste.
(1)
5.2.4.2.3 Improving the end of life of products A major action for more responsible management of end-of-life products is the transition from single to multi-patient use, particularly in France. This transition reduces the amount of waste produced during examinations, by disposable medical devices, and unused portions of contrast medium.
1|
|
2|
|
3|
|
In addition, Guerbet has committed to managing leftover portions of products through two main actions: • partnership and sponsorship with the MeGadoRe (Medical Gadolinium Recycling) Chair to recycle gadolinium: this project focuses on collecting unused portions of contrast media in healthcare facilities across France. The goal is to recycle gadolinium; • a pilot program for recycling unused iodinated products: Guerbet is rolling out a pilot program with hospitals and clinics to recover non-injected iodinated products and recycle them. Iodine recycled by an industrial partner is used in the textile industry.
5.2.4.2.4 Sustainable management of industrial waste
4|
|
5|
|
6|
|
All industrial sites have programs for waste optimization, recovery, and recycling, either internally or externally.
Resource outflow metrics and targets As part of its CSR roadmap, the Group plans to study the implementation of a waste management objective in 2026.
7|
|
In 2025, a packaging mapping project was initiated in order to identify the proportion of recycled and recyclable materials for the main product references. This mapping is still to be completed, and a consolidated indicator cannot yet be established at Group level. Guerbet will continue this work, depending in particular on the clarifications expected as part of the revised version of the ESRS, while ensuring their confidentiality.
The SmPC is a document intended for healthcare professionals that summarizes information relating to the therapeutic indications, contraindications, methods of use and adverse effects of a medicinal product.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
147
SUSTAINABILITY STATEMENT Planet (environmental data)
TYPE OF WASTE AND RECOVERY 2024
2025
Hazardous
Not hazardous
Total quantity of waste (tons)
15,211
18,772
13,424
5,349
Total quantity of recovered waste (tons)
8,891
10,283
5,621
4,662
• of which preparation for reuse (tons)
—
—
—
—
• of which recycling (tons)
5,051
6,603
2,024
4,580
• of which other recovery (tons)
3,840
3,680
3,598
82
Total quantity of waste disposed of (tons)
6,320
8,489
7,802
687
• of which incineration (tons)
4,402
7,127
7,003
124
• of which incineration (tons)
757
705
201
504
• of which other disposal (tons)
1,161
657
599
58
—
—
—
Total quantity of radioactive waste (tons) Total quantity of non-recovered waste (tons)
6,320
8,489
7,802
687
Total quantity of non-recycled waste (tons)
10,160
12,169
11,400
769
Rate of non-recovered waste
42%
45%
42%
4%
Rate of non-recycled waste
67%
65%
61%
4%
Rate of recovered waste
58%
55%
30%
25%
Rate of recycled waste
33%
35%
11%
24%
The main types of waste from Guerbet’s production processes are organic waste, solvents and packaging waste (cardboard, plastic, etc.).
Guerbet is continuing its efforts to reduce the share of waste destined for landfill, which now accounts for 3.8% of its waste, compared with 5.0% in 2024.
In 2025, the total amount of waste generated by the Group’s industrial sites and treated externally increased by 23% in absolute terms compared with 2024. This increase is mainly due to the increase in production at our sites and an increase in the share of waste treated externally at the Dublin site in order to optimize the operation of its wastewater treatment plant.
Waste sorting and recovery programs are also in place at the head office and in some subsidiaries, e.g. in Prague.
55% of the waste from industrial sites treated externally is recovered (versus 58% in 2024), and 35% is recycled. The recovery rate is down compared with 2024, in particular due to the increase in the quantity of waste at Lanester, the Group’s largest contributor in terms of volume.
148
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
5.2.4.2.5 Resources allocated to action plans The iodine recycling facility included in the effluents at the Lanester site required an investment of €2.5 million and allowed the site to recycle more than 96.4% of iodine in 2025.
SUSTAINABILITY STATEMENT People (social data)
5.3 5.3.1
PEOPLE (SOCIAL DATA) GUERBET EMPLOYEES – ESRS S1
150
5.3.3
LOCAL COMMUNITIES – ESRS S3
165
5.3.1.1 Impact management and dialogue process
150
5.3.3.1 Impact management and dialogue process
165
5.3.1.2 Human resources policy
152
5.3.3.2 Policy
165
5.3.1.3 Health and safety
152
5.3.3.3 Actions
165
5.3.1.4 Quality of life at work and working conditions
155
5.3.3.4 Metrics and targets
166
5.3.1.5 Skills development
156
166
5.3.1.6 Compensation, recognition and attractiveness
157
5.3.3.5 Management of negative impacts and channels for raising concerns
5.3.1.7 Diversity and inclusion
159
5.3.4
167
5.3.1.8 Human rights commitments
162
5.3.1.9 Social commitment
162
5.3.4.1 Impact management and dialogue process
167
5.3.1.10 Management of negative impacts and channels for raising concerns
163
5.3.4.2 Innovation and contribution to health
168
5.3.4.3 Product quality and patient safety
169
5.3.2
163
5.3.4.4 Access to products
171 171
5.3.2.1 Impact management and dialogue process
163
5.3.4.5 Management of negative impacts and channels for raising concerns
5.3.2.2 Responsible purchasing and human rights commitments
164
5.3.2.3 Management of negative impacts and channels for raising concerns
164
WORKERS IN THE VALUE CHAIN – ESRS S2
COMMITMENT AND RESPONSIBILITY IN HEALTHCARE – ESRS S4
— — —
1|
|
2|
|
3|
Five areas of commitment
|
The Group seeks to forge lasting ties to protect people by creating the conditions for cooperation with its stakeholders around five key areas: • prevention;
4|
|
• quality; • engagement; • development; • inclusion.
5|
|
The purpose of our commitment: safety, well-being and health for stakeholders.
6|
|
7|
|
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
149
SUSTAINABILITY STATEMENT People (social data)
5.3.1
Guerbet employees – ESRS S1 The Group employs 2,746 746 people worldwide(1). In line with the long-term vision of its strategy, Guerbet favors long-term employment: 96% of the workforce is on permanent contracts. Guerbet does not hire employees under contracts with unguaranteed hours. Guerbet markets its products in more than 114 countries across five continents with teams in more than 30 countries.
YEAR-END WORKFORCE BY TYPE OF CONTRACT (broken down by region)
Total year 2025
Total year 2024
Europe North America
Latin America
Asia-Pacific
NUMBER OF GUERBET EMPLOYEES
2,905
2,746
1,740
443
303
260
Permanent
2,763
2,637
1,642
443
294
258
Temporary
142
109
98
—
9
2
Full-time
2,778
2,653
1,658
441
295
259
Part-time
127
93
82
2
8
1
YEAR-END WORKFORCE BY COUNTRY (in countries where Guerbet has at least 50 employees and representing more than 10% of the total workforce)
Country
Number of employees (headcount)
France
1,299
United States
5.3.1.1
443
Impact management and dialogue process
to the business sector. People in field positions on industrial sites are more exposed to the risk of accidents. These persons are considered vulnerable within the meaning of the CSRD. This issue is taken into account on an ongoing basis at the sites. Regular dialogue with employees is achieved through routine safety visits and discussions, making it possible to take greater account of and prevent potential impacts. An update of the HSE policy is planned for 2026, based on international standards such as OHSAS 18001.
5.3.1.1.1 IROs and link to the business model and strategy The negative material impacts that may affect employees and external participants mainly concern safety. This is a risk inherent SUMMARY OF MATERIAL IROS IRO type Sub-issue
IRO
Health and safety
Consequences of a serious/fatal accident Impact on pay equity, integration and employability
Diversity and inclusion Retention and development Working conditions
Loss of attractiveness, competitiveness and innovation in the event of poor skills management Consequences of psychological and social risks
Y
R
I+
l
Scope I-
l l
l l
←
OO
Horizon →
ST
l
l
l
l
l l
l
MT
LT
l l
With respect to the resources allocated to the management of material impacts and risks, Guerbet will not publish this type of information.
(1)
150
Workforce at December 31, 2025, i.e. the number of Guerbet employees on full-time, part-time, permanent or temporary contracts and excluding interns. See note 15.5 Geographic breakdown of workforce, snapshot at December 31.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
SUSTAINABILITY STATEMENT People (social data)
Consequences of the climate transition on employees
Corporate social network
The Group supports the climate transition strategy through awareness-raising and training sessions that aim to develop the skills needed to support the environmental transition (see Engaging employees).
Employees are also encouraged to express their views via Guerbet Inside, the Group’s internal social network. This portal centralizes reference documents and serves as a collaborative forum where geographical and thematic communities share initiatives and interact.
Guerbet’s operations require advanced technical expertise, creating a dependency on internal skills. Difficulties in attracting and maintaining these skills could affect competitiveness and business continuity. The skills management process aims to ensure that employees have the required qualifications, particularly in the context of the climate transition.
5.3.1.1.2 Dialogue process Dialogue is a driver of the Group’s success. Close interaction between managers and employees is preferred on a daily basis and during key events such as annual performance and development reviews. Guerbet strives to foster regular social dialogue, which aims in particular to: • promote communication between all internal stakeholders: between social partners and Management, between managers and teams; • prevent conflict by encouraging free expression and being receptive, dealing early with potential situations of conflict, giving attention to working conditions, and gathering proposals for improvements; • guiding decisions to meet the expectations and needs of employees. For example, the cultural transformation, presented in section 5.4.1 Corporate culture, was initiated following feedback from employees via the Guerbet Listens survey.
Guerbet Listens internal engagement survey The Guerbet Listens survey, conducted since 2022, allows employees to express their views on all aspects of their working lives, based on 13 categories: commitment, CSR, inclusion, well-being, development, performance and responsibility, cooperation, customer focus, leadership, strategic alignment, communication, change management and innovation, recognition. The survey conducted in 2024 focused on the following themes: engagement, leadership, strategic alignment and change management and innovation. 79% of employees answered the questionnaire (+2 points compared with the previous survey).
Dialogue with Management To strengthen the sense of belonging and provide information on the progress of the strategic plan, the Executive Committee organizes a quarterly video conference for all employees. Regular visits and meetings with the teams promote direct and constructive dialogue.
Dialogue with representative bodies The Group has always encouraged dialogue with employee representative bodies, which it considers to be full-fledged partners. This dialogue is based on mutual trust and relies on transparency, communication, and respect. Within this framework, at Group level, the social dialogue structure is organized into three channels:
— — —
1|
|
• at entity and/or institution level through representation of elected staff; • at the trade union level within various entities; • at the Board of Directors level: an Employee Director has the same rights as any other Director, and an employee representative also attends meetings, without voting rights. Social dialogue is structured in particular around agreements relating to professional equality between men and women, quality of life and working conditions, organization of working hours, employment conditions, teleworking, and employment more broadly. The subject of health and safety is also a subject of regular discussions with employee representative bodies. The Group ensures that trade union rights are recognized and respected in all the countries in which it operates, through human resources and the management team, which are the points of contact for this dialogue between the Group and employees and their representatives. The Group also ensures free dialogue between employees and their representatives with regard to the legal framework applicable locally.
2|
|
3|
|
4|
|
5|
|
RATE OF COVERAGE OF COLLECTIVE BARGAINING AND SOCIAL DIALOGUE (for countries with more than 50 employees and representing more than 10% of the total)
Country/region
France United States
Collective bargaining coverage(a)
Social dialogue coverage(b)
100%
100%
—%
N/A
(a) Percentage of employees covered by collective labor agreements. (b) Percentage of employees covered by employee representatives.
6|
|
7|
|
In France, the Social Relations Director ensures that a constructive social dialogue is established within each institution or entity, in accordance with the regulations in force. In the USA, while collective bargaining is not legally mandatory, Guerbet promotes social dialogue with trade unions to ensure the develop of a collaborative and engaging work environment.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
151
SUSTAINABILITY STATEMENT People (social data)
5.3.1.2
Human resources policy
Guerbet has two Human Resources (HR) policies: a general policy and a social policy, both aligned with international standards, in particular the United Nations Guiding Principles on Business and Human Rights. These policies apply to the entire Group and are accessible to employees via the internal document management system.
Health and safety
At Guerbet, the health and safety of its employees and all external stakeholders is the top priority, embodied in particular through the value of CARE. “Zero accidents” is now more than ever our goal. With this in mind, the Group is pursuing a policy of continuous improvement. It complies with the applicable laws and regulations in this area, wherever it conducts its business.
The Human Resources Department oversees their implementation, and each entity adapts them to local conditions.
5.3.1.3.1 Policy
General HR policy
- a continuous improvement approach and performance measurement;
Guerbet implements a Human Resources policy that aims to support the strategic priorities by responding to the challenges of recruitment, development, performance evaluation and employee recognition.
The six HSE policy commitments emphasize the importance of a shared health and safety culture:
- employees respectful of the Guerbet Values (CARE), involved in and responsible for their own safety and that of their colleagues;
This Group-wide policy defines the fundamental principles to be respected:
- responsible management to maintain an environment conducive to the prevention of incidents and accidents;
• adapt the organization to increase flexibility and efficiency;
- clearly defined and widely shared fundamental safety principles;
• ensure balance, fairness and ethics; • simplify life at work; • facilitate change; • harmonize practices. This policy is based on two pillars: • Organization: continuous optimization of work organization and company structures; • Practices: offer a motivating and ethical environment, ensure that skills match the Group’s ambitions, develop employability, support change, assess and reward fairly and provide tools suited for each stage of the career path.
Responsible social policy The success of the Group’s ambitious strategy depends on the performance of its teams. To this end, Guerbet implements a responsible social policy based on five areas: • diversity and inclusion: apply a policy of openness and non-discrimination; • prevention: guarantee a climate of trust, promote good quality communication, develop employability, and preserve physical and mental integrity; • recognition: value each contribution through compensation and development; • commitment: reconcile the economic, ecological and social interests of all stakeholders; • responsibility: act with respect for people, laws and the environment, with complete transparency.
152
5.3.1.3
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
- a stronger presence in the field to identify any risk situation in order to prevent it;
- maintaining an effective dialogue with our stakeholders. These commitments apply to all employees and external contractors. The implementation of the HSE policy is the responsibility of the Chief Executive Officer, the Technical Operations Director and the Human Resources Director.
Monitoring procedure The monitoring and improvement of safety results requires the definition of an annual objective for all Group employees, in particular for the Chief Executive Officer, members of the Executive Committee and the management team. For eligible employees, the reduction in the number of accidents is a criterion used in calculating variable compensation and/or included in the profit-sharing calculation. Guerbet ensures compliance with applicable health and safety regulations, including the European REACH regulation.
SUSTAINABILITY STATEMENT People (social data)
The HSE management system supports the HSE policy and provides a more operational dimension, based on 10 areas:
— — —
1|
|
2|
|
3|
|
5.3.1.3.2 Actions
Procedures for critical operations
Guerbet takes a proactive approach to risk prevention. The actions presented are long-term.
Safety leadership
Guerbet has vital procedures based on existing best practices. Their purpose is to define prevention and protection measures for operations likely to cause serious accidents (such as working at height and confined space).
Guerbet consolidates the safety culture at its industrial sites thanks to the active involvement of managers via:
These standards are made available in the Group’s document system. Specific procedures can be applied to the sites.
• regular dialogue to identify high-risk situations, share feedback and promote best practices;
Response plans and crisis management
• regular field visits; • daily routines.
HSE network At all industrial sites, dedicated HSE teams work closely with the management teams. Safety ambassadors reinforce this system by coordinating prevention, disseminating key messages and ensuring the escalation of alerts so that they can be handled quickly and effectively.
The industrial sites have response teams that receive specific training that is regularly renewed. Their mission is to secure the area and act quickly in the event of an accidental event using the appropriate means, in order to facilitate the intervention of external emergency services.
4|
|
5|
|
6|
|
Seveso sites, by their very nature, are subject to specific actions such as conducting hazard studies and implementing specific response plans in the event of a major scenario occurring. Guerbet has developed a crisis management procedure and associated business continuity plans.
Risk assessment and control
Performance monitoring and control
At all its industrial sites and entities in France, Guerbet has a system for assessing and controlling risks, including in particular chemical and biological risks, as well as those related to exposure to hazardous substances or noise.
To measure the effectiveness of the actions in place, Guerbet deploys systems for monitoring and controlling the performance of industrial sites:
Procedures for critical operations
• regular visits by management;
At all its industrial sites and entities in France, Guerbet has a system for assessing and controlling risks, including in particular chemical and biological risks, as well as those related to exposure to hazardous substances or noise.
• visits to employee representative committees.
7|
|
• regular performance review meetings;
In addition, the sites are inspected by the supervisory authorities.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
153
SUSTAINABILITY STATEMENT People (social data)
Training Regular risk-related training and awareness-raising sessions are provided to employees, including on the wearing of personal protective equipment.
Collective commitment: People & Planet Week Guerbet organizes an annual People & Planet Week for all employees. This initiative aims to strengthen HSE & CSR culture and commitment. The 2025 week featured: • a launch speech by Management; • the screening of the film “I CARE for Safety. Every action counts”; • more than 165 employees committed to organizing or coordinating the event; • over 1,900 participants in workshops and webinars, i.e. 65% of employees; • example of safety workshops: • safety leadership, • electrical and fluid lockout, • prevention of pedestrian-vehicle co-activity, • fire extinguisher handling, • first aid measures, • ergonomics when working on a screen to prevent musculoskeletal disorders (MSDs). Some workshops are organized in cooperation with local partners (fire brigade, road safety, ergonomist).
Occupational health programs Preventive actions are carried out in collaboration with the occupational health services, local health and safety bodies or with safety ambassadors.
5.3.1.3.3 Metrics and targets Objectives Guerbet has set safety objectives: • internal objective: reduction of the TRIR(1); • external target for investors: reduction of the 2-year average accident severity rate.
Performance indicators Guerbet tracks the TRIR indicator as well as an indicator that aggregates the frequency of reported accidents and their frequency.
Action indicators To measure the effectiveness of its policy and actions, Guerbet tracks action indicators: number of field safety visits, safety dialogues, action completion rate, etc.
Performance The number of reported accidents has continued to fall for several years. 2025 marks an even more significant improvement, with a more marked decrease than in previous years. This significant improvement directly reflects the effectiveness of the enhanced prevention policies, the awareness-raising actions carried out in the field, and the ongoing investments made to improve the safety culture at all our sites. The severity rate increased slightly due to two accidents leading to long stoppages. CHANGE IN THE GROUP’S SAFETY PERFORMANCE
Prevention programs are implemented according to locally identified risks (atmospheric exposure, noise, ergonomics, etc.) and give rise to initiatives such as the deployment of appropriate equipment and/or organizational measures aimed at preventing risks. Through appropriate medical follow-up, Guerbet takes care to prevent occupational risks and unfitness for work. For employees with disabilities, Guerbet looks for job redeployment solutions, with the help of its specialist committees, to try to keep these employees in the workplace. Vaccination campaigns are carried out, along with awareness initiatives on topics such as nutrition, climate risks, and cancer prevention (Pink October to raise awareness of breast cancer and Blue November for prostate cancer). Guerbet offers teleconsultation or medical assistance programs in several entities (5.3.2.5 Quality of life at work and working conditions), including a psychological support unit for France.
(1)
154
Coverage rate of management systems The management systems cover 100% of the employees at the Group’s industrial sites, who are the most exposed employees. They also cover French sites outside Intrasense. This represents 71% of the Group’s employees. Guerbet aims to cover 100% of employees by 2026.
TRIR: Total Recordable Incident Rate, i.e. the number of reported accidents relative to the number of employees.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
SUSTAINABILITY STATEMENT People (social data)
2023
2024
2025
0.48
0.41
0.25
• 2025 target: 0.095 • 2028 target: 0.065
0.09
0.083
0.124
Rate of severity of accidents
0.06
0.11
0.14
Rate of frequency of lost-time accidents
2.56
2.14
1.59
Rate of frequency of accidents with and without lost time
2.98
2.57
1.59
Number of deaths
—
—
—
Number of workplace accidents reported
14
12
7
Number of lost-time work accidents
11
10
7
Number of days lost due to workplace accidents METRICS FOR OTHER WORKERS (NON-EMPLOYEES)
269
498
605
—
—
—
Non-consolidated
71%
71%
GUERBET EMPLOYEE METRICS TRIR 2025 target: 0.7 (Guerbet-specific) 2-year average severity rate
Number of deaths CONSOLIDATED METRIC – GUERBET EMPLOYEES % of employees covered by the Health and Safety Management System
5.3.1.4
Quality of life at work and working conditions
5.3.1.4.1 Policy Quality of work life (QWL) and quality of life and working conditions (QLWC) are essential elements to ensure the wellbeing of all Group employees and the Group’s overall performance. QLWC issues are covered by the Human Resources and HSE policies, as well as by taking into account the interests of employees, social dialogue and approaches to skills development, diversity and inclusion.
5.3.1.4.2 Actions Guerbet’s ambition is to promote a good work-life balance by providing employees with a pleasant and motivating work environment. This approach includes, in particular, maintaining and continuously improving a safe working environment, developing management practices and measures that enhance employees’ quality of life at work, and paying close attention to their well-being. The Guerbet Listens survey measures employee engagement. Within the scope of France, QLWC is the subject of annual negotiations and is currently structured around action levers that apply to employees:
- life in the Company: Guerbet implements measures that promote a friendly atmosphere and shared events;
- work-life balance: in order to offer a better work-life balance, several measures are offered: • the right to disconnect and teleworking agreement,
• one hour granted for the first day of school,
— — —
1|
|
2|
|
3|
|
• time granted in the event of absence, for single-parent families or parents of sick or disabled children, • specific measures for teleworking for pregnant women, employees who are caregivers and employees with disabilities,
4|
|
• provision of childcare places, • recognition of the specific circumstances of employees who are caregivers from 2026 (formalized three-days paid leave per year), • communication and appointing of a contact person;
5|
|
- prevention of psychological and social risks (PSRs): • training in the prevention of PSRs given to managers so that they are able to objectively assess the workload of their teams, • training of PSR representatives within SECs (Social and Economic Committee, employee representation body within the Company), • psychological hotline available and promoted on Guerbet Inside and via posters. This is an external line available 24 hours a day, guaranteeing confidentiality and anonymity.
6|
|
7|
|
• network of listening ambassadors, trained in listening, signal detection and orientation, • raising awareness of bullying and sexual harassment available on the HR intranet. Initiatives to prepare employees for retirement and improve the QLWC of persons with disabilities are detailed in section 5.3.1.7 Diversity and inclusion.
• a guide to good practices for organization of working from home and on-screen work,
Telehealth and support programs are available to employees in Dublin, Asia-Pacific and the USA.
• annual interview on managers’ workload,
These actions are long-term.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
155
SUSTAINABILITY STATEMENT People (social data)
5.3.1.4.3 Metrics and targets
Preparing for the future
Annual manager/employee reviews, dialogue with employee representatives and internal surveys make it possible to measure the effectiveness of the quality of life at work and working conditions policy and action plans.
To anticipate the needs of healthcare professionals and patients, Guerbet is developing key skills in Diagnostic Imaging, Interventional Radiology, Digital and Artificial Intelligence, strategic areas for its future projects.
5.3.1.5
To enhance Operational Excellence and continuous improvement, Guerbet deploys programs in lean management(1), problem solving, digitization and data analysis.
Skills development
5.3.1.5.1 Policy Skills development is a key focus of our People & Planet commitment. It contributes to the Group’s sustainability and performance. It offers opportunities for professional development for employees, thereby improving their satisfaction, their commitment, and their employability. The Human Resources Department has established a skills development policy at Group level, defining the roles and responsibilities. This policy is based on the continuous development of skills, enabling employees to acquire, develop, and strengthen the knowledge, know-how, and interpersonal skills necessary to master their job roles. It also aims to anticipate development needs in order to meet expected changes in the sector, thereby supporting the fulfillment of its strategic priorities. Employees are involved by their manager in developing their skills development plan. An annual needs gathering campaign is conducted among employees and the main directions of the policy are communicated to them via a webinar. The development plans are formalized and monitored on an HRIS platform (human resources management software), with an LMS (Learning Management System) module which makes it possible in particular to distribute training courses, facilitate access to online training and ensure traceability. This policy is applied locally. The same applies to the actions presented below, which are part of a global approach and do not necessarily apply to all sites.
5.3.1.5.2 Actions The actions presented are long-term.
Quality training Guerbet offers rigorous training on good manufacturing practices (GMP) and regulatory standards to ensure the quality of its products and the safety of its patients, particularly to employees at industrial sites. These training courses help ensure that quality and safety control procedures are mastered, while promoting a culture of vigilance and continuous improvement.
(1)
156
Cross-disciplinary training related to CSR is offered in particular as part of the annual People & Planet Week initiative, which aims to raise employee awareness of societal and environmental issues. Workshops, webinars and events are offered on physical and mental health, safety, inclusion, climate and sustainable development. To support its international growth, Guerbet invests in language learning through an online platform accessible to all, complemented by teacher-led courses.
Leadership skills development In parallel with skills development, the Group has formalized succession plans, management tools aimed at ensuring the sustainability of skills and know-how. Deployed in all managerial positions, these plans ensure the continuity of key company functions while anticipating future movements within the teams, promoting internal mobility. To prepare succession plans for key managerial functions, Guerbet offers a one-year mentoring program that reinforces the transfer of know-how and expertise between generations and fosters innovation. More generally, Guerbet invests in enhancing the managerial and human skills of its managers through a program aimed at giving them the tools and outlook needed to build their trust, develop their leadership, and engage their teams.
Learning culture A variety of learning formats are offered to meet these technical or human skills development objectives: instructor-led courses, coaching/mentoring, conferences, e-learning, reading of documents, on-the-job training, etc., in a work situation, in person, or remotely. Guerbet encourages all employees to develop, depending on what is relevant to their needs and their role. The use of the Guerbet Inside corporate social network also fosters co-development, the exchange of information, best practices and tutorials, etc., thereby contributing to the learning culture.
Lean management: a method of managing and organizing work that aims to improve a company’s performance.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
SUSTAINABILITY STATEMENT People (social data)
Network of internal trainers
Result
This culture of learning between employees is reinforced by the involvement of internal trainers. During the collective training sessions that they lead, they share their expertise and knowhow, contributing to the transfer and capitalization of knowledge and the development of networks.
94% of employees received training.
To support them, Guerbet offers training for the profession of trainer, including teaching tools and methods for designing and running modules, face-to-face or remotely. Digital solutions are also made available to facilitate the creation of e-learning content.
Matching of personal initiatives Guerbet also supports the personal initiatives of employees who wish to invest in these development activities by offering a matching scheme.
A performance assessment was carried out for 98% of employees. These results contribute to enhancing the Group’s recognition and attractiveness.
5.3.1.6
Compensation, recognition and attractiveness
5.3.1.6.1 Policy Guerbet’s employees are key to the Group’s success. The recognition policy is an essential factor in its long-term performance.
Internal and international mobility
Guerbet offers all its employees worldwide competitive compensation linked to the assessment of their contribution to the Company’s success.
Guerbet encourages all teams to consider career prospects within the Group.
This policy covers several objectives:
Regardless of their seniority and position in the Company, all employees are eligible for internal mobility and are encouraged to express their wishes to their manager and Human Resources during career discussions.
2|
• individual and collective motivation; • attract and retain employees; • give fair recognition to the contribution.
News about internal mobility is posted on the Company’s intranet portal, and open positions are accessible to everyone in real time on MyHR (the HR information system).
Evaluation of the effectiveness of actions
Guerbet regularly analyzes the competitiveness and structure of compensation compared with market baselines by country. The Chief Executive Officer and the Human Resources Director are responsible for implementing this policy. The Director of Payroll, Compensation and Benefits is responsible for monitoring this.
3|
|
4|
|
5|
|
5.3.1.6.2 Actions The actions described in this section are implemented Groupwide and are long-term.
5.3.1.5.3 Metrics and targets Target Skills development plans are defined and monitored through the annual target definition, monitoring and evaluation campaigns, managed via the HR information system. Although the Group does not set a quantitative target in this area, it is committed to actively promoting the development of its employees’ skills. 2024
2025
Attractive direct and indirect compensation
In addition to this fixed compensation, there is a variable compensation component linked to individual and collective objectives, which includes, among other things, CSR criteria, in the form of bonuses and/or profit-sharing (see section 5.1.2.3 CSR criteria in variable compensation).
94%
• Women
94%
Equal pay
93%
At Guerbet, compensation is based on the principle of equality. It is based exclusively on skills and experience regardless of gender, age, marital status, sexual orientation, disability, national or ethnic origin, as well as religious or political beliefs.
Nonconsolidated
12.7
• Women
10.9
• Men Share of employees who participated in the performance assessment
14.0 98%
98%
• Women
98%
97%
• Men
99%
97%
6|
|
Annual increases therefore take into account the employee’s individual performance, in addition to the positioning of the employee’s salary relative to the market.
% of employees trained • Men Average number of training hours per employee
1|
|
|
The global compensation policy incorporates all elements of compensation for the employees of the entire Group. It includes monetary and non-monetary components, such as profit sharing and long-term compensation.
The effectiveness of training is assessed by following several approaches depending on the nature of the training and its impact: at a minimum, the results are assessed during the yearend review between the trained employee and the employee’s manager. This assessment may be reinforced by an in-situation assessment by the trainer or via a questionnaire, or even be presented to a panel.
— — —
7|
|
The Group ensures equal pay for men and women, as assessed by the professional equality index (see section 5.3.2.7 Diversity and inclusion).
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
157
SUSTAINABILITY STATEMENT People (social data)
Pay transparency Pay transparency helps ensure pay equity while preventing social discrimination and serves as a way to strengthen employee trust. There are specific wage transparency regulations, as in some North American states and Brazil, with which Guerbet complies, and others are to come in Europe in 2026. Guerbet is preparing a standardized approach on pay transparency for 2026, to make it available to employees.
5.3.1.6.3 Metrics and targets Employee departures and turnover 2024
2025
537
573
Employee turnover rate Total number of permanent employee departures
18.5%
20.3%
440
455
Permanent employee turnover rate
15.9%
16.1%
Total number of employee departures
Compensation and benefits Guerbet offers a “Compensation and Benefits” package for monetary and non-monetary recognition of individual and collective performance. This package includes the following components: • competitive personal protection, health and retirement cover: given changes in expenditure and health cover, Guerbet ensures that employees receive a good level of health benefits, in particular by carrying out regular audits. Regarding personal protection, Guerbet insures its employees against major personal risks; • allocation of bonus performance shares for certain employees since 2016. The most recent plan was approved by the Board of Directors in 2025 and includes financial and CSR criteria;
The Group measures employee engagement and retention using indicators such as the number of departures and the employee turnover rate. The turnover rate of employees on permanent contracts of 16.1% is the sum of the departures of employees on permanent contracts over the year, compared with the average of the Guerbet workforce over the full year. The turnover rate for employees on permanent contracts remains stable compared with 2024.
• company vehicles for certain employees;
Indicators relating to departures and the turnover rate include the employees on temporary contracts who move on to permanent contracts, as well as the end of internships and work-study programs. This increases the number of departures and therefore the turnover rate presented.
• the option to work from home, based on eligibility.
Pay gap and compensation ratio
Guerbet’s CSR commitments are also subject to recognition mechanisms, through the integration of CSR criteria and objectives to be achieved by certain employees.
2024
2025
Gender pay gap
8.6%
7.02%
Annual compensation ratio
19.4%
29.41%
Attractiveness and retention To increase its attractiveness, commitment and the sense of belonging of its employees, Guerbet is developing and embodying its employer brand to reflect the Group’s strategic changes. Guerbet has strengthened its integration program while emphasizing its strategy for relations with schools (see section 5.4.1 Corporate culture). The Group implements an individualized integration pathway, adapted locally. Guerbet has an integration e-learning program to present its values, history, ambition, sites and activities. The industrial sites offer immersion days for employees from other entities. Guerbet tends to develop its teams’ sense of pride in belonging through employee testimonials, reported internally and/or on social media, particularly in connection with behavioral principles and CSR commitment (see section 5.4.1 Corporate culture).
In its compensation policy, Guerbet bases its decisions on skills and experience, promoting a practice that aims for pay equity. The equality index reflects Guerbet’s equal pay practices and is therefore used in this report (section 5.3.2.7 Diversity and inclusion). It takes into account the structure of the workforce by country, business lines and seniority and thus differs from the compensation calculation proposed by the CSRD. In 2025, the change in the annual compensation ratio for the Guerbet group (29.41% versus 19.4% in 2024) is explained by: • a methodological change was initiated in 2025, improving the calculation of the ratio, which now includes shares held by employees and by the Chief Executive Officer; • the transition period during which the Chief Financial Officer served as CEO. This temporary employment had a slight impact on the consolidated ratio. This payment is aligned with the Group’s objectives and was validated by the General Meeting. The monitoring of these metrics is a means of measuring actions and initiatives. Guerbet does not have a quantified objective.
158
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
SUSTAINABILITY STATEMENT People (social data)
Social protection The Group’s social protection covers loss of income due to one of the major life events, which are illness, unemployment, workplace accident, acquired disability, parental leave and retirement. All Group employees have social protection in accordance with the local rules in force.
Adequate wages Guerbet offers attractive levels of compensation, which reflect the importance and complexity of the skills required in the pharmaceutical sector. Salaries are reviewed regularly based on specialized benchmarks to ensure that its practices remain consistent with the pharmaceutical market. The wage and social benefits offered by the pharmaceutical sector are known to exceed the wage standards of other industries and the cost of living and contribute to an adequate wages approach. Employee compensation is compared with the Willis Tower Watson benchmarks in the global pharmaceutical market. The Group does not publish metrics on adequate wages. Guerbet wants to explore this topic further within a timeframe of one to three years.
5.3.1.7
Diversity and inclusion
Guerbet believes that employee diversity is an asset as well as an opportunity to develop the Group’s sustainable performance, innovation and creativity.
5.3.1.7.1 Policy The IROs relating to this issue are covered by the responsible social policy and the ethics charter. A policy on diversity and inclusion will be formalized over the next one to two years.
5.3.1.7.2 Actions The actions presented are long-term.
Inclusive work environment Guerbet promotes inclusion, applying a zero-tolerance approach to discrimination, in all its forms (gender, age, marital status, sexual orientation, disability, national or ethnic origin, religious or political beliefs). These themes are integrated into managerial training. The Group’s ambition is to offer an environment centered on equal opportunities and based exclusively on skills and experience, from recruitment to training, development, mobility, recognition and compensation. Human Resources and managers are responsible for this approach focused on diversity, inclusion and equal opportunity. In the event of discrimination, employees may contact the managerial chain or the HR team. A whistleblowing platform (see section 5.4.2.2.5) is made available to employees, making it possible to collect reports confidentially and anonymously.
In France, Guerbet holds negotiations annually on professional equality, the employment of young people and seniors and the employment of persons with disabilities. Guerbet has materialized major commitments on the theme of diversity in the United States through a non-discrimination charter. The Raleigh site has a Diversity and Inclusion Committee.
Gender equality The Group aims to achieve professional equality regardless of gender and aims to have the same proportion of men and women at the level of senior managers and the Executive Committee. With 44% women on the Executive Committee, Guerbet is ahead of the requirements of article 14 of Law No. 2021-1774, which has a target of 30% female senior managers by 2026 and 40% by 2029. In terms of gender equality in the workplace, Guerbet has established action plans with social partners to identify areas for improvement based on several indicators (recruitment, qualification, training and compensation).
— — —
1|
|
2|
|
Wage increase budget A wage increase budget was put in place to reduce the pay gap between men and women.
3|
|
Employment of persons with disabilities The Group is committed to promoting the employment of workers with disabilities in order to improve their inclusion and working conditions. It is supported by the Human Resources contact persons and the team of disability advisers present in France. The latter ensure that they support the employees concerned in the day-to-day management of their disability, during contact with the Departmental Centers for Disabled People (MDPH), renewal of disabled worker status recognition (RQTH), or in obtaining job adjustments. They answer questions from all employees about disability in the Company. They also support managers in adapting their managerial practices to meet the needs of their employees with disabilities as closely as possible. This approach is reflected in concrete actions carried out over several years within the French entities, such as:
4|
|
5|
|
6|
|
• granting a bonus when an RQTH is first applied and then at the time of renewal; • training managers and teams onboarding an employee with disabilities;
7|
|
• authorizing paid leave of absence for employees with an RQTH for any appointment related to their disability; • identifying job modifications or personalized redeployment solutions to help employees remain in the workforce, in collaboration with the occupational health department and with the assistance of disability committees; • rolling out of annual awareness campaigns for European Disability Week and People & Planet Week.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
159
SUSTAINABILITY STATEMENT People (social data)
5.3.1.7.3 Metrics and targets Gender equality
Employment of seniors Guerbet is committed to the well-being and retention in employment of seniors (50 years of age and over) and to promoting their recruitment. The Group’s French entities benefit from several commitments to supporting the employment of seniors:
For several years now, Guerbet has achieved the objective of having at least 40% women in management, middle management or senior management positions and at least 40% women on the Executive Committee.
• flexible working arrangements;
The Group aims for a balanced representation of women at all levels.
• initiatives for the transfer of skills; • end-of-career arrangements:
At the end of 2025, the breakdown of the workforce was as follows:
• leave to prepare for retirement and part-time working, • conversion of variable compensation or end-of-career benefits to capitalized leave,
YEAR-END WORKFORCE BY GENDER
• professional interviews incorporating a senior component, • dedicated interview three years before retirement, • customized tools via the Pension Fund for employees over 57 years of age.
Employment of young people
Gender
2024
2025
Male
1,683
1,176
Female
1,222
1,570
Other
—
—
Undeclared
Guerbet is committed to young people’s access to long-term job opportunities and implements measures to promote their inclusion. International corporate volunteer (VIE) contracts offer individuals under the age of 28 the opportunity to carry out multiple international assignments. Guerbet actively welcomes apprentices and interns, thereby contributing to youth training and access to their first job. Guerbet develops partnerships with local primary and secondary schools and universities and organizes site visits and introductory internships to introduce young people to its activities and the business world.
TOTAL EMPLOYEES
—
—
2,905
2,746
YEAR-END WORKFORCE BY TYPE OF CONTRACT (broken down by gender)
2024
2025
Female
Male
Other
Not communicated
NUMBER OF EMPLOYEES
2,905
2,746
1,176
1,570
—
—
Permanent
2,764
2,637
1,116
1,521
—
—
Temporary
141
109
60
49
—
—
Full-time
2,778
2,653
1,102
1,551
—
—
Part-time
127
93
74
19
—
—
Guerbet favors long-term employment: 96% of the workforce is on permanent contracts, an equivalent level for women (95%) and for men (97%), reflecting an employment policy implemented regardless of gender. To assess the effectiveness of action plans within the scope of France, Guerbet also complies with the professional equality index.
160
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
SUSTAINABILITY STATEMENT People (social data)
For 2025, the Guerbet entities in France achieved the following results: EQUALITY INDEX IN FRANCE
Employment of seniors 57 senior employees joined the Group, representing over 14% of new hires. Of these 57 employees, 16% hold senior management positions.
Employment of young people 14% of interns and apprentices secured their first job at Guerbet sites in France (on either a permanent or temporary contract).
— — —
GUERBET AGE PYRAMID
1|
|
FOCUS ON GUERBET S.A.
2|
|
3|
|
YEAR-END WORKFORCE BY AGE, BROKEN DOWN BY GENDER 2024
Age
2025
2025
(%)
(%)
(number)
UNDER 30
11%
11%
304
Female
5%
5%
148
These results reflect the Group’s commitment to gender equality.
Male
6%
6%
156
Employment of persons with disabilities
Other
—%
—%
—
Not communicated
—%
—%
—
2024
2025
Percentage of employees with disabilities, in France
4.4%
4.2%
• Women
2.7%
2.8%
• Men
3.5%
3.4%
To date, the percentage of employees with disabilities is consolidated only for France due to certain legislative and regulatory specificities internationally. In France, the obligation to employ workers with disabilities is accompanied by specific reporting and monitoring mechanisms, facilitating the collection and consolidation of data. This percentage only includes Guerbet employees and does not include employees of our suppliers. Guerbet S.A.’s employment rate for workers with disabilities, calculated in 2025 for 2024, is 5.2%. This rate also includes indirect jobs and reflects the initiatives carried out over the past several years within the entities in France that encourage the use of the adapted sector.
BETWEEN 30 AND 50
54%
53%
1,460
Female
23%
23%
632
Male
31%
30%
828
Other
—%
—%
—
Not communicated
—%
—%
—
OVER 50
34%
36%
980
Female
13%
14%
396
Male
21%
21%
584
Other
—%
—%
—
Not communicated
—%
—%
—
0.1%
2
100%
100%
2,746
NOT COMMUNICATED TOTAL
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
4|
|
5|
|
6|
|
7|
|
161
SUSTAINABILITY STATEMENT People (social data)
Cultural diversity With a presence in 30 countries and 75 nationalities in its workforce, Guerbet promotes diversity, regardless of ethnic or cultural origin. Monitoring the metrics relating to the distribution of nationalities at Group and managerial level ensures the effectiveness of its Human Resources policy. Of the 75 nationalities represented, 37 include someone who holds a managerial position.
its Human Resources policies, its secure whistleblowing platform and its responsible purchasing policy. The ethics charter on which employees are trained annually, which is publicly accessible, and the responsible purchasing policy are essential pillars of the corporate culture. They are distributed internally. All Guerbet employees and partners are required to comply. In order to ensure that human rights are respected and protected, Guerbet provides stakeholders with a secure whistleblowing platform. This system allows anyone to report, in complete confidentiality, concerns or complaints about our performance or impact on human rights. To date, Guerbet has not been subject to any convictions, fines or penalties related to human rights.
5.3.1.9
Social commitment
Guerbet has a volunteer program: Guerbet Positive. Each employee volunteer can devote three days a year of working time to engage in volunteer activities related to the causes supported by the program: health, environment, diversity & inclusion, and solidarity with local issues. The program, led by local representatives, is active in France, the Czech Republic, United Kingdom, South Africa, Japan, the United States and Latin America. This program demonstrates the commitment of Guerbet and its employees to bringing concrete and human value to charities, their beneficiaries and the causes supported, in line with the Group’s purpose, values and CSR strategy.
5.3.1.8
Human rights commitments
Guerbet is committed to complying with the fundamental conventions of the International Labor Organization (ILO), namely: • recognition of freedom of association and collective bargaining rights; • elimination of discrimination with regard to employment and occupation; • elimination of forced or compulsory labor; • the effective abolition of child labor. Guerbet is committed to integrating respect for human rights at the heart of its activities and partnerships. Guerbet incorporates human rights into its internal policies such as its ethics charter,
162
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
This issue is presented to meet the expectations of stakeholders. Guerbet mapped the issue through the double materiality assessment and concluded that it is not material within the meaning of the CSRD.
Key initiatives for the year • Relaunch of the mentoring program with the association Nos Quartiers ont des Talents (Our Neighborhoods Have Talent – NQT): Guerbet employees support young graduates from priority neighborhoods or disadvantaged backgrounds to help them define their career plans. • Events for Pink October, breast cancer awareness month: around a hundred employees took part in the Odyssea race and numerous local initiatives were relayed internally. • Raising awareness of sustainable development during European Sustainable Development Week.
SUSTAINABILITY STATEMENT People (social data)
5.3.1.10 Management of negative impacts and channels for raising concerns
This figure includes possible cases of incidents of discrimination, including harassment. In 2025, no serious human rights issues were reported via the hotline.
To address the negative health and safety impacts that could affect employees, Guerbet offers its employees social protection.
An annual report on escalations is presented to the Ethics Committee of the Board of Directors annually.
In terms of channels for raising concerns, any inappropriate behavior or actions contrary to ethical principles can be reported to a manager, Human Resources contacts, the Legal or Ethics Department, or through the whistleblowing platform made available to employees.
This whistleblowing system, which is also supplemented by feedback channels at the sites, reinforces Guerbet’s proactive approach to a safe and sustainable working environment, by integrating health, safety, inclusion and quality of life into each person’s daily practices.
2025
Number of reports received during the year through the whistleblowing system related to human resources issues
— — —
1|
|
22
2|
|
5.3.2
Workers in the value chain – ESRS S2
5.3.2.1
Impact management and dialogue process
Guerbet works with a few suppliers with production sites located in countries more exposed to labor rights and human rights risks (child labor or forced labor).
5.3.2.1.1 IROs and link to the business model and strategy
If negative impacts occurred to people working for subcontractors and suppliers, Guerbet would be exposed to a reputational risk or risk of disruption. To minimize the impacts for workers in its upstream value chain and minimize its risks, the Group strives to control its dependencies on a subcontractor or supplier and to carry out preventive actions with its suppliers.
Guerbet is committed to working only with honest suppliers that respect human rights and labor law according to the Fundamental Conventions of the International Labour Organization and the Guiding Principles of the United Nations.
With respect to the resources allocated to the management of material impacts and risks, Guerbet will not publish this type of information.
For Guerbet, the workers in the upstream value chain most exposed to negative impacts are workers at the manufacturing sites of subcontractors and suppliers. This identification was carried out as part of the double materiality assessment work, in connection with the supplier risk analysis using the “PESTEL” method. SUMMARY OF MATERIAL IROS
4|
|
5|
|
6|
|
IRO type IRO
3|
|
Y
Consequences of an industrial incident on workers and supply
5.3.2.1.2 Dialogue process The procurement teams ensure that regular and transparent discussions are held with subcontractors and strategic suppliers. There is a formalized dialogue process with key suppliers, through performance reviews that incorporate CSR aspects (see section 5.1.3.4 Responsible purchasing approach). These
R
l
I+
Scope I-
Upstream
l
l
OO
Horizon Downstream
ST
MT
LT
l
7|
|
reviews allow for discussions with its strategic suppliers on their sustainability commitments and take into account their priorities and challenges, in order to support them in the deployment of progress plans. Social issues such as workplace safety are included in these reviews. The frequency of these interactions is defined on a case-by-case basis according to needs.
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
163
SUSTAINABILITY STATEMENT People (social data)
5.3.2.2
Responsible purchasing and human rights commitments
5.3.2.2.1 Policy Through its responsible purchasing policy and supplier code of conduct, Guerbet promotes its ethical, social and environmental values to its suppliers and asks them to do the same to their own business partners. The first six principles of this code deal with social issues:
- support and respect for the protection of human rights, including at international level;
- no complicity in human rights abuses;
purchasing kit made available to LEEM members. The kit contains a series of practical tools and a supplier charter defining several responsible purchasing commitments made by member companies and their suppliers.
5.3.2.2.3 Metrics and targets Guerbet does not yet have specific targets and metrics on social issues for its upstream value chain. The Group will work on this in 2026 in connection with the rollout of a CSR assessment tool. In 2025, the Group did not record any human rights reports that would involve workers in the value chain. This is a measure of the effectiveness of policies and initiatives.
- respect for workers’ rights, health and safety;
- elimination of all forms of forced or compulsory labor;
- effective abolition of child labor;
- combating discrimination in employment.
5.3.2.2.2 Actions The processes and actions related to responsible purchasing are detailed in section 5.1.3.4 Responsible purchasing approach. This section is supplemented by some additional initiatives outlined below.
Assessing and strengthening the supply chain In connection with the analysis of the HSE risks of its strategic suppliers and subcontractors using the “PESTEL” method, Guerbet applies, where possible, the second supplier qualification process for strategic raw materials. With one of its major partners in Asia, Guerbet has deployed a specific approach, including a progress plan based on a process safety audit carried out in 2023 and renewed in 2025 to measure the effectiveness of the actions.
Developing the sector In 2024, Guerbet took part in a sector-wide LEEM (Les Entreprises du médicament) initiative aimed at encouraging other pharmaceutical players to deploy responsible purchasing approaches. This initiative led to the creation of a responsible
164
GUERBET
2025 UNIVERSAL REGISTRATION DOCUMENT
5.3.2.3
Management of negative impacts and channels for raising concerns
In the event of negative impacts, the buyer and the business
2025 Full year results
March 12, 2026
WELCOME
KARIM BOUSSEBAA Chief Executive Officer
JÉRÔME ESTAMPES CFO and SVP Business Development & Licensing
1
A renewed and strengthened executive committee
KARIM BOUSSEBAA
CHRISTINE ALLARD
CHARLOTTE BAMIÈRE
PHILIPPE BOURRINET
VALÉRIE BRISSART
Chief Executive Officer
SVP Public Affairs & Corporate Communications
General Counsel
SVP Development, Medical & Regulatory Affairs and Group Responsible Pharmacist
SVP Diagnostic Imaging
FRANCOIS CONVENANT
JÉRÔME ESTAMPES
ERIC KUMMER
FRANÇOIS NICOLAS
EVA OHLSSON
SVP of Interventional Radiology
CFO and SVP Business Development & Licensing
SVP of Technical Operations
SVP R&D, R&I and Chief Digital Officer
SVP Human Resources
2
01
Activity & highlights 2025
01 Highlights 2025 | 02 Financial results |
|
3
Three headwinds in 2025
WHAT HAPPENED
THE SITUATION TODAY
The reform in France
› Market share lost in X-ray following the reform of the distribution channels and the fast switch in packaging (from mono-doses to large vials)
› Return to growth in Q4 in France with manufacturing fully adapted to new packaging ; market share recovery starting and due to continue with upcoming tenders
Customer mix in the US
› Significant pressure on prices and margins in the US linked to the increased weight of distributors in the customer mix
› Rebalancing of the mix underway with gradual reconquest of direct customers
The Raleigh situation
› Remediation plan initiated in Q4 at Raleigh, following a warning letter from the FDA regarding quality process documentation
› Release of batches produced on the Raleigh site remaining below its normal level
4
Focus – The Raleigh situation
FDA comprehensive assessments
Remediation plan in progress
Current situation at the plant
› FDA inspection in H1 2025 followed by a warning letter dated 17 October
› External technical and compliance experts hired and accompanying Guerbet to address all FDA observations
› Newly implemented improvements and upgrades require additional validation steps before product can be released.
› Observations related to certain manufacturing practices (documentation process) and physical characteristics of the site
› No product safety signals related to FDA’s observations
› Plant improvements : working diligently to address the FDA observations as quickly as possible › Completing plant upgrades by implementing new process and equipment for the plant
5
Financial performance impacted by headwinds SALES ▪ Full-year revenue at like-for-like and CER down 3.5%, largely due to the fall in business in France ▪ A decline in Q4 (-5.6%) linked to the situation at the Raleigh site in the United States
PROFITABILITY ▪ Restated EBITDA margin* at 12.0% of sales, at the top of the range announced on 2 December ▪ Profitability affected by margin pressures in the US (customer mix), turmoil in France, and, in Q4, the cost of the Raleigh situation
FINANCIAL STRUCTURE ▪ FCF in positive territory (+19.2 M€) due to improvement in the DSO ▪ Net debt/EBITDA ratio at 4.0 at end 2025
*excluding exceptional costs related to the optimization of the operational structure & changes in the sales model
6
Full year revenue down 3.5% at CER and on a LFL basis Annual sales (in €m)
Like-for-like basis*
-3.5%
2025 sales evolution
-6.3% 836.9
807.3
784.6
2024
▪
Significant negative FX impact of €22.8 m
▪
€807.3 m in annual sales at constant exchange rates (CER) and on a like-for-like (LFL) basis*
▪
Without France, sales would have been stable year on year
2025 At current FX
At CER
*Excluding divested businesses (Accurate and urology) 7
Robust growth in EMEA (excl. France), low activity in Americas & APAC Split of sales & evolution by zone (in m€ at CER and on a LFL basis, variation in %)
EMEA: positive growth outside France ▪ Fall in French activity following the supply chain reform ▪ Excluding France, +7.6% growth at CER & on a LFL basis, driven by volumes
2025 APAC -4.8%
Americas: H2 evolution impacted by the Raleigh situation
218.0
▪ A decline largely concentrated in H2, linked to the situation at Raleigh 343.5
EMEA -2.5%
▪ Over the year, growing volumes but pressure on prices due to customer mix
(+7.6% excl. France)
APAC: weak performance concentrated in certain markets Americas -3.8%
245.8
EMEA
▪ Most of the decrease due to Vietnam (loss of a tender)
Americas
APAC
▪ Decline in South Korea linked to discontinuation of deliveries to one distributor to protect margins
8
Revenue breakdown by activity DIAGNOSTIC IMAGING (DI) (revenues in m€ at CER and on a LFL basis, variation in %)
INTERVENTIONAL RADIOLOGY (IR) (revenues in m€ at CER and on a LFL basis, variation in %)
-7.2%
(+4.2% excl. France)
-1.9% (+0.5% excl. France)
474.5
440.1
MRI
+9.7%
14%
32%
262.6
257.6
2024
2025
99.9
109.6
2024
2025
54%
2024
2025
▪ 2025 activity for the DI business at -5.3% at CER and on a LFL basis
▪ In X Ray, positive price effects offset by lower volumes for both Xenetix® and Optiray®, mainly in France ▪ Positive trend over the first 9 months for the MRI franchise (Dotarem ® + EluciremTM ) followed by a decline in Q4 due to the situation at the Raleigh site
▪ New sales record of over €100 m reached in 2025 for the IR business ▪ Solid momentum in volumes and prices for Lipiodol®, particularly in vascular embolization
9
02
Financial results
01 Highlights 2025 | 02 Financial results |
|
10
An unfavorable FX effect due to US, Asian & LATAM currencies Annual sales (in €m)
FX impact on 2025 sales (in €m)
Reported basis
2025 sales evolution
-3.8% -6.5% 841.1 786.4
▪
Significant negative FX impact of €22.8 m, mainly due to the US dollar, Brazilian real & Korean won
▪
Reported sales down -3.8% at constant exchange rates (CER)
809.3
APAC -10
LATAM -8
NAM -5
2024 At current FX
2025 At CER
11
EBITDA 2024 As published
% Revenue
2025 As published
% Revenue
Variation
Net sales
841.1
100.0%
786.4
100.0%
-6.5%
Other revenues
11.4
1.4%
12.9
1.6%
+13.2%
Supplies used in operations
(189.3)
-22.5%
(199.3)
-25.3%
+5.3%
Staff costs
(274.0)
-32.6%
(254.3)
-32.3%
-7.2%
External expenses
(255.0)
-30.3%
(238.6)
-30.3%
-6.5%
Taxes other than on income
(16.4)
-1.9%
(16.8)
-2.1%
+2.3%
Other operating income and expenses
1.6
0.2%
(8.2)
-1.0%
ns
EBITDA published
119.4
14.2%
82.3
10.5%
-31.1%
EBITDA restated*
125.4
14.9%
94.5
12.0%
-24.7%
IFRS €m
*excluding exceptional costs related to the optimization of the operational structure & changes in the sales model 12
EBITDA Evolution 140 130 120 110
+6.0
14.9%
14.2% 125.4
-3.2
119.4 -13.2
100
-2.4
+18.0
90
12.0%
94.5
80
10.5% -12.2
82.3
Restructuring costs
EBITDA 25 published
-30.1
70 60 50 EBITDA 24 published
Restructuring costs
EBITDA 24 restated
FX impact
France and NAM impact
Volume, Mix & Manufacturing Price (excl. costs France and NAM)
Fixed costs
EBITDA 25 restated
*excluding exceptional costs related to the optimization of the operational structure & changes in the sales model 13
Operating & Net Income IFRS €m
2024 As published
% Revenue
2025 As published
% Revenue
Variation
EBITDA
119.4
14.2%
82.3
10.5%
-31.1%
Allowances for depreciation
(61.2)
(7.3%)
(150.2)
(19.1%)
+145.4%
Provisions
(8.6)
(1.0%)
(20.2)
(2.6%)
+134.0%
Operating Income
49.6
5.9%
(88.2)
(11.2%)
ns
Net interest expense
(22.3)
(2.7%)
(19.4)
(2.5%)
-12.8%
Net currency gains/losses & Other Financial income/loss
(7.9)
(0.9%)
(2.0)
(0.3%)
-75.0%
Income tax
(5.9)
(0.7%)
(3.1)
(0.4%)
-47.7%
Net Income
13.5
1.6%
(112.7)
(14.3%)
ns
Change in Depreciations = -€89.0 m including group assets impairment of €85.9 m
14
Balance sheet December 31. 2024 As published
December 31. 2025 As published
EQUITY & LIABILITIES
December 31. 2024 As published
December 31. 2025 As published
Non-current assets
456
329
of which fixed assets
398
276
Shareholders’ equity Non controlling interests
394 -3
267 -7
391 351
362 325
95
85
159 44
223 116
1 037
930
ASSETS
Inventories
301
295
Non-current liabilities of which financial debt
Trade receivables
173
145
Trade payables
Other current assets of which CCE
107 50
161 115
Other current liabilities of which financial debt
Total Balance sheet
1 037
930
Total Balance sheet
15
Free cash-flow IFRS in €m
FY 2024
FY 2025
Cash-flow from operations
119.4
81.8
Change in WCR
(19.1)
(0.5)
Net capital expenditure
(62.1)
(31.6)
Dividends
(6.3)
(0.0)
Interests paid
(20.5)
(19.8)
Income tax paid
(12.6)
(10.6)
Exchange
(8.0)
(0.0)
Free cash flow
(9.1)
19.2
16
3.4
Net debt evolution Net debt
335.8
Net debt / EBITDA
344.9
Net debt / Shareholder Equity
1,22 325.7* 4.0
0.89
0.87
FY 2023
FY 2024
3.4 2.9
FY 2023
FY 2024
FY 2025
FY 2023
FY 2024
FY 2025
FY 2025
*Waiver obtained in December on the maximum value of debt ratio (covenant) 17
03
Status update on Raleigh
01 Highlights 2025 | 02 Financial results |
|
18
Our focus : back to normal at Raleigh TODAY
YEAR END
New management team in place External consultants assisting us with remediation
Product release back to normal
Actions plan defined, shared with FDA and on track
Getting ready for FDA reinspection Full production capacity in place Increasing product release ratio
19
2026 – Material negative financial impact of the situation at Raleigh
ACTIVITY
PROFITABILITY
▪ Sales impacted mainly in NAM and LATAM
▪ Expenses related to the remediation plan
▪ Sales in APAC and EMEA also affected due to prefilled syringes (100% produced in Raleigh)
▪ Increase in unit cost due to lower production ▪ Stocks destruction
CASH GENERATION & DEBT ▪ Expected negative FCF ▪ Increase of net debt and leverage ratio deterioration ▪ Potential covenant breach risk on June 30, 2026
20
04
Our strategic priorities
01 Highlights 2025 | 02 Financial results |
|
21
Our mid-term strategic priorities
1
Improving sales & profitability in Diagnostic Imaging
2
Capturing Interventional Radiology’s High-Growth
3
Improving competitiveness and enhancing cash generation
22
1
Improving sales & profitability in Diagnostic Imaging Focus on X-Ray margins and consolidated leadership in MRI Our levers for improvement in X-Ray profitability:
Gaining market share in MRI with : ▪ The strongest MRI portfolio backed by a unique duo Dotarem® / EluciremTM
▪ SKU rationalization ▪ Proactively push multi-use (big vials) & adapting industrial sites to the shift towards multi-use ▪ Optimize product flow through industrial network ▪ Leveraging AI for process efficiency and quality (electronic batch records and releases)
▪ Complete solutions (incl. X-Ray & injection solutions) in line with customer expectations
▪ Elucirem journey Geographic expansion › Significative ramp-up in the United States & very successful launch in Switzerland in 2025 › Recent approval in Chile, Mexico, Taiwan, Australia › Next steps in 2026 : launch in Mexico, Portugal, Belgium, Greece, Croatia, and South Korea New indication in children from birth approved in EU & USA
Improve margin through : Cost of goods sold (COGS) reduction & Cost of quality improvement 23
2
Capturing Interventional Radiology’s High-Growth Leverage strong fundamentals in IR
IR aligned with structural trends in Healthcare
Solid double-digit growth for GUERBET over a decade Interventional Radiology revenue (Reported sales in €m)
▪ Rapid growth: driven by an aging population and demand for minimally invasive treatments
100
▪ Technological innovation: integration of AI, robotics, and precision imaging to improve the safety and effectiveness of procedures
80
▪ Clinical impact: reduction in costs related to complications and improvement in patients' quality of life
20
CAGR +16.1%
60 40
0
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
24
2
Powering Interventional Imaging’s High-Growth Path Beyond HCC*, new growth drivers for Lipiodol®
Maintain our position in HCC treatment ▪
Lipiodol® as gold standard through cTACE standardization
▪
Leveraging on emerging new therapeutic strategies against HCC*
▪
▪
Accelerate Lipiodol® development in VE
New horizons : Lipiojoint & more to come
Vascular Embolization indication expansion in Europe to be leveraged, in other countries
▪
Deployment of VE solution in Europe through partnerships
R&D investments in new applications for Lipiodol®
▪
▪
Lipiojoint clinical study preparation to claim benefits in osteoarthritis
*Hepatocellular carcinoma (Liver cancer) 25
3
Improving competitiveness and enhancing cash generation
Organizational costs improvements
Cash generation supporting financial strength
Streamlined organization
Improve group profitability
Improved sales forces efficiency and effectiveness
Continue managing DSO (day sales outstanding) and overdue receivables
Improving our manufacturing reliability
Inventory optimization and tighter control of purchasing
Full effect expected from 2027 onwards 26
Financial communication calendar Financial communication calendar
1st quarter 2023 revenue 2026 1st quarter revenue
Half-year Sales 2023 2026 Half-year sales
2023 Half-year results 2026 Half-year results
April 20. 2023 Apriltrading 23, 2026 after after trading
July 20. 2023 Julytrading 23, 2026 after after trading
September 15, 2026 after trading
27
Change in Guerbet’s Board of Directors Villepinte, March 11th, 2026: Guerbet (FR0000032526 GBT), a global leader in contrast agents and solutions for medical imaging, today announced, at its Board of Directors’ meeting, the appointment of Mr. Antoine Fady as “censeur” (non-voting director) effective immediately.
The appointment of Mr. Antoine Fady as a Director will be submitted for approval at the next Shareholders’ Meeting. Following this Shareholders’ Meeting, it will be proposed that the Board of Directors of Guerbet appoint Mr. Antoine Fady as Chairman, succeeding Mr. Hugues Lecat, who has decided to step down from his duties for personal reasons.
The members of the Board of Directors stated: “We are delighted to welcome Mr. Antoine Fady to the Guerbet Group as a Board Observer, with the objective—subject to Shareholders’ Meeting approval—of him becoming a director and subsequently Chairman of the Company. His experience leading large industrial companies, his strong understanding of governance issues, and his strategic vision will be valuable assets in supporting the Group through a successful transformation and toward new achievements. We would like to sincerely thank Mr. Hugues Lecat for his unwavering commitment alongside us over the past two years.”
Mr Antoine Fady commented: “I am very pleased to join Guerbet’s Board of Directors, with the prospect, subject to shareholder approval, of assuming its Chairmanship, and I would like to thank the Board members for their trust. In this year when Guerbet is celebrating a highly symbolic milestone, its 100th anniversary, I am extremely enthusiastic about contributing to the Group's development and working closely with Karim Boussebaa to develop and implement strategies that will strengthen our market position and promote long-term sustainable growth.”
2025 full-year results • Revenue: €786.4 million, down 3.5% at CER1 and like-for-like2, mainly due to the fall in activity in France • Profitability: restated EBITDA margin3 of 12.0% (at the high end of the adjusted range communicated in December) • Net Income: loss of €112.7 million, which includes a non-recurring impairment of €86 million • Free cash flow: in positive territory at €19.2 million • Indebtedness: net debt/EBITDA ratio of 4.0x, below the ceiling of 4.8x set in December 2025 under the waiver obtained by the Group from its lenders.
2026 • Significant negative impact expected from the situation in Raleigh on revenue, profitability, cash generation and group indebtedness with a probable risk of covenant breach on June 30, 2026 • No dividend distribution in respect of the 2025 fiscal year • Continuation of the transformation plan and strategic focus on sustainably improving the Group’s sales momentum and competitiveness
Villepinte, March 11, 2026, 5.45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is publishing its consolidated financial statements for fiscal 2025.
1
At constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous fiscal year. 2
Excluding the urology and Accurate activities (including sales in 2025 of inventories of components and finished products), which were sold in July 2024 and January 2025 respectively. 3 Excluding non-recurring costs related to the optimization of the operational framework and changes to the sales model.
Adjustment of 2025 financial targets Villepinte, 2 December 2025, 5.45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing a downward revision to its financial targets for full-year 2025. Following an inspection by the U.S. Food and Drug Administration (FDA) during the first half of the year, the Guerbet Group developed and initiated the implementation of a compliance plan at its Raleigh site in the United States. This plan has been reinforced over the past weeks in response to FDA’s observations1. Guerbet always puts the patient front and centre of its commitments and affirm its determination to ensure production meets the highest regulatory and quality standards. Guerbet mobilised human, financial and technical internal resources and hired external experts to conduct comprehensive assessments and take other interim measures under the compliance plan, in alignment with FDA guidance to industry. The implementation of the compliance plan has delayed the release of batches manufactured at the site, and this is expected to result in a loss of revenue for the Group in the 2025 financial year. The implementation of compliance plan activities will also give rise to exceptional costs. Under these conditions, Guerbet will not be able to meet its 2025 targets and now anticipates: – A decrease in revenue of between -4 % and -5 % at constant exchange rates and on a like-for-like basis, compared with a slight decrease of -1% previously announced; – A restated EBITDA margin of between 10,5% and 12% of revenue, compared with between 12% and 13% previously announced; – Free cash flow of between -5M€ and -15M€, versus slightly negative previously announced The operational consequences and financial impact for the 2026 financial year are currently being analysed. The company will inform the market as soon as it has additional information.
1 Warning Letter dated 17 October 2025
Financial agenda for 2026 Villepinte, November 19, 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2026.
Publications calendar • 2025 ANNUAL REVENUE February 05, 2026, after trading
• 2025 ANNUAL RESULTS March 11, 2026, after trading
•
•
2026 1ST QUARTER REVENUE April 23, 2026, after trading
ANNUAL SHAREHOLDERS’ MEETING May 22, 2026
•
2026 2ND QUARTER REVENUE July 23, 2026, after trading
• 2026 FIRST HALF RESULTS September 15, 2026, after trading
•
2026 3RD QUARTER REVENUE October 22, 2026, after trading
2026 Blackout periods calendar Dates of publications
Blackout periods
• 2025 ANNUAL REVENUE February 05, 2026, after trading
January 21, 2026 to February 6, 2026 included
• 2025 ANNUAL RESULTS March 11, 2026, after trading
February 9, 2026 to March 12, 2026 included
•
2026 1ST QUARTER REVENUE April 23, 2026, after trading
April 8, 2026 to April 24, 2026 included
•
2026 2ND QUARTER REVENUE July 23, 2026, after trading
July 8, 2026 to July 24, 2026 included
• 2026 FIRST HALF RESULTS September 15, 2026, after trading
August 16, 2026 to September 16, 2026 included
2026 3RD QUARTER REVENUE October 22, 2026, after trading
October 7, 2026 to October 23, 2026 included
•
A “blackout period” is a period during which it is forbidden to carry out transactions, to intervene on the company’s securities (restricted trading period):
- 30 calendar days before the publication of the press release announcing the annual and halfyearly results until the day of publication (included),
- 15 calendar days prior to the release of the quarterly results announcement if applicable until the day of publication (inclusive). This prohibition applies to:
- to managers and people assimilated to managers,
- to insiders,
- to any person who has regular or occasional access to inside information. It is recalled that the obligation to refrain applies in any event when the persons concerned are the holders of inside information which has not been made public. For example, any forecast of the current half-year or year’s results; any acquisition, disposal or restructuring plans; a significant financial transaction; any conclusion or termination of a major contract or significant partnership; technical or legal elements relating to a trial, litigation; the departure or recruitment of an officer, etc. The possession of inside information imposes obligations to refrain. It is thus prohibited: • to disclose this information to a person outside the normal scope of his or her work, profession or duties, or for purposes other than those for which it was disclosed, • recommend to another person to acquire or dispose of securities, or to have any other person acquire or dispose of securities, • use this information by acquiring, transferring, attempting to acquire or transfer the financial instruments to which this information relates. Failure to comply with one of these obligations may result in a severe financial penalty, decided by the AMF’s sanctions commission. In addition, these acts may constitute a criminal insider dealing offence.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Guerbet SA
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.